annu al scientific

Transcription

annu al scientific

www.idibaps.ub.edu
000 Cubierta.indd 1
Your gateway to IDIBAPS. A channel that is
open to medical communication professionals,
scientists and biomedicine enthusiasts
where you will find full information about the
institution and its activities.
Report 2008
Annual Scientific
Annual Scientific Report 2008
Institut d’Investigacions Biomèdiques August Pi i Sunyer
Villarroel, 170
08036 Barcelona
www.idibaps.ub.edu
Hospital Clínic - Fundació Clínic
University of Barcelona - Faculty of Medicine
CSIC – Institut d’Investigacions Biomèdiques de Barcelona
Generalitat de Catalunya – Departament de Recerca
21/10/09 17:26:03
209-211 Ind PUBLICACIONS.indd 211
20/10/09 10:47:51
ANNUAL
SCIENTIFIC
REPORT 2008
Villarroel, 170
08036 Barcelona
www.idibaps.ub.edu
003-009 AREA0.indd 3
Hospital Clínic - Fundació Clínic
University of Barcelona - Faculty of Medicine
CSIC – Institut d’Investigacions Biomèdiques de Barcelona
Generalitat de Catalunya – Departament de Recerca
21/10/09 17:23:40
fhklghfljghlfd
Published by: IDIBAPS
Villarroel, 170 – 08036 Barcelona
Coordination and production:
IDIBAPS Communication Division
Production and design:
BPMO Edigrup
C/ Guitard, 43, 1a planta
08014 Barcelona
Tel. +34933637840
www.grupobpmo.com
Legal deposit: B-51.810-2005
Centres de recerca
de Catalunya
This centre has been cofinanced by the European Union through
the European Regional Development Fund (ERDF)
21/10/09 17:23:40
summary IDIBAPS 2008
Foreword IDIBAPS
Introduction . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
7
Research Areas Index
Area 1: Biologic Aggression and Response Mechanisms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
10
Area 2: Biopathology and Respiratory, Cardiovascular and Renal Bioengineering . . . . . . . . . . . . . . . . . . . . . . . . . . .
40
Area 3: Liver, Digestive System and Metabolism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
72
Area 4: Clinical and Experimental Neurosciences . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
Area 5: Oncology and Hematology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
154
Area 6: International Health
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
194
Groups Associated with the Instituto de
Investigaciones Sanitarias Hospital Clínic-IDIBAPS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 204
Index
Team Leader index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
208
Journal index . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
209
21/10/09 17:23:47
Foreword IDIBAPS
Image: 3d rendered close up of some cells with nucleus
21/10/09 17:23:49
IDIBAPS: Research with a Future
It is my pleasure to present to you Annual Scientific Report of the Institut d’Investigacions
Biomèdiques August Pi i Sunyer (IDIBAPS).
This research carried out in this center is organized into 6 thematic areas, bringing together more than 50 top-level teams. Scientific progress is never the result of coincidence.
It involves long-term commitments that include not only the researchers but also society as a whole. IDIBAPS is a consortium that allows Catalonia to take on one of these
commitments: To promote translational research, innovation and technological advances in the field of biomedicine, by means of different programs that revolve around diseases with high prevalence, morbidity and mortality. The annual scientific report holds
a mirror to this activity and is a tool for evaluating the work of the IDIBAPS researchers;
this evaluation is critical for society as a whole to be able to see the efficient use of social and economic resources received from public and private institutions and the return
for the social and economic fabric of some of the advances achieved.
This year, IDIBAPS signed the program agreement with the Catalan Government, with
a total financial attribution of €30 million by 2012. This program agreement defines the
development of scientific priorities and has been accompanied by an external audit of
all the research groups in order to evaluate their scientific excellence. IDIBAPS has also
been accredited as a Health Care Research Institute by the Carlos III Health Institute,
another external indicator of the importance of the scientific work carried out. In the
framework of this new institute, we are laying the basis for stable collaboration with
other reference institutions, such as the Barcelona Biomedical Research Institute (IRB)
and Hospital Sant Joan de Déu.
In 2008, IDIBAPS published 736 original articles in international journals, with an overall impact factor of 3421. This gives a mean impact factor per article of 4.65. The
scientific production of IDIBAPS has grown year after year and has now stabilized
with approximately 700 articles per year. The challenge is not so much to increase
the number of publications but to improve their scientific quality and the innovative
impact of the findings.
I would also like to point out the involvement of IDIBAPS in large national and international projects, such as the Network of Centers for Biomedical Research (CIBER), promoted by the Ministry of Science and Innovation. We lead the CIBER on Hepatic and
Digestive Diseases (CIBEREHD), on Respiratory Diseases (CIBERES) and on Diabetes
and Associated Metabolic Diseases (CIBERDEM). We continue to take part in and lead
projects of the Thematic Cooperative Research Networks (RETIC), also promoted by the
Carlos III Health Institute, and every day we take part in more projects funded by the
European Commission. IDIBAPS currently coordinates 14 of these projects and takes
part in 50 more. We also collaborate on projects carried out by both CRESIB, the driving
21/10/09 17:23:50
Foreword IDIBAPS
force of our international health program, and on other initiatives of other institutions
such as the Carreras Foundation, the Cellex Foundation, the Sardà Farriol Foundation
and the Seny Foundation.
At this difficult time due to the state of the economy of the western world, the commitment to research and innovation is even more critical. There are sectors of society
that remain unaware of the critical role that research plays in the progress of humanity
and biomedical research in the prevention, diagnosis and treatment of diseases. Years
of scientific research may be required before some of the findings find their way into
clinical practice. History has shown that quality scientific research with ambitious objectives is the basis for developing scientific and technological systems and for providing
support to the business fabric in order to reach the stage of practical applications.
Thus, IDIBAPS, together with the centers that make up this consortium (Hospital Clínic,
University of Barcelona, Catalan Government and CSIC), are taking on the commitment
to reinforce their vocation in the field of biomedical research and are playing a decisive
role in the promotion of the new CIBEK research building, via the activity of the Clínic
Foundation and the Esther Koplowitz Foundation, and in other structural initiatives for
research support, specifically aimed at incorporating talent with its own programs and
also with the collaboration of those proposed by ICREA, Ramon y Cajal, Miquel Servet
and Río Hortega.
We believe that this joint commitment will allow us not only to consolidate everything we
have achieved, but also to commit to a far better scientific, economic and social future.
All this makes me feel a great admiration for the professionals that move this institute
forward and allows me to look to the future with optimism. In the pages of this annual
report, you will find interesting lines of research and cutting-edge initiatives. We have
achieved many things, but we can surely achieve even more. We have human potential,
institutional and financial support, and the enthusiasm to continue going forward.
8
Ramon Gomis
Director of IDIBAPS
21/10/09 17:23:55
Research Areas Index
Area 1
Biologic Aggression and Response Mechanisms . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 10
.
Area 2
Biopathology and Respiratory, Cardiovascular
and Renal Bioengineering . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 40
Area 3
Liver, Digestive System and Metabolism . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 72
Area 4
Clinical and Experimental Neurosciences . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 114
Area 5
Oncology and Hematology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 154
Area 6
International Health
. . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
194
Groups Associated with the Instituto de Investigaciones
Sanitarias Hospital Clínic-IDIBAPS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 204
Image: 3d rendered close up of some cells with nucleus
21/10/09 17:23:58
010-039 AREA1.indd 10
21/10/09 17:05:38
Area 1
Biological Aggression and
Response Mechanisms
Inflammatory Arthropathies . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 12
Systemic Autoimmune Diseases . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 14
Infectious Diseases and AIDS . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 19
Immunoreceptors of the Innate and Adaptive System . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 27
Musculoskeletal Repair and Plasticity . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 30
Immunogenetics in the Autoinflammatory Response
. . . . . . . . . . . . . . . . . . . . . . . . . . . . .
33
Research and Development in Microbiology and
Molecular Clinical Parasitology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 35
Molecular and Cellular Bases of Inflammation
Structural and Biologic Mass Spectrometry . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 38
Image: HIV-infected T-cells under high magnification
010-039 AREA1.indd 11
21/10/09 17:05:41
Inflammatory Arthropathies
Team Members
Area 1 Biologic Aggression and Response Mechanisms
Inflammatory arthropathies
Team Leader:
■ Raimon Sanmartí (Hospital Clínic)
Tel.: 93 227 54 00 (Ext.: 2236)
E-mail: [email protected]
12
IDIBAPS Members:
■ Juan D. Cañete (Hospital Clínic)
Collaborators:
Guadalupe Ercilla (Hospital Clínic)
Jaume Pomés (Hospital Clínic)
Xavier Tomas (Hospital Clínic)
Odette Viñas (Hospital Clínic)
J.A. Gómez-Puerta (Hospital Clínic)
Strategic Objectives
To promote research into the most prevalent forms of
chronic arthritis:
rheumatoid arthritis (RA) and spondylarthritis, including
psoriatic arthritis.
Doctoral Students:
Raquel Celis (Fundació Clínic)
Gertrudis Sánchez (Fundació Clínic)
Eduard Graell (Fundació Clínic)
Maria Victoria Hernández (Fundació Clínic)
4.Role of autoinflammatory genes in the
pathogenesis of chronic arthritis
• Mutations of MEFV in intermittent arthritis.
Principal Lines of Research
1.Prognostic factors in early-stage arthritis
• Prognostic factors (clinical and immunogenetic) in
patients with early-stage rheumatoid arthritis.
• Synthesis of new synthetic citrullinated peptides
for designing immunoassay tests with diagnostic
and prognostic value in early-stage rheumatoid
arthritis.
2.Immunopathology of synovitis in chronic
arthritis
• Value in differential diagnosis and prognosis. Immunopathologic changes related to biologic therapies. Synovial response biomarkers.
3.Predictive factors of the therapeutic
response in rheumatoid arthritis
• Polymorphism of the FcgammR gene, serum
values of ds TNFR2.
010-039 AREA1.indd 12
Synthesis of chimeric filaggrin peptides and the fibrin alpha chain.
Immunoassay tests using these citrullinated peptidase antigens have
shown a high sensitivity and specificity in detecting antibodies in the
serum of patients with rheumatoid arthritis.
21/10/09 17:05:50
I.F.: 21,42
PublicaTions
Original Articles
Reviews
1
4
3
Moll C, Hernandez MV, Canete JD, Gomez-Puerta
JA, Soriano A, Collado A, Sarimarti R. Ilium osteitis
as the main manifestation of the SAPHO syndrome:
Response to infliximab therapy and review of the
literature. SEMIN ARTHRITIS RHEU. 37:299-306.
I.F.:3,68.
Grants for Research in Progress
Sans M. Development of a new DNA array-based
diagnostic system (“IBDCHIP”) to predict clinical course,
development of complications, and response to therapy
in patients with Inflammatory Bowel Disease (IBD). Grant:
Ministerio Sanidad y Consumo, AI07/90033. Duration:
26/10/2007-30/12/2009.
Panes J, Cañete J. Desarrollo de un kit diagnóstico para
las enfermedades inflamatorias mediadas por mecanismos
inmunes (IMID-Kit). Subproyecto 1: Estudio de asociación
de genoma completo en las enfermedades inflamatorias.
Grant: Ministerio de ducación y Ciencia, PSE-010000-2008-9.
Duration: 01/01/2008-31/12/2009.
Inflammatory arthropathies
2
Dieguez-Gonzalez R, Calaza M, Perez-Pampin E,
DeLaSerna AR, Fernandez-Gutierrez B, Castaneda
S, Largo R, Joven B, Narvaz J, Navarro F, Marenco
JL, Vicario JL, Blanco FJ, Fernandez-Lopez JC, Caliz
R, Collado-Escobar MD, Carreno L, Lopez-Longo J,
Canete JD, Gomez-Reino JJ, Gonzalez A. Association
of interferon regulatory factor 5 haplotypes, similar
to that found in systemic lupus erythematosus, in a
large subgroup of patients with rheumatoid arthritis.
ARTHRITIS RHEUM. 58:1264-+. I.F.:7,68.
Cantaert T, Kolln J, Timmer T, Kraan TCV, Vandooren
B, Thurlings RM, Canete JD, Catrina AI, Out T, Verweij
CL, Zhang YP, Tak PP, Baeten D. B lymphocyte autoimmunity in rheumatoid synovitis is independent of
ectopic lymphoid neogenesis. J IMMUNOL. 181:785794. I.F.:6,07.
Julia A, Ballina J, Canete JD, Balsa A, Tornero-Molina
J, Naranjo A, Alperi-Lopez M, Erra A, Pascual-Salcedo
D, Barcelo P, Camps J, Marsal S. Genome-wide association study of rheumatoid arthritis in the Spanish population. ARTHRITIS RHEUM. 58:2275-2286.
I.F.:7,68.
Biologic Aggression and Response Mechanisms Area 1
13
010-039 AREA1.indd 13
21/10/09 17:05:54
Systemic Autoimmune Diseases
Team Members
Systemic autoimmune diseases
Team Leader:
■ Dr. Ricard Cervera Segura
(Hospital Clínic)
Tel.: 93 227 57 74
Fax: 93 227 17 07
IDIBAPS Members:
■ Alfredo Adán (Hospital Clínic)
■ Albert Bové (Facultat de Medicina)
■ Maria Cinta Cid (Hospital Clínic)
■ Gerard Espinosa Garriga(Hospital Clínic)
■ José Hernández Rodríguez (Hospital Clínic)
■ Miguel Ingelmo Morín (Hospital Clínic)
■ Ricardo P. Casaroli (Hospital Clínic)
■ Manuel Ramos Casals (Hospital Clínic)
Area 1 Biological Aggression and Response Mechanisms
Collaborators:
Silvia Bucciarelli (Hospital Clínic)
Xavier Bosch Aparici (Hospital Clínic)
María Teresa Sainz de la Maza (Hospital Clínic)
14
Doctoral Students:
Joan Plaza Nicolau (Hospital Clínic)
Ana García Martínez (Hospital Clínic)
Sergio Prieto (Hospital Clínic)
Georgina Espígol (IDIBAPS)
Ester Lozano García (IDIBAPS)
Marc Corbera (IDIBAPS)
Montserrat Butjosa (Hospital Clínic)
The research group on systemic autoimmune diseases promotes basic, clinical and translational research
into these diseases in a multidisciplinary manner, with
the participation of members of the Autoimmune Disease Department, Ophthalmology, Internal Medicine,
Nephrology, Immunology, Hemostasis, Hepatology,
Obstetrics and Dermatology, and others.
1.Systemic lupus erythematosus
And antiphospholipid syndrome
• Multicenter epidemiologic studies on the
clinical presentation and long-term course
of these diseases.
• Clinical trials of new biologic therapies.
• Study of genetic polymorphisms as risk
factors of different clinical presentations
of these diseases.
• Study of cardiovascular and endothelial lesion risk
factors implicated in these diseases.
• Basic research in animal models on the mechanism of action of antiphospholipid antibodies.
These activities are carried out in close collaboration with
different international working groups, of which members of the team are national and/or international coordinators: European Working Party on Systemic Lupus
Erythematosus (EWPSLE), European Forum on Antiphospholipid Antibodies (EFAPL), Catastrophic Antiphospholipid Syndrome (CAPS) Registry Project Group, International Pediatric Register of Antiphospholipid Syndrome
(Ped-APS Register), Systemic Lupus International Collaborative Centers (SLICC), Sjögren’s Syndrome-Hepatitis
C Virus (SS-HCV) Study Group, HISPAMEC Study Group,
Grupo de Estudio de Enfermedades Autoinmunes Sistémicas-Uso de Terapias Biológicas (BIOGEAS), Grupo de
Estudio Multicéntrico Español de Síndrome de Sjögren
(GEMESS), European Vasculitis Study Group (EUVAS),
European League Against Rheumatism (EULAR) Systemic Vasculitis Task Force, EULAR Standing Committee
for International Clinical Studies Including Therapeutics,
and the American College of Rheumatology (ACR) Work
Group for Development of Classification Criteria for Polymyalgia Rheumatica, among others.
010-039 AREA1.indd 14
2.Sjörgen syndrome and autoimmune
manifestations of infection by the
hepatitis C virus:
• Multicenter epidemiologic studies on the clinical
presentation and long-term course of these
d
iseases.
• Study of lymphomas associated with Sjörgen syndrome.
• Study of cardiovascular and endothelial lesion risk
factors implicated in this syndrome.
• Clinical and basic studies on mixed
cryoglobulinemia.
• International register of treatments with
biologic drugs for systemic autoimmune
diseases (BIOGEAS).
21/10/09 17:06:02
• Study of genetic genetic polymorphism in uveitis
as risk factors of the different clinical presentations
of these ophthalmopathies.
• Treatment with anti-vascular endothelial growth
factor (VEGF) drugs for choroidal neovascularization and cystic macular edema due to uveitis.
4.Autoimmune ophthalmopathies
• Clinical trials of new biologic therapies.
LInflammatory and thrombotic vascular lesions responsible
for gangrene lesion which required foot amputation
in the antiphospholipid antibody syndrome.
3.Systemic vasculitis
• Development of a model of organ culture for studying the factors involved in the perpetuation of
inflammation and in vascular remodeling.
• Research into the mechanisms implicated in and
clinical consequences of vascular inflammation in
giant cell arteritis. Identification of new therapeutic
targets.
• Study of the mechanisms involved in the development of ischemic neurological complications in
giant cell arteritis.
• Studies of the inflammatory involvement of large
vessels in the early stages and during the course
of giant cell arteritis.
• Clinical trials of new biologic therapies in the
treatment of systemic vasculitis.
• Spanish register of systemic vasculitis.
• Spanish register of Behçet disease.
Emerging Group
Research group on autoimmune ophthalmopathies
Principal Investigator:
■ Adán, Alfredo Manuel (ICOF)
Associated Group
Research group on vasculitis
■ Cid, Maria Cinta (ICMiD)
This group works on the study of clinical, diagnostic and therapeutic aspects of systematic vasculitis and
the mechanisms of production of vascular lesions in these forms of vasculitis. The scientific contribution of
this line of research is highly competitive and internationally recognized. It also focuses on clinical studies of
systemic vascular lesions in giant cell arteritis, the study of mechanisms of production of vascular lesions in giant cell arteritis,
different clinical trials of new biologic therapies and coordinates Spanish registers of vasculitis associated with anti-neutrophil
cytoplasmic antibodies (ANCA) and Behçet disease.
PublicaTions
Original Articles
1
2
Ramos-Casals M, Brito-Zeron P, Munoz S, Soto MJ. A
Systematic Review of the Off-Label Use of Biological
Therapies in Systemic Autoimmune Diseases. MEDICINE. 87:345-364. I.F.:4,72.
Urowitz MB, Gladman D, Ibanez D, Fortin P, SanchezGuerrero J, Bae S, Clarke A, Bernatsky S, Gordon C,
010-039 AREA1.indd 15
I.F.: 147,55
Biological Aggression and Response Mechanisms Area 1
This group works on the study of clinical, diagnostic and therapeutic aspects of autoimmune ophthalmopathies. The scientific contribution of this line of research is highly competitive and internationally recognized.
It also focuses on the study of genetic genetic polymorphism in uveitis as risk factors of the different clinical
presentations of these ophthalmopathies and different clinical trials of new biologic therapies.
15
Hanly J, Wallace D, Isenberg D, Ginzler E, Merrill J,
Alarcon GS, Steinsson K, Petri M, Dooley MA, Bruce I,
Manzi S, Khamashta M, Ramsey-Goldman R, Zoma A,
Sturfelt G, Nived O, Maddison P, Font J, VanVollenhoven R, Aranow C, Kalunian K, Stoll T. Accumulation of
coronary artery disease risk factors actors over three
years: Data from an international inception cohort.
ARTHRIT RHEUM-ARTHR. 59:176-180. I.F.:7,68.
21/10/09 17:06:07
3
4
5
6
7
8
9
10 11 12 16
13 14 010-039 AREA1.indd 16
Ramos-Casal M, Cuadrado MJ, Alba P, Sanna G, BritoZeron P, Bertolaccini L, Babini A, Moreno A, D’cruz D,
Khamashta MA. Acute Viral Infections in Patients With
Systemic Lupus Erythematosus Description of 23 Cases
and Review of the Literature. MEDICINE. 87:311-318.
I.F.:4,72.
Asherson RA, Cervera R, Klumb E, Stojanovic L, SarziPuttini P, Yinh J, Bucciarelli S, Espinosa G, Levy R, Shoenfeld Y. Amputation of digits or limbs in patients with
antiphospholipid syndrome. SEMIN ARTHRITIS RHEU.
38:124-131. I.F.:3,68.
Gomez-Puerta JA, Burlingame RW, Cervera R. Anti-chromatin (anti-nucleosome) antibodies: Diagnostic and
clinical value. AUTOIMMUN REV. 7:606-611. I.F.:3,86.
Sebastiani GD, Morozzi G, Bellisai F, Fineschi I, Bacarelli MR, Simpatico A, Font J, Cervera R, Houssiau F,
Fernandez-Nebro A, Garrido ER, DePita O, Smolen J,
Galeazzi M. Anti-cofactor autoantibodies in systemic lupus erythematosus: Prevalence, clinical and HLA class
II associations. IMMUNOL INVEST. 37:375-385. I.F.:1,53.
Asherson RA, Cervera R, Merrill JT, Erkan D. Antiphospholipid antibodies and the antiphospholipid
syndrome: Clinical significance and treatment. SEMIN
THROMB HEMOST. 34:256-266. I.F.:3,20.
Hanly JG, Urowitz MB, Siannis F, Farewell V, Gordon
C, Bae SC, Isenberg D, Dooley MA, Clarke A, Bernatsky
S, Gladman D, Fortin PR, Manzi S, Steinsson K, Bruce
IN, Ginzler E, Aranow C, Wallace DJ, Ramsey-Goldman
R, VanVollenhoven R, Sturfelt G, Nived O, SanchezGuerrero J, Alarcon GS, Petri M, Khamashta M, Zoma
A, Font J, Kalunian K, Douglas J, Qi Q, Thompson K,
Merrill JT. Autoantibodies and neuropsychiatric events
at the time of systemic lupus erythematosus diagnosis.
ARTHRITIS RHEUM. 58:843-853. I.F.:7,68.
Ramos-Casals M, Brito-Zeron P, Soto MJ, Cuadrado
MJ, Khamashta MA. Autoimmune diseases induced
by TNF-targeted therapies. BEST PRACT RES CL RH.
22:847-861. I.F.:2,09.
Cibeira MT, Rozman M, Segarra M, Lozano E, Rosinol L,
Cid MC, Filella X, Blade J. Bone marrow angiogenesis
and angiogenic factors in multiple myeloma treated
with novel agents. CYTOKINE. 41:244-253. I.F.:2,17.
Varela DC, Quintana G, Somers EC, Rojas-Villarraga
A, Espinosa G, Hincapie ME, Mccune WJ, Cervera R,
Anaya JM. Delayed lupus nephritis. ANN RHEUM DIS.
67:1044-1046. I.F.:6,41.
Garcia-Martinez A, Hernandez-Rodriguez J, Arguis P,
Paredes P, Segarra M, Lozano E, Nicolau C, Ramirez
J, Lomena F, Josa M, Pons F, Cid MC. Development of
aortic aneurysm/dilatation during the followup of patients with giant cell arteritis: A cross-sectional screening
of fifty-four prospectively followed patients. ARTH RHEUM/AR C RES. 59:422-430. I.F.:7,68.
Jimenez S, Tassies D, Espinosa G, Garcia-Criado A,
Plaza J, Monteagudo J, Cervera R, Reverter JC. Double
heterozygosity polymorphisms for platelet glycoproteins Ia/IIa and IIb/IIIa increases arterial thrombosis and
arteriosclerosis in patients with the antiphospholipid
syndrome or with systemic lupus erythematosus. ANN
RHEUM DIS. 67:835-840. I.F.:6,41.
Bertsias G, Ioannidis JPA, Boletis J, Bombardieri S,
Cervera R, Dostal C, Font J, Gilboe IM, Houssiau F, Hui-
15 16 17 18 19
20
21 22 23 24 25 zinga T, Isenberg D, Kallenberg CGM, Khamashta M,
Piette JC, Schneider M, Smolen J, Sturfelt G, Tincani
A, VanVollenhoven R, Gordon C, Boumpas DT. EULAR
recommendations for the management of systemic lupus erythematosus. Report of a task force of the EULAR
standing committee for international clinical studies
including therapeutics. ANN RHEUM DIS. 67:195-205.
I.F.:6,41.
Casaroli-Marano RP, Adan A. Eye infections associated
with ocular implants. ENFERM INFEC MICR CL. 26:581588. I.F.:1,10.
Ramos-Casals M, Munoz S, Zeron PB. Hepatitis C Virus
and Sjogren’s Syndrome: Trigger or Mimic?. RHEUM
DIS CLIN N AM. 34:869-+. I.F.:2,16.
Lozano E, Segarra M, Garcia-Martinez A, HernandezRodriguez J, Cid MC. Imatinib mesylate inhibits in vitro
and ex vivo biological responses related to vascular occlusion in giant cell arteritis. ANN RHEUM DIS. 67:15811588. I.F.:6,41.
Mansour AM, Mackensen F, Arevalo JF, Ziemssen F,
Mahendradas P, Mehio-Sibai A, Hrisomalos N, Lai TYY,
Dodwell D, Chan WM, Ness T, Banker AS, Pai SA, Berrocal MH, Tohme R, Heiligenhaus A, Bashshur ZF, Khairallah M, Salem KM, Hrisomalos FN, Wood MH, Heriot
W, Adan A, Kumar A, Lim L, Hall A, Becker M. Intravitreal bevacizumab in inflammatory ocular neovascularization. AM J OPHTHALMOL. 146:410-416. I.F.:2,63.
Cervera R. Lessons from the “Euro-Phospholipid” project. AUTOIMMUN REV. 7:174-178. I.F.:3,86.
Asherson RA, Cervera R. Microvascular and microangiopathic antiphospholipid-associated syndromes
(“MAPS”) - Semantic or antisemantic?. AUTOIMMUN
REV. 7:164-167. I.F.:3,86.
Espinosa G, Bucciarelli S, Asherson RA, Cervera R.
Morbidity and mortality in the catastrophic antiphospholipid syndrome: Pathophysiology, causes of death,
and prognostic factors. SEMIN THROMB HEMOST.
34:290-294. I.F.:3,20.
Adan A, Pelegrin L, Alforja S, Giralt J. Optical coherence tomography findings and management of
sub-internal limiting membrane haemorrhage. ACTA
OPHTHALMOL SCAN. 86:582-583. I.F.:1,85.
Mukhtyar C, Flossmann O, Hellmich B, Bacon P, Cid M,
Cohen-Tervaert JW, Gross WL, Guillevin L, Jayne D,
Mahr A, Merkel PA, Raspe H, Scott D, Witter J, Yazici H,
Luqmani RA. Outcomes from studies of antineutrophil
cytoplasm antibody associated vasculitis: a systematic
review by the European League Against Rheumatism systemic vasculitis task force. ANN RHEUM DIS.
67:1004-1010. I.F.:6,41.
Adan A, Casaroli-Marano RP, Gris O, Navarro R, Bitrian
E, Pelegrin L, Sanchez-Dalmau B. Pathological findings
in the lens capsules and intraocular lens in chronic
pseudophakic endophthalmitis: An electron microscopy
study. EYE. 22:113-119. I.F.:2,29.
Avcin T, Cimaz R, Silverman ED, Cervera R, Gattorno M,
Garay S, Berkun Y, Sztajnbok FR, Silva CA, Campos LM,
Saad-Magalhaes C, Rigante D, Ravelli A, Martini A, Rozman B, Meroni PL. Pediatric Antiphospholipid Syndrome: Clinical and Immunologic Features of 121 Patients
in an International Registry. PEDIATRICS. 122:E1100E1107. I.F.:4,47.
21/10/09 17:06:12
Reviews
1
2
3
4
5
6
Espinosa G, Cervera R. Antiphospholipid syndrome.
ARTHRITIS RES THER. 10:-. I.F.:4,04.
Cervera R, Balasch J. Bidirectional effects on autoimmunity and reproduction. HUM REPROD UPDATE.
14:359-366. I.F.:7,26.
Bosch X, Guilabert A, Espinosa G, Mirapeix E. Immunotherapy for antineutrophil cytoplasmic anti bodyassociated vasculitis: challenging the therapeutic status
quo?. TRENDS IMMUNOL. 29:280-289. I.F.:9,48.
Brito-Zeron P, Ramos-Casals M. Prognosis of patients
with primary Sjogren’s syndrome. MED CLIN-BARCELONA. 130:109-115. I.F.:1,34.
Hernandez-Rodriguez J, Molloy ES, Hoffman GS. Single-organ vasculitis. CURR OPIN RHEUMATOL. 20:4046. I.F.:4,30.
Garcia-Carrasco M, Jimenez-Hernandez M, Escarcega RO, Mendoza-Pinto C, Pardo-Santos R, Levy R,
Maldonado CG, Chavez GP, Cervera R. Treatment of
Raynaud’s phenomenon. AUTOIMMUN REV. 8:62-68.
I.F.:3,86.
Editorials
1
2
3
4
5
Shoenfeld Y, Meroni PL, Cervera R. Antiphospholipid
syndrome dilemmas still to be solved: 2008 status.
ANN RHEUM DIS. 67:438-+. I.F.:6,41.
Shoenfeld Y, Cervera R. Asherson’s syndrome of the catastrophic antiphospholipid antibodies. J RHEUMATOL.
35:2066-2068. I.F.:3,15.
Cervera R, Shoenfeld Y. Microangiopathic Antiphospholipid Antibody-Associated Syndromes: A Tribute
to Ronald Asherson. ISR MED ASSOC J. 10:894-895.
I.F.:0,58.
Cid MC. Systemic vasculitis: still a long and winding
road. CURR OPIN RHEUMATOL. 20:1-2. I.F.:4,30.
Ramos-Casals M. Viruses and lupus: the viral hypothesis. LUPUS. 17:163-165. I.F.:2,25.
Multicentric
1
Dasgupta B, Salvarani C, Schirmer M, Crowson CS,
Maradit-Kremers H, Hutchings A, Matteson EL. Developing classification criteria for polymyalgia rheumatica:
Comparison of views from an expert panel and wider
survey. J RHEUMATOL. 35:270-277. I.F.:3,15.
010-039 AREA1.indd 17
34 Hernandez-Rodriguez J, Tan CD, Molloy ES, Khasnis
A, Rodriguez ER, Hoffman GS. Vasculitis involving the
breast - A clinical and histopathologic analysis of 34
patients. MEDICINE. 87:61-69. I.F.:4,72.
26 Siso A, Ramos-Casals M, Bove A, Brito-Zeron P, Soria
N, Munoz S, Testi A, Plaza J, Sentis J, Coca A. Previous
antimalarial therapy in patients diagnosed with lupus
nephiritis: Influence on outcomes and survival. LUPUS.
17:281-288. I.F.:2,25.
27 Mejia-Romero R, Garcia-Carrasco M, Galarza-Maldonado C, Santos P, Mendoza-Pinto C, Escarcega RO,
Salinas-Saldivar S, Soto-Vega E, Lopez-Colombo A,
Cervera R. Primary antiphospholipid syndrome in Latin
American mestizo patients: clinical and immunologic
characteristics and comparison with European patients.
CLIN RHEUMATOL. 27:891-897. I.F.:1,64.
28 Ramos-Casals M, Solans R, Rosas J, Maria CT, Gil A,
DelPino-Montes J, Calvo-Alen J, Jimenez-Alonso J,
Mico ML, Beltran J, Belenguer R, Pallares L. Primary
Sjogren syndrome in Spain - Clinical and immunologic
expression in 1010 patients. MEDICINE. 87:210-219.
I.F.:4,72.
29 Asherson RA, Espinosa G, Menahem S, Yinh J, Bucciarelli S, Bosch X, Cervera R. Relapsing catastrophic antiphospholipid syndrome: Report of three cases. SEMIN
ARTHRITIS RHEU. 37:366-372. I.F.:3,68.
30 Hanly JG, Urowitz MB, Su L, Sanchez-Guerrero J, Bae
SC, Gordon C, Wallace DJ, Isenberg D, Alarcon GS,
Merrill JT, Clarke A, Bernatsky S, Dooley MA, Fortin PR,
Gladman D, Steinsson K, Petri M, Bruce IN, Manzi S,
Khamashta M, Zoma A, Font J, VanVollenhoven R, Aranow C, Ginzler E, Nived O, Sturfelt G, Ramsey-Goldman
R, Kalunian K, Douglas J, Qi KQ, Thompson K, Farewell
V. Short-term outcome of neuropsychiatric events in
systemic lupus erythematosus upon enrollment into an
international inception cohort study. ARTHRIT RHEUMARTHR. 59:721-729. I.F.:7,68.
31 Pelegrin L, Gris O, Adan A, Plazas A. Superficial keratectomy and amniotic membrane patch in the treatment of corneal plaque of vernal keratoconjunctivitis.
EUR J OPHTHALMOL. 18:131-133. I.F.:1,02.
32 Petri M, Kasitanon N, Singh S, Link K, Magder L, Bae
SC, Hanly JG, Nived O, Sturfelt G, VanVollenhoven
R, Wallace DJ, Alarcon GS, Adu D, Avila-Casado C,
Bernatsky SR, Bruce IN, Clarke AE, Contreras G, Fine
DM, Gladman DD, Gordon C, Kalunian KC, Madaio MP,
Rovin BH, Sanchez-Guerrero J, Steinsson K, Aranow
C, Balow JE, Buyon JP, Ginzler EM, Khamashta MA,
Urowitz MB, Dooley MA, Merrill JT, Ramsey-Goldman
R, Font J, Tumlin J, Stoll T, Zoma A. Systemic lupus
international collaborating clinics renal activity/response exercise - Comparison of agreement in rating renal
response. ARTHRITIS RHEUM. 58:1789-1795. I.F.:7,68.
33 Petri M, Kasitanon N, Lee SS, Link K, Magder L, Bae SC,
Hanly JG, Isenberg DA, Nived O, Sturfelt G, VanVollenhoven R, Wallace DJ, Alarcon GS, Adu D, Avila-Casado
C, Bernatsky SR, Bruce IN, Clarke AE, Contreras G, Fine
DM, Gladman DD, Gordon C, Kalunian KC, Madaio MP,
Rovin BH, Sanchez-Guerrero J, Steinsson K, Aranow
C, Balow JE, Buyon JP, Ginzler EM, Khamashta MA,
Urowitz MB, Dooley MA, Merrill JT, Ramsey-Goldman
R, Font J, Tumlin J, Stoll T, Zoma A. Systemic lupus international collaborating clinics renal activity/response
exercise - Development of a renal activity score and renal response index. ARTHRITIS RHEUM. 58:1784-1788.
I.F.:7,68.
17
Cid MC. Mechanisms involved in the development of
neurologic ischemic complications in giant-cell arteritis.
Grant: Fundació Marató TV3, 60710. Duration: 06/02/200705/02/2010.
Cid MC. Factores relacionados con el mantenimiento de
la inflamación y la oclusión vascular. Imoplicaciones en
21/10/09 17:06:16
la evolución clínica de los pacientes con arteritis de células
gigantes. Grant: Ministerio Educación y Ciencia, SAF200506250. Duration: 31/12/2005-31/12/2008.
Sainz M, Adan AM. A 6 Week, Phase 3, Multicenter,
Masked, Randomized Trial (with a 20-Week Safety
Extension) to Assess the Safety and Efficacy of Study
Drug Applicator System Compared with Sham Study Drug
Applicator System in the Treatment of Non-Infectious
Ocular Inflamm. Grant: Allergan, 206207-014. Duration:
01/01/2006-31/12/2008.
Thesis
Cid MC. Factors relacionats amb el manteniment de la
inflamació i l’oclusió vascular. Implicacions en l’evolució
dels pacients amb arteritis de cèl·lules gegants.
Doctorand: Ester Lozano García
Ramos-Casals M, Coca A. Historia natural de la nefropatía
lúpica. Doctorand: Antoni Sisó (Universitat Barcelona)
Ramos M. Susceptibilitat immunogenètica i alteracions metabòliques com a factors etiopatogènics de dolor crònic en
pacients amb síndrome de Sjögren en comparació amb pacients atesos a l’àmbit de l’atenció primària. Grant: Fundació
La Marató de TV3, 071810. Duration: 13/02/2008-12/02/2011.
Casaroli R. Estudio de extension de fase IV,
multicéntrico, abierto y con seguimiento a largo
plazo para evaluar la seguridad y la tolerabilidad de
ranibizumab en pacientes con neovascularizacion
coroidea (NVC) subfoveal secundaria a degeneración
macular. Grant: Novartis SA, CRFBOO2A2402. Duration:
01/01/2007-31/12/2008.
18
010-039 AREA1.indd 18
21/10/09 17:06:20
Infectious Diseases and AIDS
Team members
Team Leader:
■ Josep M. Gatell (Hospital Clínic)
Tel.: 93 227 54 30
Fax: 93 451 54 38
Collaborators:
José Luis Blanco (Hospital Clínic)
Marta Calvo (Fundació Clínic)
Carlos Cervera (Hospital Clínic)
Nuria Climent (IDIBAPS)
Ana del Rio (Fundació Clínic)
Teresa Gallart (Hospital Clínic)
Cristina Gil (IDIBAPS)
Joan Joseph (Fundació Clínic)
Elisa de Lazzari (Fundació Clínic)
Agathe León (Fundació Clínic)
Montserrat Loncà (Fundació Clínic)
Ana Milinkovic (Fundacio Clínic)
Jose Ignacio Pérez (Fundació Clínic)
Technicians:
Pilar Callau (IDIBAPS)
Tuixent Escriba (IDIBAPS)
Ana García (Fundació Clínic)
Maria Teresa García (Fundació Clínic)
Sonia Gil (Fundació Clínic)
Carmen Hurtado (Fundació Clínic)
M. José Maleno (Fundació Clínic)
Diego Martínez (Fundacio Clínic)
Laia Miralles (IDIBAPS)
Laura Muñoz (IDIBAPS)
Sara Nieto (IDIBAPS)
Cristina García de la María (Fundació Clínic)
Yolanda Armero (Fundació Clínic)
In AIDS
1. Immunotherapy of the disease and natural and
acquired defense mechanisms, including the development of therapeutic and preventive vaccines.
2. Efficacy, resistance mechanisms and tolerance of
new antiviral drugs.
3. Immunopathogenesis, response to treatment and
resistance mechanisms of some IOs, including tuberculosis, PCP and toxoplasmosis.
In general infections
1. Prophylaxis and support of endocarditis due to multiresistant germs, including experimental models.
2. Infections in recipients of solid organ transplants.
010-039 AREA1.indd 19
Doctoral Students:
Fernando Agüero (Fundació Clínic)
Victor Casanova (Facultat de Farmacia)
Meritxell Guilá (Facultat de Medicina)
Maria Lopez-Dieguez (Fundacio Clínic)
Christian Manzardo (Fundació Clínic)
3. Interactions between nosocomial infections and
the use of antibiotics.
In AIDS
1. The most important line focuses on the peripheral
response (blood) and central response (lymphatic
tissue and cerebrospinal fluid) to different antiretroviral treatment regimens when administered in
very early evolution stages (CD4 > 500 mm3). We
have prepared highly sensitive techniques for determining viral load in plasma and tissues; techniques
for determining genotypic resistance and immunophenotyping and proliferation of CD4+ lymphocytes
Sonsoles Sánchez (Fundació Clínic)
Narcís Saubí (IDIBAPS)
Alex Soriano (Hospital Clínic)
Sara Varea (Fundació Clínic)
Laura Zamora (IDIBAPS)
Emmanuela Fernandez (Fundació Clínic)
Maria Larrousse (Hospital Clínic)
María Martínez (Hospital Clínic)
Víctor Manuel Sánchez (IDIBAPS)
Infectious diseases and AIDS
IDIBAPS Members:
■ Mireia Arnedo (Fundació Clínic)
■ Miguel Caballero (Hospital Clínic)
■ Felipe García (Hospital Clínic)
■ Montserrat Laguno (Fundació Clínic)
■ Josep Mallolas (Hospital Clínic)
■ Esteban Martínez (Hospital Clínic)
■ José Antonio Martínez (Hospital Clínic)
■ José Mensa (Hospital Clínic)
■ José M. Miró (Hospital Clínic)
■ Asunción Moreno (Hospital Clínic)
■ Montserrat Plana (Fundació Clínic)
■ M. Eloisa Yuste (IDIBAPS)
19
21/10/09 17:06:27
Infectious disease and AIDS
in the presence of HIV antigens; and, in collaboration with the clinical pharmacology group, techniques for determining drug levels. The working
hypothesis, once the possibility of eradicating HIV
has been ruled out, is to see whether it is possible
to suppress, almost completely and over the long
term, the replication of HIV, recover the immune
system and quantify the degree of this recovery. Interruption of treatment leads to a rapid relapse.
2. The mechanism by which the virus is able to escape the cytotoxic response is the object of our study
and may be the selection of different quasispecies
from the reservoirs (immunologic resistance). For
this reason, we have started a line of research aimed at developing techniques for stimulating the
immune system to associated with antiretroviral
treatment. Cyclic interruption of treatment may
lead to a recovery of the specific immune response to HIV antigens associated with a spontaneous
drop in the viral load, which correlates to the level of proliferative and specific cytotoxic response
against HIV-1 in a small percentage of patients.
3. We have also prepared an immunotherapy technique
based on the administration of autologous dendritic
cells stimulated ex vivo with the patient’s virus. The
first study, in phase I with patients, has already been
completed and published. The second study, using
higher concentrations of the virus to stimulate the autologous dendritic cells ex vivo is near completion.
4. We are developing different immunogens that may
be potential candidates for therapeutic or preventive vaccines.
In general infections
1. Clinical and experimental endocarditis including
endocarditis in drug addicts (Dr. J.M. Miró).
2. Infections in transplant recipients. Diagnosis, microbiology and prognostic markers (Dr. A Moreno).
3. Predictive factors and treatment response markers
of nosocomial infections (Dr. J. Mensa)
4. Treatment response, resistance and transmission
of tuberculosis.
5. Prognostic factors for community-acquired and
nosocomial respiratory infection, in both immunocompetent and immunosuppressed hosts.
6. The genetic bases of host susceptibility and the
biochemical and molecular bases in the replication
ability of the resistant strains.
20
010-039 AREA1.indd 20
Evolution of mean
CD4+ T lymphocyte
counts in the plasma
of patients subject to
cyclical interruptions
of treatment and
patients who
received continuous
treatment. In the 2
groups with cyclical
interruptions, the
CD4+ T lymphocyte
count did not recover
and this strategy
should, therefore, not
be used. (León A. et
al. JAC 2009, 63;184188. Advance Access
11 Nov 2008).
Associated Group
Endocarditis. Cardiovascular infections.
Experimental model
■ Miró, Josep Maria (ICMiD)
This group works on the study of clinical, diagnostic and therapeutic aspects
of infectious endocarditis. We do this
by means of local, national and international (ICE)
cohort studies that have shown the increase in endocarditis produced by methicillin-sensitive Staphylococcus aureus (MSSA) and methicillin-resistant S aureus
(MRSA). The studies in the experimental model of endocarditis due to MRSA and GISA have evaluated the
activity of new combinations of antibiotics (fosfomycin
and imipenem) or new antibiotics such as daptomycin
and telavancin.
Associated Group
Infections in recipients of solid organ
transplants
■ Moreno, Asunción (ICMiD)
Over the last year, this group has
studied the clinical and evolutionary
characteristics of bacteremia in patients
with different solid organ transplants (kidney, liver, heart
and kidney and pancreas). We have shown that mannose-binding lectin (MBL) polymorphisms condition an increase in the prevalence of the disease due to CMV and
we have analyzed mortality risk factors in pneumonia in
transplant patients. The prevalence of other virus of the
herpes family (HVV-6 and 7) in the transplant population
and its pathogenic role in the post-transplant period
have been studied. These studies have been carried out
together with researchers in microbiology, immunology
and the different transplant units (Institutes for Digestive
Diseases, Nephrology and Thorax).
Associated Group
AIDS and HIV Infection
■ Gatell, Josep Maria (ICMiD)
This group works on the clinical, diagnostic, therapeutic and preventive
aspects of HIV infection. The scientific
contribution of this line of research is highly competitive and internationally recognized. This group of
researchers focuses on exploring the potential for eradicating HIV infection and reconstituting the immune
system, including the development of preventive and
therapeutic vaccines. Since its beginning in 2002, Dr.
Gatell has coordinated the Spanish network of research
groups on AIDS (RIS), financed by the FIS and, since
2007, the HIVACAT project for research on HIV vaccines.
21/10/09 17:06:32
I.F.: 309,56
Publications
Original articles
1
13 14
15 16
17
18
19
20
010-039 AREA1.indd 21
12
Ramos-Casal M, Cuadrado MJ, Alba P, Sanna G, BritoZeron P, Bertolaccini L, Babini A, Moreno A, D’cruz D,
Khamashta MA. Acute Viral Infections in Patients With
Systemic Lupus Erythematosus Description of 23 Cases
and Review of the Literature. MEDICINE. 87:311-318.
I.F.:4,72.
2 Clotet B, Capetti A, Soto-Ramirez LE, Gatell JM, Rowell
L, Salgo M, Schapiro JM. A randomized, controlled
study evaluating an induction treatment strategy in
which enfuvirtide was added to an oral, highly active
antiretroviral therapy regimen in treatment-experienced patients: the INTENSE study. J ANTIMICROB CHEMOTH. 62:1374-1378. I.F.:4,04.
3 Laufer N, Laguno M, Perez I, Cifuentes C, Murillas J, Vidal F, Bonet L, Veloso S, Gatell JM, Mallolas J. Abacavir
does not influence the rate of virological response in
HIV-HCV-coinfected patients treated with pegylated interferon and weight-adjusted ribavirin. ANTIVIR THER.
13:953-957. I.F.:4,55.
4 Sierra JM, Rodriguez-Puig D, Soriano A, Mensa J, Piera C, Vila J. Accumulation of Tc-99m-ciprofloxacin in
Staphylococcus aureus and Pseudomonas aeruginosa.
ANTIMICROB AGENTS CH. 52:2691-2692. I.F.:4,39.
5 DelSaz SV, Sued O, Falco V, Aguero F, Crespo M, Pumarola T, Curran A, Gatell JM, Pahissa A, Miro JM, Ribera E.
Acute meningoencephalitis due to human immunodeficiency virus type 1 infection in 13 patients: clinical description and follow-up. J NEUROVIROL. 14:474-479. I.F.:1,94.
6 Dambrava PG, Torres A, Valles X, Mensa J, Marcos
MA, Penarroja G, Camps M, Estruch R, Sanchez M,
Menendez R, Niederman MS. Adherence to guidelines’
empirical antibiotic recommendations and communityacquired pneumonia outcome. EUR RESPIR J. 32:892901. I.F.:5,35.
7 Miravitlles M, Monso E, Mensa J, Perez JA, Barberan
J, Caamano MB, Merino JLC, Martinez M, DeZarate O,
Mir MSM, Picazo JJ, Jimenez JAQ, Garcia-Rodriguez
JA. Antimicrobial treatment of exacerbation in chronic
obstructive pulmonary disease: 2007 consensus statement. ARCH BRONCONEUMOL. 44:100-108. I.F.:1,56.
8 Ortega M, Almela M, Soriano A, Marco F, Martinez JA,
Munoz A, Penarroja G, Mensa J. Bloodstream infections among human immunodeficiency virus-infected
adult patients: epidemiology and risk factors for mortality. EUR J CLIN MICROBIOL. 27:969-976. I.F.:2,31.
9 Baddley JW, Benjamin DK, Patel M, Miro J, Athan E,
Barsic B, Bouza E, Clara L, Elliott T, Kanafani Z, Klein J,
Lerakis S, Levine D, Spelman D, Rubinstein E, Tornos P,
Morris AJ, Pappas P, Fowler VG, Chu VH, Cabell C, Gatell JM, Miro JM. Candida infective endocarditis. EUR J
CLIN MICROBIOL. 27:519-529. I.F.:2,31.
10 Soto SM, Bosch J, JimenezDeAnta MT, Vila J. Comparative study of virulence traits of Escherichia coli
clinical isolates causing early and late neonatal sepsis.
J CLIN MICROBIOL. 46:1123-1125. I.F.:3,71.
11 Durante-Mangoni E, Bradley S, Selton-Suty C, Tripodi
MF, Barsic B, Bouza E, Cabell CH, Ramos AIDO, Fowler
V, Hoen B, Konecny P, Moreno A, Murdoch D, Pappas P,
Sexton DJ, Spelman D, Tattevin P, Miro JM, VanDerMeer JTM, Utili R, Gatell JM. Current Features of Infective
Endocarditis in Elderly Patients - Results of the International Collaboration on Endocarditis Prospective Cohort
Study. ARCH INTERN MED. 168:2095-2103. I.F.:8,39.
Marco F, DeLaMaria CG, Armero Y, Amat E, Soy D,
Moreno A, DelRio A, Almela M, Mestres CA, Gatell
JM, JimenezDeAnta MT, Miro JM. Daptomycin is effective in treatment of experimental endocarditis due
to methicillin-resistant and glycopeptide-intermediate
Staphylococcus aureus. ANTIMICROB AGENTS CH.
52:2538-2543. I.F.:4,39.
Jaen A, Esteve A, Miro JM, Tural C, Montoliu A, Ferrer
E, Riera M, Segura F, Force L, Sued O, Vilaro J, Garcia I,
Masabeu A, Altes J, Clotet B, Podzamczer D, Murillas J,
Navarro G, Gatell JM, Casabona J. Determinants of HIV
progression and assessment of the optimal time to initiate highly active antiretroviral therapy - PISCIS cohort
(Spain). JAIDS-J ACQ IMM DEF. 47:212-220. I.F.:4,41.
Lifson AR, Belloso WH, Carey C, Davey RT, Duprez
D, El-Sadr WM, Gatell JM, Gey DC, Hoy JF, Krum EA,
Nelson R, Nixon DE, Paton N, Pedersen C, Perez G,
Price RW, Prineas RJ, Rhame FS, Sampson J, Worley J.
Determination of the underlying cause of death in three
multicenter international HIV clinical trials. HIV CLIN
TRIALS. 9:177-185. I.F.:1,62.
Grau JJ, Caballero M, Monzo M, Munoz-Garcia C,
Domingo-Domenech J, Navarro A, Conill C, Campayo
M, Bombi JA. Dihydropyrimidine dehydrogenases and
cytidine-deaminase gene polymorphisms as outcome
predictors in resected gastric cancer patients treated
with fluoropyrimidine adjuvant chemotherapy. J SURG
ONCOL. 98:130-134. I.F.:2,38.
Caballero M, Vilaseca I, Bernal-Sprekelsen M, Guilemany JM, Moragas M, Blanch JL. DISTANT METASTASES AFTER TRANSORAL LASER MICROSURGERY FOR
LARYNGEAL AND HYPOPHARYNGEAL SQUAMOUS
CELL CARCINOMA. HEAD NECK-J SCI SPEC. 30:15991606. I.F.:2,01.
AntiretroviralTherapyCohortCollaboration (ART-CC),
Gatell JM, Miro JM, Agusti C. Does short-term virologic
failure translate to clinical events in antiretroviral-naive
patients initiating antiretroviral therapy in clinical practice? The Antiretroviral Therapy Cohort Collaboration
(ART-CC)anti. AIDS. 22:2481-2492. I.F.:5,84.
Len O, Gavalda J, Blanes M, Montejo M, Juan RS,
Moreno A, Carratala J, DeLaTorre-Cisneros J, Bou G,
Cordero E, Munoz P, Cuervas-Mons V, Alvarez MT,
Borrell N, Fortun J, Pahissa A. Donor infection and
transmission to the recipient of a solid allograft. AM J
TRANSPLANT. 8:2420-2425. I.F.:6,42.
Marcos M, Inurrieta A, Soriano A, Martinez JA, Almela
M, Marco F, Mensa J. Effect of antimicrobial therapy on
mortality in 377 episodes of Enterobacter spp. bacteraemia. J ANTIMICROB CHEMOTH. 62:397-403. I.F.:4,04.
Carr A, Ritzhaupt A, Zhang W, Zajdenverg R, Workman
C, Gatell JM, Cahn P, Chaves R. Effects of boosted tipranavir and lopinavir on body composition, insulin sen-
21
21/10/09 17:06:37
21
22
23
24
25
26
27
28 29 22
30 31 010-039 AREA1.indd 22
sitivity and adipocytokines in antiretroviral-naive adults.
AIDS. 22:2313-2321. I.F.:5,84.
Chu VH, Woods CW, Miro JM, Hoen B, Cabell CH, Pappas PA, Federspiel J, Athan E, Stryjewski ME, Nacinovich
F, Marco F, Levine DP, Elliott TS, Fortes CQ, Tornos P,
Gordon DL, Utili R, Delahaye F, Corey GR, Fowler VG.
Emergence of coagulase-negative staphylococci as a
cause of native valve endocarditis. CLIN INFECT DIS.
46:232-242. I.F.:6,75.
Petti CA, Simmon KE, Miro JM, Hoen B, Marco F, Chu
VH, Athan E, Bukovski S, Bouza E, Bradley S, Fowler VG,
Giannitsioti E, Gordon D, Reinbott P, Korman T, Lang
S, Garcia-De-La-Maria C, Raglio A, Morris AJ, Plesiat
P, Ryan S, Doco-Lecompte T, Tripodi F, Utili R, Wray D,
Federspiel JJ, Boisson K, Reller LB, Murdoch DR, Woods
CW. Genotypic diversity of coagulase-negative staphylococci causing endocarditis: a global perspective. J CLIN
MICROBIOL. 46:1780-1784. I.F.:3,71.
Autran B, Murphy RL, Costagliola D, Tubiana R, Clotet B,
Gatell J, Staszewski S, Wincker N, Assoumou L, El-Habib
R, Calvez V, Walker B, Katlama C. Greater viral rebound
and reduced time to resume antiretroviral therapy after
therapeutic immunization with the ALVAC-HIV vaccine
(vCP1452). AIDS. 22:1313-1322. I.F.:5,84.
DeLazzari E, Leon A, Arnaiz JA, Martinez E, Knobel H,
Negredo E, Clotet B, Montaner J, Storfer S, Asenjo MA,
Mallolas J, Miro JM, Gatell JM. Hepatotoxicity of nevirapine in virologically suppressed patients according
to gender and CD4 cell counts. HIV MED. 9:221-226.
I.F.:3,35.
Navarro G, Nogueras MM, Segura F, Casabona J, Miro
JM, Murillas J, Tural C, Ferrer E, Jaen A, Force L, Vilaro
J, Garcia I, Masabeu A, Altes J, Esteve A, Sued O, Riera
M, Clotet B, Podzamczer D, Gatell JM. HIV-1 infected patients older than 50 years. PISCIS cohort study. J INFECTION. 57:64-71. I.F.:2,84.
Anton A, Cervera C, Pumarola T, Moreno A, Benito N,
Linares L, Esteva C, Cofan F, JimenezDeAnta MT, Marcos
MA. Human herpesvirus 7 primary infection in kidney
transplant recipients. TRANSPLANTATION. 85:298-302.
I.F.:3,64.
Perello R, Moreno A, Camps M, Cervera C, Linares L, Pumarola T, Marcos MA. Human immunodeficiency virusinfected patients with community-acquired pneumonia:
implication of respiratory viruses. ENFERM INFEC MICR
CL. 26:85-87. I.F.:1,10.
Crespo G, Cervera C, Michelena J, Marco F, Moreno
A, Navasa M. Immune Reconstitution Syndrome After
Voriconazole Treatment for Cryptococcal Meningitis in a
Liver Transplant Recipient. LIVER TRANSPLANT. 14:16711674. I.F.:3,75.
Mallolas J, Pich J, Penaranda M, Domingo P, Knobel H,
Pedrol E, Gutierrez F, Barrufet P, Peraire J, Asenjo MA,
Vidal F, Gatell JA. Induction therapy with trizivir plus efavirenz or lopinavir/ritonavir followed by trizivir alone in
naive HIV-1-infected adults. AIDS. 22:377-384. I.F.:5,84.
Marti J, Cervera C, Filella X, Marin JL, Almela M, Gatell
JM, Moreno A. Inflammatory response in elderly patients with bacteremia. ENFERM INFEC MICR CL. 26:146149. I.F.:1,10.
Soriano A, Marco F, Martinez JA, Pisos E, Almela M, Dimova VP, Alamo D, Ortega M, Lopez J, Mensa J. Influen-
32 33 34 35 36 37 38 39 40 41 42 ce of vancomycin minimum inhibitory concentration on
the treatment of methicillin-resistant Staphylococcus aureus bacteremia. CLIN INFECT DIS. 46:193-200. I.F.:6,75.
Mocroft A, Kirk O, Aldins P, Chies A, Blaxhult A, Chentsova N, Vetter N, Dabis F, Gatell J, Lundgren JD. Loss to
follow-up in an international, multicentre observational
study. HIV MED. 9:261-269. I.F.:3,35.
Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen CJ,
Gatell JM, Girard PM, Grund B, Law M, Losso MH, Palfreeman A, Wood R, Arnaiz JA. Major clinical outcomes
in antiretroviral therapy (ART)-naive participants and in
those not receiving ART at baseline in the SMART study.
J INFECT DIS. 197:1133-1144. I.F.:6,04.
Menendez R, Cavalcanti M, Reyes S, Mensa J, Martinez
R, Marcos MA, Filella X, Niederman M, Torres A. Markers
of treatment failure in hospitalised community acquired
pneumonia. THORAX. 63:447-452. I.F.:6,23.
Vila J, Soriano A, Mensa J. Molecular basis of microbial
adherence to prosthetic materials. Role of biolayers in
prosthesis-associated infection. ENFERM INFEC MICR
CL. 26:48-55. I.F.:1,10.
Perno CF, Moyle G, Tsoukas C, Ratanasuwan W, Gatell J,
Schechter M. Overcoming resistance to existing therapies in HIV-infected patients: The role of new antiretroviral
drugs. J MED VIROL. 80:565-576. I.F.:2,83.
Mussini C, Manzardo C, Johnson M, Monforte AD,
Uberti-Foppa C, Antinori A, Gill MJ, Sighinolfi L, Borghi
V, Lazzarin A, Sabin C, Miro JM. Patients presenting with
AIDS in the HAART era: a collaborative cohort analysis.
AIDS. 22:2461-2469. I.F.:5,84.
Simmon KE, Hall L, Woods CW, Marco F, Miro JM,
Cabell C, Hoen B, Marin M, Utili R, Giannitsioti E, DocoLecompte T, Bradley S, Mirrett S, Tambic A, Ryan S, Gordon D, Jones P, Korman T, Wray D, Reller LB, Tripodi MF,
Plesiat P, Morris AJ, Lang S, Murdoch DR, Petti CA. Phylogenetic analysis of viridans group streptococci causing
endocarditis. J CLIN MICROBIOL. 46:3087-3090. I.F.:3,71.
Alvarez-Martinez MJ, Moreno A, Miro JM, Valls ME,
Rivas PV, DeLazzari E, Sued O, Benito N, Domingo P, Ribera E, Santin M, Sirera G, Segura F, Vidal F, Rodriguez
F, Riera M, Cordero ME, Arribas JR, JimenezDeAnta MT,
Gatell JM, Wilson PE, Meshnick SRM. Pneumocystis
jirovecii pneumonia in Spanish HIV-infected patients
in the combined antiretroviral therapy era: prevalence
of dihydropteroate synthase mutations and prognostic
factors of mortality. DIAGN MICR INFEC DIS. 62:34-43.
I.F.:2,45.
Gordin FM, Roediger MP, Girard PM, Lundgren JD, Miro
JM, Palfreeman A, Rodriguez-Barradas MC, Wolff MJ,
Easterbrook PJ, Clezy K, Slater LN. Pneumonia in HIVinfected persons - Increased risk with cigarette smoking
and treatment interruption. AM J RESP CRIT CARE.
178:630-636. I.F.:9,07.
Moyle G, Perno CF, Ratanasuwan W, Schechter M, Tsoukas C, Gatell JM. Potential for new antiretrovirals to
address unmet needs in the management of HIV-1 infection. AIDS PATIENT CARE ST. 22:459-471. I.F.:2,40.
Trullas JC, Barril G, Cofan F, Moreno A, Cases A,
Fernandez-Lucas M, Martinez-Ara J, Ceballos M, GarciaDe-Diego J, Muniz ML, Molina J, Martinez-Castelao A,
Gonzalez-Garcia J, Miro JM. Prevalence and Clinical
Characteristics of HIV Type 1-Infected Patients Receiving
21/10/09 17:06:45
43
44
46
48
49
50
51
010-039 AREA1.indd 23
Reviews
1
2
3
Miro JM, Sanz J, Lozano F, Mallolas J, Moreno S,
Aguirrebengoa K, Perez-Molina J. 2008 prevention of
opportunistic infections in HIV-infected adolescents and
adults guidelines - Recommendations of GESIDA/National AIDS Plan. ENFERM INFEC MICR CL. 26:437-464.
I.F.:1,10.
Almirante B, Miro JM. Infections associated with prosthetic heart valves, vascular prostheses, and cardiac
pacemakers and defibrillators. ENFERM INFEC MICR CL.
26:647-664. I.F.:1,10.
Martin-Davila P, Forun J, Lopez-Velez R, Norman F, DeOca MM, Zamarron P, Gonzalez MI, Moreno A, Pumarola T,
Garrido G, Candela A, Moreno S. Transmission of tropical and geographically restricted infections during solidorgan transplantation. CLIN MICROBIOL REV. 21:60-+.
I.F.:15,76.
Editorials
1
Almirante B, Alonso J, Martinez-Martinez L, Miro JM,
Pascual A. Toward Modernization of the Editorial Process
in Enfermedades Infecciosas y Microbiologia Clinica. ENFERM INFEC MICR CL. 26:605-606. I.F.:1,10.
Multicentrics
1
2
3
4
Sabin CA, Monforte AD, Friis-Moller N, Weber R, El-Sadr
WM, Reiss P, Kirk O, Mercie P, Law MG, DeWit S, Pradier
C, Phillips AN, Lundgren JD, Gatell JM, Miro JM, Zamora L. Changes over time in risk factors for cardiovascular
disease and use of lipid-lowering drugs in HIV-infected
individuals and impact on myocardial infarction. CLIN
INFECT DIS. 46:1101-1110. I.F.:6,75.
DeLuca A, Ammassari A, Pezzotti P, Cinque P, Gasnault
J, Berenguer J, DiGiambenedetto S, Cingolani A, Taoufik
Y, Miralles P, Marra CM, Antinori A, Mallolas J. Cidofovir
in addition to antiretroviral treatment is not effective
for AIDS-associated progressive multifocal leukoencephalopathy: a multicohort analysis. AIDS. 22:1759-1767.
I.F.:5,84.
[ANON], Gatell JM, Miro JM. Comparison of genotypic
resistance profiles and virological response between
patients starting nevirapine and efavirenz in EuroSIDA.
AIDS. 22:367-376. I.F.:5,84.
Cozzi-Lepri A, Phillips AN, Clotet B, Mocroft A, Ruiz L,
Kirk O, Lazzarin A, Wiercinska-Drapalo A, Karlsson A,
Lundgren JD, Gatell JM, Miro JM. Detection of HIV drug
resistance during antiretroviral treatment and clinical
47
52 Serra MC, Cervera C, Pumarola T, Moreno A, Perello R,
Torres A, JimenezDeAnta MT, Marcos MA. Virological
diagnosis in community-acquired pneumonia in immunocompromised patients. EUR RESPIR J. 31:618-624.
I.F.:5,35.
53 Ferrer E, Gatell JM, Sanchez P, Domingo P, Puig T, Niubo
J, Cortes C, Veloso S, Pedrol E, Leon A, Gutierrez M,
Podzamczer D. Zidovudine/lamivudine/abacavir plus
tenofovir in HIV-Infected naive patients: A 96-week prospective one-arm pilot study. AIDS RES HUM RETROV.
24:931-934. I.F.:2,02.
45
Dialysis in Spain: Results of a Spanish Survey in 2006:
GESIDA 48/05 Study. AIDS RES HUM RETROV. 24:12291235. I.F.:2,02.
Laguno M, Larrousse M, Blanco JL, Leon A, Milinkovic
A, Martinez-Rebozler M, Lonca M, Martinez E, SanchezTapias JM, DeLazzari E, Gatell JM, Costa J, Mallolas J.
Prevalence and clinical relevance of occult hepatitis B
in the fibrosis progression and antiviral response to INF
therapy in HIV-HCV-Coinfected patients. AIDS RES HUM
RETROV. 24:547-553. I.F.:2,02.
Steigbigel RT, Cooper DA, Kumar PN, Eron JE, Schechter
M, Markowitz M, Loutfy MR, Lennox JL, Gatell JM, Rockstroh JK, Katlama C, Yeni P, Lazzarin A, Clotet B, Zhao J,
Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ, Nessly
ML, Dinubile MJ, Isaacs RD, Nguyen B, Teppler H. Raltegravir with optimized background therapy for resistant
HIV-1 infection. NEW ENGL J MED. 359:339-354. I.F.:52,59.
Martin M, DelCacho E, Codina C, Tuset M, DeLazzari E,
Mallolas J, Miro JM, Gatell JM, Ribas J. Relationship
between Adherence Level, Type of the Antiretroviral
Regimen, and Plasma HIV Type 1 RNA Viral Load: A
Prospective Cohort Study. AIDS RES HUM RETROV.
24:1263-1268. I.F.:2,02.
Linares L, Cervera C, Cofan F, Lizaso D, Marco F, Ricart
MJ, Esforzado N, Oppenheimer F, Campistol JM, Moreno
A. Risk factors for infection with extended-spectrum and
AmpC beta-lactamase-producing gram-negative rods in
renal transplantation. AM J TRANSPLANT. 8:1000-1005.
I.F.:6,42.
Montaner J, Yeni P, Clumeck NN, Fatkenheuer G, Gatell
J, Hay P, Seminari E, Peeters MP, Scholler-Gyure M,
Simonts M, Woodfall B. Safety, tolerability, and preliminary efficacy of 48 weeks of etravirine therapy in a phase
IIb dose-ranging study involving treatment-experienced
patients with HIV-1 infection. CLIN INFECT DIS. 47:969978. I.F.:6,75.
Mestre G, Garcia F, Martinez E, Milinkovic A, Leon A,
Mora B, Argelich R, Lozano JM, Pena J, Gatell JM, Plana
M. Short Communication Natural Killer Cells and Expression of KIR Receptors in Chronic HIV Type 1-Infected
Patients after Different Strategies of Structured Therapy
Interruption. AIDS RES HUM RETROV. 24:1485-1495.
I.F.:2,02.
Cooper DA, Steigbigel RT, Gatell JM, Rockstroh JK,
Katlama C, Yeni P, Lazzarin A, Clotet B, Kumar PN, Eron
JE, Schechter M, Markowitz M, Loutfy MR, Lennox JL,
Zhao J, Chen J, Ryan DM, Rhodes RR, Killar JA, Gilde
LR, Strohmaier KM, Meibohm AR, Miller MD, Hazuda DJ,
Nessly ML, Dinubile MJ, Isaacs RD, Teppler H, Nguyen
BY. Subgroup and resistance analyses of raltegravir for
resistant HIV-1 infection. NEW ENGL J MED. 359:355365. I.F.:52,59.
Soriano A, Bori G, Garcia-Ramiro S, Martinez-Pastor JC,
Miana T, Codina C, Macule F, Basora M, Martinez JA,
Riba J, Suso S, Mensa J. Timing of antibiotic prophylaxis
for primary total knee arthroplasty performed during ischemia. CLIN INFECT DIS. 46:1009-1014. I.F.:6,75.
Vives N, Almeda J, Contreras CA, Garcia F, Campins M,
Casabona J. Use of non-occupational HIV post-exposure
prophylaxis in Spain (2001-2005). ENFERM INFEC MICR
CL. 26:546-551. I.F.:1,10.
23
21/10/09 17:06:50
5
6
7
8
9
10
11
12
13
24
14
010-039 AREA1.indd 24
progression in a large European cohort study. AIDS.
22:2187-2198. I.F.:5,84.
Reekie J, Mocroft A, Sambatakou H, Machala L, Chiesi
A, VanLunzen J, Clumeck N, Kirk O, Gazzard B, Lundgren
JD, Miro JM, Gatell JM. Does less frequent routine monitoring of patients on a stable, fully suppressed cART
regimen lead to an increased risk of treatment failure?.
AIDS. 22:2381-2390. I.F.:5,84.
Calmy A, Carey D, Mallon PWG, Wand H, Law M, Cooper
DA, Carr A, Gatell JM. Early changes in adipokine levels
and baseline limb fat may predict HIV lipoatrophy over
2 years following initiation of antiretroviral therapy. HIV
MED. 9:101-110. I.F.:3,35.
Podlekareva D, Mocroft A, Kirk O, Reiss P, Aldins P, Katlama C, Kovari H, Stellbrink HJ, Monforte AD, Lundgren
JD, Gatell JM, Miro JM. Fungal infection as a risk factor
for HIV disease progression among patients with a CD4
count above 200/l in the era of cART. SCAND J INFECT
DIS. 40:908-913. I.F.:1,21.
Monforte AD, Abrams D, Pradier C, Weber R, Reiss P,
Bonnet F, Kirk O, Law M, DeWit S, Friis-Moller N, Phillips
AN, Sabin CA, Lundgren JD, Gatell JM, Miro JM, Zamora L. HIV-induced immunodeficiency and mortality from
AIDS-defining and non-AIDS-defining malignancies.
AIDS. 22:2143-2153. I.F.:5,84.
Valor L, Navarro J, Carbone J, Rodriguez-Sainz C, Gil J,
Lopez F, Fernandez-Cruz E, Gatell JM. Immunization with
an HIV-1 immunogen induces CD4(+) and CD8(+) HIV-1specific polyfunctional responses in patients with chronic HIV-1 infection receiving antiretroviral therapygatega.
VACCINE. 26:2738-2745. I.F.:3,38.
Bannister WP, Friis-Moller N, Mocroft A, Viard JP, VanLunzen J, Kirk O, Gargalianos P, Banhegyi D, Chiesi A,
Lundgren JD, Gatell JM, Miro JM. Incidence of abacavir
hypersensitivity reactions in EuroSIDA. ANTIVIR THER.
13:687-696. I.F.:4,55.
Smith CJ, Mocroft A, Lundgren JD, Gatell JM. Incidence
of pancreatitis in HIV-infected patients, and the association with antiretroviral therapy. AIDS. 22:997-998. I.F.:5,84.
Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund B,
Neaton JD, Neuhaus J, Phillips AN, Gatell JM, Arnaiz
JA. Inferior clinical outcome of the CD4(+) cell count guided antiretroviral treatment interruption strategy in the
SMART study: Role of CD4(+) cell counts and HIV RNA
levels during follow-up. J INFECT DIS. 197:1145-1155.
I.F.:6,04.
Caram LB, Linefsky JP, Read KM, Murdoch DR, Lalani T,
Woods CW, Reller LB, Kanj SS, Premru MM, Ryan S, AlHegelan M, Donnio PY, Orezzi C, Paiva MG, Tribouilloy
C, Watkin R, Harris O, Eisen DP, Corey GR, Cabell CH,
Petti CA, Gatell JM, Miro JM, Almela M. Leptotrichia
endocarditis: Report of two cases from the International
Collaboration on Endocarditis (ICE) database and review
of previous casesgatell. EUR J CLIN MICROBIOL. 27:139143. I.F.:2,31.
Hogg R, Lima V, Sterne JAC, Grabar S, Battegay M,
Bonarek M, Monforte AD, Esteve A, Gill MJ, Harris R,
Justice A, Hayden A, Lampe F, Mocroft A, Mugavero
MJ, Staszewski S, Wasmuth JC, VanSighem A, Kitahata
M, Guest J, Egger M, May M, AntiretroviralTherapyCohortCollaboration (ART-CC), Gatell JM, Miro JM. Life
expectancy of individuals on combination antiretroviral
15
16
17
18
19
20 21
22
therapy in high-income countries: a collaborative analysis of 14 cohort studies. LANCET. 372:293-299. I.F.:28,64.
Pineda JA, Perez-Elias MJ, Pena JM, Luque I, RodriguezAlcantara F, Mallolas J. Low Rate of Adverse Hepatic
Events Associated with Fosamprenavir/Ritonavir-Based
Antiretroviral Regimens. HIV CLIN TRIALS. 9:309-313.
I.F.:1,62.
Deforche K, Cozzi-Lepri A, Theys K, Clotet B, Camacho RJ,
Kjaer J, VanLaethem K, Phillips A, Moreau Y, Lundgren
JD, Vandamme AM, Gatell JM, Miro JM. Modelled in vivo
HIV fitness under drug selective pressure and estimated
genetic barrier towards resistance are predictive for virological response. ANTIVIR THER. 13:399-407. I.F.:4,55.
Molina JM, Andrade-Villanueva J, Echevarria J, Chetchotisakd P, Corral J, David N, Moyle G, Mancini M, Percival
L, Yang R, Thiry A, Mcgrath D, Gatell JA. Once-daily
atazanavir/ritonavir versus twice-daily lopinavir/ritonavir,
each in combination with tenofovir and erntricitabine,
for management of antiretroviral-naive HIV-1-infected
patients: 48 week efficacy and safety results of the CASTLE study. LANCET. 372:646-655. I.F.:28,64.
Tedaldi E, Peters L, Neuhaus J, Puoti M, Rockstroh
J, Klein MB, Dore GJ, Mocroft A, Soriano V, Clotet B,
Lundgren JD, Gatell JM. Opportunistic Disease and Mortality in Patients Coinfected with Hepatitis B or C Virus
in the Strategic Management of Antiretroviral Therapy
(SMART) Study. CLIN INFECT DIS. 47:1468-1475. I.F.:6,75.
Gomez-Lopez A, Alastruey-Izquierdo A, Rodriguez D,
Almirante B, Pahissa A, Rodriguez-Tudela JL, Cuenca-Estrella A, Mensa J, Almela M, Reverter J, Soler C. Prevalence and susceptibility profile of Candida metapsilosis
and Candida orthopsilosis: Results from populationbased surveillance of candidemia in Spain. ANTIMICROB
AGENTS CH. 52:1506-1509. I.F.:4,39.
Mocroft A, Horban A, Clotet B, Monforte AD, Bogner JR,
Aldins P, Staub T, Antunes F, Katlama C, Lundgren JD,
Gatell JM, Miro JM. Regional differences in the risk of
triple class failure in European patients starting combination antiretroviral therapy after 1 January 1999. HIV
MED. 9:41-46. I.F.:3,35.
Sabin CA, Smith CJ, Monforte AD, Battegay M, Gabiano
C, Galli L, Geelen S, Gibb D, Guiguet M, Judd A, Leport C,
Dabis F, Pantazis N, Porter K, Raffi F, Thorne C, Torti C, Walker S, Warszawski J, Wintergerst U, Chene G, Lundgren J,
Weller I, Costagliola D, Ledergerber B, Touloumi G, Meyer
L, Krause MM, Goujard C, DeWolf F, Reiss P, Dorrucci M,
Sabin C, Amo J, Obel N, Mocroft A, Kirk O, Staszewski S,
Perez-Hoyos S, Almeda J, Antinori A, Tovo PA, Salzberger
B, Fatkenheuer G, Ramos J, Mussini C, Tookey P, Casabona
J, Miro JM, Castagna A, Wit S, Teira R, Garrido M, Dedes
N, Phillips A, Furrer H, Egger M, Newell ML, Sterne J, Telenti A, [ANON]. Response to combination antiretroviral
therapy: variation by age - The Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study
group. AIDS. 22:1463-1473. I.F.:5,84.
El-Sadr WM, Grund B, Neuhaus J, Babiker A, Cohen CJ,
Darbyshire J, Emery S, Lundgren JD, Phillips A, Neaton
JD, Gatell JM, Arnaiz JA. Risk for opportunistic disease
and death after reinitiating continuous antiretroviral therapy in patients with HIV previously receiving episodic
therapy - a randomized trial. ANN INTERN MED. 149:289W62. I.F.:15,52.
21/10/09 17:07:00
23 Soriano V, Mocroft A, Rockstroh J, Ledergerber B, Knysz
B, Chaplinskas S, Peters L, Karlsson A, Katlama C, Toro
C, Kupfer B, Vogel M, Lundgren J, Gatell JM, Arnaiz JA.
Spontaneous viral clearance, viral load, and genotype
distribution of hepatitis C virus (HCV) in HIV-infected patients with anti-HCV antibodies in Europe. J INFECT DIS.
198:1337-1344. I.F.:6,04.
24 Bannister WP, Cozzi-Lepri A, Clotet B, Mocroft A, Kjaer
J, Reiss P, VonWyl V, Lazzarin A, Katlama C, Phillips AN,
Ruiz L, Lundgren JD, Gatell JM, Miro JM. Transmitted
drug resistant HIV-1 and association with virologic and
CD4 cell count response to combination Antiretroviral
therapy in the EuroSIDA study. JAIDS-J ACQ IMM DEF.
48:324-333. I.F.:4,41.
25 Podzamczer D, Miro JM, Mallolas J, Moreno S, Berenguer J. Treatment of opportunistic infections in
adolescent and adult patients infected by the human
immunodeficiency virus during the era of highly active
antiretroviral therapy - AIDS Study Group (GESIDA) and
National AIDS Plan Expert Committe. ENFERM INFEC
MICR CL. 26:356-379. I.F.:1,10.
26 Lundgren JD, Neuhaus J, Babiker A, Cooper D, Duprez
D, Ei-Sadr W, Emery S, Gordin F, Kowalska J, Phillips A,
Prineas OJ, Reiss P, Sabin C, Tracy R, Weber R, Grund B,
Neaton AD, Gatell JM, Miro JM, Zamora A. Use of nucleoside reverse transcriptase inhibitors and risk of myocardial infarction in HIV-infected patients. AIDS. 22:F17-F24.
I.F.:5,84.
27 Sabin CA, Worm SW, Weber R, Reiss P, El-Sadr W, Dabis
F, DeWit S, Law M, Monforte AD, Friis-Moller N, Kirk
O, Pradier C, Weller I, Phillips AN, Lundgren JD, Gatell
JM, Miro JM, Zamora L. Use of nucleoside reverse
transcriptase inhibitors and risk of myocardial infarction
in HIV-infected patients enrolled in the D : A : D study:
a multi-cohort collaboration. LANCET. 371:1417-1426.
I.F.:28,64.
28 Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter J, Emery
S, Hirschel B, Hullsiek KH, Stephan C, Lundgren J, Arnaiz
JA, Gatell JM. Viral resuppression and detection of drug
resistance following interruption of a suppressive nonnucleoside reverse transcriptase inhibitor-based regimen. AIDS. 22:2279-2289. I.F.:5,84.
Gatell JM. Construcción de una vacuna contra el virus de
la inmunodeficiencia humana tipo 1 basada en BCG y virus
vaccinia recombinante. Grant: Fundacion Mutua Madrileña,
FundMM_500992. Duration: 05/07/2005-04/07/2008.
Gatell JM. Red de SIDA. Grant: Ministerio Sanidad y Consumo, RD06/0006/0000. Duration: 01/01/2007-31/12/2010.
Martinez JA. Comparación de dos estrategias de uso de antibióticos con actividad anti-P aeruginosa (rotación frente a
mezcla) en la adquisición de bacilos gram negativos resistentes en pacientes ingresados en una unidad de cuidado intensivo médica. Grant: Ministerio Sanidad y Consumo, PI050167.
Duration: 01/01/2006-30/12/2008.
Martinez E. Estudio exploratorio de los factores genéticos
asociados a la lipoatrofia y a la enfermedad cardiovascular
en pacientes infectados por el VIH en tratamiento antirretrovial. Grant: Ministerio Sanidad y Consumo, PI050255. Duration: 01/01/2006-30/12/2008.
Plana M. Caracterización Ex Vivo de la respuesta inmunitaria
celular frente al VIH-1 mediante vectores virales. Grant: Ministerio Sanidad y Consumo, PI070291. Duration: 26/11/200730/12/2010.
Caballero M. Desarrollo de un modelo experimental en
cobaya de enfermedad de vías aéreas superiores por
exposición al humo de tabaco. Estudio de los cambios
anatomopatológicos y de los marcadores de inflamación.
Grant: Ministerio Sanidad y Consumo, PI070434. Duration:
26/11/2007-30/12/2010.
Gatell JM. Estudio de la respuesta inmunitaria “in vitro” a
una vacuna terapéutica contra el VIH-1 preparada con células
dendríticas mieloides autólogas pulsadas con diferentes inmunógeno. Grant: Ministerio Educación y Ciencia, SAF200505566. Duration: 31/12/2005-31/12/2008.
Gatell JM. Unitat de SIDA. Grant: Comissionat per a Universitats i Recerca, 2005SGR00369. Duration: 19/10/200531/12/2008.
Miro JM. Estudio FIPSE de trasplante hepático en pacientes infectados por el VIH en España (2002-2007). Estudio GESIDA 4505. Grant: Fundación para la Investigación y la Prevención del
Sida en España, TOH/VIH/05. Duration: 16/01/2006-16/01/2008.
Mallolas J. Cohorte de GESIDA de pacientes coinfectados
por VIH y virus de hepatitis C que reciben tratamiento para la
hepatitis C (2008-2010). Grant: Fundación para la Investigación y la Prevención del Sida en España, 36702/07. Duration:
19/11/2007-18/11/2010.
Arnedo M. Factores genéticos implicados en el desarrollo
de dislipemia en pacientes infectados por VIH-1 que inician
tratamiento antiretroviral de gran actividad. Grant: FIPSEFundación para la Investigación y Prevención del SIDA en
España, 36715/08. Duration: 30/10/2008-29/10/2011.
010-039 AREA1.indd 25
Gatell JM. NoE - European AIDS Treatment Network. Grant:
European Commision, LSHP-CT-2006-037570. Duration:
01/02/2007-31/01/2012.
Garcia F. Estudio en fase I de inmunogenicidad y seguridad
de una vacuna preventiva para el VIH basada en un vector
poxvirus que expresa proteinas ENV, GAG, POL y NEF del
VIH-1 subtipo B en individuos no infectados por el VIH.
01/01/2006-30/12/2008.
Garcia F. STREP - Mucosal Nano Vaccine Candidate for HIV.
Grant: European Commision, LSHP-CT-2006-037200. Duration: 01/01/2007-31/12/2009.
Garcia F. Desarrollo de vectores virales seguros para el uso
en vacunas terapéuticas contra el VIH-a preparadas con células dendríticas derivadas de monocitos. Grant: Fundacion
Mutua Madrileña, FundMM_501138. Duration: 03/07/200603/07/2009.
25
21/10/09 17:07:05
Joseph J. Second International Workshop on Lipid Mediators. Grant: Ministerio de Educación y Ciencia, SAF200730206-E. Duration: 01/02/2008-31/12/2008.
Plana M. Estudi de la resposta immune en pacients infectats
pel VIH-1 sotmesos a teràpies immunomediades. Doctorand:
Anna López Plana. Universitat de Barcelona.
Arnedo M. Factores genéticos implicados en el desarrollo
de dislipemia en pacientes infectados por VIH-1 que inician
tratamiento antiretroviral de gran actividad. Grant: FIPSEFundación para la Investigación y Prevención del SIDA en
España, 36715/08. Duration: 30/10/2008-29/10/2011.
Garcia F, Plana M. Evaluación de las características fenotípicas en las poblaciones de linfocitos T y células natural killer
y de la expresión de los NK cell receptors inhibitorios en pacientes infectados por el VIH con diversas estrategias de interrupción del tratamiento. Doctorand: Gabriel Mestre Roca.
Univarsitat de Barcelona.
Plana M, Miro JM. Factores inmunitarios protectivos del
huesped contra la infección por el VIH-1 y la progresión del
sida: Quimiocinas y sus receptores. Doctorand: Catalina Martínez Ibarra. Univarsitat de Barcelona.
Garcia F, Plana M. Estudio de la influencia de estímulos inmunológicos repetidos en forma de un calendario vacunal en
pacientes adultos infectados por el virus de la inmunodeficiencia humana en estadios tempranos de la infección. Doctorand: Pdreo Castro Rebollo. Universitat de Barcelona.
Miro JM, Plana M. Infección por VIH en pacientes muy inmunodeprimidos: características clínico-epidemiológicas,
reconstitución inmunológica y optimización del tratamiento
antirretroviral. Doctorand: Christian manzardo. Universitat
de Barcelona.
Serra JM, Martinez-Chamorro E. Atrofia de la grasa facial en
los pacientes VIH+. Tratamiento mediante inyección de tejido
adiposo antólogo. Doctorand: Joan Fontdevila Font. Universitat de Barcelona.
Thesis
26
010-039 AREA1.indd 26
21/10/09 17:07:09
Immunoreceptors of the Innate and Adaptive System
Team members
Team Leader:
■ Francisco Lozano (Hospital Clínic/UB)
Tel.: 93 227 54 88
Fax: 93 451 80 38
Collaborators:
Carles Serra Pagès (Hospital Clínic)
Maria Rosa Sarrias (FIS/Hospital Clínic)
Cristina Escoda (MEC/FPI)
Technicians:
Mireia Antón (IDIBAPS/AVCRI)
Clara Estévez (MEC)
Belén Suárez (Hospital Clínic)
Cristina Astasio (FIS)
Adriana Lázaro (Fundació Clínic)
Laia Llinas (IDIBAPS)
1. Genetic and molecular characterization of the receptors of the innate and adaptive immune system.
2. Functional characterization of the ligand-receptor interactions responsible for intracellular communication between components of the innate and adaptive
immune system.
3. Molecular characterization of pathogen-host interactions.
4. Molecular characterization of the biology, pathogenesis and immunology of cytomegalovirus (CMV).
Doctoral Students:
Erola Ainsua (FPI/MEC)
Lyzette Bonet (ACRIBIM)
Rafael Fenutría (MCyT)
Montse Gustems (MCyT)
Elena Isern (IDIBAPS)
Gloria Montañés (MEC)
Irene Oliver (IDIBAPS)
Ifigenia Saborit (FIS)
Jose Manuel de Salort (Fundació Clinic)
Jordi Sintes (UB)
Jorge Vera (MEC)
Antonio Guilabert Vidal (FIS-FSE)
Maite Figueras (MEC)
Mario Martínez Florensa (FBG)
Esther Carrasco Miguel (FC)
Cristina Miró (MEC/FPU)
Natalia Pérez Carmona (UB)
Immunoreceptors of the innate
and adaptive system
IDIBAPS Members:
■ Ana Angulo (RyC/IDIBAPS)
■ Pablo Engel (UB)
■ Margarita Martín (RyC/IDIBAPS)
27
1. Study of the structure and function of leukocyte molecules of the signalling lymphocytic activation molecule (SLAM) and SLAM-associated protein (SLAP)
families.
2. Identification and characterization of leukocyte receptors and intracellular ligands of the adaptor mo-
010-039 AREA1.indd 27
Molecular modelling of CD6 interaction with its ligand ALCAM/CD166.
Two details of the interaction surface of the two involved extracellular
domains are included: The SRCR domain of CD6, more proximal to the
membrane (DIII), and the immunoglobulin-type domain (Ig) of ALCAM,
more distal to the membrane (IgI).
21/10/09 17:07:16
and adaptive system
1
Molecular mechanisms of the
pathogenesis of cytomegalovirus
■ Angulo, Ana (IDIBAPS)
Cytomegalovirus (CMV) is a ubiquitous pathogen that establishes latent
infections that last for life, leading to
severe consequences in immunocompromised individuals. The group studies different aspects of the interaction of CMV with its host, with special emphasis on
the mechanisms that regulate viral genetic expression,
determination of new functions coded for the virus and
the identification of the processes of interference with
the immune system.
I.F.: 34,54
PublicaTions
Original Articles
28
Emerging Group
lecule 3BP2. Molecular dissection of the signal pathways of 3BP2 in lymphocytes.
3. Study of molecules that play a role in leukocyte adhesion and inflammation.
4. Immunogenetics of receptors and molecules implicated in the regulation of the innate and adaptive
immune responses.
5. Study of the role of CD5 and CD6 receptors in lymphocyte differentiation and activation.
6. Molecular and functional characterization of nonlymphoid members of the superfamily of receptors
with extracellular dominions rich in cysteine, such
as scavenger (scavenger receptor cysteine-rich,
SRCR).
7. Characterization of gene regulation mechanisms of
CMV and identification of functions coded for CMV.
8. Study of the modulation of the immune response
due to CMV and immunoevasion strategies.
2
3
4
5
6
7
010-039 AREA1.indd 28
Martin M, DelCacho E, Codina C, Tuset M, DeLazzari E,
24:1263-1268. I.F.:2,02.
Huerva V, Martin M, Canto LM, Yague J. Absence of
cornea verticillata in hemizygotes of a novel mutation
in Fabry disease. CORNEA. 27:970-972. I.F.:1,78.
Sintes J, Romero X, Marin P, Terhorst C, Engel P. Differential expression of CD150 (SLAM) family receptors by
human hematopoietic stem and progenitor cells. EXP
HEMATOL. 36:1199-1204. I.F.:3,15.
Lozano M, Peidro L, Merino I, Segur JM, Pereira A, Cid
J, Lozano L, Mazzara R, Macule F, Basora M, Salazar F.
Effectiveness and safety of tranexamic acid administration during total knee arthroplasty. VOX SANG. 95:3944. I.F.:2,59.
Domingo P, Suarez-Lozano I, Torres F, Teira R, Lopez-Aldeguer J, Vidal F, Munoz A, Viciana P, Lozano F, Vergara
A, Roca B, Alcalde MLG, Cosin J, Terron A, Galindo MJ,
Geijo P, Ribera E, Gonzalez J, Sanchez T, Lacalle JR,
Garrido M. First-line antiretroviral therapy with efavirenz or lopinavir/ritonavir plus two nucleoside analogues: the SUSKA study, a non-randomized comparison
from the VACH cohort. J ANTIMICROB CHEMOTH.
61:1348-1358. I.F.:4,04.
Gustems M, Busche A, Messerle M, Ghazal P, Angulo
A. In Vivo Competence of Murine Cytomegalovirus
under the Control of the Human Cytomegalovirus
Major Immediate-Early Enhancer in the Establishment
of Latency and Reactivation. J VIROL. 82:10302-10307.
I.F.:5,33.
Teixe T, Nieto-Blanco P, Vilella R, Engel P, Reina M,
Espel E. Syndecan-2 and-4 expressed on activated primary human CD4(+) lymphocytes can regulate T cell
activation. MOL IMMUNOL. 45:2905-2919. I.F.:3,74.
8
Saborit-Villarroya I, Martinez-Barriocanal A, Oliver-Vila
I, Engel P, Sayos J, Martin M. The adaptor 3BP2 activates CD244-mediated cytotoxicity in PKC- and SAP-dependent mechanisms. MOL IMMUNOL. 45:3446-3453.
I.F.:3,74.
9 Oliver-Vila I, Saborit-Villarroya I, Engel P, Martin M. The
leukocyte receptor CD84 inhibits Fc epsilon RI-mediated
signaling through homophilic interaction in transfected
RBL-2H3 cells. MOL IMMUNOL. 45:2138-2149. I.F.:3,74.
10 Darwich L, Cabrera C, Romeu J, Martinez-Picado J, Este
JA, Tural C, Bellido R, Clotet B, Angulo A, Ruiz L, Bofill
M. The Magnitude of Interferon-gamma Responses to
Human Cytomegalovirus Is Predictive for HIV-1 Disease Progression. JAIDS-J ACQ IMM DEF . 49:507-512.
I.F.:4,41.
Reviews
1
2
3
Miro JM, Sanz J, Lozano F, Mallolas J, Moreno S,
Aguirrebengoa K, Perez-Molina J. 2008 prevention of
opportunistic infections in HIV-infected adolescents and
adults guidelines - Recommendations of GESIDA/National AIDS Plan. ENFERM INFEC MICR CL. 26:437-464.
I.F.:1,10.
Busche A, Angulo A, Kay-Jackson P, Ghazal P, Messerle
M. Phenotypes of major immediate-early gene mutants
of mouse cytomegalovirus. MED MICROBIOL IMMUN .
197:233-240. I.F.:1,54.
Calpe S, Wang NH, Romero X, Berger SB, Lanyi A,
Engel P, Terhorst C. The SLAM and SAP gene families
control innate and adaptive immune responses. ADV
IMMUNOL . 97:177-250. I.F.:6,26.
Sarrias M. Estudio de las propiedades inmunoreguladoras
de la proteina Scavenger Spalpha en la respuesta antiinfecciosa. Grant: Ministerio Sanidad y Consumo, PI070036.
Duration: 26/11/2007-30/12/2010.
21/10/09 17:07:25
Angulo A. Identificación de determinantes moleculares de la
activación del citomegalovirus: enfoque en el locus principal
inmediatamente temprano. Grant: Ministerio Educación y Ciencia, SAF2005-05633. Duration: 15/10/2005-14/10/2008.
Martin M. Identificación y caracterización de receptores leucocitarios y ligandos intrecelulares que regulan la función de
la molecula adaptadora 3BP2 en celulas hematopoyeticas.
Grant: Ministerio Educación y Ciencia, SAF2006-00574. Duration: 01/10/2006-30/09/2009.
Engel P. Función del inmunoreceptor CD229 y del adaptador
de la familia SAP EAT2. Grant: Ministerio Educación y Ciencia,
SAF2006-00490. Duration: 01/01/2006-01/01/2009.
Lozano F. Nova bioteràpia en sepsis fùngica i polimicrobiana. Grant: CIDEM, VALTEC08-2-0034. Duration: 01/01/200831/12/2010.
Angulo A. Regulación transcripcional y funciones de los genes principales inmediatamente tempranos: implicaciones en
la patogénesis viral. Grant: Ministerio Educación y Ciencia,
SAF2008-00382. Duration: 01/01/2008-31/12/2011.
Lozano F. Red Española de Investigación en Patología Infecciosa (REIPI). Grant: Instituto de Salud Carlos III, RD06/0008.
Duration: 01/01/2008-31/12/2010.
Engel P. Study of CD84 induced innate and adaptive immune
responses in experimental colitis. Grant: Crhon’s and Colitis
Foundation of America. Duration: 01/01/2006-31/12/2008.
Patents
Lozano F. Interacción de CD6 recombinante soluble humano
(rsCD6) con componentes de las superficies microbianas (bacterianas, virales y fúngicas) y sus implicaciones terapéuticas
Jorge Vera, Francisco Lozano. Composiciones farmaceúticas
de CD5.
and adaptive system
Lozano F. Estudio de las propiedades inmunomoduladoras
de miembros linfoides y no linfoides de la superfamilia de
receptores SRCR (Scavenger Receptor Cysteine-Rich). Grant:
Ministerio Educación y Ciencia, SAF2007-62197. Duration:
01/12/2007-30/11/2010.
en las infecciones y sus procesos inflamatorios asociados.
Grant: AVCRI, PPV017-07. Duration: 01/01/2008-31/12/2009.
29
010-039 AREA1.indd 29
21/10/09 17:07:29
Musculoskeletal Repair and Plasticity
Team Members
Area 1 Biologic Aggression and Response Mechanisms
Musculoskeletal repair and plasticity
Team Leader:
■ Joaquim Forés i Viñeta
(Hospital Clínic)
Tel.: 93 227 93 14
30
IDIBAPS Members:
■ Jesús Benito (Hospital Clínic)
■ Andrés Combalía (Hospital Clínic)
■ Francisco Maculé (Hospital Clínic)
■ Montserrat Nuñez (Hospital Clínic)
■ Jaume Pomés (Hospital Clínic)
■ Josep M. Segur (Hospital Clínic)
■ Josep M. Serra (Hospital Clínic)
■ Àlex Soriano (Hospital Clínic)
Collaborators:
M.ª Teresa Anglada (Hospital Clínic)
Jordi Asunción (Hospital Clínic)
Misericordia Basora (Hospital Clínic)
Guillem Bori (Hospital Clínic)
Xavier Carné (Hospital Clínic)
Ana Carreño (Hospital Clínic)
Adela Faulí (Hospital Clínic)
Pablo Fernández de Retana (Hospital Clínic)
Jenaro A. Fernández-Valencia (Hospital Clínic)
Joan Xavier Fontdevila (Hospital Clínic)
Salvador Fuster (Hospital Clínic)
Xavier Gallart (Hospital Clínic)
Eloy M. García Díez
Ruben García Elvira
Sebastian Garcia Ramiro
Raquel García Tarriño
Our research group, which joined IDIBAPS in 2007,
aims to agglutinate and generate synergies between
professionals from different specialties working in
the area of the motor apparatus. This is an area
with growing social and technological demand but
with little incidence in the area of research of this
institution.
Many aspect of the knew knowledge relate to the musculoskeletal system: cellular, gene and drug therapy;
new materials and implants; robotics; state-of-the-art
surgical and anesthetic technology; and sophisticated
imaging techniques. The lack of clinical scientific evidence for much knew knowledge and the extraordinary volume of patients in our area are, with very few
resources, an important source of work that provides
010-039 AREA1.indd 30
Anna López Gutiérrez
Francisco Maculé (Hospital Clínic)
Montserrat Nuñez (Hospital Clínic)
Felipe Orient (Hospital Clínic)
Lluis Peidro (Hospital Clínic
Daniel Poggio (Hospital Clínic)
Dragos Popescu (Hospital Clínic)
Salvi Prat (Hospital Clínic)
Josep Riba (Hospital Clínic)
Moisés Rios (Hospital Clínic)
Xavier Sala (Hospital Clínic)
Isabel Sañudo (Hospital Clínic)
Sergi Sastre (Hospital Clínic)
Josep M. Segur (Hospital Clínic)
Santiago Suso (Hospital Clínic)
Xavier Tomás (Hospital Clínic)
Pere Torner (Hospital Clínic)
Antoni Trilla (Hospital Clínic)
Raquel Vilarrasa (Hospital Clínic)
Secretary:
Antònia Bayo (Hospital Clínic)
intellectual productivity. Working with humility but
thinking big, we believe, is the best strategy for achieving the objective of becoming a reference standard
group in our field.
1. Bone pathophysiology, disease variation with age,
evaluation of techniques for fixing fractures and
bone replacements.
2.Cartilage, degeneration and repair using tissue engineering.
3.Evaluation and design of new prosthetic implants.
4.Minimally invasive surgery with new technology
and instruments.
5.Infections of the motor system, their prophylaxis
and treatment.
21/10/09 17:07:41
15.Surgical treatment of facial lipoatrophy by the injection of autologous fat in patients with HIV infection.
Navigation and robotics applied to skeletal stents.
I.F.: 49,43
PublicaTions
Original Articles
1
3
4
5
6
7
8
010-039 AREA1.indd 31
9
10
11 12 13
14
15
16
Biologic Aggression and Response Mechanisms Area 1
2
Sierra JM, Rodriguez-Puig D, Soriano A, Mensa J, Piera C, Vila J. Accumulation of Tc-99m-ciprofloxacin in
Ortega M, Almela M, Soriano A, Marco F, Martinez JA,
Munoz A, Penarroja G, Mensa J. Bloodstream infections among human immunodeficiency virus-infected
adult patients: epidemiology and risk factors for mortality. EUR J CLIN MICROBIOL. 27:969-976. I.F.:2,31.
M, Marco F, Mensa J. Effect of antimicrobial therapy
on mortality in 377 episodes of Enterobacter spp.
bacteraemia. J ANTIMICROB CHEMOTH. 62:397-403.
I.F.:4,04.
Soriano A, Marco F, Martinez JA, Pisos E, Almela M,
Dimova VP, Alamo D, Ortega M, Lopez J, Mensa J.
Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant
Staphylococcus aureus bacteremia. CLIN INFECT DIS.
46:193-200. I.F.:6,75.
Vila J, Soriano A, Mensa J. Molecular basis of microbial adherence to prosthetic materials. Role of
biolayers in prosthesis-associated infection. ENFERM
INFEC MICR CL. 26:48-55. I.F.:1,10.
Soriano A, Bori G, Garcia-Ramiro S, Martinez-Pastor
JC, Miana T, Codina C, Macule F, Basora M, Martinez
JA, Riba J, Suso S, Mensa J. Timing of antibiotic prophylaxis for primary total knee arthroplasty performed
during ischemia. CLIN INFECT DIS. 46:1009-1014.
I.F.:6,75.
J, Lozano L, Mazzara R, Macule F, Basora M, Salazar
F. Effectiveness and safety of tranexamic acid administration during total knee arthroplasty. VOX SANG.
95:39-44. I.F.:2,59.
Sastre S, Suso S, Segur JM, Bori G, Carbonell JA,
Agusti E, Nunez M. Cryopreserved and frozen hyaline
cartilage imaged by environmental scanning electron
microscope. An experimental and prospective study. J
RHEUMATOL. 35:1639-1644. I.F.:3,15.
Gandia J, Galino J, Amaral OB, Soriano A, Lluis C,
Franco R, Ciruela F. Detection of higher-order G protein-coupled receptor oligomers by a combined BRETBiFC technique. FEBS LETT. 582:2979-2984. I.F.:3,26.
Conill C, Setoain X, Colomo L, Palacin A, CombaliaAleu A, Pomes J, Marruecos J, Vargas M, Maurel J.
Diagnostic efficacy of bone scintigraphy, magnetic resonance imaging, and positron emission tomography
in bone metastases of myxoid liposarcoma. J MAGN
RESON IMAGING. 27:625-628. I.F.:2,21.
Kumru H, Vidal J, Kofler M, Benito J, Garcia A, VallsSole J. Exaggerated auditory startle responses in patients with spinal cord injury. J NEUROL. 255:703-709.
I.F.:2,48.
Lozano LM, Segur JM, Macule F, Nunez M, Torner P,
Castillo F, Suso S. Intramedullary versus Extramedullary Tibial Cutting Guide in Severely Obese Patients
Undergoing Total Knee Replacement: A Randomized Study of 70 Patients with Body Mass Index > 35
kg/m(2). OBES SURG. 18:1599-1604. I.F.:2,85.
Aleu AC, Popescu D, Pomes J, Palacin A. Long-standing pain in a 25-year-old patient with a non-diagnosed cervical osteoblastoma: a case report. ARCH
ORTHOP TRAUM SU. 128:567-571. I.F.:0,91.
Raigosa M, Clavero JA, Benito-Ruiz J, Yoon T, Carreras A,
Ferreres A. Multislice Computed Tomography Angiography of the Fourth Dorsal Interosseous Space in Cadavers.
J HAND SURG-AM. 33A:1860-1867. I.F.:1,07.
Sanzana ES, Macule F, Suso S, Planell JA, Ginebra
MP, Navarro M. Of the in vivo behavior of calcium
phosphate cements and glasses as bone substitutes.
ACTA BIOMATER. 4:1924-1933. I.F.:3,11.
Nunez M, Nuñez S, Segur JM, Macule F, Sastre S.
Prevalence of knee osteoarthritis and analysis of pain,
rigidity, and functional incapacity. ORTHOPEDICS. 8:-.
I.F.:0,58.
6. Nervous system:
a) repair by tubulization of lesions of the peripheral
nervous system
b) e
xperimental reimplantation of paraganglial avulsed nerve roots.
7. Acute postoperative pain and chronic musculoskeletal pain.
8. Functional rehabilitation and prevalence of degenerative arthropathy.
9. Biology of autologous adipose tissue grafts.
10.Musculoskeletal tissue bank.
11.Diagnostic imaging, new technologies in diagnosis
and follow-up.
12.Collaboration on joint projects with UASP.
13.Acute-phase response in open fractures. Utility of
IL-6, PCR and CK in predicting results and correlation with the Gustilo classification.
14.Vascular anatomy of the upper limbs applied to reconstructive procedures.
31
21/10/09 17:07:45
17 Psychometric characteristics of the Spanish version of
instruments to measure neck pain disability. BMC MUSCULOSKEL DIS. 9:-. I.F.:1,32.
18 Raigosa M, Benito-Ruiz J, Fontdevila J, Ballesteros JR.
Waterproof camera case for intraoperative photographs. AESTHET PLAST SURG. 32:368-370. I.F.:0,56.
Reviews
Moll C, Hernandez MV, Canete JD, Gomez-Puerta JA,
Soriano A, Collado A, Sarimarti R. Ilium osteitis as the
main manifestation of the SAPHO syndrome: Response
to infliximab therapy and review of the literature. SEMIN ARTHRITIS RHEU. 37:299-306. I.F.:3,68.
Fores J. Eficacia del tratamiento con infiltraciones de ácido
hialurónico en las rizartrosis. Medición con tests sensoriales
y funcionales cuantitativos y tests subjetivos. Análisis de
concordancia. Grant: Sociedad Española de Cirugía Ortopédica y Traumatología. Duration: 30/11/2007-30/11/2009.
Fores J. Taller sobre el dolor per pacients i familiars
(Chronic pain workshop for patients and relatives). Grant:
Fundació La Marató de TV3, 72810. Duration: 22/01/200821/01/2011.
Thesis
Fores J. A controlled, randomized, comparison, blind evaluation of repair of upper extremity nerve lesions in man
using an implanted collagen nerve guide conduit. Grant:
Integra LifeSciences Corporation, PNG-EU-9901. Duration:
01/03/2001-01/03/2009.
Fores J. Tratamiento fármaco-celular de las lesiones por
avulsión de las raíces nerviosas. Grant: Fundació de la So-
Serra JM, Martinez-Chamorro E. Atrofia de la grasa facial
en los pacientes VIH+. Tratamiento mediante inyección de
tejido adiposo antólogo. Doctorand: Joan Fontdevila Font.
Universitat de Barcelona.
Patents
Jordi Asunción. Trefina para la extracción de un injerto óseo
y para la colocación de dicho injerto.
1
cietat Española de Cirurgia Ortopèdic y Traumatologia. Duration: 20/09/2007-30/09/2009.
32
010-039 AREA1.indd 32
21/10/09 17:07:54
Immunogenetics in the Autoinflammatory Response
Team members
Team Leader:
■ Jordi Yagüe (Hospital Clínic)
Tel.: 93 227 54 00 (Ext: 2155)
Fax: 93 451 80 38
Immunogenetics in the
autoinflammatory response
IDIBAPS Members:
■ Juan Ignacio Aróstegui (Hospital Clínic)
■ Manel Juan (Hospital Clínic)
Collaborators:
Laura Carretero (IDIBAPS)
Mariona Pascal (Hospital Clínic)
In the field of autoinflammatory diseases
To promote basic, clinical and translational research
on the physiopathics of autoinflammatory diseases
as a model for a deeper understanding of the regulation of the normal inflammatory response, its dysfunctions and their repercussion on the immune response.
In the field of autoinflammatory diseases
1. Determination of the genetic and molecular bases
of the autoinflammatory response.
2. Characterization of inflammasome regulator mechanisms and their dysfunction.
3. Characterization of the specific transcriptional profiles of autoinflammatory diseases.
4.Isolation of new genes responsible for hereditary
autoinflammatory disease and identification of genetic susceptibility factors for the development of
polygenic autoinflammatory processes.
5.Definition of new therapeutic targets for the
treatment of autoinflammatory diseases.
In the field of the immune response
To determine which components of the normal and
pathologic inflammatory response are essential to
modulating the phenomena of specific recognition of
the immune response.
PublicaTions
Original Articles
1
Huerva V, Martin M, Canto LM, Yague J. Absence
of cornea verticillata in hemizygotes of a novel
mutation in Fabry disease. CORNEA. 27:970-972.
I.F.:1,78.
2 Gunduz Z, Dursun I, Arostegui JI, Yague J, Dusunsel
R, Poyrazoglu HM, Gurgoze MK, Yikilmaz A. A
fatal turkish case of CINCA-NOMID syndrome due
to the novel Val-351-Leu CIAS1 gene mutation.
RHEUMATOL INT. 28:379-383. I.F.:1,27.
3 Granell M, Urbano-Ispizua A, Pons A, Arostegui JI,
Gel B, Navarro A, Jansa S, Artells R, Gaya A, Talarn
010-039 AREA1.indd 33
I.F.: 48,44
C, Fernandez-Avilles F, Martinez C, Rovira M, Carreras
E, Rozman C, Juan M, Yague J, Montserrat E, Monzo
M. Common variants in NLRP2 and NLRP3 genes are
strong prognostic factors for the outcome of HLAidentical sibling allogeneic stem cell transplantation.
BLOOD. 112:4337-4342. I.F.:10,90.
4 Puigdomenech I, Massanella M, Izquierdo-Useros
N, Ruiz-Hernandez R, Curriu M, Bofill M, MartinezPicado J, Juan M, Clotet B, Blanco J. HIV transfer
between CD4 T cells does not require LFA-I binding
to ICAM-I and is governed by the interaction of HIV
envelope glycoprotein with CD4. RETROVIROLOGY.
5:-. I.F.:4,04.
33
21/10/09 17:08:00
5
Yague J. Análisis de las bases moleculares responsables de
las enfermedades autoinflamatorias sistémicas no filiadas: desarrollo y validación de pruebas diagnósticas e identificación
de potenciales dianas para terapias biológicas inmunomoduladoras. Grant: Ministerio Sanidad y Consumo, PI060241. Duration: 18/10/2006-30/12/2009.
Juan M. Variantes de CCL4 (MIP-1beta) y linfocitos T intratiroideos: modelo de la implicación de las quimiocinas en
el reconocimiento de los linfocitos T CD4+ autorreactivos.
Grant: Instituto de Salud Carlos III, PI070329. Duration:
23/01/2008-30/12/2010.
Reviews
1
Arstegui JI, Yague J. Hereditary systemic autoinflammatory diseases. Part II: cryopyrin-associated periodic
syndromes, pediatric systemic granulomatosis and PAPA
syndrome. MED CLIN-BARCELONA. 130:429-438. I.F.:1,34.
Immunogenetics in the
autoinflammatory response
6
Colobran R, Comas D, Faner R, Pedrosa E, Anglada R,
Pujol-Borrell R, Bertranpetit J, Juan M. Population structure in copy number variation and SNPs in the CCL4L
chemokine gene. GENES IMMUN. 9:279-288. I.F.:4,09.
VonBernuth H, Picard C, Jin ZB, Pankla R, Xiao H, Ku CL,
Chrabieh M, BenMustapha I, Ghandil P, Camcioglu Y,
Vasconcelos J, Sirvent N, Guedes M, Vitor AB, HerreroMata MJ, Arostegui JI, Rodrigo C, Alsina L, Ruiz-Ortiz E,
Juan M, Fortuny C, Yague J, Anton J, Pascal M, Chang
HH, Janniere L, Rose Y, Garty BZ, Chapel H, Issekutz A,
Marodi L, Rodriguez-Gallego C, Banchereau J, Abel L, Li
XX, Chaussabel D, Puel A, Casanova JL. Pyogenic bacterial infections in humans with MyD88 deficiency. SCIENCE. 321:691-696. I.F.:26,37.
34
010-039 AREA1.indd 34
21/10/09 17:08:09
Research and Development in Microbiology and Molecular Clinical Parasitology
Team members
Team Leader:
■ Jordi Vila Estapé (Hospital Clínic)
Tel.: 93 227 55 22
Collaborators:
Manel Almela Prades (Hospital Clínic)
Jordi Bosch Mestres (Hospital Clínic)
Jorge Puig de la Bellacasa Brugada (Hospital Clínic)
Jordi Más Capó (Hospital Clínic)
M. Eugenia Valls Lolla (Hospital Clínic)
The general research objectives of the microbiology
department of Hospital Clínic include the following 3
areas of microbiology:
1. New diagnostic techniques
2. Microbial pathogenesis
3. Antimicrobial resistance
The principal objective is to translate the results obtained in research to the daily clinical practice of the microbiology department. However, the development of
basic research to explain problems or situation that regularly occur in clinical practice is also very common.
2. New microbiology techniques in etiologic diagnosis
of pneumonia.
3. Research on the relationship between antibiotic resistance and virulence.
4. Molecular bases of antibiotic resistance in multiresistant bacteria.
5. Design of new antibacterial agents.
The lines of research aimed at achieving the above objectives are:
1. Mechanisms of resistance of Mycobacterium tuberculosis.
I.F.: 118,74
PublicaTions
Doctoral Students:
Cristina Pitarch (Hospital Clínic)
Griselda Tudó Vilanova (Hospital Clínic)
Ignasi Roca (Hospital Clínic)
Anna Fábrega Santamaria (Hospital Clínic)
Paula Andrea Espinal (Hospital Clínic)
Emma Rey Jurado (Hospital Clínic)
Sonia Borell Farnov (Hospital Clínic)
Andrés Antón (Hospital Clínic)
Xavier Vila Farrés (Hospital Clínic)
Research and Development in Microbiology
and Molecular Clinical Parasitology
IDIBAPS Members:
■ Julià Gonzàlez Martín (Hospital Clínic)
■ M. Teresa Jiménez de Anta (Hospital Clínic)
■ Francesc Marco Reverté (Hospital Clínic)
■ M. Angeles Marcos Maeso (Hospital Clínic)
■ Tomás Pumarola Suñe (Hospital Clínic)
■ Sara Soto González (Hospital Clínic)
35
Original Articles
1
2
DelSaz SV, Sued O, Falco V, Aguero F, Crespo M, Pumarola T, Curran A, Gatell JM, Pahissa A, Miro JM, Ribera
E. Acute meningoencephalitis due to human immuno-
010-039 AREA1.indd 35
3
deficiency virus type 1 infection in 13 patients: clinical
description and follow-up. J NEUROVIROL. 14:474-479.
I.F.:1,94.
Dambrava PG, Torres A, Valles X, Mensa J, Marcos
23/10/09 10:36:57
4
5
6
36
7
8
9
10 11 12 13 14 15 16 010-039 AREA1.indd 36
Ortega M, Almela M, Soriano A, Marco F, Martinez JA,
Munoz A, Penarroja G, Mensa J. Bloodstream infections
among human immunodeficiency virus-infected adult patients: epidemiology and risk factors for mortality. EUR J
CLIN MICROBIOL. 27:969-976. I.F.:2,31.
Soto SM, Bosch J, JimenezDeAnta MT, Vila J. Comparative study of virulence traits of Escherichia coli clinical
isolates causing early and late neonatal sepsis. J CLIN
MICROBIOL. 46:1123-1125. I.F.:3,71.
Marco F, DeLaMaria CG, Armero Y, Amat E, Soy D, Moreno A, DelRio A, Almela M, Mestres CA, Gatell JM,
JimenezDeAnta MT, Miro JM. Daptomycin is effective in
treatment of experimental endocarditis due to methicillinresistant and glycopeptide-intermediate Staphylococcus
aureus. ANTIMICROB AGENTS CH. 52:2538-2543. I.F.:4,39.
Marcos M, Inurrieta A, Soriano A, Martinez JA, Almela M,
Marco F, Mensa J. Effect of antimicrobial therapy on mortality in 377 episodes of Enterobacter spp. bacteraemia. J
ANTIMICROB CHEMOTH. 62:397-403. I.F.:4,04.
Chu VH, Woods CW, Miro JM, Hoen B, Cabell CH, Pappas
PA, Federspiel J, Athan E, Stryjewski ME, Nacinovich F,
Marco F, Levine DP, Elliott TS, Fortes CQ, Tornos P, Gordon
DL, Utili R, Delahaye F, Corey GR, Fowler VG. Emergence
of coagulase-negative staphylococci as a cause of native
valve endocarditis. CLIN INFECT DIS. 46:232-242. I.F.:6,75.
Petti CA, Simmon KE, Miro JM, Hoen B, Marco F, Chu VH,
Athan E, Bukovski S, Bouza E, Bradley S, Fowler VG, Giannitsioti E, Gordon D, Reinbott P, Korman T, Lang S, GarciaDe-La-Maria C, Raglio A, Morris AJ, Plesiat P, Ryan S,
Doco-Lecompte T, Tripodi F, Utili R, Wray D, Federspiel JJ,
Boisson K, Reller LB, Murdoch DR, Woods CW. Genotypic
diversity of coagulase-negative staphylococci causing
endocarditis: a global perspective. J CLIN MICROBIOL.
46:1780-1784. I.F.:3,71.
Anton A, Cervera C, Pumarola T, Moreno A, Benito N, Linares L, Esteva C, Cofan F, JimenezDeAnta MT, Marcos MA.
Human herpesvirus 7 primary infection in kidney transplant
recipients. TRANSPLANTATION. 85:298-302. I.F.:3,64.
Perello R, Moreno A, Camps M, Cervera C, Linares L,
Pumarola T, Marcos MA. Human immunodeficiency virusinfected patients with community-acquired pneumonia:
implication of respiratory viruses. ENFERM INFEC MICR
CL. 26:85-87. I.F.:1,10.
Crespo G, Cervera C, Michelena J, Marco F, Moreno A, Navasa M. Immune Reconstitution Syndrome After Voriconazole
Treatment for Cryptococcal Meningitis in a Liver Transplant
Recipient. LIVER TRANSPLANT. 14:1671-1674. I.F.:3,75.
Soriano A, Marco F, Martinez JA, Pisos E, Almela M, Dimova VP, Alamo D, Ortega M, Lopez J, Mensa J. Influence
of vancomycin minimum inhibitory concentration on the
treatment of methicillin-resistant Staphylococcus aureus
bacteremia. CLIN INFECT DIS. 46:193-200. I.F.:6,75.
Menendez R, Cavalcanti M, Reyes S, Mensa J, Martinez
R, Marcos MA, Filella X, Niederman M, Torres A. Markers
of treatment failure in hospitalised community acquired
pneumonia. THORAX. 63:447-452. I.F.:6,23.
Vila J, Soriano A, Mensa J. Molecular basis of microbial
adherence to prosthetic materials. Role of biolayers in
prosthesis-associated infection. ENFERM INFEC MICR CL.
26:48-55. I.F.:1,10.
Simmon KE, Hall L, Woods CW, Marco F, Miro JM, Cabell
C, Hoen B, Marin M, Utili R, Giannitsioti E, Doco-Lecompte
17 18 19 20 21 22 23 24 25 26 T, Bradley S, Mirrett S, Tambic A, Ryan S, Gordon D, Jones P, Korman T, Wray D, Reller LB, Tripodi MF, Plesiat P,
Morris AJ, Lang S, Murdoch DR, Petti CA. Phylogenetic
analysis of viridans group streptococci causing endocarditis. J CLIN MICROBIOL. 46:3087-3090. I.F.:3,71.
Alvarez-Martinez MJ, Moreno A, Miro JM, Valls ME, Rivas
PV, DeLazzari E, Sued O, Benito N, Domingo P, Ribera E,
Santin M, Sirera G, Segura F, Vidal F, Rodriguez F, Riera M,
Cordero ME, Arribas JR, JimenezDeAnta MT, Gatell JM,
Wilson PE, Meshnick SRM. Pneumocystis jirovecii pneumonia in Spanish HIV-infected patients in the combined
antiretroviral therapy era: prevalence of dihydropteroate
synthase mutations and prognostic factors of mortality.
DIAGN MICR INFEC DIS. 62:34-43. I.F.:2,45.
Linares L, Cervera C, Cofan F, Lizaso D, Marco F, Ricart
MJ, Esforzado N, Oppenheimer F, Campistol JM, Moreno
A. Risk factors for infection with extended-spectrum and
AmpC beta-lactamase-producing gram-negative rods in
renal transplantation. AM J TRANSPLANT. 8:1000-1005.
I.F.:6,42.
Serra MC, Cervera C, Pumarola T, Moreno A, Perello R,
Torres A, JimenezDeAnta MT, Marcos MA. Virological diagnosis in community-acquired pneumonia in immunocompromised patients. EUR RESPIR J. 31:618-624. I.F.:5,35.
Domingo P, Suarez-Lozano I, Torres F, Teira R, Lopez-Aldeguer J, Vidal F, Munoz A, Viciana P, Lozano F, Vergara A,
Roca B, Alcalde MLG, Cosin J, Terron A, Galindo MJ, Geijo
P, Ribera E, Gonzalez J, Sanchez T, Lacalle JR, Garrido M.
First-line antiretroviral therapy with efavirenz or lopinavir/
ritonavir plus two nucleoside analogues: the SUSKA study,
a non-randomized comparison from the VACH cohort. J
ANTIMICROB CHEMOTH. 61:1348-1358. I.F.:4,04.
Rodriguez-Bano J, Marti S, Soto S, Fernandez-Cuenca F,
Cisneros JM, Pachon J, Pascual A, Martinez-Martinez L,
Mcqueary C, Actis LA, Vila J. Biofilm formation in Acinetobacter baumannii: associated features and clinical implications. CLIN MICROBIOL INFEC. 14:276-278. I.F.:2,98.
Marti S, Sanchez-Cespedes J, Blasco MD, Ruiz M, Espinal
P, Alba V, Fernandez-Cuenca F, Pascual A, Vila J. Characterization of the carbapenem-hydrolyzing oxacillinase
Oxa-58 in an Acinetobacter genospecies 3 clinical isolate.
Marti S, Sanchez-Cespedes J, Blasco MD, Espinal P, Ruiz
M, Alba V, Vila J. Characterization of the carbapenemhydrolyzing oxacillinase OXA-58 in an Acinetobacter
phenon 6/ct13TU clinical isolate. DIAGN MICR INFEC DIS.
61:468-470. I.F.:2,45.
Fernandez-Cuenca F, Egea P, Lopez-Cerero L, Alba PDD,
Vila J, Pascual A. Comparison of 3 methods for determining sensitivity to imipenem and meropenem in Acinetobacter baumannii with a carbapenem-heteroresistant
phenotype. ENFERM INFEC MICR CL. 26:485-488. I.F.:1,10.
Ruiz J, Mensa L, Pons MJ, Vila J, Gascon J. Development
of Escherichia coli rifaximin-resistant mutants: frequency of selection and stability. J ANTIMICROB CHEMOTH.
61:1016-1019. I.F.:4,04.
Beceiro A, Fernandez-Cuenca F, Ribera A, MartinezMartinez L, Pascual A, Vila J, Rodriguez-Bano J, Cisneros
JM, Pachon J, Bou G. False extended-spectrum betalactamase detection in Acinetobacter spp. due to intrinsic
susceptibility to clavulanic acid. J ANTIMICROB CHEMOTH. 61:301-308. I.F.:4,04.
21/10/09 17:08:27
27 Tomas M, Vazquez E, Fernandez-Fernandez JM, Subiranaa I,
Plata C, Heras M, Vila J, Marrugat J, Valverde MA, Senti M.
Genetic variation in the KCNMA1 potassium channel alpha
subunit as risk factor for severe essential hypertension and
myocardial infarction. J HYPERTENS. 26:2147-2153. I.F.:4,36.
28 Camps M, Vilella A, Marcos MA, Letang E, Muñoz J,
Salvado E, Gonzalez A, Gascon J, JimenezDeAnta MT,
Pumarola T. Incidence of respiratory viruses among travelers with a febrile syndrome returning from tropical and
subtropical areas. J MED VIROL. 80:711-715. I.F.:2,83.
29 Madurga S, Sanchez-Cespedes J, Belda I, Vila J, Giralt E.
Mechanism of binding of fluoroquinolones to the quinolone resistance-determining region of DNA gyrase: Towards
an understanding of the molecular basis of quinolone
resistance. CHEMBIOCHEM. 9:2081-2086. I.F.:3,45.
30 Mendez-Arancibia E, Vargas M, Soto S, Ruiz J, Kahigwa E,
Schellenberg D, Urassa H, Gascon J, Vila J. Prevalence of
different virulence factors and biofihn production in enteroaggregative Escherichia coli isolates causing diarrhea
in children in Ifakara (Tanzania). AM J TROP MED HYG.
78:985-989. I.F.:2,18.
31 Camps M, Ricart S, Dimova V, Rovira N, Munoz-Almagro
C, Garcia JJ, Pons-Odena M, Marcos MA, Pumarola T.
Prevalence of human metapneumovirus among hospitalized children younger than 1 year in Catalonia, Spain. J
MED VIROL. 80:1452-1460. I.F.:2,83.
32 Mensa L, Marco F, Vila J, Gascon J, Ruiz J. Quinolone resistance among Shigella spp. isolated from travellers returning
from India. CLIN MICROBIOL INFEC. 14:279-281. I.F.:2,98.
Vila J. Bases moleculars de la resistència bacteriana als antibiòtics. Disseny de noves estratègies terapèutiques. Grant:
Comissionat per a Universitats i Recerca, 2005SGR00444. Duration: 19/10/2005-31/12/2008.
Reviews
Gonzalez J. Eficacia in vitro del tratamiento antibiótico frente
a cepas resistentes de Mycobacterium tuberculosis. Estudio
de la capacidad infectiva sobre macrófagos y evaluación de la
actividad sinérgica de diversas combinaciones de fármacos.
01/01/2006-30/12/2008.
3
4
Multicentrics
1
Conejo MC, Mata C, Navarro F, Pascual A, Marco F. Detection and reporting beta-lactam resistance phenotypes in
Escherichia coli and Klebsiella pneumoniae: a multicenter proficiency study in Spain. DIAGN MICR INFEC DIS.
62:317-325. I.F.:2,45.
Jimenez De Anta M. Investigar la relación entre la resistencia a
quinolonas y virulencia en aislamientos clínicos de Escherichia
coli uropatógenos, Salmonella spp. y Yersinia enterocolítica.
01/01/2006-30/12/2008.
Marco F. Evaluación de las pautas actuales y de nuevos antibióticos en el tratamiento de la endocarditis experimental en
conejos por Staphylococcus epidermidis resistentes a la meticilina (SERM) o con sensibilidad disminuida a los glucopéptidos (GISE). Grant: Ministerio Sanidad y Consumo, PI050170.
Duration: 01/01/2006-30/12/2008.
Marcos M. Diagnóstico de la neumonia por virus respiratorios,
Chlamydophila pneumoniae y Mycoplasma pneumoniae en
el paciente inmunodeprimido mediante PCR a tiempo real.
18/10/2006-30/12/2009.
Vila J. Análisis proteomico para identificar biomarcadores de
infección en los líquidos articular y pleural. Grant: Ministerio
Sanidad y Consumo, PI070423. Duration: 26/11/200730/12/2010.
Vila J. REIPI - Red Española de Investigación en patología Infecciosa. Grant: Ministerio Sanidad y Consumo,
RD06/0008/0008. Duration: 01/01/2007-31/12/2010.
Thesis
2
Martin-Davila P, Forun J, Lopez-Velez R, Norman F,
DeOca MM, Zamarron P, Gonzalez MI, Moreno A, Pumarola T, Garrido G, Candela A, Moreno S. Transmission of
tropical and geographically restricted infections during
solid-organ transplantation. CLIN MICROBIOL REV.
21:60-+. I.F.:15,76.
Vila J, Martinez JL. Clinical Impact of the Over-Expression
of Efflux Pump in Nonfermentative Gram-Negative Bacilli,
Development of Efflux Pump Inhibitors. CURR DRUG TARGETS. 9:797-807. I.F.:4,04.
Fabrega A, Sanchez-Cespedes J, Soto S, Vila J. Quinolone resistance in the food chain. INT J ANTIMICROB AG.
31:307-315. I.F.:2,34.
Vila J, Pachon J. Therapeutic options for Acinetobacter
baumannii infections. EXPERT OPIN PHARMACO. 9:587599. I.F.:1,70.
Vila J. Caracterización, inducción e inhibición de sistemas
de expulsión activa en Escherichia coli y Acinetobacter
baumannii y su relación con la producción de biofilm.
01/01/2006-30/12/2008.
1
Pumarola T. Estudio de la prevalencia la clínica y los factores
epidemiológicos asociados a la infección por el metapneumovirus humano (MPVh) en población infantil y adulta..
01/01/2006-30/12/2008.
37
Vila J. Implicación de diversos mecanismos de resistencia a
quinolonas en bacilos Gram-negativos: diseño de una nueva
fluoroquinolona. Doctorand: Javier Sánchez-Céspedes.
Vila J. IP - Mastering Hospital Antimicrobial Resistance and
its spread into the Community. Grant: European Commision,
2005-037941. Duration: 01/02/2007-31/01/2012.
010-039 AREA1.indd 37
Vila J. Molecular bases of antimicrobial resistance in Acinetobacter spp.clinical isolates. Doctorand: Sara Martí Martí.
21/10/09 17:08:31
Structural and Biologic Mass Spectrometry
Team members
Team Leader:
■ Daniel Closa (IIBB-CSIC)
Tel.: 93 363 83 43
38
IDIBAPS Members:
■ Joaquín Abián (IIBB-CSIC-UAB)
■ Oriol Bulbena (IIBB-CSIC)
■ Emili Gelpí (IIBB-CSIC)
■ Pere Puig (Faculty of Medicine)
Collaborators:
E. Folch (RC)
F. Pí (IIBB-CSIC)
A. Salas (RC)
A. Serrano (IIBB-CSIC)
N. Franco (CIBEREHD)
R. Rodriguez de la Flor (IIBB-CSIC)
Doctoral Students:
M. Ferrés (Becaria IIBB-CSIC)
Pedro Hortúa (Hospital Clínic)
Marisol Veny (Becaria FPI, IIBB-CSIC)
B. Alguero (TS-WHO)
V. Casas (TS- I3P)
I. Forné Ferrer (UB)
M. Gay (TS)
D. Ovelleiro (Proteored)
M. Trigo (TS-I3P)
S. Gea (TS)
M. Gorga (Fundació Clínic)
C. Lebrero (GENAME)
M. Gay (TS)
Molecular and cellular
bases of inflammatioN
Study of the inflammatory response in general.
Structural and biologic mass spectrometry
Development of techniques for resolving problems in
proteomics and in the analysis of biomolecules in general. Application to the study of antigenic presentation
in autoimmune diseases and research on therapeutic
targets and disease markers.
010-039 AREA1.indd 38
Technicians:
L. Ignacio Sanchez
Gemma Gay
M. Carrascal (IIBB-CSIC)
Mª T. Del Hierro (Empresa)
Marisa Garcia (Proteored)
Judith (Proteored)
V. Sirenko (IDIBAPS)
F. Vilà (CIBEREHD)
A. Navarrete (IIBB-CSIC)
Principal Lines
of Research
Molecular and cellular
bases of inflammation
1. Oxidative stress and its relation to diet.
2.Mechanisms implicated in the development of systemic inflammatory processes.
3.New therapies for idiopathic pulmonary fibrosis.
4. Study of the protein associated with pancreatitis.
5.Mechanisms of the protective effect of ischemic preconditioning.
21/10/09 17:08:46
Structural and biologic mass spectrometry
1. Toxic oil syndrome.
2. Phosphoproteomics of human T-lymphocyte.
3. Diagnostic and prognostic markers in cancer and
other diseases.
4. External technical-scientific services. Proteomics services and coordination of the Proteored network.
I.F.: 40,25
Original Articles
1
2
3
5
6
8
9
Gutierrez PT, Folch-Puy E, Bulbena O, Closa D. Oxidised lipids present in ascitic fluid interfere with the
regulation of the macrophages during acute pancreatitis, promoting an exacerbation of the inflammatory
response. GUT. 57:642-648. I.F.:10,02.
Franco-Pons N, Marsillach J, Joven J, Camps J, Closa
D. Serum paraoxonase undergoes inhibition and
proteolysis during experimental acute pancreatitis.
J GASTROINTEST SURG. 12:891-899. I.F.:2,27.
Muixi L, Carrascal M, Alvarez I, Daura X, Marti M,
Armengol MP, Pinilla C, Abian J, Pujol-Borrell R, Jaraquemada D. Thyroglobulin peptides associate in
vivo to HLA-DR in autoimmune thyroid glands. J IMMUNOL. 181:795-807. I.F.:6,07.
Closa D. Regulació de la inflamació aguda i crònica. Grant:
Comissionat per a Universitats i Recerca, 2005SGR00797.
Duration: 19/10/2005-31/12/2008.
Roselló J. Estudio de la proteína asociada a la pancreatitis
(PAP/REG) como agente inmunomodulador y anti-inflamatorio. Grant: Ministerio Sanidad y Consumo, PIO50219.
Duration: 23/12/2005-31/12/2008.
Roselló J. Análisis proteómico de marcadores de enfermedad en suero humano. Grant: Ministerio Sanidad y Consumo - Iniciativa Ingenio 2000/CENIT, PI060679. Duration:
31/03/2005-31/03/2008.
4
Navaza AP, Encinar JR, Carrascal M, Abian J, SanzMedel A. Absolute and site-specific quantification of
protein phosphorylation using integrated elemental
and molecular mass spectrometry: Its potential to assess phosphopeptide enrichment procedures. ANAL
CHEM. 80:1777-1787. I.F.:5,29.
Guillen J, Soriano S, Demestre M, Falques A, Palanques A, Puig P. Alteration of bottom roughness by
benthic organisms in a sandy coastal environment.
CONT SHELF RES. 28:2382-2392. I.F.:1,68.
Casanovas A, Carrascal M, Abian J, Lopez-Tejero MD,
Llobera M. Application of proteomic tools to detect
the nonspecificity of a polyclonal antibody against
lipoprotein lipase. J PROTEOME RES. 7:4173-4177.
I.F.:5,68.
Carbo C, Arderiu G, Escolar G, Fuste B, Cases A,
Carrascal M, Abian J, Diaz-Ricart M. Differential expression of proteins from cultured endothelial cells
exposed to uremic versus normal serum. AM J KIDNEY DIS. 51:603-612. I.F.:3,98.
Gelpi E. From large analogical instruments to small
digital black boxes: 40 years of progress in mass spectrometry and its role in proteomics. Part I 1965-1984. J
MASS SPECTROM. 43:419-435. I.F.:3,06.
Almendros I, Gutierrez PT, Closa D, Navajas D, Farre
R. One-lung overventilation does not induce inflammation in the normally ventilated contralateral lung.
RESP PHYSIOL NEUROBI. 162:100-102. I.F.:2,20.
7
PublicaTions
39
010-039 AREA1.indd 39
21/10/09 17:08:51
040-071 AREA2.indd 40
21/10/09 16:56:31
Area 2
Biopathology and Respiratory,
Cardiovascular and Renal Bioengineering
Atherosclerosis and Coronary Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 42
Arrhythmias and Cardiac Stimulation . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 46
Nephro-Urologic Diseases and Kidney Transplant . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 50
Hypertension, Lipids and Cardiovascular Risk . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 54
Respiratory Biophysics and Bioengineering . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 57
Applied Research on Infectious Respiratory Diseases,
Critical Patients and Lung Cancer . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 60
Pathophysiologic Mechanisms of Respiratory Diseases . . . . . . . . . . . . . . . . . . . . . . . . . 64
Clinical and Experimental Respiratory Immunoallergy (IRCE) . . . . . . . . . . . . . . . . . . 68
Image: Alveoli in the lung
040-071 AREA2.indd 41
21/10/09 16:56:35
Atherosclerosis and Coronary Disease
Team Members
Area 2 and Renal Bioengineering
Atherosclerosis and coronary disease
Team Leader:
■ Magda Heras Fortuny
(Hospital Clínic)
Tel.: 93 227 93 05
Fax: 93 451 41 48
42
IDIBAPS Members:
■ Amadeu Betriu (Hospital Clínic)
■ Xavier Bosch (Hospital Clínic)
■ Ana Paula Dantas (IDIBAPS)
■ Carles Paré (Hospital Clínic)
■ Félix Pérez Villa (Hospital Clínic)
■ José Luis Pomar (Hospital Clínic)
■ Montserrat Rigol (IDIBAPS)
■ Eulàlia Roig (Hospital Clínic)
■ Mercè Roqué (Hospital Clínic)
Collaborators:
Montserrat Batlle (IDIBAPS)
Mònica Masotti (Hospital Clínic)
África Muxí (Hospital Clínic)
Núria Solanes (FCRB)
José Ortiz Pérez (Hospital Clínic)
Alessandro Sionis (Hospital Clínic)
1. Pathophysiology and prognosis of patients with
acute coronary syndromes
a. Stratification of risk of patients with chest pain
and negative troponins. Evaluation and validation of a clinical index allows a better diagnosis
of these patients and stratification of their risk.
b. Evaluation of the diagnostic and prognostic value of different inflammation and hemodynamic
stress markers. Performance of a randomized
prospective clinical trial.
2. Pathophysiology of heart failure. Study of its molecular and cellular bases.
3. Mechanisms of control of post-lesion vascular intimal hyperplasia and regulation of vascular tone:
a. Pig model with transplant of femoral arteries
b. Vasculopathy model of graft by by means of aorta transplant in rats
c. Model of vascular lesion in p27 and p21 Knockout
mouse
d. Model of femoral artery lesion in BPH (spontaneously hypertensive) mouse
4. Post-infarct myocardial regeneration: Study of the
differentiation mechanism of pluripotent stem cells
in myocardial regeneration in a pig model.
5. Determination of the mechanisms implicated in the
regulation of the nitric oxide and superoxide anion
040-071 AREA2.indd 42
Technicians:
Laura Novensà (IDIBAPS)
Mireia Nicolás (IDIBAPS)
Nadia Castillo (IDIBAPS)
Nurses:
Teresa Martorell (FCRB)
Mª Jesús Alcocer (IDIBAPS)
Secretary:
Montserrat Vázquez González (FCRB)
Mª Angeles Alvarez (Hospital Clínic)
system via steroidal receptors and its role in regulating the development of cardiovascular diseases
such as atherosclerosis, hypertension, diabetes and
metabolic syndrome.
1. Pathophysiology and prognosis of acute coronary
syndrome with and without T-segment elevation.
Role of vascular inflammation and thrombosis mechanisms in its etiopathogenesis in patients with
abnormal glucose metabolism.
2. MASCARA register (Management of Acute Coronary Syndrome. Updated Register)
3.Stratification of risk of patients with chest pain, with
no change in the electrocardiogram and negative
troponins.
4. Study of the impact of gender differences in ischemic cardiopathy. Evaluation of the characteristics of
cardiovascular disease in women and the different
factors that affect its outcome.
5. Vascular biology. Study of the mechanisms of formation of intimal hyperplasia following revascularization procedures. Within this line of research,
we have different projects in which we use different
models of vascular lesion, in both large animals,
such as pigs, and small animals, such as rats and
21/10/09 16:56:39
PublicaTions
1
2
3
4
5
Tomas M, Vazquez E, Fernandez-Fernandez JM, Subiranaa I, Plata C, Heras M, Vila J, Marrugat J, Valverde
MA, Senti M. Genetic variation in the KCNMA1 potassium channel alpha subunit as risk factor for severe
essential hypertension and myocardial infarction. J
HYPERTENS. 26:2147-2153. I.F.:4,36.
Delgado V, Sitges M, Vidal B, Silva E, Azqueta M, Tolosana JM, Mont L, Pare C, Brugada J. Assessment of left
ventricular dyssynchrony by real-time three-dimensional echocardiography. REV ESP CARDIOL. 61:825-834.
I.F.:2,21.
Egea CJ, Azpuru F, Pinto JA, Ayuela JM, Ballester E,
Zamarron C, Sojo A, Montserrat JM, Barbe F, Angel
M, Gomez A, Rubio R, Loobo JL, Duran-Cantolla J,
Zorrila V, Nunez R, Cortes J, Jimenez A, Cifrian J,
Ortega M, Carpizo R, Sanchez A, Teran J, Iglesias L,
Fernandez C, Alonso ML, Cordero J, Roig E, Perez F,
Muxi A, Gude F, Amaro A, Calvo U, Masa JF, Utrabo I,
Porras Y, Lanchas I, Sanchez E. Cardiac function after
CPAP therapy in patients with chronic heart failure
and sleep apnea: A multicenter study. SLEEP MED.
9:660-666. I.F.:2,80.
Betriu A. Clinical implications of the results of recent
atherothrombotic trials on patient management. EUR
HEART J SUPPL. 10:30-32. I.F.:1,62.
Sanchis J, Bosch X, Bodi V, Bellera N, Nunez J, Benito
B, Ordonez J, Consuegra L, Heras M, Llacer A. Combination of clinical risk profile, early exercise testing and
circulating biomarkers for evaluation of patients with
040-071 AREA2.indd 43
Trichrome stain for mouse femoral artery elastic fibers apoE KO.
I.F.: 111,39
acute chest pain without ST-segment deviation or troponin elevation. HEART. 94:311-315. I.F.:4,14.
6 Gomez-Caro A, Martinez E, Rodriguez A, Sanchez D,
Martorell J, Gimferrer JM, Haverich A, Harringer W, Pomar JL, Macchiarini P. Cryopreserved Arterial Allograft
Reconstruction After Excision of Thoracic Malignancies.
ANN THORAC SURG. 86:1753-1761. I.F.:2,02.
7 Rigol M, Solanes N, Sionis A, Galvez C, Martorell J,
Rojo I, Brunet M, Ramirez J, Roque M, Roig E, PerezVilla F, Barquin L, Pomar JL, Sanz G, Heras M. Effects
of cyclosporine, tacrolimus and sirolimus on vascular
changes relate to immune response. J HEART LUNG
TRANSPL. 27:416-422. I.F.:3,09.
8 Ellis SG, Tendera M, DeBelder MA, VanBoven AJ, Widimsky P, Janssens L, Andersen HR, Betriu A, Savonitto
S, Adamus J, Peruga JZ, Kosmider M, Katz O, Neunteufl T, Jorgova J, Dorobantu M, Grinfeld L, Armstrong P,
Brodie BR, Herrmann HC, Montalescot G, Neumann FJ,
Effron MB, Barnathan ES, Topol EJ. Facilitated PCI in
patients with ST-elevation myocardial infarction. NEW
ENGL J MED. 358:2205-2217. I.F.:52,59.
9 Delgado V, Vidal B, Sitges M, Tamborero D, Mont L,
Berruezo A, Azqueta M, Pare C, Brugada J. Fate of left
atrial function as determined by real-time three-dimensional echocardiography study after radiofrequency
catheter ablation for the treatment of atrial fibrillation.
AM J CARDIOL. 101:1285-1290. I.F.:3,60.
10 Rigol M, Solanes N, Roque M, Farre J, Batle M, Roura
S, Bellera N, Prat-Vidal C, Sionis A, Ramirez J, Sitges
M, Sanz G, Bayes-Genis A, Heras M. Hemosiderin Deposits Confounds Tracking of Iron-Oxide-Labeled Stem
and Renal Bioengineering Area 2
Original Articles
oxide and superoxide systems and their role in regulating cardiovascular function during the ageing
process, in both healthy people and people with
pre-existing cardiovascular diseases.
mice. In the experimental cardiology laboratory, we
have a model of angioplasty and stent implant in
pigs, a model of development of intimal hyperplasia in mice, which we use to carry out studies on
genetically modified animals, and two models of
vascular transplant in pigs and rats.
6. Study of neurohormonal activation and the fibrotic
process associated with ventricular remodeling in
heart failure, in idiopathic dilated myocardiopathies
of ischemic origin. We use molecular biology and
immunohistochemical techniques in myocardial
tissue and serum neurohormonal determinations.
This line will allow us to gain greater knowledge of
the pathophysiologic methods and course of heart
failure.
7. Analysis of the mechanisms involved in the process
of differentiation of mesenchymal stem cells derived from subcutaneous fat in post-infarct myocardial regeneration, using a pig model of myocardial
infarct. This model allows us to study therapeutic
strategies (different routes of administration for
stem cells, differences between transplant of autologous and heterologous stem cells) for clinical
application.
8. Investigation of the mechanisms by which estrogen
receptors regulate the signal pathways of the nitric
43
21/10/09 16:56:42
11
12
44
13
14
15
16
17
18
19
20
040-071 AREA2.indd 44
Cells: An Experimental Study. TRANSPL P. 40:36193622. I.F.:1,03.
Benito B, Conget I, Bosch X, Heras M, Ordonez J, Sionis
A, Diaz G, Esmatjes E. Intensive insulin therapy in nondiabetic patients with myocardial infarction and hyperglycemia. INSUCOR study. MED CLIN-BARCELONA.
130:601-605. I.F.:1,34.
Sanchis J, Bodi V, Nunez J, Bosch X, Lorna-Sorio P,
Mainar L, Santas E, Minana G, Robles R, Llacer A. Limitations of clinical history for evaluation of patients with
acute chest pain, non-diagnostic electrocardiogram,
and normal troponin. AM J CARDIOL. 101:613-617.
I.F.:3,60.
Crespo-Leiro MG, Alonso-Pulpon L, DePrada JAV,
Almenar L, Arizon JM, Brossa V, Delgado JF, Fernandez-Yanez J, Manito N, Rabago G, Lage E, Roig E, DiazMolina B, Pascual D, Muniz J. Malignancy after heart
transplantation: Incidence, prognosis and risk factors.
AM J TRANSPLANT. 8:1031-1039. I.F.:6,42.
Ferreira-Gonzalez I, Permanyer-Miralda G, Marrugat J,
Heras M, Cunat J, Civeira E, Aros F, Rodriguez JJ, Sanchez PL, Bueno H. MASCARA (Manejo del Sindrome
Coronado Agudo. Registro Actualizado) study. General
findings. REV ESP CARDIOL. 61:803-816. I.F.:2,21.
Arzamendi D, Garcia-Alvarez A, Roig E, Benito B, Kiamco R, Perez-Villa F, Loma-Osorio P, Bosch X, Pomar
JL, Cartana R, Castella M, Massotti M, Betriu A. New
insights in the management of cardiogenic shock complicating myocardial infarction: Role of urgent heart
transplantation. J HEART LUNG TRANSPL. 27:984-989.
I.F.:3,09.
Feffeira-Gonzalez I, Permanyer-Miralda G, Heras M,
Cunat J, Civeira E, Aros F, Rodriguez JJ, Sanchez PL,
Marsal JR, Ribera A, Marrugat J, Bueno H. Patterns of
use and effectiveness of early invasive strategy in nonST-segment elevation acute coronary syndromes: An
assessment by propensity score. AM HEART J. 156:946953. I.F.:3,65.
DeIsla LP, Porro R, Pare JC, DeLaMorena G, Macaya
C, Zamorano J. Relationship between intraventricular
cardiac asynchrony and degree of systolic dysfunction.
J AM SOC ECHOCARDIOG. 21:214-218. I.F.:2,06.
Vahanian A, Alfieri O, Al-Attar N, Antunes M, Bax J, Cormier B, Cribier A, DeJaegere P, Fournial G, Kappetein AP,
Kovac J, Ludgate S, Maisano F, Moat N, Mohr F, Nataf P,
Pierard L, Pomar JL, Schofer J, Tornos P, Tuzcu M, VanHout B, VonSegesser LK, Walther T. Transcatheter valve
implantation for patients with aortic stenosis: a position
statement from the European Association of CardioThoracic Surgery (EACTS) and the European Society of
Cardiology (ESC), in collaboration with the European Association of Percu. EUR HEART J. 29:1463-1470. I.F.:7,92.
Parra V, Fita G, Rovira I, Matute P, Gomar C, Pare C.
Transoesophageal echocardiography accurately detects
cardiac output variation: a prospective comparison with
thermodilution in cardiac surgery. EUR J ANAESTH.
25:135-143. I.F.:1,44.
Lafuente S, Trilla A, Bruni L, Gonzalez R, Bertran MJ,
Pomar JL, Asenjo MA. Validation of the EuroSCORE
Probabilistic model in patients undergoing coronary
bypass grafting. REV ESP CARDIOL. 61:589-594.
I.F.:2,21.
Reviews
1
2
Torbicki A, Perrier A, Konstantinides S, Agnelli G,
Galie N, Pruszczyk P, Bengel F, Brady AJB, Ferreira
D, Janssens U, Klepetko W, Mayer E, Remy-Jardin
M, Bassand JP, Vahanian A, Camm J, DeCaterina R,
Dean V, Dickstein K, Filippatos G, Funck-Brentano C,
Hellemans I, Kristensen SD, Mcgregor K, Sechtem
U, Silber S, Tendera M, Widimsky P, Zamorano
JL, Andreotti F, Ascherman M, Athanassopoulos
G, DeSutter J, Fitzmaurice D, Forster T, Heras M,
Jondeau G, Kjeldsen K, Knuuti J, Lang I, Lenzen M,
Lopez-Sendon J, Nihoyannopoulos P, Isla LP, Schwehr
U, Torraca L, Vachiery JL. Guidelines on the diagnosis
and management of acute pulmonary embolism The task force for the diagnosis and management of
acute pulmonary embolism of the European Society
of Cardiology (ESC). EUR HEART J. 29:2276-2315.
I.F.:7,92.
VanDeWerf F, Bax J, Betriu A, Blomstrom-Lundqvist
C, Crea F, Falk V, Filippatos G, Fox K, Huber K, Kastrati
A, Rosengren A, Steg PG, Tubaro M, Verheugt F, Weidinger F, Weis M, Vahanian A, Camm J, DeCaterina R,
Dean V, Dickstein K, Funck-Brentano C, Hellemans I,
Kristensen SD, Mcgregor K, Sechtem U, Silber S, Tendera M, Widimsky P, Zamorano JL, Aguirre FV, Al-Attar
N, Alegria E, Andreotti F, Benzer W, Breithardt O, Danchin N, Mario CD, Dudek D, Gulba D, Halvorsen S, Kaufmann P, Kornowski R, Lip GYH, Rutten F. Management
of acute myocardial infarction in patients presenting
with persistent ST-segment elevation. EUR HEART J.
29:2909-2945. I.F.:7,92.
Editorials
1
2
Marrugat J, Lopez-Lopez JR, Heras M, Tamargo J, Valverde M. The HERACLES cardiovascular network. REV
ESP CARDIOL. 61:66-75. I.F.:2,21.
Vahanian A, Alfieri OR, At-Attar N, Antunes MJ, Bax J,
Cormier B, Cribier A, DeJaegere P, Fournial G, Kappetein AP, Kovac J, Ludgate S, Maisano F, Moat N, Mohr
FW, Nataf P, Pierard L, Pomar JL, Schofer J, Tornos
P, Tuzcu M, VanHout B, VonSegesser LK, Walther T.
Transcatheter valve implantation for patients with aortic stenosis: a position statement from the European
Association of Cardio-Thoracic Surgery (EACTS) and
the European Society of Cardiology (ESC), in collaboration with the European Association of Percu. EUR J
CARDIO-THORAC. 34:1-8. I.F.:2,01.
Multicentrics
1
2
Fox K, Ford I, Steg PG, Tendera M, Ferrari R. Ivabradine for patients with stable coronary artery disease
and left-ventricular systolic dysfunction (BEAUTIFUL):
a randomised, double-blind, placebo-controlled trial.
LANCET. 372:807-816. I.F.:28,64.
Fox K, Recena JB, Garcia-Aranda VL, Valderrama JC,
Alonso LFI, Calvar ASR, Aviles FF, Villa FP, Cortada
JB, Alvarez RF, Peiro FN, Iglesias FC, Toral BS,
Bescos LL, DeBurgos FG, Casado RS, Galve E, Garcia
GC, Dellborg M, Herlitz J, Ullman B, Blomgren J,
21/10/09 16:56:48
Bosch X. Grado de inflamación vascular y trombogenicidad
en pacientes no diabéticos con síndrome coronario agudo
sin elevación del segmento ST y alteración en el metabolismo de la glucosa. Grant: Ministerio Sanidad y Consumo,
PI050120. Duration: 01/01/2006-30/12/2008.
Rigol M. Regeneración miocárdica mediante células madre mesenquimales en un modelo porcino de infarto de
miocardio: comparación entre las vías de administración
intracoronaria e intramiocárdica dirigida por sistema carto.
18/10/2006-30/12/2009.
Heras M. HERACLES - Determinantes Genéticos y Ambientales de la Disfunción Vascular en la Hipertensión y Cardiopatía Isquémica. Grant: Ministerio Sanidad y Consumo,
RD06/0009/0008. Duration: 01/01/2007-31/12/2010.
Perez F. Aplicación de nuevos marcadores circulantes para
el diagnóstico y el seguimiento de al cardiopatía isquémica. Grant: Ministerio Educación y Ciencia, SAF200506643-C03-02. Duration: 31/12/2005-31/12/2008.
Bandh S, Ohlin H, Dubach P, Gallino A, Hess O,
Moccetti T, Eeckhout E, Vontobel H, Delabays A,
Erol K, Kozan O, Mutlu B, Ergene O, Acarturk E,
Yilmaz H, Ural D, Parkhomenko O, Polyvoda S,
Dyadyk A, Vatutin M, Karpenko O, Kubyshkin V,
Rudenko L, Putintsev V, Krayz I, Kovalsky I, Rudyk
Y, Yurlov V, Mostovoy Y, Rishko M, Barna O, Slyvka
Y, Perepelytsya M, Seredyuk N, Bazylevych A,
Glushko L, Tashchuk V, Girina O, Vizir V, Pertseva T,
Vlasenko M, Goloborodko B, Kolomiets S, Dzyak G,
Sharuk O, Storozhuk B, Kovalenko V, Khomazyuk T,
Soldatchenko S, Lutay M, Zharinov O, Serkova V,
Korkushko O, Korzh O, Netyazhenko V, Sakharchuk
I, Stadnyuk L, Bereznyakov I, Semidotska Z, Kolchin
Y, Voronkov L, Tseluyko V, Amosova K, Batushkin
V, Hall A, Lindsay S, Moriarty A, Kadr H, Francis
CM, Saltissi S, Rozkovec A, Groves P, Crook JR,
Purvis J, Brooksby P, Stewart M, Dutka D, Timmis A,
Baig MW, Brady A, Williams S, Brooks N, Greaves
K. The BEAUTIFUL study: Randomized trial of
ivabradine in patients with stable coronary artery
disease and left ventricular systolic dysfunction
baseline characteristics of the study population.
CARDIOLOGY. 110:271-282. I.F.:1,70.
3 Garin O, Soriano N, Ribera A, Ferrer M, Pont A, Alonso
J, Permanyer G. Validation of the Spanish version of
the Minnesota living with heart failure questionnaire.
REV ESP CARDIOL. 61:251-259. I.F.:2,21.
Pomar JL. Computational disease modellingCentre coordinador: IDIBAPS. Grant: European Science Foundation,
08/003. Duration: 25/09/2008-26/09/2008.
45
040-071 AREA2.indd 45
21/10/09 16:56:53
Arrhythmias and Cardiac Stimulation
Team Members
Arrhythmias and cardiac stimulation
Team Leader:
■ Josep Brugada (Hospital Clínic)
Tel.: 93 227 55 51
Fax: 93 452 30 45
IDIBAPS Members:
■ Lluis Mont (Hospital Clínic)
■ Marta Sitges (Hospital Clínic)
Collaborators:
Xavi Alsina (Hospital Clínic)
Antonio Berruezo (Hospital Clínic)
Mª Àngels Castel (Fundació Clínic)
Mariona Matas (Hospital Clínic)
Neus Portella (Fundació Clínic)
Sílvia Ruvira (Hospital Clínic)
José Mª Tolosana (Hospital Clínic)
Bárbara Vidal (Hospital Clínic)
Silvia Poyatos (Fundació Clínic)
Valeria Sirenko (Fundació Clínic)
Diego Pérez (Hospital Clínic - Fundació Clínic)
Mercè Nadal (Hospital Clínic - Fundació Clínic)
Marta Aceña (Hospital Clínic - Fundació Clínic)
The objectives for the coming year are essentially to
continue developing the group’s four principal lines of
research (conduction disorders, effect of exercise in an
experimental model, atrial fibrillation and cardiac resynchronization) and consolidating the new line of research on ablation of ventricular tachycardia. Furthermore, we want to continue to potentiate multicenter
projects that allow for more ambitious results with
greater transcendency. At the same time we will continue to encourage practical clinical research aimed at
continuing to improve our patient-care activity.
Ana Martín (Hospital Clínic - Fundació Clínic)
Eduard Guasch (Hospital Clínic - Fundació Clínic)
David Andreu (Fundació Clínic)
Silvia Montserrat (Hospital Clínic - Fundació Clínic)
José T Ortiz (Hospital Clínic)
Teresa M De Caralt (Hospital Clínic)
Rosario J Perea (Hospital Clínic)
Doctoral Students:
Gemma Gay-Jordi (Beca FIS)
Etel Silva (Beca CENIT)
David Tamborero (Beca IDIBAPS)
Paola Berne (Beca FIS)
Begoña Benito Villabriga (IDIBAPS)
model and, at the same time, to initiate a stable collaboration with Dr. Nattel at the Montreal Heart Institute in order to expand studies on the inducibility of
arrhythmias in the model.
46
1. Conduction disorders: We are continuing to recruit
patients on the Brugada syndrome register and
to analyze the value of electrophysical studies in
prognosis. We also analyze the utility of ajmaline
in diagnosing the disease. Furthermore, several genetic studies are in progress, in collaboration with
Dr. Ramon Brugada of the University of Girona.
2. Resistance exercise model in rats: We intend to continue analyzing the mechanisms that condition the
development of atrial and ventricular fibrosis in the
040-071 AREA2.indd 46
Three-dimensional reconstruction of a fused ventricle with anteroposterior
MRI scan of a patient with TV ablation. Region of fractionated signal with
low potential exclusively at the epicardial level, where the application of
RF made the tachycardia non-inducible.
21/10/09 16:57:01
3. Atrial fibrillation (AF): We continue to study etiologic factors in primary atrial fibrillation, specifically the role of hypertension not detected during
physical exercise. We have also started the SARA
study (Spanish Atrial Fibrillation vis Antiarrhythmic
Drugs). Comparative multicenter study of the efficacy of ablation vs drug treatment and different studies comparing different AF ablation techniques.
4. Cardiac resynchronization: This year saw the start of
the SPARE II study to prospectively evaluate the result
of resynchronization in patients with atrial fibrillation
and we expect to initiate multicenter studies to evaluate the effect of optimization on the success of resynchronization. We are continuing to recruit patients for
the ECHO-CRT study and we will start a study on the
acute repercussions of resynchronization.
Associated Group
Cardiac resynchronization
This group has completed the collection of data from the SCAR II studies (Spanish Cardiac Resynchronization Study), which will analyze the contribution of echocardiogram dyssynchrony in the selection of
patients, and the SPARE study (Spanish Atrial Fibrillation and Resynchronization). The next objective is
to start the SPARE II study to prospectively evaluate the result of resynchronization in patients with atrial fibrillation. We
also continue to collect data on the study of the efficacy of resynchronization in patients with narrow QRS and we are designing a multicenter study in these patients associated with the indication of prophylactic defibrillation (Spanish Narrow
QRS and Resynchronization study, SNAQE).
PublicaTions
Original Articles
2
3
4
5
6
7
Delgado V, Sitges M, Vidal B, Silva E, Azqueta M, Tolosana JM, Mont L, Pare C, Brugada J. Assessment of left
ventricular dyssynchrony by real-time three-dimensional echocardiography. REV ESP CARDIOL. 61:825-834.
I.F.:2,21.
Delgado V, Vidal B, Sitges M, Tamborero D, Mont L,
Berruezo A, Azqueta M, Pare C, Brugada J. Fate of left
atrial function as determined by real-time three-dimensional echocardiography study after radiofrequency
catheter ablation for the treatment of atrial fibrillation.
AM J CARDIOL. 101:1285-1290. I.F.:3,60.
Rigol M, Solanes N, Roque M, Farre J, Batle M, Roura
Cells: An Experimental Study. TRANSPL P. 40:36193622. I.F.:1,03.
Benito B, Brugada R, Perich RM, Lizotte E, Cinca J, Mont
L, Berruezo A, Tolosana JM, Freixa X, Brugada P, Brugada J. A mutation in the sodium channel is responsible
for the association of long QT syndrome and familial
atrial fibrillation. HEART RHYTHM. 5:1434-1440. I.F.:4,20.
Freixa X, Berruezo A, Mont L, Magnani S, Benito B, Tolosana JM, Perafan P, Tarnborero D, Brugada J. Characterization of focal right atrial appendage tachycardia.
EUROPACE. 10:105-109. I.F.:1,38.
Oliva A, Bjerregaard P, Hong K, Evans S, Vernooy K,
Mccormack J, Brugada J, Brugada P, Pascali VL, Brugada R. Clinical heterogeneity in sodium channelopathies
- What is the meaning of carrying a genetic mutation?.
CARDIOLOGY. 110:116-122. I.F.:1,70.
Tolosana JM, Madrid AH, Brugada J, Sitges M, Bolao
IG, Lozano IF, Ferrer JM, Quesada A, Macias A, Marin
040-071 AREA2.indd 47
W, Escudier JM, Gomez AA, Alcala MG, Tamborero D,
Berruezo A, Mont L. Comparison of benefits and mortality in cardiac resynchronization therapy in patients
with atrial fibrillation versus patients in sinus rhythm
(results of the Spanish atrial fibrillation and resynchronization [SPARE] study). AM J CARDIOL. 102:444-449.
I.F.:3,60.
8 Matiello M, Mont L, Tamborero D, Berruezo A, Benito B,
Gonzalez E, Brugada J. Cooled-tip vs. 8 mm-tip catheter
for circumferential pulmonary vein ablation: comparison of efficacy, safety, and lesion extension. EUROPACE. 10:955-960. I.F.:1,38.
9 Junttila MJ, Brugada P, Hong K, Lizotte E, DeZutter M,
Sarkozy A, Brugada J, Benito B, Perkiomaki JS, Makikallio TH, Huikuri HV, Brugada R. Differences in 12-lead
electrocardiogram between symptomatic and asymptomatic brugada syndrome patients. J CARDIOVASC
ELECTR. 19:380-383. I.F.:3,48.
10 Benito B, Sarkozy A, Mont L, Henkens S, Berruezo A,
Tamborero D, Arzamendi D, Berne P, Brugada R, Brugada P, Brugada J. Gender Differences in Clinical Manifestations of Brugada Syndrome. J AM COLL CARDIOL.
52:1567-1573. I.F.:11,05.
11 Boussy T, Paparella G, DeAsmundis C, Sarkozy A,
Chierchia GB, Brugada J, Brugada R, Brugada P. Genetic basis of ventricular arrhythmias. CARDIOL CLIN.
26:335-+. I.F.:0,97.
12 Wilkoff BL, Auricchio A, Brugada J, Cowie M, Ellenbogen KA, Gillis AM, Hayes DL, Howlett JG, Kautzner J,
Love CJ, Morgan JM, Priori SG, Reynolds DW, Schoenfeld MH, Vardas PE. HRS/EHRA expert consensus on
the monitoring of cardiovascular implantable electronic
devices (CIEDs): Description of techniques, indications,
personnel, frequency and ethical considerations. EUROPACE. 10:707-725. I.F.:1,38.
1
I.F.: 70,43
■ Mont, Lluis (ICT)
47
21/10/09 16:57:07
48
13 Mont L, Ruiz-Granell R, Martinez JG, Carmona JR,
Fidalgo M, Cobo E, Riera M, Navarro X. Impact of
anti-tachycardia pacing on atrial fibrillation burden
when added on top of preventive pacing algorithms:
results of the prevention or termination (POT) trial.
EUROPACE. 10:28-34. I.F.:1,38.
14 Junttila MJ, Gonzalez M, Lizotte E, Benito B, Vernooy K,
Sarkozy A, Huikuri HV, Brugada P, Brugada J, Brugada
R. Induced brugada-type electrocardiogram, a sign
for imminent malignant Arrhythmias. CIRCULATION.
117:1890-1893. I.F.:12,76.
15 Perea RJ, Tamborero D, Mont L, DeCaralt TM, Ortiz JT,
Berruezo A, Matiello M, Sitges M, Vidal B, Sanchez M,
Brugada J. Left atrial contractility is preserved after
successful circumferential pulmonary vein ablation in
patients with atrial fibrillation. J CARDIOVASC ELECTR.
19:374-379. I.F.:3,48.
16 Muxi A, Paredes P, Mont L, Setoain FJ, Duch J, Fuertes
S, Ortin J, Diaz-Infante E, Pons F. Left ventricular
function and visual phase analysis with equilibrium
radionuclide angiography in patients with biventricular
device. EUR J NUCL MED MOL I. 35:912-921. I.F.:4,10.
17 Molina L, Mont L, Marrugat J, Berruezo A, Brugada J,
Bruguera J, Rebato C, Elosua R. Long-term endurance
sport practice increases the incidence of lone atrial
fibrillation in men: a follow-up study. EUROPACE.
10:618-623. I.F.:1,38.
18 Roguin A, Schwitter J, Vahlhaus C, Lombardi M,
Brugada J, Vardas P, Auricchio A, Priori S, Sommer
T. Magnetic resonance imaging in individuals with
cardiovascular implantable electronic devices.
EUROPACE. 10:334-344. I.F.:1,38.
19 Mont L, Tamborero D, Elosua R, Molina I, Coll-Vinent
B, Sitges M, Vidal B, Scalise A, Tejeira A, Berruezo A,
Brugada J. Physical activity, height, and left atrial size
are independent risk factors for lone atrial fibrillation in
middle-aged healthy individuals. EUROPACE. 10:15-20.
I.F.:1,38.
20 Arriagada G, Berruezo A, Mont L, Tamborero D, Molina
I, Coll-Vinent B, Vidal B, Sitges M, Berne P, Brugada J.
Predictors of arrhythmia recurrence in patients with
lone atrial fibrillation. EUROPACE. 10:9-14. I.F.:1,38.
21 Funck RC, Boriani G, Manolis AS, Puererfellner H,
Mont L, Tukkie R, Pisapia A, Israel CW, Grovale N,
Grammatico A, Padeletti L. The MINERVA study design
and rationale: A controlled randomized trial to assess
the clinical benefit of minimizing ventricular pacing in
pacemaker patients with atirial tachyarrhythmias. AM
HEART J. 156:445-451. I.F.:3,65.
22 Brignole M, Menozzi C, Botto GL, Mont L, Asensi JO,
Medina DG, Oddone D, Navazio A, Luzi M, Iacopino
S, DeFabrizio G, Proclemer A, Vardas P. Usefulness
of echo-guided cardiac resynchronization pacing in
patients undergoing “Ablate and Pace” therapy for
permanent atrial fibrillation and effects of heart rate
regularization and left ventricular resynchronization.
AM J CARDIOL. 102:854-860. I.F.:3,60.
Reviews
1
040-071 AREA2.indd 48
Benito B, Brugada R, Brugada J, Brugada P. Brugada
syndrome. PROG CARDIOVASC DIS. 51:1-22. I.F.:2,78.
Editorials
1
2
Berruezo A, Brugada J. Betablockers: Is the reduction
of sudden death related to pure electrophysiologic
effects?. CARDIOVASC DRUG THER. 22:163-164.
I.F.:1,86.
Mont L, Sitges M. Improving the results of Cardiac
Resynchronization Therapy: the Role of Imaging
Techniques. REV ESP CARDIOL. 61:914-916. I.F.:2,21.
Multicentrics
1
2
Alegret JM, Vinolas X, Sagrista J, HernandezMadrid A, Berruezo A, Moya A, Sande JLM, Pastor
A. Clinical characteristics of patients with persistent
atrial fibrillation referred for cardioversion: Spanish
cardioversion registry (REVERSE). REV ESP CARDIOL.
61:630-634. I.F.:2,21.
Almendral J, Arribas F, Wolpert C, Ricci R, Adragao
P, Cobo E, Navarro X, Quesada A. Dual-chamber
defibrillators reduce clinically significant adverse events
compared with single-chamber devices: results from
the DATAS (Dual chamber and Atrial Tachyarrhythmias
Adverse events Study) trial. EUROPACE. 10:528-535.
I.F.:1,38.
Brugada J. Grup d’Arítmies i Estimulació Cardíaca. Grant:
Duration: 19/10/2005-31/12/2008.
Brugada J. Integración de las diferentes técnicas de imagen
médica en una única imagen multimodal. Desarrollo de
distintos modelos de aplicación. Estudios electrofisiológicos
y de imagen cardiaca. Grant: Ministerio de Industria
Turismo y Comercio, CDTEAM1. Duration: 11/01/200611/01/2010.
Mont L. Beneficio de la resincronización en pacientes con
QRS estrecho y Papel pronóstico de las metaloproteasas
y del procolageno tipo I (PIP) en la resignación cardiaca.
01/01/2006-30/12/2008.
Sitges M. Análisis de la metodología y de la utilidad clínica
de la optimazación de los dispositivos de resincronización
cardiaca en los pacientes con insuficiencia cardiaca..
01/01/2006-30/12/2008.
Brugada J. Relación entre la fibrilación auricular aislada y
la práctica deportiva crónica. Estudio de las repercusiones
estructurales y electrofisiológicas en la aurícula derivadas
del ejercicio crónico mediante el desarrollo de un modelo
experimental con ratas. Grant: Ministerio Sanidad y
Consumo, PI050210. Duration: 01/01/2006-30/12/2008.
Brugada J. REDISCOR - Red de Investigación en
Insuficiencia Cardíaca en España. Grant: Ministerio
Sanidad y Consumo, RD06/0003/0008.
Duration: 01/01/2007-31/12/2010.
21/10/09 16:57:13
Thesis
Mont L, Sitges M. Teràpia de resincronització cardíaca a
la insuficiència cardíaca: paper de les noves tècniques
d’imatge cardíaca en la seva implementació i seguiment.
Doctorand: Dra. Bàrbara Vidal Hagemeijer. Universitat de
Barcelona.
Mont L. Estudio de los factores predictores de mejoría clínica mediante la resincronización cardiaca en la insuficiencia
cardíaca avanzada. Doctorand: Dr. Ernesto Díaz Infante. Universidad de Sevilla.
Brugada J. Genética y caos eléctrico. Doctorand: Dr. Ramon
Brugada Terradellas. Universitat Autònoma de Barcelona.
49
040-071 AREA2.indd 49
21/10/09 16:57:18
Nephro-Urologic Diseases and Kidney Transplant
Team Members
Nephro-urologic diseases
and kidney transplant
Team Leader:
■ Josep Mª Campistol
(Hospital Clínic)
Tel.: 93 227 54 00 (Ext.: 9346)
IDIBAPS Members:
■ Antonio Alcaraz (Hospital Clínic)
■ Pilar Arrizabalaga (Hospital Clínic)
■ Albert Botey (Hospital Clínic)
■ Mercè Brunet (Hospital Clínic)
■ Aleix Cases (Hospital Clínic)
■ Guadalupe Ercilla (Hospital Clínic)
■ Georgina Hotter (IIBB-CSIC)
■ Jaume Martorell (Hospital Clínic)
■ Eduard Mirapeix (Hospital Clínic)
■ Federico Oppenheimer (Hospital Clínic)
■ Esteban Poch (Hospital Clínic)
Collaborators:
N. Amezaga (Hospital Clínic)
Celia Bádenas (Fundació Clínic)
Pablo Carretero (Hospital Clínic)
Federico Cofán (Hospital Clínic)
Elisabeth Coll (Hospital Clínic)
Marta Crespo (Hospital Clínic)
Nuria Esforzado (Hospital Clínic)
V. Fortuna (Hospital Clínic)
J. Jiménez (Hospital Clínic)
Judith Jo (Fundació Clínic)
Sergio Lario (IDIBAPS)
M.A. Millán (Hospital Clínic)
O. Millán (Hospital Clínic)
Vicenç Torregrosa (Hospital Clínic)
Anna Sola (IIBB-CSIC)
José Luis Viñas (IIBB-CSIC)
Eugenia Vinuesa (IIBB-CSIC)
Doctoral Students:
Mónica Bescos (Fundació Clínic)
Sonia López (Fundació Clínic)
Joan Nistal (Fundació Clínic)
Michaela Jung (IIBB-CSIC)
Albert Pérez Ladaga (IIBB-CSIC)
Marina Ventayol (IIBB-CSIC)
Chrysa Mastora (IIBB-CSIC)
Technicians:
Mª Angeles Muñoz Herrero (IIBB-CSIC)
Maite del Hierro (IIBB-CSIC)
The general objectives of this research team are to
gain greater knowledge of the pathophysiology and
treatment of diseases of the kidneys and male urinary and reproductive apparatus, and of the medical complications deriving from replacement renal
treatment by means of dialysis or transplant. The
objectives include, especially, the study of immunosuppression in pharmacokinetic and pharmacodynamic aspect.
1. Hereditary kidney diseases, particularly renal polycystosis, Alport syndrome and benign family hematuria.
2. Amyloidosis associated with dialysis or beta-2
microglobulin, other types of hereditary and nonhereditary amyloidosis with renal involvement.
3. Diabetic nephropathy, antiproteinuric of ARA II.
4. Anemia of renal origin, erythropoiesis-stimulating
proteins in uremia.
5. Uremic myopathy.
6. Renal osteodystrophy and calcium-phosphorous
metabolism.
7. Cardiovascular risk and accelerated arteriosclerosis in kidney patients.
8. Infection by hepatitis C virus in dialysis and kidneytransport patients.
9. Endothelial dysfunction, the effect of the uremic
medium in endothelial cells.
10.Chronic rejection, role of TGF-beta.
50
Furthermore, with the incorporation of a team specializing in transplant immunology, our objectives also
include improving the tolerance to allografts and xenografts and reducing as far as possible the need for
immunosuppressants. Another new challenge is to
increase our knowledge regarding the level of immunosuppression recommended in patients according to
their needs: pharmacokinetic-pharmacodynamic relationship.
040-071 AREA2.indd 50
21/10/09 16:57:25
which, therefore, determine tolerance to transplant
antigens.
18.Establishment of the pharmacokinetic and pharmacodynamic parameters that make it possible to
adjust the minimum necessary and sufficient immunosuppression for each organ recipient.
19.Identification of strategies that make it possible to
substitute the functions of cells, organs or tissues,
minimizing the use of immunosuppressants.
Our researchers also have shared lines of research
with other IDIBAPS teams, particularly in the areas
of arterial hypertension, endothelial dysfunction
and systemic autoimmune diseases with renal involvement.
I.F.: 103,36
PublicaTions
Original Articles
1
040-071 AREA2.indd 51
8
9
10
11
12
13
14 Biopathology and Respiratory, Cardiovascular
Trullas JC, Barril G, Cofan F, Moreno A, Cases A,
Fernandez-Lucas M, Martinez-Ara J, Ceballos M,
Garcia-De-Diego J, Muniz ML, Molina J, MartinezCastelao A, Gonzalez-Garcia J, Miro JM. Prevalence
and Clinical Characteristics of HIV Type 1-Infected
Patients Receiving Dialysis in Spain: Results of a
Spanish Survey in 2006: GESIDA 48/05 Study. AIDS
RES HUM RETROV. 24:1229-1235. I.F.:2,02.
2 Linares L, Cervera C, Cofan F, Lizaso D, Marco
F, Ricart MJ, Esforzado N, Oppenheimer F,
Campistol JM, Moreno A. Risk factors for
infection with extended-spectrum and AmpC betalactamase-producing gram-negative rods in renal
transplantation. AM J TRANSPLANT. 8:1000-1005.
I.F.:6,42.
3 Carbo C, Arderiu G, Escolar G, Fuste B, Cases A,
Carrascal M, Abian J, Diaz-Ricart M. Differential
expression of proteins from cultured endothelial
cells exposed to uremic versus normal serum. AM J
KIDNEY DIS. 51:603-612. I.F.:3,98.
4 Gomez-Caro A, Martinez E, Rodriguez A, Sanchez
D, Martorell J, Gimferrer JM, Haverich A, Harringer
W, Pomar JL, Macchiarini P. Cryopreserved Arterial
Allograft Reconstruction After Excision of Thoracic
Malignancies. ANN THORAC SURG. 86:1753-1761.
I.F.:2,02.
5 Rigol M, Solanes N, Sionis A, Galvez C, Martorell
J, Rojo I, Brunet M, Ramirez J, Roque M, Roig E,
Perez-Villa F, Barquin L, Pomar JL, Sanz G, Heras
M. Effects of cyclosporine, tacrolimus and sirolimus
on vascular changes relate to immune response. J
HEART LUNG TRANSPL. 27:416-422. I.F.:3,09.
6 Vallancien G, Emberton M, Alcaraz A, Matzkin H,
VanMoorselaar RJA, Hartung R, Harving N, Elhilali
M. Alfuzosin 10 mg once daily for treating benign
prostatic hyperplasia: a 3-year experience in reallife practice. BJU INT. 101:847-852. I.F.:2,75.
7 DeOca J, Azuara D, Sanchez-Santos R, Navarro
M, Capella G, Moreno V, Sola A, Hotter G, Biondo
S, Osorio A, Marti-Rague J, Rafecas A. Caspase-3
activity, response to chemotherapy and clinical
outcome in patients with colon cancer. INT J
COLORECTAL DIS. 23:21-27. I.F.:1,92.
Coll E, Larrousse M, DeLaSierra A, Collado S,
Jimenez W, Cases A. Chronic hypotension in
hemodialysis patients: role of functional vascular
changes and vasodilator agents. CLIN NEPHROL.
69:114-120. I.F.:1,32.
Macchiarini P, Jungebluth P, Go T, Asnaghi MA,
Rees LE, Cogan TA, Dodson A, Martorell J, Bellini S,
Parnigotto PP, Dickinson SC, Hollander AP, Mantero
S, Conconi MT, Birchall MA. Clinical transplantation
of a tissue-engineered airway. LANCET. 372:20232030. I.F.:28,64.
Maduell F, Serra N, Arias M, Vera M, Bergada E,
Cases A. Control of hypertension refractory to
medical management by means of short daily
hemodialysis. NEFROLOGIA. 28:99-101. I.F.:0,52.
Diekmann F, Budde K, Slowinski T, Oppenheimer
F, Fritsche L, Neumayer HH, Campistol JM.
Conversion to sirolimus for chronic allograft
dysfunction: long-term results confirm predictive
value of proteinuria. TRANSPL INT. 21:152-155.
I.F.:2,30.
Bergua C, Torregrosa JV, Fuster D, GutierrezDalmau A, Oppenheimer F, Campistol JM.
Effect of Cinacalcet on hypercalcemia and
bone mineral density in renal transplanted
patients with secondary hyperparathyroidism.
TRANSPLANTATION. 86:413-417. I.F.:3,64.
Rovira J, Arellano EM, Burke JT, Brault Y, Moya-Rull
D, Banon-Maneus E, Ramirez-Bajo MJ, GutierrezDalmau A, Revuelta I, Quintana LF, Campistol JM,
Diekmann F. Effect of mTOR inhibitor on body
weight: from an experimental rat model to human
transplant patients. TRANSPL INT. 21:992-998.
I.F.:2,30.
Seron D, Oppenheimer F, Pallardo LM, Lauzurica R,
Errasti P, Gomez-Huertas E, Bosmans LL, SanchezPlumed J, Romero R, Marques M, Fulladosa X,
Moreso F. Fluvastatin in the prevention of renal
transplant vasculopathy: Results of a prospective,
11.Dyslipidemia and cardiovascular risk in kidney
transplant, polymorphisms of apolipoprotein.
12.Pharmacokinetics and pharmacodynamics of immunosuppressant drugs: calcineurin inhibitors, sirolimus, rapamycin and MMF.
13.Kidney and pancreas transport, metabolic control.
14.Neoplasias of the urinary apparatus (kidney, prostate and bladder).
15.Erectile dysfunction, the use of sildenafil in kidney
transplant.
16.Experimental kidney transplant.
17.Establishment of the molecular bases of the mechanisms that govern clonal deletion or anergy in a
model of allogenic or xenogenic presentation and
51
21/10/09 16:57:31
15 Nephro-urologic diseases
16 17 18 19 Biopathology and Respiratory, Cardiovascular
20 21 22 23 24 52
25 26 040-071 AREA2.indd 52
randomized, double-blind, placebo-controlled trial.
Maduell F, Vera M, Arias M, Fontsere N, Blasco
M, Serra N, Bergada E, Cases A, Campistol JM.
How much should dialysis time be increased when
catheters are used?. NEFROLOGIA. 28:633-636.
I.F.:0,52.
Morales JM, Grinyo JM, Campistol JM, GarciaMartinez J, Arias M, Paul J, Sanchez-Fructuoso
A, Brunet M, Granados E, Munoz-Robles JA.
Improved renal function, with similar proteinuria,
after two years of early tacrolimus withdrawal
from a regimen of sirolimus plus tacrolimus.
Maduell F, Vera M, Arias M, Serra N, Blasco M,
Bergada E, Fontsere N, Cases A, Campistol JM.
Influence of the ionic dialysance monitor on Kt
measurement in hemodialysis. AM J KIDNEY DIS.
52:85-92. I.F.:3,98.
Maduell F, Vera M, Serra N, Collado S, Carrera M,
Fernandez A, Arias M, Blasco M, Bergada E, Cases
A, Campistol JM. Kt as control and follow-up of the
dose at a hemodialysis unit. NEFROLOGIA. 28:4347. I.F.:0,52.
Vinuesa E, Sola A, Jung M, Alfaro V, Hotter G.
Lipocalin-2-induced renal regeneration depends on
cytokines. AM J PHYSIOL-RENAL. 295:F1554-F1562.
I.F.:4,42.
Vinuesa E, Hotter G, Jung M, Herrero-Fresneda I,
Torras J, Sola A. Macrophage involvement in the
kidney repair phase after ischaemia/reperfusion
injury. J PATHOL. 214:104-113. I.F.:5,42.
Marin-Aguilera M, Mengual L, Burset M, Oliver A,
Ars E, Ribal MJ, Colomer D, Mellado B, Villavicencio
H, Algaba F, Alcaraz A. Molecular Lymph Node
Staging in Bladder Urothelial Carcinoma: Impact on
Survival. EUR UROL. 54:1363-1372. I.F.:5,63.
Seron D, Anaya F, Marcen R, DelMoral RG, Martul
EV, Alarcon A, Andres A, Burgos D, Capdevila L,
Molina MG, Jimenez C, Morales JM, Oppenheimer
F, Pallardo L, Fructuoso AS. Recommendations by
indication, obtaining, processing and evaluation of
biopsies in renal transplants. NEFROLOGIA. 28:385396. I.F.:0,52.
Arrizabalaga P, Sole M, Abellana R, Ascaso C.
Renal expression of adhesion molecules in Ancaassociated disease. J CLIN IMMUNOL. 28:411-419.
I.F.:2,89.
Ramos R, Poveda R, Bernis C, Ara J, Sunyer M,
Arrizabalaga P, Grinyo JM. Renal involvement
in benign monoclonal gammopathies: an
underdiagnosed condition. NEFROLOGIA. 28:525529. I.F.:0,52.
Domingo-Domenech J, Fernandez PL, Filella X,
Martinez-Fernandez A, Molina R, Fernandez E, Alcaraz
A, Codony J, Gascon P, Mellado B. Serum HER2
extracellular domain predicts an aggressive clinical
outcome and biological PSA response in hormoneindependent prostate cancer patients treated with
docetaxel. ANN ONCOL. 19:269-275. I.F.:4,88.
Molina MG, Diekmann F, Burgos D, Cabello M,
Lopez V, Oppenheimer F, Navarro A, Campistol J.
Sympathetic dystrophy associated with sirolimus
therapy. TRANSPLANTATION. 85:290-292. I.F.:3,64.
27 Delgado P, Diaz JM, Silva I, Osorio JM, Osuna
A, Bayes B, Lauzurica R, Arellano E, Campistol
JM, Dominguez R, Gomez-Alamillo C, Ibernon M,
Moreso F, Benitez R, Lampreave I, Porrini E, Torres
A. Unmasking glucose metabolism alterations in
stable renal transplant recipients: A multicenter
study. CLIN J AM SOC NEPHRO. 3:808-813. I.F.:2,24.
Reviews
1 Bosch X, Guilabert A, Espinosa G, Mirapeix E.
Immunotherapy for antineutrophil cytoplasmic
anti body-associated vasculitis: challenging the
therapeutic status quo?. TRENDS IMMUNOL.
29:280-289. I.F.:9,48.
Editorials
1 Poch E, Riviello ED, Christopher K. Acute renal
failure in the intensive care unit. MED CLINBARCELONA. 130:141-148. I.F.:1,34.
2 Alcaraz A. Management of the hormone sensitivity
of prostate cancer: Where are we now?. EUR UROL.
54:247-250. I.F.:5,63.
3 Trullas JC, Sanchez M, Sole M, Mirapeix E. Wife of
50 years with infiltrates. MED CLIN-BARCELONA.
131:699-709. I.F.:1,34.
Hotter G. Bioregeneració i micromonitorització hipòxica.
Grant: Comissionat per a Universitats i Recerca,
2005SGR00703. Duration: 19/10/2005-31/12/2008.
Poch E. Análisis proteómico de la orina en la afección
renal asociada a diabetes tipo II. Efecto del bloqueo del
sistema renina angiotensina. Grant: Ministerio Sanidad
y Consumo, PI050015. Duration: 01/01/2006-31/01/2008.
Campistol JM. Análisis y utilidad del proteoma urinario
en el diagnóstico precoz de la nefropatia crónica del
injerto renal. Grant: Ministerio Sanidad y Consumo,
PI061222. Duration: 18/10/2006-30/12/2009.
Alcaraz A. Determinación de la diseminación linfática del
carcinoma urotelial de vejiga mediante marcadores moleculares y utilización de éstos para pronosticar la evolución
clínica de la enfermedad. Grant: Ministerio Sanidad y Consumo, PI070040. Duration: 26/11/2007-30/12/2010.
Poch E. REDINREN - Red de Investigación en
Enfermedades Renales. Grant: Ministerio Sanidad
y Consumo, RD06/0016/0015. Duration: 01/01/200731/12/2010.
Hotter G. Papel de la apoptosis del neutrofilo en
la resolución del proceso inflamatorio asociado al
síndrome de isquemia/reperfusión intestina. Grant:
Ministerio Sanidad y Consumo, PIO50156. Duration:
23/12/2005-31/12/2008.
21/10/09 16:57:37
Alcaraz A. Red de Investigación de Reacciones Adversas
a Alérgenos y Fármacos (RIRAAF). Grant: Instituto de
Salud Carlos III, RD07/0064/0006. Duration: 29/02/200831/12/2011.
Hotter G. Hypoxic renal proliferation (PROLIGEN). Grant:
European Comission, LIFESCI/STREP/03/0652. Duration:
01/01/2006-31/12/2009.
Thesis
Alcaraz A. Estudio molecular y citogenético del carcinoma urotelial. Detección temprana en la enfermedad y de
su diseminación. Doctorand: Mercedes Marín Aguilera.
Luis F. Quintana, Amanda Sole, Elisenda BañonManeus, Josep Mª Campistol, Pedro Rodriguez. Healthy
kidney Biomarkers.
Luis F. Quintana, Elisenda Bañon-Maneus, Josep Mª
Campistol. WNT1 como Biomarcador de daño renal.
Hotter G. Terapia celular regenerativa en la isquemiareperfusión renal: tratamiento con macrófagos. Grant:
FIS, 20062B810. Duration: 01/01/2006-31/12/2009.
Patents
53
040-071 AREA2.indd 53
21/10/09 16:57:42
Hypertension, Lipids and Cardiovascular Risk
Team Members
Hypertension, lipids and
cardiovascular risk
Team Leader:
■ Emili Ros (Hospital Clínic)
Tel.: 93 227 93 83
54
IDIBAPS Members:
■ Antonio Coca (Hospital Clínic)
■ Alejandro de la Sierra (Hospital Clinic)
■ Cristina Sierra (Hospital Clínic)
■ Daniel Zambón (Hospital Clínic)
Collaborators:
N. Bargalló (Hospital Clínic)
M.T. de Caralt (Hospital Clínic)
M. Doménech (Fundació Clínic)
R. Estruch (Hospital Clínic)
R. Gilabert (Hospital Clínic)
I. Núñez (Hospital Clínic)
M. Cofán (ISCIII)
A Sala-Vila (ISCIII)
Nurses:
M. Peña (Fundació Clínic)
Statistician:
E. Corbella (Fundació Clínic)
Dieticians:
A. Pérez-Heras (Fundació Clínic)
M. Serra (ISCIII)
Doctoral Students:
V. Escurriol (AGAUR)
C. Valls (ISCIII)
The general objective of our team is to advance in the
study of the epidemiology, pathogenesis, diagnosis,
treatment and prevention of arterial hypertension,
dyslipidemias and associated cardiovascular risk. The
lines of research we wish to continue consolidating
are the following:
1.In collaboration with other laboratories, characterization of genetic dyslipidemias, essentially hypercholesterolemias of autosomal dominant transmission, including family hypercholesteremia (FH)
and combined family hyperlipidemia (CFH), with:
the study of specific mutations of the genes of the
LDL receptor and apo B in FH, influence of cholesterol absorption in the lipid phenotype when
no mutations are detected, and search for genetic determinants of CFH; detection, treatment and
monitoring of patient families and index of affected members; relationship between genotype and
phenotype and therapeutic response; and study of
emerging risk factors and their relationship with
preclinical atherosclerosis.
2. External ultrasound of carotid and femoral arteries,
coronary CT and NMRI of carotic plaques Relationship between preclinical atherosclerosis and conventional and emergent risk factors and markers of
the regular diet, including omega-3 fatty acids and
phytosterols. Influence of diet on the vulnerability
of atheroma plaques of the carotid vessels, evaluated by sequential NMRI. Plaque composition correlation by NMRI with histology.
1. Mechanisms and consequences of the silent lesion
of hypertension target organs
2. Interaction of environmental determinants in cardiovascular disease with the consumption of salt
and the phenomenon of sensitivity to salt
3. Candidate genes for hypertension and its complications
4. Characterization of genetic dyslipidemias
5. Detecting preclinical atherosclerosis
6. Study of intestinal absorption of cholesterol
7. Determination of the fatty-acid pattern in phospholipids and blood-cell membranes and its association with diet and the phenotype of cardiovascular risk
8. Study of the cardiovascular functionality of foods
9.Evaluation of mild cognitive deterioration in patients with high cardiovascular risk
040-071 AREA2.indd 54
21/10/09 16:57:50
Original Articles
1
2
3
4
5
Siso A, Ramos-Casals M, Bove A, Brito-Zeron P, Soria
17:281-288. I.F.:2,25.
Coll E, Larrousse M, DeLaSierra A, Collado S, Jimenez
W, Cases A. Chronic hypotension in hemodialysis patients: role of functional vascular changes and vasodilator agents. CLIN NEPHROL. 69:114-120. I.F.:1,32.
Zazpe I, Sanchez-Tainta A, Estruch R, LamuelaRaventos RM, Schroder H, Salas-Salvado J, Corella
D, Fiol M, Gomez-Gracia E, Aros F, Ros E, Ruiz-Gutierrez V, Iglesias P, Conde-Herrera M, Martinez-Gonzalez MA. A large randomized individual and group
intervention conducted by registered dietitians increased adherence to Mediterranean-type diets: The
PREDIMED study. J AM DIET ASSOC. 108:1134-1144.
I.F.:3,01.
Sanchez-Tainta A, Estruch R, Bullo M, Corella D, Gomez-Gracia E, Fiol M, Algorta J, Covas MI, Lapetra J,
Zazpe I, Ruiz-Gutierrez V, Ros E, Martinez-Gonzalez MA.
Adherence to a Mediterranean-type diet and reduced
prevalence of clustered cardiovascular risk factors in a
cohort of 3204 high-risk patients. EUR J CARDIOV PREV
R. 15:589-593. I.F.:2,22.
Fuentes F, Lopez-Miranda J, Garcia A, Perez-Martinez
P, Moreno J, Cofan M, Caballero J, Paniagua JA, Ros E,
Perez-Jimenez F. Basal plasma concentrations of plant
sterols can predict LDL-C response to sitosterol in pa-
040-071 AREA2.indd 55
Dispersion graph of carotidal intima-media thickness compared to the
Framingham risk score for suffering from coronary disease after 10 years.
Symbols: Green triangles, individuals with estimated vascular age lower
than their chronologic age; orange circles, vascular age up to 10 years
higher than chronologic age; red squares, vascular age >10 years higher
than chronologic age. Junyent et al. Atherosclerosis 2007; Feb 20 [Epub
ahead of print] PMID: 17320091.
I.F.: 83,27
tients with familial hypercholesterolemia. EUR J CLIN
NUTR. 62:495-501. I.F.:2,33.
6 Junyent M, Zambon D, Gilabert R, Nunez I, Cofan M,
Ros E. Carotid atherosclerosis and vascular age in the
assessment of coronary heart disease risk beyond the
Framingham Risk Score. ATHEROSCLEROSIS. 196:803809. I.F.:4,29.
7 Junyent M, Zambon D, Gilabert R, Cofan M, Nunez I,
Ros E. Carotid atherosclerosis in familial combined
hyperlipidemia associated with the APOB/APOA-1 ratio.
ATHEROSCLEROSIS. 197:740-746. I.F.:4,29.
8 Vinyoles E, Felip A, Pujol E, DeLaSierra A, Dura R, DelRey R, Sobrino J, Gorostidi M, DeLaFiguera M, Segura
J, Banegas JR, Ruilope LM. Clinical characteristics of
isolated clinic hypertension. J HYPERTENS. 26:438-445.
I.F.:4,36.
9 Civeira F, Ros E, Jarauta E, Plana N, Zambon D, Puzo J,
DeEsteban JPM, Ferrando J, Zabala S, Almagro F, Gimeno JA, Masana L, Pocovi M. Comparison of Genetic
Versus Clinical Diagnosis in Familial Hypercholesterolemia. AM J CARDIOL. 102:1187-1193. I.F.:3,60.
10 Salas-Salvado J, Garcia-Arellano A, Estruch R, Marquez-Sandoval F, Corella D, Fiol M, Gomez-Gracia E,
Vinoles E, Aros F, Herrera C, Lahoz C, Lapetra J, Perona
JS, Munoz-Aguado D, Martinez-Gonzalez M, Ros E.
Components of the mediterranean-type food pattern
and serum inflammatory markers among patients at
high risk for cardiovascular disease. EUR J CLIN NUTR.
62:651-659. I.F.:2,33.
11 Salas-Salvado J, Fernandez-Ballart J, Ros E, MartinezGonzalez MA, Fito M, Estruch R, Corella D, Fiol M,
PublicaTions
cal atherosclerosis of the carotid vessels, evaluated
using high-resolution ultrasound with microbubble
contrast and NMR.
cardiovascular risk
3. Circadian patterns, variability of arterial pressure
and injury of target organs. Sensitivity to salt in arterial hypertension. Inflammation in hypertension.
Hypertension and atrial fibrillation as a manifestation of cardiac lesion induced by hypertension.
4. Candidate genes for stroke risk in hypertensive patients. Candidate genes for the appearance of left
ventricular hypertrophy and heart failure in hypertensive patients.
5. Functionality of diet patterns and complete foods:
influence on arterial pressure evaluated by means
of outpatient and domiciliary monitoring, resistance to insulin, biologic markers of cholesterol absorption and vascular risk, oxidation of low-density
lipoproteins (LDLs).
6. Mild cognitive deterioration in situations of high
cardiovascular risk: evaluation of patients with FH
and effects of the Mediterranean diet. Evaluation of
rates of neurodegeneration in follow-up.
7. Absorption and synthesis of cholesterol: measurement, genetic determinants, influence on cardiovascular risk, effect of foods with a high phytosterol
content and relationship with the lipid response to
phytosterols and hypolipemiant drugs.
8. Influence of highly polyunsaturated long-chain fatty
acids (vegetable and marine omega-3) on preclini-
55
21/10/09 16:57:55
cardiovascular risk
12 13 14 Biopathology and Respiratory, Cardiovascular
15 16 17 18 19 20 Gomez-Gracia E, Aros F, Flores G, Lapetra J, LamuelaRaventos R, Ruiz-Gutierrez V, Bullo M, Basora J, Covas
MI. Effect of a Mediterranean Diet Supplemented With
Nuts on Metabolic Syndrome Status One-Year Results
of the PREDIMED Randomized Trial. ARCH INTERN
MED. 168:2449-2458. I.F.:8,39.
DeLaSierra A, Gorostidi M, Marin R, Redon J, Banegas
JR, Armario P, Puig JG, Zarco J, Llisterri JL, Sanchis C,
Abarca B, Palomo V, Gomis R, Otero A, Villar F, Honorato J, Tamargo J, Lobos JM, Macias-Nunez J, Sarria A,
Aranda P, Ruilope LM. Evaluation and management of
hypertension in Spain. A consensus guide. MED CLINBARCELONA. 131:104-116. I.F.:1,34.
Junyent M, Gilabert R, Zambon D, Pocovi M, Mallen M,
Cofan M, Nunez I, Civeira F, Tejedor D, Ros E. Femoral
atherosclerosis in heterozygous familial hypercholesterolemia influence of the genetic defect. ARTERIOSCL
THROM VAS. 28:580-586. I.F.:7,22.
Junyent M, Gilabert R, Nunez I, Corbella E, Cofan
M, Zambon D, Ros E. Femoral ultrasound in the assessment of preclinical atherosclerosis. Distribution
of intima-media thickness and frequency of atheroma
plaques in a Spanish community cohort. MED CLINBARCELONA. 131:566-571. I.F.:1,34.
Civeira F, Jarauta E, Cenarro A, Garcia-Otin AL, Tejedor
D, Zambon D, Mallen M, Ros E, Pocovi M. Frequency of
Low-Density Lipoprotein Receptor Gene Mutations in
Patients With a Clinical Diagnosis of Familial Combined
Hyperlipidemia in a Clinical Setting. J AM COLL CARDIOL. 52:1546-1553. I.F.:11,05.
Banegas JR, Segura J, DeLaSierra A, Gorostidi M, Rodriguez-Artalejo F, Sobrino J, DeLaCruz JJ, Vinyoles E,
DelRey RH, Graciani A, Ruilope LM. Gender Differences
in Office and Ambulatory Control of Hypertension. AM
J MED. 121:1078-1084. I.F.:4,91.
Guizy M, David M, Arias C, Zhang L, Cofan M, RuizGutierrez V, Ros E, Lillo MP, Martens JR, Valenzuela C.
Modulation of the atrial specific Kv1.5 channel by the
n-3 polyunsaturated fatty acid, alpha-linolenic acid. J
MOL CELL CARDIOL. 44:323-335. I.F.:5,25.
Llaverias G, Pou J, Ros E, Zambon D, Cofan M, Sanchez
A, Vazquez-Carrera M, Sanchez RM, Laguna JC, Alegret
M. Monocyte gene-expression profile in men with familial combined hyperlipidemia and its modification by
atorvastatin treatment. PHARMACOGENOMICS. 9:10351054. I.F.:3,37.
Coca A, Messerli FH, Benetos A, Zhou Q, Champion A,
Cooper-Dehoff RM, Pepine CJ. Predicting stroke risk in
hypertensive patients with coronary artery disease - A
report from the INVEST. STROKE. 39:343-348. I.F.:6,30.
DeLaSierra A, Egocheaga MI, Aguilera MT. Prevalence
and clinical characteristics of microalbuminuria in the
Spanish hypertensive population. MED CLIN-BARCELONA. 130:201-205. I.F.:1,34.
21 Kjeldsen SE, Mcinnes GT, Mancia G, Hua TA, Julius S,
Weber MA, Coca A, Girerd X, Jamerson K, Larochelle
P, Macdonald T, Schmieder RE, Schork MA, Viskoper
R, Widimsky J, Zanchetti A. Progressive effects of
valsartan compared with amlodipine in prevention of
diabetes according to categories of diabetogenic risk in
hypertensive patients: The VALUE trial. BLOOD PRESSURE. 17:170-177. I.F.:1,39.
22 Oliveras A, LaSierra A, Martinez-Estrada OM, Larrousse
M, Vazquez S, Soler MJ, Zuasti M, Vila JS, Reina M,
Roca-Cusachs A, Lloveras J. Putative endothelial progenitor cells are associated with flow-mediated dilation
in refractory hypertensives. BLOOD PRESSURE. 17:298305. I.F.:1,39.
Reviews
1
Coca A. Economic benefits of treating high-risk hypertension with angiotensin II receptor antagonists (blockers). CLIN DRUG INVEST. 28:211-220. I.F.:0,60.
Editorials
1
2
DeLaSierra A. Pulse pressure and cardiovascular risk:
from epidemiology to pathophysiology. MED CLINBARCELONA. 130:374-375. I.F.:1,34.
Ruilope LM, DeLaSierra A. Recient evidence of support
to arterial hypertension treatment guides. MED CLINBARCELONA. 131:101-103. I.F.:1,34.
Coca A. NoE - Integrated Genomics, Clinical Research and
Care in Hypertension. Grant: European Commision, LHSMCT-2006-037093. Duration: 01/11/2006-31/10/2010.
Ros E. Caracterización de las hipercolesterolemias autosómicas dominantes no dependientes de los genes del receptor LDL o apoB. Subproyecto 2: Concentraciones séricas de
fitoesteroles y aterosclerosis carotídea. Grant: Ministerio
Ros E. Subproject 1: Effects of Mediterranean diet intervention on the primary prevention of cardiovascular diseaseProject: Effects of a mediterranean diet intervention on the
atherosclerotic burden measured by imaging techniques
and systemic biomarkers. Modulat. Grant: Centro Nacional
de Investigaciones Cardiovasculares (CNIC), 06-2007-S01.
Duration: 19/02/2008-18/02/2012.
56
040-071 AREA2.indd 56
21/10/09 16:58:01
Respiratory Biophysics and Bioengineering
Team members
Team Leader:
■ Ramon Farré
(University of Barcelona)
Tel.: 93 402 45 15
Fax: 93 403 52 78
Collaborators:
Carles Falcón (IDIBAPS)
Raúl Tudela (CIBER-BBN)
Albert Cot (CIBER-BBN)
Francisco Pino (ICO)
Jordi Alcaraz (UB)
Xavier Trepat (UB-IBEC)
Theodora Tsapikouni (CIBERES)
Valentina Isetta (UE)
Raul Tudela (CIBER-BBN)
Doctoral Students:
Irene Acerbi (MEC)
Alba Carreras (MEC)
Núria Roé (IDIBAPS)
Raimon Sunyer (DURSI)
Valentina Isseta (UE)
Naira Martínez (IDIBAPS)
Berta Martí (CIBER-BBN)
Esther Melo (MEC)
Tomas Luque (CIBERES)
The general objectives of the group are the study of the
biophysical mechanisms that determine respiratory
function, and the development of models and methods for processing biomedical signals and images. The
group’s work is based on an interdisciplinary approach
and on the integration of basic and clinical research. In
parallel to the scientific objectives, our group potentiates the transfer to industry of the technologic advances deriving from the research.
Technicians:
Miguel Rodríguez (UB)
Rocío Nieto (CIBERES)
Respiratory biophysics and bioengineering
IDIBAPS Members:
■ Daniel Navajas (UB-IBEC)
■ Javier Pavía (Hospital Clínic)
■ Domènec Ros (University of Barcelona)
■ Mar Rotger (University of Barcelona)
1. Respiratory mechanics
The objective of research on respiratory mechanics is
to study the viscoelastic properties of the airways and
lung tissue. Work uscurrently aimed at studying the
collapsibility of the upper airways in obstructive sleep
apnea-hypopnea and monitoring noninvasive mechanical ventilation during respiratory failure. The clinical
objective of this research is to obtain better noninvasive diagnostic techniques and to optimize treatment
methods by means of ventilatory support.
040-071 AREA2.indd 57
57
Axial sections of a mouse cranium. The images correspond to a SPECT
bone study with 99mTc-HDP, using tomography and a reconstruction
algorithm developed by the group.
21/10/09 16:58:07
58
2. Molecular and cellular nanomechanics
The event of nanotechnology means that we can handle
matter at the nanometer and picoNewton scale and this
has opened up new opportunities for studying individual cells and biomolecules. Our group uses the atomic
force microscope, magnetic microspheres and traction
microscope to study cell adhesion and the mechanical
properties of lung cells and leukocytes. We also study
the mechanical properties of embryo and adult stem
cells during the differentiation process and how mechanical stimuli can encourage differentiation into the
alveolar epithelial phenotype.
3. Analysis of biomedical images
Research into image analysis is currently aimed at processing photon emission tomography (SPECT) and
positron emission tomography (PET) with the objective
of achieving a more accurate quantification of scintigraphy studies. With this aim in mind, we are developing iterative algorithms to reconstruct images in three
dimensions and to merge SPECT images and nuclear
magnetic resonance images (NMRI).
For more information:
http://www.ub.edu/biofisica
I.F.: 45,10
PublicaTions
Original Articles
1
Almendros I, Gutierrez PT, Closa D, Navajas D, Farre R.
One-lung overventilation does not induce inflammation
in the normally ventilated contralateral lung. RESP
PHYSIOL NEUROBI. 162:100-102. I.F.:2,20.
2 Pareto D, Aguiar P, Pavia J, Gispert JD, Cot A, Falcon
C, Benabarre A, Lomena F, Vieta E, Ros D. Assessment
of SPM in perfusion brain SPECT studies. A numerical
simulation study using bootstrap resampling methods.
IEEE T BIO-MED ENG. 55:1849-1853. I.F.:1,62.
3 Farre R, Montserrat JM, Navajas D. Assessment of
upper airway mechanics during sleep. RESP PHYSIOL
NEUROBI. 163:74-81. I.F.:2,20.
4 Almendros I, Acerbi I, Vilaseca I, Montserrat JM, Navajas D, Farre R. Continuous positive airway pressure
(CPAP) induces early nasal inflammation. SLEEP.
31:127-131. I.F.:4,34.
5 Aguiar P, Pareto D, Gispert JD, Crespo C, Falcon C, Cot
A, Lomena F, Pavia J, Ros D. Effect of anatomical variability, reconstruction algorithms and scattered photons
on the SPM output of brain PET studies. NEUROIMAGE. 39:1121-1128. I.F.:5,46.
6 Parellada E, Lomena F, Font M, Pareto D, Gutierrez F,
Simo M, Fernandez-Egea E, Pavia J, Ros D, Bernardo
M. Fluordeoxyglucose-PET study in first-episode schizophrenic patients during the hallucinatory state, after
remission and during linguistic-auditory activation.
NUCL MED COMMUN. 29:894-900. I.F.:1,30.
7 Gavara N, Roca-Cusachs P, Sunyer R, Farre R, Navajas
D. Mapping cell-matrix stresses during stretch reveals
inelastic reorganization of the cytoskeleton. BIOPHYS J.
95:464-471. I.F.:4,63.
8 Roca-Cusachs P, Alcaraz J, Sunyer R, Samitier J, Farre R,
Navajas D. Micropatterning of single endothelial cell shape reveals a tight coupling between nuclear volume in G1
and proliferation. BIOPHYS J. 94:4984-4995. I.F.:4,63.
9 Farre R, Montserrat JM, Navajas D. Morbidity due to
obstructive sleep apnea: insights from animal models.
CURR OPIN PULM MED. 14:530-536. I.F.:2,65.
10 Crespo C, Gallego J, Cot A, Falcon C, Bullich S, Pareto
D, Aguiar P, Sempau J, Lomena F, Calvino F, Pavia J,
Ros D. Quantification of dopaminergic neurotransmission SPECT studies with I-123-labelled radioligands. A
comparison between different imaging systems and
040-071 AREA2.indd 58
data acquisition protocols using Monte Carlo simulation. EUR J NUCL MED MOL I. 35:1334-1342. I.F.:4,10.
11 Paredes P, Vidal-Sicart S, Zanon G, Roe N, Rubi S,
Lafuente S, Pavia J, Pons F. Radioguided occult lesion
localisation in breast cancer using an intraoperative
portable gamma camera: first results. EUR J NUCL
MED MOL I. 35:230-235. I.F.:4,10.
12 Catafau AM, Bullich S, Danus M, Penengo MM, Cot A,
Abanades S, Farre M, Pavia J, Ros D. Test-retest variability and reliability of 123I-IBZM SPECT measurement
of striatal dopamine D2 receptor availability in healthy
volunteers and influence of iterative reconstruction algorithms. SYNAPSE. 62:62-69. I.F.:2,52.
13 Almendros I, Carreras A, Ramirez J, Montserrat JM,
Navajas D, Farre R. Upper airway collapse and reopening induce inflammation in a sleep apnoea model.
EUR RESPIR J. 32:399-404. I.F.:5,35.
Editorials
1
Trepat X, Farre R. Alveolar permeability and stretch: too
far, too fast. EUR RESPIR J. 32:826-828. I.F.:5,35.
Navajas D. Fisiopatologia i tractament de les malalties respiratòries. Grant: Comissionat per a Universitats i Recerca,
2005SGR00822. Duration: 19/10/2005-31/12/2008.
Farré R. Estudio de los mecanismos de ruptura de la membrana epitelial alveolar por sobredistensión en la lesión
pulmonar inducida por el ventilador. Grant: Ministerio
Educación y Ciencia, SAF2005-00110. Duration: 30/12/200531/12/2008.
Navajas D. Micromechanics of the airway smooth muscle
cell. Grant: National Institutes of Health, R01HL65960-06.
Duration: 01/06/2005-31/12/2010.
Farré R. An open, ubiquitous and adaptive chronic disease
management platform for COPD and renal insufficiency (CHRONIOUS). Grant: European Commission, FP7ICT-2007-1. Duration: 01/01/2007-31/12/2011.
Navajas D. Aplicación de pinzas ópticas el estudio de la
cinética del enlace ligando-selectina en neutrófilos. Grant:
21/10/09 16:58:13
Ministerio de Educación y Ciencia, Acción Estratégica de
Nanociencia y Nanotecnología, NAN2004-09348-C04-04. Duration: 30/12/2005-31/12/2008.
Navajas D. Integrated molecular and cellular mechanotransduction mediated by protein p130Cas (CELL-TRANS). Grant:
European Commission, PIOF-GA-2008-219401. Duration:
30/12/2008-31/12/2010.
Ros D. Consorcio para el Desarrollo de Tecnologías Avanzadas Para La Medicina (CDTEAM). Grant: Ministerio de
Industria, Comercio y Turismo, CDTI, Convocatoria CenitIngenio., CDTEAM. Duration: 01/01/2006-31/12/2009.
Farré R. CIBER de Enfermedades Respiratorias (CIBERES).
Grant: Ministerio de Sanidad y Consumo (FIS), CB06. Duration: 01/01/2008-31/12/2008.
Ritort F, Navajas D. Contribution of active processes to the
cytoskeleton dynamics of living cells. Doctorand: Raimon
Sunyer Borrell.
Ros D, Pavia J. Procesamiento de imágenes en SPECT cerebral:
Cuantificación de estudios de neurotransmisión en el sistema
dopaminérgico y registro de estudios de flujo en la epilepsia
farmacorresistente. Doctorand: Cristina Crespo Vázquez.
Pavia J, Ros D. Reconstruction, quantification and standardization methods in positron emission tomography. Doctorand: Pablo Aguiar Fernández.
Patents
Francisco Pino, Carles Falcón, Albert Cot, Domènec Ros,
Javier Pavía. Software de Reconstrucció Iterativa per
SPECT d’animal petit de radi de gir variable equipat amb
col·limador Pin-hole (SORIP).
Navajas D. Estudi dels mecanismes biofísics de l’adhesió
cel·lular mitjançant microscòpia de força atòmica. Grant: DURSI – Generalitat de Catalunya. Duration: 30/12/2008-31/12/2009.
Thesis
59
040-071 AREA2.indd 59
21/10/09 16:58:19
Applied Research on Infectious Respiratory Diseases,
Critical Patients and Lung Cancer
Team Members
Applied research on infectious
respiratory diseases, critical
patients and lung cancer
Team Leader:
■ Antoni Torres (Hospital Clínic)
Tel.: 93 227 55 49
Fax: 93 227 55 49
60
IDIBAPS Members:
■ Carles Agustí (Hospital Clínic)
■ Joan Ramon Badia (Hospital Clínic)
■ Eugeni Ballester (Hospital Clínic)
■ Miquel Ferrer (Hospital Clínic)
■ Ramon Marrades (Hospital Clínic)
■ Josep Mª Montserrat (Hospital Clínic)
■ Néstor Soler (Hospital Clínic)
■ Dolors Soy (Hospital Clínic)
Collaborators:
Marc Miravitlles (Fundació Clínic)
Núria Sànchez (CAPSE)
Jacobo Sellarés (Hospital del Mar)
Pilar Martínez (Hospital Clínic)
Eva Polverino (Hospital Clínic/ CibeRes)
Montserrat Rigol (IDIBAPS/CibeRes)
Doctoral Students:
Sònia Borrell (UB)
Mateu Espasa (FIS)
Mariano Esperatti (FIS)
Arnoldo Guerrero (Hospital Clínic)
Arturo Huerta (FIS)
Sònia Juarez (UB)
Néstor Luque (FIS/La Marató)
Griselda Tudó (MEC)
Emma Rey (Fundació Clínic)
Mantó Liapikou (ERS)
Catia Cillóniz (FIS)
Gema Tirado (SEPAR)
Patrícia Gutiérrez (La Marató TV3)
Laia Fernàndez (CibeRes)
Anna Theessen (UB)
Technicians:
Marta Cardiel (Fundació Clínic)
Nurses:
Alicia Borràs (IDIBAPS/Hospital Clínic)
Cristina Esquinas (IDIBAPS/Hospital Clínic)
Raquel Piñer (IDIBAPS/CibeRes)
Patrícia Fernández (FIS)
Encarnación Moreno (Fundació Clínic)
Secretary:
Elisabet Sancho
1. Study of community-acquired and nosocomial respiratory infections and respiratory infections in immunosuppressed patients.
2. Study of invasive and noninvasive mechanical ventilation in acute respiratory failure, with special interest in weaning from artificial ventilation.
3. Study of exacerbations of COPD and the implication
of bacterial, viral and fungal infectious agents.
4. Pathophysiologic studies and treatment in an animal model of ventilator-associated pneumonia.
5. Study of the resistance of microorganisms to antibiotics and antituberculosis drugs.
6. Study of the transmission of tuberculosis.
7. Studies of human research in animal models of
sleep apnea syndrome.
8. Multicenter studies in relation to sleep respiratory
pathology and the cardiovascular apparatus.
9. Epidemiology and diagnosis of lung cancer.
1.Epidemiology, prevention, diagnosis and new
treatments for ventilator-associated pneumonia.
Microorganism resistance. Study of biofilm in endotracheal tubes.
2. Epidemiology and diagnosis of community-acquired pneumonia. Multicenter studies in communityacquired pneumonia. New treatments. Microorganism resistance.
3. Studies of the risk factors, microbiology and
outcomes of health care associated pneumonia
(HCAP).
4. Etiopathogenesis, bronchial infection and inflammation in patients with chronic obstructive pulmonary
disease (COPD). Role of infection in exacerbations
of the disease. Study of the bronchial and associated systemic response. Analysis of risk factors and
outcomes in exacerbations. Smoking. Epidemiology and diagnosis of alpha-1-antitrypsin.
040-071 AREA2.indd 60
21/10/09 16:58:26
PublicaTions
Original Articles
1
2
3
4
5
Dambrava PG, Torres A, Valles X, Mensa J, Marcos MA,
Penarroja G, Camps M, Estruch R, Sanchez M, Menendez
R, Niederman MS. Adherence to guidelines’ empirical
antibiotic recommendations and community-acquired
pneumonia outcome. EUR RESPIR J. 32:892-901. I.F.:5,35.
Marco F, DeLaMaria CG, Armero Y, Amat E, Soy D,
Moreno A, DelRio A, Almela M, Mestres CA, Gatell JM,
JimenezDeAnta MT, Miro JM. Daptomycin is effective in
treatment of experimental endocarditis due to methicillinresistant and glycopeptide-intermediate Staphylococcus
aureus. ANTIMICROB AGENTS CH. 52:2538-2543. I.F.:4,39.
AntiretroviralTherapyCohortCollaboration (ART-CC),
Gatell JM, Miro JM, Agusti C. Does short-term virologic
failure translate to clinical events in antiretroviral-naive
patients initiating antiretroviral therapy in clinical practice? The Antiretroviral Therapy Cohort Collaboration
(ART-CC)anti. AIDS. 22:2481-2492. I.F.:5,84.
Menendez R, Cavalcanti M, Reyes S, Mensa J, Martinez R, Marcos MA, Filella X, Niederman M, Torres A.
Markers of treatment failure in hospitalised community
acquired pneumonia. THORAX. 63:447-452. I.F.:6,23.
Serra MC, Cervera C, Pumarola T, Moreno A, Perello R,
Torres A, JimenezDeAnta MT, Marcos MA. Virological diagnosis in community-acquired pneumonia in immunocompromised patients. EUR RESPIR J. 31:618-624. I.F.:5,35.
040-071 AREA2.indd 61
9.Tuberculosis and mycobacteriosis: epidemiology and
molecular diagnosis, drug-resistance mechanisms.
10.Pig animal model of acute lung injury due to P aeruginosa and MR S aureus: study of new adjuvant
drugs in the treatment of pneumonia, study if new
antibiotics, prevention of VAP, new forms of mechanical ventilation.
11.Chronic models of sleep apnea.
12.Basic molecular biology, epidemiology and diagnosis of lung cancer.
13.European studies of respiratory infections. Participation in the GRACE, MOSAR and THERAEDGE
projects that study respiratory infections in the
community, in hospitals, and new diagnostic methodologies, respectively.
For further information:
www.idibapsrespiratoryresearch.org
I.F.: 76,37
6 Egea CJ, Azpuru F, Pinto JA, Ayuela JM, Ballester E,
Zamarron C, Sojo A, Montserrat JM, Barbe F, Angel
M, Gomez A, Rubio R, Loobo JL, Duran-Cantolla J,
Zorrila V, Nunez R, Cortes J, Jimenez A, Cifrian J,
Ortega M, Carpizo R, Sanchez A, Teran J, Iglesias L,
Fernandez C, Alonso ML, Cordero J, Roig E, Perez F,
Muxi A, Gude F, Amaro A, Calvo U, Masa JF, Utrabo I,
Porras Y, Lanchas I, Sanchez E. Cardiac function after
CPAP therapy in patients with chronic heart failure
and sleep apnea: A multicenter study. SLEEP MED.
9:660-666. I.F.:2,80.
7 Farre R, Montserrat JM, Navajas D. Assessment of
upper airway mechanics during sleep. RESP PHYSIOL
NEUROBI. 163:74-81. I.F.:2,20.
8 Almendros I, Acerbi I, Vilaseca I, Montserrat JM, Navajas D, Farre R. Continuous positive airway pressure
(CPAP) induces early nasal inflammation. SLEEP.
31:127-131. I.F.:4,34.
9 Farre R, Montserrat JM, Navajas D. Morbidity due to
obstructive sleep apnea: insights from animal models.
CURR OPIN PULM MED. 14:530-536. I.F.:2,65.
10 Almendros I, Carreras A, Ramirez J, Montserrat JM,
Navajas D, Farre R. Upper airway collapse and reopening induce inflammation in a sleep apnoea model.
EUR RESPIR J. 32:399-404. I.F.:5,35.
11 Sibila O, Luna CM, Agusti C, Baquero S, Gando S, Patron JR, Morato JG, Absi R, Bassi N, Torres A. Effects of
5. Chronic pulmonary infections: bronchiectasis, immunodeficiencies and adult cystic fibrosis. Control
of bronchial colonization. Study of the bronchial inflammatory and associated systemic response. New
therapeutic forms (nebulizer antibiotic treatment).
Replacement therapy with immunoglobulin.
6. Infectious pulmonary complications in immunocompromised patients. Evaluation of etiologic factors. Optimization of diagnostic techniques. Study
of the bronchial inflammatory and associated systemic response. Analysis of outcome factors.
7. Invasive and noninvasive mechanical ventilation:
Epidemiology, cost-effectiveness and pathophysiology. New techniques. Weaning from mechanical
ventilation: role of the inflammatory response and
post-extubation respiratory failure.
8. Study of the pharmacokinetics of antibiotics and
other drugs in ventilated and nonventilated patients.
Effects of the semi-recumbent position and ventilatory patterns on mucus clearance during mechanical ventilation. Tracheal mucus movement
studies in a pig in the prone position and in a model of the semi-recumbent position, after 72 hours of mechanical ventilation. Red line indicates orientation
of the surgical bed 30 degrees above horizontal. The pig was ventilated with an inspiratory-expiratory ratio of 1:3 that produced an inspiratory flow bias,
directing mucus toward the lungs. Black upper and lower arrows indicate the dorsal (non-dependent) and ventral (dependent) tracheal surface, respectively.
Mucus was tracked through tracheal insufflation of tantalum disks (weight of each tantalum disk was 1 mg and diameter and thickness were 0.6 and 0.1
mm, respectively), and movement was computed via timed serial lateral fluoroscopic images. Each red circle highlights a tracked tantalum disk. A total of
6 tantalum disks were deposited on the most dependent part of the trachea (A). Fluoroscopic image taken after 5 min (B) showed mucus moving towards
the lungs. After only 7 min, 5 of the 6 tantalum disks were outside the fluoroscopic field, showing that mucus moved towards the lungs (C).
61
21/10/09 16:58:32
12 Applied research on infectious
13 14 15 16 Biopathology and Respiratory, Cardiovascular
17 18 19 Reviews
1
2
62
glucocorticoids in ventilated piglets with severe pneumonia. EUR RESPIR J. 32:1037-1046. I.F.:5,35.
Iglesias M, Martinez E, Badia JR, Macchiarini P. Extrapulmonary ventilation for unresponsive severe acute
respiratory distress syndrome after pulmonary resection. ANN THORAC SURG. 85:237-244. I.F.:2,02.
Garcia-Esteve L, Navarro P, Ascaso C, Torres A, Aguado
J, Gelabert E, Martin-Santos R. Family caregiver role
and premenstrual syndrome as associated factors for
postnatal depression. ARCH WOMEN MENT HLTH.
11:193-200. I.F.:1,91.
Torres A, Garau J, Arvis P, Carlet J, Choudhri S, Kureishi A, LeBerre MA, Lode H, Winter J, Read RC.
Moxifloxacin monotherapy is effective in hospitalized
patients with community-acquired pneumonia: The
MOTIV study - A randomized clinical trial. CLIN INFECT
DIS. 46:1499-1509. I.F.:6,75.
Molina R, Auge JM, Escudero JM, Marrades R, Vinolas
N, Carcereny E, Ramirez J, Filella X. Mucins CA 125, CA
19.9, CA 15.3 and TAG-72.3 as Tumor Markers in Patients with Lung Cancer: Comparison with CYFRA 21-1,
CEA, SCC and NSE. TUMOR BIOL. 29:371-380. I.F.:2,48.
Almirall J, Bolibar I, Serra-Prat M, Roig J, Hospital I,
Carandell E, Agusti M, Ayuso P, Estela A, Torres A.
New evidence of risk factors for community-acquired
pneumonia: a population-based study. EUR RESPIR J.
31:1274-1284. I.F.:5,35.
Alvarez-Lerma F, Olaechea P, Grau S, Marin M, Dominguez A, Martinez-Lanao J, Soy D, Alos M, Calvo MV,
Sadaba B, Mediavilla A, Fatelaj D. Recommendations
for antibiotic monitoring in ICU patients. ENFERM INFEC MICR CL. 26:230-239. I.F.:1,10.
Ramirez P, Garcia MA, Ferrer M, Aznar J, Valencia M,
Sahuquillo JM, Menendez R, Asenjo MA, Torres A. Sequential measurements of procalcitonin levels in diagnosing ventilator-associated pneumonia. EUR RESPIR J. 31:356-362. I.F.:5,35.
Molina-Molina M, Xaubet A, Marrades RM, Luburich
P, Ramirez J, Torres A, Augusti C, Martínez-Olondris P.
Transbronchial needle aspiration in the study of mediastinal lymph nodes: Yield and cost-effectiveness.
ARCH BRONCONEUMOL. 44:290-294. I.F.:1,56.
Sibila O, Agusti C, Torres A. Corticosteroids in severe
pneumonia. EUR RESPIR J. 32:259-264. I.F.:5,35.
Jimenez JFM, Penafiel JC, Ledesma EG, Montserrat
JM. Sleep Apnea Year 2006: Review of Publications in
Archivos de Bronconeumologia. ARCH BRONCONEUMOL. 44:611-620. I.F.:1,56.
Editorials
1
2
3
040-071 AREA2.indd 62
Torres A, Menendez R. Hospital admission in community-acquired pneumonia. MED CLIN-BARCELONA.
131:216-217. I.F.:1,34.
Ferrer M, Torres A. Maintenance of tracheal tube
cuff pressure: where are the limits?. CRIT CARE. 12:-.
I.F.:3,83.
Soler N. Systemic Markers of Exacerbated Chronic Obstructive Pulmonary Disease: How They Can Help With
4
the Decision of Whether or Not to Prescribe Antibiotics.
Badia JR, Ferguson ND. Ventilator-induced lung injury:
another sign of aging?. INTENS CARE MED. 34:796-799.
I.F.:4,62.
Multicentrics
1
Bordon J, Peyrani P, Brock GN, Blasi F, Rello J, File T,
Ramirez J, Torres A. The presence of pneumococcal bacteremia does not influence clinical outcomes in patients
with community-acquired pneumonia - Results from the
Community-Acquired Pneumonia Organization (CAPO)
International Cohort Study. CHEST. 133:618-624. I.F.:4,14.
Agusti C. COPD: Effect of stop smoking on airway inflammation. Grant: Fundació Marató TV3, 40210. Duration:
02/02/2005-01/02/2008.
Torres A. Risk and pronostic factors of community-acquired
pneumonia in COPD patients. Impact of inflammatory
response. Grant: Fundació Marató TV3, 40530. Duration:
21/01/2005-20/01/2008.
Montserrat JM. CIBER Enfermedades respiratorias. Grant:
Ministerio Sanidad y Consumo, CB06/06/0025. Duration:
28/07/2006-27/07/2010.
Torres A. CIBER Enfermedades respiratorias. Grant: Ministerio Sanidad y Consumo, CB06/06/0028. Duration:
28/07/2006-27/07/2010.
Torres A. Premio Fundacion Lilly de Investigación Biomédica Clínica 2007. Grant: Fundación Lilly, Lilly_501222. Duration: 09/05/2007-31/12/2009.
Torres A. Factores de riesgo y pronóstico de la neumonía
adquirida en la comunidad en pacientes con EPOC. Impacto
de la respuesta inflamatoria. Grant: Ministerio Sanidad y
Badia JR. Evaluación diagnóstica invasiva frente a no invasiva en la neumonía asociada a la ventilación mecánica
que no responde a tratamiento. Impacto sobre la evolución
y pronóstico y desarrollo de un algoritmo de diagnóstico.
01/01/2006-30/12/2008.
Torres A. Modelo animal de neumonía asociada a la ventilación mecánica (NAVM). Estudio de la respuesta inflamatoria asociada y su modulación por glucocorticoides.
01/01/2006-30/12/2008.
Ballester E. Estudio validez, coste-efectividad y análisis de
decisiones de un sistema monocal experto (MicroMesam)
para el diagnóstico de pacientes con sospecha clínica
de síndrome de apneas.Hipopneas del sueño (SAHS).
01/01/2006-30/12/2008.
21/10/09 16:58:38
Montserrat JM. Estudio de validez diagnóstica y análisis de
coste de la poligrafía respiratoria domiciliaria con transmisión telemática de los datos. Grant: Ministerio Sanidad y
Ferrer M. Traqueostomía precoz en ventilación mecánica.
Eficacia en la prevención de la neumonía asociada al ventilador y en la formación de biofilm en los tubos endotraqueales. Grant: Ministerio Sanidad y Consumo, PI050620.
Duration: 01/01/2006-30/12/2008.
Torres A. Genomic to combat resistance against antibiotics
in community-acquired LRTI in Europe. Grant: Universiteit
Antwerpen, LSHM-CT-2005-518226. Duration: 01/03/200728/02/2011.
Torres A. An integrated platform enabling Theranostic
applications at the Point of Primary Care. Grant: NTE, S.A.,
216027. Duration: 01/03/2008-29/02/2012.
Soy D. Eficacia del tratamiento con Linezolid comparado
con vancomicina en la neumonia asociada a la ventilación
mecánica (NAVM) por Staphylococcus Aureus Meticilinresistente. Estudio en un modelo porcino. Grant: Ministerio
Soler N. Evalución prospectiva de la purulencia del esputo y
la procalcitonina como marcadores de infección respiratoria
discal en la agudización de la enfermedad pulmonar obstructiva crónica (EPOC). Grant: Ministerio Sanidad y Consumo, PI070472. Duration: 26/11/2007-30/12/2010.
63
040-071 AREA2.indd 63
21/10/09 16:58:43
Pathophysiologic Mechanisms of Respiratory Diseases
Team Members
Pathophysiologic mechanisms of
respiratory diseases
Team Leader:
■ Joan Albert Barberà
(Hospital Clínic)
Tel.: 93 227 57 47
Fax: 93 227 54 55
64
IDIBAPS Members:
■ Ricard Bastos (Fundació Clínic)
■ Paolo Macchiarini (Hospital Clínic)
■ Josep Roca (Hospital Clínic)
■ Robert Rodríguez-Roisín (Hospital Clínic)
■ Elizabeth Zavala (Hospital Clínic)
Collaborators:
Albert Alonso (Fundació Clínic)
Isabel Blanco (Hospital Clínic)
Felip Burgos (Hospital Clínic)
Federico Gómez (University of Barcelona)
Carme Hernández (Hospital Clínic)
Graciela Martínez-Pallí (Hospital Clínic)
Mª Teresa Melgosa (Fundació Clínic)
Melina Musri (IDIBAPS)
Victor I. Peinado (CIBERES)
Sandra Pizarro (Hospital Clínic)
Karina Portillo (Fundació Clínic)
Giovanni Ricci (IDIBAPS)
Bárbara Vallespin (IDIBAPS)
Jordi Vilaró (Fundació Clínic)
Vitaly Selivanov (CIBERES)
Cesar Valdés (Fundació Clínic)
Lisbeth Hernández (Fundació Clínic)
Gemma Alcarraz (Fundació Clínic)
Lluís Solanell (Fundació Clínic)
Doctoral Students:
Denisse Carpio (SEPAR)
Rose Carvalho (CAPES, Ministerio Educación Brasil)
Marta Díez (FIS)
Elisabeth Ferrer (FIS)
Elena Gimeno (IDIBAPS)
Hernán Manrique (ERS-SEPAR)
Phillip Muñoz (IDIBAPS)
Diego Rodríguez (ERS-SEPAR)
Claudio Villaquirán (SEPAR-ALAT)
Technicians:
Carmen Argaña (Hospital Clínic)
David Domínguez (IDIBAPS)
Raquel Puig-Pey (IDIBAPS)
Marta Vives (IDIBAPS)
Philip Junglebuth (Fundació Clínic)
Nurses:
Conchi Gistau (Hospital Clínic)
Yolanda Torralba (CIBERES)
Maite Simó (Hospital Clínic)
Maria Palomo (Fundació Clínic)
1. Investigation of the molecular and cellular bases of
chronic respiratory diseases, with special interest in
pulmonary circulation disorders and systemic manifestations.
2. Study of the pathophysiologic and pathogenetic
mechanisms related to acute and chronic respiratory failure, focusing on chronic obstructive disases, liver and lung disorders and obesity.
3. Evaluation of the potential of cell therapy and tissue
engineering applied to respiratory diseases.
4. Development of artificial and bioartificial lung models for supporting patients with acute and chronic
respiratory failure.
5. Study of the factors that determine the clinical course and use of health care resources in patients with
chronic respiratory diseases.
1.Biopathology and physiopathology of lung circulation disorders.
2.Physical activity, cell bioenergetics and systemic
effects of chronic obstructive pulmonary disease
(COPD).
3. Pathophysiologic mechanisms of abnormal gas exchange in obstructive diseases of the airways.
4. Interaction between systemic and pulmonary inflammation in COPD and morbid obesity.
5.Tissue engineering and bioartificial lung models.
6.Factors that determine the clinical course and use of
health care resources in patients with chronic respiratory diseases.
7.Analysis of inflammation and oxidative stress biomarkers in exhaled air for the study of respiratory
diseases.
040-071 AREA2.indd 64
21/10/09 16:58:51
Objectives Achieved
1. To analyze the mechanisms that affect the differentiation of stem cells in smooth muscle cells of the
vascular wall.
Image of two vascular progenitor cells taken with interdifferential
technique. One of the cells keeps the progenitor phenotype, and the
other one acquires the smooth muscle cell phenotype.
I.F.: 72,67
PublicaTions
Original Articles
1
2
3
4
Gomez-Caro A, Martinez E, Rodriguez A, Sanchez D,
Martorell J, Gimferrer JM, Haverich A, Harringer W, Pomar JL, Macchiarini P. Cryopreserved Arterial Allograft
Reconstruction After Excision of Thoracic Malignancies.
ANN THORAC SURG. 86:1753-1761. I.F.:2,02.
Macchiarini P, Jungebluth P, Go T, Asnaghi MA, Rees LE,
Cogan TA, Dodson A, Martorell J, Bellini S, Parnigotto
PP, Dickinson SC, Hollander AP, Mantero S, Conconi MT,
Birchall MA. Clinical transplantation of a tissue-engineered airway. LANCET. 372:2023-2030. I.F.:28,64.
Iglesias M, Martinez E, Badia JR, Macchiarini P. Extrapulmonary ventilation for unresponsive severe acute
respiratory distress syndrome after pulmonary resection. ANN THORAC SURG. 85:237-244. I.F.:2,02.
Manrique HA, Gomez FP, Munoz PA, Pena AM, Barbera
JA, Roca J, Rodriguez-Roisin R. Adenosine 5 ‘-monophosphate in asthma: gas exchange and sputum cellular responses. EUR RESPIR J. 31:1205-1212. I.F.:5,35.
040-071 AREA2.indd 65
5
6
7
8
Jungebluth P, Ostertag H, Macchiarini P. An experimental animal model of postobstructive pulmonary hypertension. J SURG RES. 147:75-78. I.F.:1,84.
Peces-Barba G, Barbera JA, Agusti A, Casanova C,
Casas A, Izquierdo JL, Jardim J, Varela VL, Monso E,
Montemayor T, Viejo JL. Diagnosis and management
of chronic obstructive pulmonary disease: Joint Guidelines of the Spanish Society of Pulmonology and Thoracic Surgery (SEPAR) and the Latin American Thoracic
Society (ALAT). ARCH BRONCONEUMOL. 44:271-281.
I.F.:1,56.
Peinado VI, Paris R, Ramirez J, Roca J, RodriguezRoisin R, Barbera JA. Expression of BKCa channels in
human pulmonary arteries: Relationship with remodeling and hypoxic pulmonary vasoconstriction. VASC
PHARMACOL. 49:178-184. I.F.:2,37.
Iglesias M, Jungebluth P, Petit C, Matute MP, Rovira
I, Martinez E, Catalan M, Ramirez J, Macchiarini P.
Extracorporeal lung membrane provides better lung
protection than conventional treatment for severe
Future Challenges
1. An experimental guinea-pig model has shown that
chronic exposure to tobacco smoke and hypoxia
have similar effects on lung circulation and that these effects are potentiate when both are combined.
2. It has been shown that patients with COPD have a
lower number of circulating endothelial stem cells
derived from bone marrow and also endothelial disorder of the systemic arteries.
3. It has been shown that abnormal mitochondrial disorder in muscle cells occurs in a subgroup of patients with COPD and low weight.
4. Studies of genome profile in lung samples from
patients with COPD have shown changes in the expression of genes related to vascular regulation.
5. It has been shown that people exposed to the spillage of the Prestige oil tanker present oxidative stress
markers in exhaled air two years after exposure.
6. The effects of inhalation of mannitol have been evaluated in asthmatic subjects and compared to those
produced by physical exercise.
7. The effect of inhaled adenosine monophosphate
(AMP) on the airways and gas exchange in patients
with asthma has been evaluated and compared
with that produced by methacholine.
8. A study has been initiated to evaluate the efficacy
and safety of a phosphodiesterase-5 inhibitor (sildenafil) in the treatment of pulmonary hypertension
associated with COPD.
2.To evaluate the effect of endothelial function modulating drugs (endothelial receptor antagonists and
phosphodiesterase inhibitors) on pulmonary vascular action caused by exposure to tobacco smoke
and hypoxia.
3.To study the effect on lung hemodynamics of intratracheal instillation of mesenchymal stem cells derived from bone marrow in an experimental model
of pulmonary hypertension.
4.To complete development of a software platform
that makes it possible to integrate genomic, proteomic and metabolomic databases with clinical and
functional data in prevalent chronic diseases.
5. To study the effects of muscle training and physical
activity in COPD.
6.To study the pathophysiologic mechanisms of benign tracheal stenosis.
65
21/10/09 16:58:57
9
10
11
12
13
14
15
postpneumonectomy noncardiogenic acute respiratory distress syndrome. J THORAC CARDIOV SUR.
135:1362-U300. I.F.:3,35.
Chappell S, Daly L, Morgan K, Guetta-Baranes T, Roca
J, Rabinovich R, Lotya J, Millar AB, Donnelly SC, Keatings V, Macnee W, Stolk J, Hiemstra PS, Miniati M,
Monti S, O’connor CM, Kalshelker N. Genetic variants
of microsomal epoxide hydrolase and glutamatecysteine ligase in COPD. EUR RESPIR J. 32:931-937.
I.F.:5,35.
Jungebluth P, Iglesias M, Go T, Sibila O, Macchiarini P.
Optimal Positive End-Expiratory Pressure During Pumpless Extracorporeal Lung Membrane Support. ARTIF
ORGANS. 32:885-890. I.F.:1,84.
Munoz PA, Gomez FP, Manrique HA, Roca J, Barbera JA, Young IH, Anderson SD, Rodriguez-Roisin R.
Pulmonary gas exchange response to exercise- and
mannitol-induced bronchoconstriction in mild asthma.
J APPL PHYSIOL. 105:1477-1485. I.F.:3,63.
Barbera JA, Escribano P, Morales P, Gomez MA, Oribe
M, Martinez A, Roman A, Segovia J, Santos F, Subirana
MT. Standards of care in pulmonary hypertension. REV
ESP CARDIOL. 61:170-184. I.F.:2,21.
Barbera JA, Escribano P, Morales P, Gomez MA, Oribe
M, Martinez A, Roman A, Segovia J, Santos F, Subirana MT. Standards of care in pulmonary hypertension.
Selivanov VA, Zeak JA, Roca J, Cascante M, Trucco M,
Votyakova TV. The Role of External and Matrix pH in
Mitochondrial Reactive Oxygen Species Generation. J
BIOL CHEM. 283:29292-29300. I.F.:5,58.
Miniati M, Monti S, Stolk J, Mirarchi G, Falaschi F, Rabinovich R, Canapini C, Roca J, Rabe KF. Value of chest
radiography in phenotyping chronic obstructive pulmonary disease. EUR RESPIR J. 31:509-514. I.F.:5,35.
3
4
5
6
sion A Randomized Trial. ANN INTERN MED. 149:521W102. I.F.:15,52.
Mascia L, Sakr Y, Pasero D, Payen D, Reinhart K, Vincent JL. Extracranial complications in patients with acute brain injury: a post-hoc analysis of the SOAP study.
INTENS CARE MED. 34:720-727. I.F.:4,62.
Sakr Y, Madl C, Filipescu D, Moreno R, Groeneveld
J, Artigas A, Reinhart K, Vincent JL. Obesity is
associated with increased morbidity but not mortality
in critically ill patients. INTENS CARE MED. 34:19992009. I.F.:4,62.
Sakr Y, Vincent JL, Ruokonen E, Pizzamiglio M, Installe
E, Reinhart K, Moreno R. Sepsis and organ system failure are major determinants of post-intensive care unit
mortality. J CRIT CARE. 23(4):475-483. I.F.:1,69.
Varela MVL, Muino A, Padille RP, Jardim JR, Talamo C,
DeOca MM, Valdivia G, Pertuze J, Halbert R, Menezes
AM, Marquez M, Hallal P, Moreno D, Rosa F, Carnelier
A. Treatment of chronic obstructive pulmonary disease
in 5 Latin American cities: The PLATINO study. ARCH
BRONCONEUMOL. 44:58-64. I.F.:1,56.
Barbera JA. IP - Pulmonary Hypertension: Functional Genomics and Therapy of Lung Vascular Remodelling. Grant:
European Commision, LSHM-CT-2005-018725. Duration:
01/01/2006-31/12/2010.
Roca J. Indicators for Monitoring COPD and Asthma in the
Eu - IMCA 11. Grant: European Commision, 2005121. Duration: 01/01/2007-31/12/2009.
Roca J. Remote Health Monitoring with Wearable Non-Invasive Mobile System. Grant: European Commision, C029402.
Duration: 01/12/2006-29/05/2008.
Reviews
1
2
3
4
Birchall M, Macchiarini P. Airway transplantation: A
debate worth having?. TRANSPLANTATION. 85:10751080. I.F.:3,64.
Rodriguez-Roisin R, Krowka MJ. Current concepts:
Hepatopulmonary syndrome - A liver-induced lung
vascular disorder. NEW ENGL J MED. 358:2378-2387.
I.F.:52,59.
Peinado VI, Pizarro S, Barbera JA. Pulmonary Vascular
Involvement in COPD. CHEST. 134:808-814. I.F.:4,14.
Rodrigo GJ, Nannini LJ, Rodriguez-Roisin R. Safety of
long-acting beta-agonists in stable COPD - A systematic
review. CHEST. 133:1079-1087. I.F.:4,14.
Roca J. Better Breathing; A New Model For Continuous Care
Of Chronic Patients Ecare, Erehabilitation, Epatient Community and Elearning For Patients With Breathing Handicaps.
Grant: European Commision, C046225. Duration: 01/06/200731/10/2008.
Roca J. STREP - Integrative Genomics and Chronic Disease
Phenotypes: modelling and simulation tools for clinicians.
Grant: European Commision, LSHG-CT-2006-037939. Duration: 01/12/2006-31/05/2009.
Roca J. IP - Healthcare by Biosensor Measurements
And Networking. Grant: European Commision, NMP4CT-2006-017333. Duration: 01/11/2005-31/10/2010.
Multicentrics
66
1
2
040-071 AREA2.indd 66
Payen D, DePont AC, Sakr Y, Spies C, Reinhart K, Vincent JL. A positive fluid balance is associated with a
worse outcome in patients with acute renal failure.
CRIT CARE. 12:-. I.F.:3,83.
Simonneau G, Rubin LJ, Galie N, Barst RJ, Fleming
TR, Frost AE, Engel PJ, Kramer MR, Burgess G, Collings L, Cossons N, Sitbon O, Badesch DB. Addition
of Sildenafil to Long-Term Intravenous Epoprostenol
Therapy in Patients with Pulmonary Arterial Hyperten-
Barbera JA. Estudi de la contribució de les cèl•lules progenitores vasculars en els mecanismes de lesió i reparació
vascular a la circulació pulmonar en la malaltia pulmonar
obstructiva crònica (MPOC). Grant: Fundació Marató TV3,
40310. Duration: 12/01/2005-11/01/2008.
Roca J. Atenció integrada I biopatologia de la MPOC
avançada. Grant: Fundació Marató TV3, 42010. Duration:
12/01/2005-11/01/2008.
21/10/09 16:59:03
Roca J. BIOBRIDGE. Grant: Ministerio Sanidad y Consumo,
AI07/90027. Duration: 26/10/2007-30/12/2009.
Barbera JA. Enfermedades respiratorias. Grant: Ministerio
Sanidad y Consumo, CB06/06/0011. Duration: 28/07/200627/07/2010.
Rodriguez R. Intercambio pulmonar gaseoso, ejercicio
físico, manitol y anticolinérgicos en pacientes con asma y
EPOC. Grant: Ministerio Sanidad y Consumo, PI050208. Duration: 01/01/2006-30/12/2008.
Gomez F. Estudio de biomarcadores en el condensado del
exhalado respiratorio en marineros expuestos al fuel del
buque Prestige y en pacientes con asma y EPOC. Patrones
de respuesta inflamatoria, estrés oxidativo y remodelado
de las vías aéreas. Grant: Ministerio Sanidad y Consumo,
PI050548. Duration: 01/01/2006-30/12/2008.
Peinado V. Mecanismos fisiopatológicos implicados en la
movilización, reclutamiento y diferenciación de células progenitoras vasculares en la circulación pulmonar en la EPOC.
18/10/2006-30/12/2009.
Roca J. Entrenamiento muscular y actividad física en la
enfermedad pulmonar obstructiva crónica. Grant: Ministerio Sanidad y Consumo, PI061510. Duration: 18/10/200630/12/2009.
Macchiarini P. Sistema de soporte respiratorio extracorpóreo sin bomba. Grant: Agència Avaluació de Tecnologia i
Recerca Mèdiques (AATRM), 07/442. Duration: 09/01/200731/03/2009.
Roca J. Nuevos modelos de prestación de servicios sanitarios utilizando telemedicina. Grant: FIS, PI050282. Duration:
23/12/2005-30/12/2008.
Barbera JA. Contribución de las células progenitoras vasculares en los mecanismos de reparación y remodelado de la
circulación pulmonar en la enfermedad pulmonar obstructiva crónica. Grant: Ministerio Sanidad y Consumo, PI050244.
Duration: 01/01/2006-30/12/2008.
Macchiarini P. Generation of a tissue engineered trachea.
01/01/2006-30/12/2009.
67
040-071 AREA2.indd 67
21/10/09 16:59:08
Clinical and Experimental Respiratory Immunoallergy (IRCE)
Team Members
Clinical and experimental
respiratory Immunoallergy (IRCE)
Team Leader:
■ César Picado (Hospital Clínic,
University of Barcelona)
Tel.: 93 451 09 93
Fax: 93 451 52 72
IDIBAPS Members:
■ Joan Bartra (Hospital Clínic)
■ Joaquim Mullol (IDIBAPS)
■ Laura Pujols (FIS)
■ Antonio Valero (Hospital Clínic)
■ Antoni Xaubet (Hospital Clínic)
Collaborators:
Isam Alobid (Hospital Clínic)
Ainhoa Fontana (CIBERes)
Josep Maria Guilemany (FIS - SEORL)
Assumpció Martínez-Antón (CIBERes)
Rosa Maria Muñoz-Cano (Fundació Clínic)
Jordi Roca-Ferrer (UB)
Ivonne Torres (Ministerio de Educación,
Gobierno de Panamá)
Rosa Torres (FIS)
María del Carmen Vennera (Fundació Clínic)
Sílvia Centellas (Hospital Clínic)
Technicians:
Mireia Fuentes Prado (FIS)
María Pérez Gonzalez(Fundació Clínic)
1. To investigate the mechanisms that regulate the inflammatory response and remodeling in bronchial
asthma, rhinosinusitis and pulmonary interstitial
diseases.
2. To investigate the mechanisms responsible for food
allergies.
3. To investigate the mechanisms involved in anaphylaxis of complex etiopathogenesis.
4. To investigate the mechanisms involved in loss of
sense of smell.
68
Doctoral Students:
Joaquim Garcia Garcia (FIS)
Laura Fernández-Bertolin (IDIBAPS)
Suha Jabr (Ministerio Asuntos Exteriores y
Cooperación)
Francisco de Borja Callejas (FIS)
1. Molecular and cellular bases of the inflammatory
response in asthma, rhinosinusitis and pulmonary
interstitial diseases.
2. Role of MUC genes in the regulation of mucus secretion in respiratory diseases and their regulation
by glucocorticoids.
3. Role of arachidonic acid metabolites (prostaglandins and leukotrienes) in the pathogenesis of asthma, chronic rhinosinusitis and pulmonary interstitial diseases.
4. Role of the angiotensin system in pulmonary fibrosis.
040-071 AREA2.indd 68
Immunohistochemical study showing the presence of mucin 5C in goblet
cells of the epithelium of a nasal polyp.
5. Study of the mechanisms that regulate the response to treatment with glucocorticoids in respiratory
inflammatory diseases.
6. Study of the mechanisms involved in severe asthma and their link to abnormal functioning of the
glucocorticoid receptor.
7. Study of the interrelation between diseases of the
upper respiratory tract (nose and sinus) and the
lower respiratory tract (asthma, bronchiectasis,
chronic obstructive pulmonary disease).
21/10/09 16:59:16
8. Study of the mechanisms that regulate the response to food allergens and their link to nonsteroidal
anti-inflammatory drugs and the metabolism of arachidonic acid.
9. New therapeutic modalities (endothelin inhibitors,
proteasome and COX-2 inhibitors, and prostaglandin E2 receptor-3 agonists) in asthma, rhinosinusitis and pulmonary interstitial disease using in vitro
models and animal models of asthma and pulmonary fibrosis.
10.Study of the mechanisms of anaphylactic reactions
of multiple origins (indolent mastocytosis, predisposing genetic disorders).
11.Study of quality of life in nasal sinus pathology.
12.Loss of sense of smell: role of nasal sinus inflammation, Parkinson disease and congenital disorders.
Associated Group
■ Mullol, Joaquim (IDIBAPS)
In this group, we investigate different aspects of nasal sinus inflammatory diseases (allergic and nonallergic rhinitis, chronic rhinosinusitis, nasal polyposis):• We study the pathophysiologic mechanisms of
nasal sinus mucus hypersecretion and regulation of mucins and MUC genes.• We analyze the pathophysiologic and clinical association of nasal sinus diseases with asthma, atopy and intolerance to NSAIDS and bronchiectasis, and their impact on patient quality of life.• We evaluate disorders of the sense of smell and their mechanism of action
as a diagnostic marker and severity marker. We have validated an olfactometry test (BAST-24) of our own and carried out
an epidemiologic study (OLFACAT) on smell in the population of Catalonia.• We use a model of eosinophil and epithelial
cell cultures to test and compare the anti-inflammatory effect of different drugs used in respiratory inflammation, such as
corticosteroids, antihistamines and antileukotrienes.
I.F.: 59,83
PublicaTions
1
2
3
4
5
P, Ramirez J, Torres A, Augusti C, Martínez-Olondris
P. Transbronchial needle aspiration in the study
of mediastinal lymph nodes: Yield and costeffectiveness. ARCH BRONCONEUMOL. 44:290-294.
I.F.:1,56.
Valero A, Herdman M, Bartra J, Ferrer M, Jauregui I,
Davilla I, DelCuvillo A, Montoro J, Mullol J, Sastre J,
Canonica GW, Baiardini I. Adaptation and Validation
of the Spanish Version of the Chronic Urticaria Quality
of Life Questionnaire (CU-Q(2)oL). J INVEST ALLERG
CLIN. 18:426-432. I.F.:1,25.
Torres R, Herrerias A, Serra-Pages M, Roca-Ferrer J,
Pujols L, Marco A, Picado C, DeMora F. An intranasal
selective antisense oligonucleotide impairs lung cyclooxygenase-2 production and improves inflammation, but worsens airway function, in house dust mite
sensitive mice. RESP RES. 9:-. I.F.:3,62.
Li XP, Molina-Molina M, Abdul-Hafez A, Uhal V,
Xaubet A, Uhal BD. Angiotensin converting enzyme-2 is protective but downregulated in human and
experimental lung fibrosis. AM J PHYSIOL-LUNG C.
295:L178-L185. I.F.:4,21.
Molina-Molina M, Xaubet A, Li X, Abdul-Hafez A,
Friderich K, Jernigan K, Fu W, Ding Q, Pereda J,
Serrano-Mollar A, Casanova A, Rodriguez-Becerra E,
Morell F, Ancochea J, Picado C, Uhal BD. Angiotensinogen gene G-6A polymorphism influences idiopathic pulmonary fibrosis disease progression. EUR
RESPIR J. 32:1004-1008. I.F.:5,35.
040-071 AREA2.indd 69
6
Ferrer A, Huertas AJ, Larramendi CH, Pagan JA, Bartra J, Garcia-Abujeta JL, Andreu C, Lavin JR, Matas
MAL, Fernandez-Caldas E, Carnes J. Antigenic and
Allergenic Differences Between Green and Mature Tomatoes. J INVEST ALLERG CLIN. 18:411-412.
I.F.:1,25.
7 Tordera MP, Viejo JL, Sanchis J, Badia X, Cobos N,
Picado C, Sobradillo V, DelRio JMG, Duce F, Cabrera
L. Assessment of patient satisfaction and preferences
with inhalers in asthma with the FSI-10 questionnaire.
8 Badiola C, Badia X, Sastre J, Olaguibel JM, Lopez-Vina
A, Vega JM, Picado C. Assessment of the simplified
versions of the Asthma Control Questionnaire. MED
CLIN-BARCELONA. 131:326-332. I.F.:1,34.
9 Navarro A, Valero A, Julia B, Quirce S. Coexistence of
asthma and allergic rhinitis in adult patients attending
allergy clinics: ONEAIR study. J INVEST ALLERG CLIN.
18:233-238. I.F.:1,25.
10 Martinez-Anton A, DeBolos C, Alobid I, Benitez P,
Roca-Ferrer J, Picado C, Mullol J. Corticosteroid therapy increases membrane-tethered while decreases
secreted mucin expression in nasal polyps. ALLERGY.
63:1368-1376. I.F.:5,01.
11 Baloira A, Xaubet A, Becerra ER, Romero AD, Casanova A, Ancochea J. Desquamative interstitial pneumonia and respiratory bronchiolitis-associated interstitial
lung disease: Data from the Spanish patient registry.
12 Rodriguez-Trigo G, Plaza V, Picado C, Sanchis J. Management according to the global initiative for asthma
guidelines of patients with near-fatal asthma reduces
Original Articles
Research Group on Nasal Sinus in Inflammation and Smell (INGENIO)
69
21/10/09 16:59:22
13
14
15
16
17
18
19
20
21
morbidity and mortality. ARCH BRONCONEUMOL.
44:192-196. I.F.:1,56.
Bartra J, Carnes J, Munoz-Cano R, Bissinger I, Picado
C, Valero AL. Occupational asthma and rhinoconjunctivitis caused by cricket allergy. J INVEST ALLERG CLIN.
18:141-142. I.F.:1,25.
Serrano C, Guilarte M, Tella R, Dalmau G, Bartra J,
Gaig P, Cerda M, Cardona V, Valero A. Oestrogendependent hereditary angio-oedema with normal C1
inhibitor: description of six new cases and review of
pathogenic mechanisms and treatment. ALLERGY.
63:735-741. I.F.:5,01.
Pujols L, Alobid I, Bentiz P, Martinez-Anton A, RocaFerrer J, Fokkens WJ, Mullol J, Picado C. Regulation
of glucocorticoid receptor in nasal polyps by systemic
and intranasal glucocorticoids. ALLERGY. 63:13771386. I.F.:5,01.
Saldana M, Pujols L, Mullol J, Roca-Ferrer J, Cardozo A, Aguilar E, Bonastre M, Marin C. Relevance of
COX-2 gene expression in dementia with Lewy bodies
associated with Alzheimer pathology. MOVEMENT DISORD. 23:804-810. I.F.:3,21.
Vizuete JAC, Mullol J. Rhinitis and Asthma Comorbidity in Spain: the RINAIR Study. ARCH BRONCONEUMOL. 44:597-603. I.F.:1,56.
Fraj J, Valero A, Vives R, Perez I, Borja J, Izquierdo I,
Picado C. Safety of triflusal (antiplatelet drug) in patients with aspirin-exacerbated respiratory diseases.
ALLERGY. 63:112-115. I.F.:5,01.
Larramendi CH, Ferrer A, Huertas AJ, Garcia-Abujeta
JL, Andreu C, Tella R, Cerda MT, Bartra J, Lavin JR,
Pagan JA, Lopez-Matas MA, Fernandez-Caldas E, Carnes J. Sensitization to tomato peel and pulp extracts
in the Mediterranean Coast of Spain: prevalence and
co-sensitization with aeroallergens. CLIN EXP ALLERGY. 38:169-177. I.F.:3,73.
Enrique E, Malek T, Pineda F, Palacios R, Bartra J,
Tella R, Basagana M, Alonso R, Cistero-Bahima A. Sublingual immunotherapy for hazelnut food allergy: A
follow-up study. ANN ALLERG ASTHMA IM. 100:283284. I.F.:2,22.
Picado C, Badiola C, Perulero N, Sastre J, Olaguibel
JM, Vina AL, Vega JM. Validation of the Spanish Version of the Asthma Control Questionnaire. CLIN THER.
30:1918-1931. I.F.:3,26.
Reviews
1
70
2
3
040-071 AREA2.indd 70
Mullol J, Valero A, Alobid I, Bartra J, Navarro AM, Chivato T, Khaltaev N, Bousquet J. Allergic Rhinitis and
its Impact on Asthma Update (ARIA 2008) The Perspective From Spain. J INVEST ALLERG CLIN. 18:327334. I.F.:1,25.
Bousquet J, Reid J, VanWeel C, Cagnani CB, Canonica
GW, Demoly P, Denburg J, Fokkens WJ, Grouse L,
Mullol K, Ohta K, Schermer T, Valovirta E, Zhong N,
Zuberbier T. Allergic rhinitis management pocket reference 2008. ALLERGY. 63:990-996. I.F.:5,01.
Alobid I, Bernal-Sprekelsen M, Mullol J. Chronic rhinosinusitis and nasal polyps: the role of generic and specific questionnaires on assessing its impact on patient’s
quality of life. ALLERGY. 63:1267-1279. I.F.:5,01.
4
5
6
7
Guilemany JM, Roca-Ferrer J, Mullol J. Cyclooxygenases and the pathogenesis of chronic rhinosinusitis and
nasal polyposis. CURR ALLERGY ASTHM R. 8:219-226.
I.F.:1,56.
Bousquet J, Fokkens W, Burney P, Durham SR,
Bachert C, Akdis CA, Canonica GW, Dahlen SE,
Zuberbier T, Bieber T, Bonini S, Bousquet PJ, Brozek
JL, Cardell LO, Crameri R, Custovic A, Demoly P,
VanWijk RG, Gjomarkaj M, Holland C, Howarth P,
Humbert M, Johnston SL, Kauffmann F, Kowalski
ML, Lambrecht B, Lehmann S, Leynaert B, LodrupCarlsen K, Mullol J, Niggemann B, NizankowskaMogilnicka E, Papadopoulos N, Passalacqua G,
Schunemann HJ, Simon HU, Todo-Bom A, Toskala E,
Valenta R, Wickman M, Zock JP. Important research
questions in allergy and related diseases: nonallergic
rhinitis: a GA(2)LEN paper. ALLERGY. 63:842-853.
I.F.:5,01.
Mullol J, Maurer M, Bousquet J. Sleep and Allergic
Rhinitis. J INVEST ALLERG CLIN. 18:415-419. I.F.:1,25.
Picado C, Vennera MD. Triamcinolone acetonide in
the treatment of corticosteroid-resistant asthma: Risks
and benefits. ARCH BRONCONEUMOL. 44:324-327.
I.F.:1,56.
Pujols L. Effects of reversible proteasome inhibitors on the
mechanisms involved in inflammatory and remodelling
responses in asthma. Grant: Fundació Marató TV3, 40630.
Duration: 12/01/2005-11/01/2008.
Picado C. Grup d’inflamació i tractament de malalties respiratòries. Grant: Comissionat per a Universitats i Recerca,
2005SGR00773. Duration: 19/10/2005-31/12/2008.
Picado C. CIBER de Enfermedades Respiratorias (CIBERes).
Grant: Ministerio Sanidad y Consumo, CB06/06/0010. Duration: 28/07/2006-27/07/2010.
Pujols L. Efecto de los inhibidores reversibles del proteasoma sobre la inflamación, la angiogénesis y la fibrosis en el asma. Grant: Ministerio Sanidad y Consumo,
PI050057. Duration: 01/01/2006-30/12/2008.
Mullol J. Estudio de los mecanismos de regulación in
vivo e in vitro de la expresión de mucinas en la poliposis
nasosinusal sin o con asma. Papel de las quinasas MAP y
del NFkB y de su regulación por corticoides. Grant: Ministerio Sanidad y Consumo, PI050069. Duration: 01/01/200630/12/2008.
Picado C. Estudio de la relación entre la intolerancia a los
antiinflamatorios no esteroideos y la producción de Prostaglandina E2 con la gravedad del asma. Grant: Ministerio
Xaubet A. Papel del sistema angiotensina en la patogenia
y predisposición genética de la fibrosis pulmonar idiopática. Grant: Ministerio Sanidad y Consumo, PI060064. Duration: 18/10/2006-30/12/2009.
21/10/09 16:59:27
Mullol J, Guilemany J. Bronquiestàsies i patologia nasosinusal. Grant: Fundació Catalana de Pneumologia (FUCAP),
Ufesa07. Duration: 01/07/2007-30/06/2009.
nistración de Rupatadina (NARUPAF). Grant: Beca Grupo
Uriach Pharma , DC/03/RUP/I/08. Duration: 01/09/200831/03/2010.
Mullol J. Global Allergy and Asthma European Network.
Grant: Universiteit Gent Directie Financiën, FOODCT-2004-506378. Duration: 01/08/2008-31/01/2010.
Valero AL. Estudio de evaluación de la respuesta nasal
tras la aplicación intranasal de Rupatadina en sujetos con
rinitis alérgica persistente (ATORUP). Grant: Beca Grupo
Uriach Pharma, DC/05/RUP/I/08. Duration: 01/07/200831/05/2009.
Valero AL. Inhibición del efecto de la administración nasal
del Factor de Activación Plaquetaria (PAF) tras la admi-
71
040-071 AREA2.indd 71
21/10/09 16:59:33
072-113 AREA3.indd 72
21/10/09 16:16:40
Area 3
Liver, Digestive System and Metabolism
Endocrinology, Gynecology and Human Reproduction . . . . . . . . . . . . . . . . . . . . . . . . . . 74
Fetal and Perinatal Medicine . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . .
77
Metabolic Regulation and Molecular Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 82
Bone Metabolic Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 83
Viral Hepatitis in Immunocompetent and Liver Transplant Patients . . . . . . . . . 85
Pathophysiology and Treatment of Ascites and Renal Function
Disorder in Cirrhosis of the Liver . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 88
Hepatic Oncology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 91
Hepatic Hemodynamics and Portal Hypertension. Digestive
Tract Bleeding due to Rupture of Esophageal Varicose Veins . . . . . . . . . . . . . . . . . . 94
Inflammatory Bowel Disease . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 98
Liver Failure and Cholestasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 101
Mitochondrial Regulation of Cell Death and Steatohepatitis . . . . . . . . . . . . . . . . . . . 103
Liver Transplant and Graft Viability . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 105
Gastrointestinal and Pancreatic Oncology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 107
Diabetes: Metabolic and Molecular Networks . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 110
Image: Liver section magnified
072-113 AREA3.indd 73
21/10/09 16:16:42
Endocrinology, Gynecology and Human Reproduction
Team Members
Endocrinology, gynecology and
human reproduction
Team Leader:
■ Juan Balasch (Hospital Clínic)
Tel.: 93 227 54 36
Fax: 93 227 93 25
IDIBAPS Members:
■ Francisco Carmona (Hospital Clínic)
■ Camil Castelo-Branco (Hospital Clínic)
■ Montserrat Creus (Hospital Clínic)
■ Francisco Fábregues
■ Dolors Manau Trullás (Fundació Clínic)
■ Jaume Ordi (Hospital Clínic)
■ Jaume Pahisa (Hospital Clínic)
■ Bienvenido Puerto (Hospital Clínic)
■ Aureli Torné (Hospital Clínic)
Area 3 Liver, Digestive System and Metabolism
Collaborators:
Gemma Casals (Fundació Clínic)
Roser Casamitjana (Hospital Clínic)
74
The global objective of this research group for the
coming years is to increase our knowledge of a broad
spectrum of the pathophysiology of human reproduction, ranging from endocrinologic aspects to the most
important benign and malignant organic processes of
the female reproductive apparatus, including investigation and treatment of human reproductive failure.
More specifically, the principal objectives of our research group are to advance in the existing lines of
research in order to achieve the following:
1. Determine the most relevant mechanisms in pathogenesis of reproductive failure (sterility, repeated
abortion, repeated failure to implant following in
vitro fertilization) and the principal pathologic processes of the female reproductive apparatus (endometriosis, uterine myoma, genital cancer).
2. Optimize and innovate as far as possible in terms of
the preventive and/or therapeutic potential in the
above situation.
Salvadora Cívico (Hospital Clínic)
Fernando Miró (Fundació Clinic)
Joana Peñarrubia (Fundació Clínic)
José Luís Ballescá (Hospital Clínic)
Doctoral Students:
Marta Guimerà (IDIBAPS)
Elena Suárez Cisneros (IDIBAPS)
syndrome. Study the value of immunohistochemical
and quantitative and qualitative proteomic parameters
in the human endometrium as markers of endometrial
receptiveness. Study further the pathogenic mechanisms implicated in blockade of in vitro pre-implant
embryo development.
2.Ovarian dysfunction and
stimulation/hyperstimulation
Investigate the potential of both ultrasound and hormonal, endocrine-metabolic and genetic markers in
their ability to predict the ovarian response. Study
the role of LH and androgens as factors that sensitize the ovaries to subsequent stimulation with FSH.
Investigate the possible role of ovarian follicular cells
(granulosa cells, macrophages) in the pathogenesis
1.Markers of reproductive failure
Analyze the possible role of new markers of abnormal
hemostasis as a new form of pathogenic mechanism
of thrombotic disease in early and advanced pregnancy in patients with or without antiphospholipid
072-113 AREA3.indd 74
Two-dimensional gel with silver stain belonging to the global proteome
of the epithelial glands of the human endometrium during the receptive
phase or window for embryo implantation.
21/10/09 16:16:46
of ovarian hyperstimulation syndrome and aim to establish new guidelines for ovarian stimulation and/or
endometrial preparation that improve the results of
assisted fertilization techniques.
3.Optimization of surgical treatment of
diseases of the reproductive apparatus
This line is aimed at analyzing the role of the surgical
variables that make it possible to improve results and
reduce morbidity in the surgical treatment of benign
and malignant diseases of the female reproductive
apparatus. It also involves establishing the prognostic value of detecting HPV (human papilloma virus)
and viral typing as prognostic markers of the course
of neoplasias in precancerous lesions of the neck of
the uterus.
Original Articles
1
2
3
5
6
7
8
9
072-113 AREA3.indd 75
Liver, Digestive System and Metabolism Area 3
4
Menendez C, Romagosa C, Ismail MR, Carrilho C, Saute
F, Osman N, Machungo F, Bardaji A, Quinto L, Mayor A,
Naniche D, Dobaño C, Alonso PL, Ordi J, Alonso P. An
autopsy study of maternal mortality in mozambique:
The contribution of infectious diseases. PLOS MED.
5:220-226. I.F.:12,60.
Creus M, Fabregues F, Carmona F, DelPino M, Manau
D, Balasch J. Combined laparoscopic surgery and
pentoxifylline therapy for treatment of endometriosisassociated infertility: a preliminary trial. HUM REPROD.
23:1910-1916. I.F.:3,54.
DelRio M, Martinez JM, Figueras F, Bennasar M, Olivella A, Palacio M, Coll O, Puerto B, Gratacos E. Doppler assessment of the aortic isthmus and perinatal
outcome in preterm fetuses with severe intrauterine
growth restriction. ULTRASOUND OBST GYN. 31:41-47.
I.F.:2,67.
Blumel JE, DelPino M, Aprikian D, Vallejo S, Sarra S,
Castelo-Branco C. Effect of androgens combined with
hormone therapy on quality of life in post-menopausal
women with sexual dysfunction. GYNECOL ENDOCRINOL. 24:691-695. I.F.:1,17.
Castelo-Branco C, Leon M, Duran M, Balasch J. Folliclestimulating hormone does not directly regulate bone
mass in human beings: evidence from nature. FERTIL
STERIL. 90:2211-2216. I.F.:3,17.
Leon-Leon P, Chedraui P, Hidalgo L, Ortiz F, CasteloBranco C. Hormone therapy for the management of the
menopause in Ecuador: Perception, use and knowledge
among middle-aged women. GYNECOL ENDOCRINOL.
24:580-585. I.F.:1,17.
Mezones-Holguin E, Blumel JE, Huezo M, Vargas R,
Castro J, Cordova W, Valenzuela G, Castelo-Branco C.
Impact of diabetes mellitus on the sexuality of Peruvian
postmenopausal. GYNECOL ENDOCRINOL. 24:470-474.
I.F.:1,17.
Civico S, Agell N, Hernandez L, Campo E, Bachs O,
Balasch J. Increased messenger ribonucleic acid
expression of the cyclin-dependent kinase inhibitor
p27(Kip1) in cleavage-stage human embryos exhibiting developmental arrest. FERTIL STERIL. 89:15571562. I.F.:3,17.
Fernandez S, Figueras F, Gomez O, Martinez JM,
Eixarch E, Comas M, Puerto B, Gratacos E. Intra- and
interobserver reliability of umbilical vein blood flow.
PRENATAL DIAG. 28:999-1003. I.F.:1,32.
10 Mandruzzato G, Antsaklis A, Botet F, Chervenak FA,
Figueras F, Grunebaum A, Puerto B, Skupski D, Stanojevic M. Intrauterine restriction (IUGR). J PERINAT MED.
36:277-281. I.F.:1,10.
11 Naniche D, Lahuerta M, Bardaji A, Sigauque B, Romagosa C, Berenguera A, Mandomando I, David C, Sanz
S, Aponte J, Ordi J, Alonso P, Menendez C. Mother-tochild transmission of HIV-1: association with malaria
prevention, anaemia and placental malaria. HIV MED.
9:757-764. I.F.:3,35.
12 Casals G, Ordi J, Creus M, Fabregues F, Casamitjana
R, Quinto L, Campo E, Balasch J. Osteopontin and
alpha(v)beta(3) integrin expression in the endometrium
of infertile and fertile women. REPROD BIOMED ONLINE. 16:808-816. I.F.:2,84.
13 Gomez O, Figueras F, Fernandez S, Bennasar M, Martinez
JM, Puerto B, Gratacos E. Reference ranges for uterine
artery mean pulsatility index at 11-41 weeks of gestation.
ULTRASOUND OBST GYN. 32:128-132. I.F.:2,67.
14 Sanjuan A, Escaramis G, Ayuso JR, Roman SM, Torne A,
Ordi J, Lejarcegui JA, Pahisa J. Role of magnetic resonance imaging and cause of pitfalls in detecting myometrial invasion and cervical involvement in endometrial
cancer. ARCH GYNECOL OBSTET. 278:535-539. I.F.:0,67.
15 Arjona JE, Mino M, Cordon J, Povedano B, Pelegrin
B, Castelo-Branco C. Satisfaction and tolerance with
office hysteroscopic tubal sterilization. FERTIL STERIL.
90:1182-1186. I.F.:3,17.
16 Figueras F, Eixarch E, Meler E, Iraola A, Figueras J,
Puerto B, Gratacos E. Small-for-gestational-age fetuses
with normal umbilical artery Doppler have suboptimal
perinatal and neurodevelopmental outcome. EUR J
OBSTET GYN R B. 136:34-38. I.F.:1,43.
17 Castelo-Branco C, Palacios S, Ferrer-Barriendos J,
Parrilla JJ, Manubens M, Alberich X, Marti A. Understanding how personality factors may influence quality
of life: development and validation of the Cervantes
Personality Scale. MENOPAUSE. 15:914-918. I.F.:3,67.
18 Palacios S, Rojo IA, Cancelo MJ, Neyro JL, CasteloBranco C. Women’s perception of the efficacy of a soy
extract with probiotic: The M3 study. GYNECOL ENDOCRINOL. 24:178-183. I.F.:1,17.
human reproduction
I.F.: 50,05
PublicaTions
75
Reviews
1
Cervera R, Balasch J. Bidirectional effects on autoimmunity and reproduction. HUM REPROD UPDATE.
14:359-366. I.F.:7,26.
21/10/09 16:16:49
2
3
4
human reproduction
5
Castelo-Branco C, Cancelo MJ. Compounds for the
treatment of atropic vaginitis. EXPERT OPIN THER PAT.
18:1385-1394. I.F.:1,59.
Castelo-Branco C, Huezo ML, Lagarda JLB. Definition
and diagnosis of sexuality in the XXI century. MATURITAS. 60:50-58. I.F.:2,02.
Szekeres-Bartho J, Balasch J. Progestagen therapy for
recurrent miscarriage. HUM REPROD UPDATE. 14:2735. I.F.:7,26.
Requena A, Herrero J, Landeras J, Navarro E, Neyro JL,
Salvador C, Tur R, Callejo J, Checa MA, Farre M, Espinos JJ, Fabregues F, Grana-Barcia M. Use of letrozole
in assisted reproduction: a systematic review and metaanalysis. HUM REPROD UPDATE. 14:571-582. I.F.:7,26.
Balasch J. Investigación del potencial fibrinolítico global del
plasma y su regulación como mecanismo patogénico en la
patología gestacional precoz y avanzada. Relación con los
anticuerpos antifosfolipídicos. Grant: Ministerio Sanidad y
Ordi J. Mortalidad materna en el África Subsahariana:
contribución de la infección por el virus de la inmunodeficiencia humana y la malaria. Grant: Ministerio Sanidad y
Editorials
Balasch J. Investigación del potencial fibrinolítico global del
plasma y su regulación como mecanismo patogénico en la
patología gestacional precoz y avanzada. Relación con los
anticuerpos antifosfolipídicos. Grant: FIS, PI050026. Duration: 23/12/2005-31/12/2008.
1
Thesis
Barriga J, Castelo-Branco C, Chedraui P, Hidalgo L, Veas
P. Educational and organizational interventions used to
improve the knowledge of metabolic syndrome among
postmenopausal women. FERTIL STERIL. 90:444-446.
I.F.:3,17.
Ordi J. Valor de p16 en el diagnóstico y clasificación etiopatogénica del carcinoma vulvar. Doctorand: Mónica Santos Santos.
Balasch J. Grup d’Endocrinologia Ginecològica i Reproducció Humana. Grant: Comissionat per a Universitats i Recerca, 2005SGR00573. Duration: 19/10/2005-31/12/2008.
76
072-113 AREA3.indd 76
21/10/09 16:16:51
Fetal and Perinatal Medicine
Team members
Team Leader:
■ Eduard Gratacós (Hospital Clínic)
Tel.: 93 227 99 46
Fax: 93 227 56 05
The principal strategic objective and the main part of
the resources are dedicated to developing infrastructure and stable lines of multidisciplinary research for
the prediction and prevention of prenatal neurologic
damage of hypoxic and/or inflammatory origin, which
incorporates as collaborators stable groups from fetal
medicine, neonatology, pediatric neurology and molecular biology.
Other objectives of the team include the development and consolidation of the existing lines in different fields, such as perinatal infections, with special
emphasis on HIV and neonatal infection, fetal therapy
and surgery, screening strategies and prediction of
072-113 AREA3.indd 77
Technicians:
Imma Mercade (Fundació Clínic)
Maite Aguilera (Fundació Clínic)
David Verde (Fundació Clínic-CIBER-ER)
Natalia Ruiz (CIBER-ER)
Nurses:
Amparo Martínez (Fundació Clínic)
Angela Arranz (Fundació Clínic)
Georgina Feixas (IDIBAPS)
fetal and maternal disease in large populations, and
premature birth.
Collaborators:
Emilia Ruthy Acosta-Rojas (Fundació Clínic-CIBER-ER)
Ivan Amat-Roldan (Fundació Clínic)
Joaquim Bartrons (Sant Joan de Déu)
Jordi Bellart (Hospital Clínic)
Bet Boatella (Fundació Clínic)
Fátima Crispi (IDIBAPS-Rio Hortega)
Olga Gómez (Hospital Clínic)
Anna Gonce (Hospital Clínic)
Edgar Hernandez-Andrade (Fundació Clínic-Juan de la
Cierva)
Xavier Miracle (Hospital Clínic)
Mª Dolors Salvía (Hospital Clínic)
Iratxe Torre (Fundació Clínic-Sara Borrell)
Rebeca Menendez (Fundació Clínic)
Marta Ros (Fundació Clínic)
Violeta Tenorio (Fundació Clínic)
Doctoral Students:
Icaria Bianchi (Fundació Clínic)
Montse Comas (Hospital Clínic)
Rogelio Cruz (Fundació Clínic)
Elisenda Eixarch (IDIBAPS-Rio Hortega)
Nelly Fabiola Padilla (Fundació Clínic)
Eva Meler (Hospital Clínic)
Bartosz Wojtas (Fundació Clínic)
Antonio Méndez (Hospital Clínic)
Magdalena Sanz (Fundació Clínic)
John Jairo Jaramillo (Hospital Clínic)
Susan Bode
IDIBAPS Members:
■ Antoni Borrell (Hospital Clínic)
■ Francesc Botet (Hospital Clínic)
■ Vicens Cararach (Hospital Clínic
■ Xavier Carbonell (Hospital Clínic)
■ Elena Casals (Hospital Clínic)
■ Oriol Coll (Hospital Clínic)
■ Francesc Figueras (Hospital Clínic)
■ Josep Figueras (Hospital Clínic)
■ Josep Maria Martinez-Crespo (Hospital Clínic)
■ Montserrat Palacio (Hospital Clínic)
1. Fetal and perinatal neurologic damage. We evaluate
changes in the fetal cerebral parenchyma via image
analysis (ultrasound, blood fraction on movement
and NMRI-DTI), correlation with new markers of fetal myocardial function and with biochemical and
genomic markers of ischemia and immune/endothelial hyperactivation, and the correlation with the
neurologic development evaluated by function and
neurostructure up to 6 years of age. Animal model
of fetal hypoxia for studying cerebral endothelial
77
21/10/09 16:16:54
activation in the genesis of neurologic damage and
interference potential by blocking immune activation. The line also includes research relating to preeclampsia and fetal growth, perinatal asphyxia and
neonatal hypoxic-ischemic encephalopathy.
2. Fetal diagnosis and therapy. As members of the European group Eurofoetus, we carry out studies on the
fetal surgical treatment of monochorial pregnancy and
congenital diaphragm hernia, and repair of fetal membranes by means of tissue engineering. Screening for
markers of aneuploidy and maternal diseases.
3. Perinatal infection. The main line of research covers
different projects in HIV and pregnancy, in national
and international collaborations. Investigation of
neonatal infection (perinatal and nosocomial infections, infections by respiratory syncytial virus, etc.
4.Perinatal disease. This is a mixed line that covers projects in premature birth (chorioamnionitis, aggressive
nutrition), medical disease (diabetes, autoimmune
diseases) and pregnancy, and neonatal respiratory
disease (study of pulmonary inflammation and prevention of bronchial-pulmonary dysplasia).
I.F.: 104,25
PublicaTions
Original Articles
1
Three-dimensional reconstruction of foetal brain.
2
3
4
5
6
78
7
072-113 AREA3.indd 78
DelRio M, Martinez JM, Figueras F, Bennasar M, Olivella A, Palacio M, Coll O, Puerto B, Gratacos E. Doppler assessment of the aortic isthmus and perinatal
outcome in preterm fetuses with severe intrauterine
growth restriction. ULTRASOUND OBST GYN. 31:41-47.
I.F.:2,67.
Fernandez S, Figueras F, Gomez O, Martinez JM,
Eixarch E, Comas M, Puerto B, Gratacos E. Intra- and
interobserver reliability of umbilical vein blood flow.
PRENATAL DIAG. 28:999-1003. I.F.:1,32.
Mandruzzato G, Antsaklis A, Botet F, Chervenak FA,
Figueras F, Grunebaum A, Puerto B, Skupski D, Stanojevic M. Intrauterine restriction (IUGR). J PERINAT MED.
36:277-281. I.F.:1,10.
Gomez O, Figueras F, Fernandez S, Bennasar M, Martinez JM, Puerto B, Gratacos E. Reference ranges for
uterine artery mean pulsatility index at 11-41 weeks
of gestation. ULTRASOUND OBST GYN. 32:128-132.
I.F.:2,67.
Figueras F, Eixarch E, Meler E, Iraola A, Figueras J,
Puerto B, Gratacos E. Small-for-gestational-age fetuses
with normal umbilical artery Doppler have suboptimal
perinatal and neurodevelopmental outcome. EUR J
OBSTET GYN R B. 136:34-38. I.F.:1,43.
Simoes EAF, Carbonell-Estrany X, Fullarton JR, Liese
JG, Figueras-Aloy J, Doering G, Guzman J. A predictive
model for respiratory syncytial virus (RSV) hospitalisation of premature infants born at 33-35 weeks of gestational age, based on data from the Spanish FLIP study.
RESP RES. 9:-. I.F.:3,62.
Soler A, Morales C, Badenas C, Rodriguez-Revenga
L, Carrio A, Margarit E, Costa D, Borrell A, Gonce A,
Mila M, Sanchez A. A retrospective and theoretical
evaluation of rapid methods for detecting chromosome
abnormalities and their implications on genetic counseling based on a series of 3868 CVS diagnoses. FETAL
DIAGN THER. 23:126-131. I.F.:0,84.
8
9
10 11 12 13 14 Moreno-Alvarez O, Hernandez-Andrade E, Oros D, Jani
J, Deprest J, Gratacos E. Association between intrapulmonary arterial Doppler parameters and degree of lung
growth as measured by lung-to-head ratio in fetuses
with congenital diaphragmatic hernia. ULTRASOUND
OBST GYN. 31:164-170. I.F.:2,67.
Figueras F, Meler E, Eixarch E, Francis A, Coll O, Gratacos
E, Gardosi J. Association of smoking during pregnancy
and fetal growth restriction: Subgroups of higher susceptibility. EUR J OBSTET GYN R B. 138:171-175. I.F.:1,43.
Figueras-Aloy J, Berrueco R, Salvia-Roiges MD,
Rodriguez-Miguelez JM, Miracle-Echegoyen X, BotetMussons F, Mur-Sierra A, Vall O, Carbonell-Estrany X.
Attempt to Normalize Simulated Exhaled Nitric Oxide
According to Ventilatory Settings. PEDIATR PULM.
43:1167-1174. I.F.:2,27.
Crispi F, Hernandez-Andrade E, Pelsers MMAL, Plasencia W, Benavides-Serralde JA, Eixarch E, LeNoble F,
Ahmed A, Glatz JFC, Nicolaides KH, Gratacos E. Cardiac dysfunction and cell damage across clinical stages
of severity in growth-restricted fetuses. AM J OBSTET
GYNECOL. 199:-. I.F.:2,92.
Figueroa-Diesel H, Hernandez-Andrade E, BenavidesSerralde A, Crispi F, Acosta-Rojas R, Cabero L, Gratacos
E. Cerebral venous blood flow in growth restricted fetuses with an abnormal blood flow in the umbilical artery
before 32 weeks of gestation. EUR J OBSTET GYN R B.
140:201-205. I.F.:1,43.
Hernandez-Andrade E, Figueroa-Diesel H, Jansson T,
Rangel-Nava H, Gratacos E. Changes in regional fetal
cerebral blood flow perfusion in relation to hemodynamic deterioration in severely growth-restricted fetuses.
ULTRASOUND OBST GYN. 32:71-76. I.F.:2,67.
Lewi L, Gucciardo L, Huber A, Jani J, VanMieghem T,
Done E, Cannie M, Gratacos E, Diemert A, Hecher K,
Lewi P, Deprest J. Clinical outcome and placental characteristics of monochorionic diamniotic twin pairs with
early- and late-onset discordant growth. AM J OBSTET
GYNECOL. 199:-. I.F.:2,92.
21/10/09 16:16:57
29 30 31 32 33
34 35 36 37 38 39 Liver, Digestive System and Metabolism Area 3
072-113 AREA3.indd 79
28 lopmental outcome in 2-year-old infants who were
small-for-gestational age term fetuses with cerebral
blood flow redistribution. ULTRASOUND OBST GYN.
32:894-899. I.F.:2,67.
Eixarch E, Meler E, Iraola A, Illa M, Crispi F, Hernandez-Andrade E, Gratacos E, Figueras F. Neurodevelopmental outcome in 2-year-old infants who were
small-for-gestational age term fetuses with cerebral
blood flow redistribution. ULTRASOUND OBST GYN.
32:894-899. I.F.:2,67.
Soria-Pastora S, Gimenez M, Narberhaus A, Falcon C,
Botet F, Bargallo N, Mercader JM, Junque C. Patterns
of cerebral white matter damage and cognitive impairment in adolescents born very preterm. INT J DEV
NEUROSCI. 26:647-654. I.F.:3,61.
Iraola A, Gonzalez I, Eixarch E, Meler E, Illa M, Gardosi J, Gratacos E, Figueras F. Prediction of adverse
perinatal outcome at term in small-for-gestational age
fetuses: comparison of growth velocity vs. customized
assessment. J PERINAT MED. 36:531-535. I.F.:1,10.
Gucciardo L, Deprest J, Done E, VanMieghem T, DeVelde MV, Gratacos E, Jani J, Peralta F, Nicolaides K.
Prediction of outcome in isolated congenital diaphragmatic hernia and its consequences for fetal therapy.
BEST PRACT RES CL OB. 22:123-138. I.F.:0,62.
Crispi F, Llurba E, Dominguez C, Martin-Gallan P, Cabero L, Gratacos E. Predictive value of angiogenic factors
and uterine artery Doppler for early- versus late-onset
pre-eclampsia and intrauterine growth restriction. ULTRASOUND OBST GYN. 31:303-309. I.F.:2,67.
Figueras F, Eixarch E, Gratacos E, Gardosi J. Predictiveness of antenatal umbilical artery Doppler for adverse
pregnancy outcome in small-for-gestational-age babies
according to customised birthweight centiles: population-based study. BJOG-INT J OBSTET GY. 115:590-594.
I.F.:2,67.
Palacio M, Cobo T, Figueras F, Gomez O, Coll O, Cararach V, Gratacos E. Previable rupture of membranes:
Effect of amniotic fluid on pregnancy outcome. EUR J
OBSTET GYN R B. 138:158-163. I.F.:1,43.
Carbonell-Estrany X, Figueras-Aloy J, Salcedo-Abizanda S, DeLaRosa-Fraile M. Probable early-onset group B
streptococcal neonatal sepsis: a serious clinical condition related to intrauterine infection.. ARCH DIS CHILDFETAL. 2:-. I.F.:2,34.
Gimenez M, Soria-Pastor S, Junque C, Caldu X, Narberhaus A, Botet F, Bargallo N, Falcon C, Mercader JM.
Proton Magnetic Resonance Spectroscopy Reveals Medial Temporal Metabolic Abnormalities in Adolescents
With History of Preterm Birth. PEDIATR RES. 64:572577. I.F.:2,84.
Fiore S, Heard I, Thorne C, Savasi V, Coll O, Malyuta R,
Niemiec T, Martinelli P, Tibaldi C, Newell ML. Reproductive experience of HIV-infected women living in Europe.
HUM REPROD. 23:2140-2144. I.F.:3,54.
Moreno R, Rosal M, Martinez I, Vilardell F, Gonzalez JR,
Petriz J, Hernandez-Andrade E, Gratacos E, Aran JM.
Restricted transgene persistence after lentiviral vectormediated fetal gene transfer in the pregnant rabbit model. J GENE MED. 10:951-964. I.F.:3,54.
Lewi L, Jani J, Blickstein I, Huber A, Gucciardo L,
VanMieghem T, Done E, Boes AS, Hecher K, Gratacos
15 Narberhaus A, Segarra D, Caldiu X, Gimenez M, Pueyo
R, Botet F, Junque C. Corpus callosum and prefrontal
functions in adolescents with history of very preterm
birth. NEUROPSYCHOLOGIA. 46:111-116. I.F.:3,63.
16 Suy A, Hernandez S, Thorne C, Lonca M, Lopez M, Coll
O. Current guidelines on management of HIV-infected
pregnant women: Impact on mode of delivery. EUR J
OBSTET GYN R B. 139:127-132. I.F.:1,43.
17 Figueras F, Meler E, Iraola A, Eixarch E, Coll O, Figueras J, Francis A, Gratacos E, Gardosi J. Customized
birthweight standards for a Spanish population. EUR J
OBSTET GYN R B. 136:20-24. I.F.:1,43.
18 Morales C, Sanchez A, Bruguera J, Margarit E, Borrell
A, Borobio V, Soler A. Cytogenetic study of spontaneous abortions using semi-direct analysis of chorionic
villi samples detects the broadest spectrum of chromosome abnormalities. AM J MED GENET A. 146A:66-70.
I.F.:2,44.
19 Sampalis JS, Langley J, Carbonell-Estrany X, Paes B,
O’brien K, Allen U, Mitchell I, Figueras J, Pedraz C,
Michaliszyn AF. Development and validation of a risk
scoring tool to predict respiratory syncytial virus hospitalization in premature infants born at 33 through 35
completed weeks of gestation. MED DECIS MAKING.
28:471-480. I.F.:2,20.
20 Pedersen NG, Figueras F, Wojdemann KR, Tabor A,
Gardosi J. Early fetal size and growth as predictors of
adverse outcome. OBSTET GYNECOL. 112:765-771.
I.F.:4,28.
21 Figueras-Aloy J, Carbonell-Estrany X, Quero-Jimenez
J, Fernandez-Colomer B, Guzman-Cabanas J, EchanizUrcelay I, Domenech-Martinez E. FLIP-2 study - Risk
factors linked to respiratory syncytial virus infection
requiring hospitalization in premature infants born in
Spain at a gestational age of 32 to 35 weeks. PEDIATR
INFECT DIS J. 27:788-793. I.F.:3,09.
22 Miracle X, DiRenzo GC, Stark A, Fanaroff A, CarbonellEstrany X, Saling E. Guideline for the use of antenatal
corticosteroids for fetal maturation. J PERINAT MED.
36:191-196. I.F.:1,10.
23 Brossard P, Boulvain M, Coll O, Barlow P, Aebi-Popp K,
Bischof P, DeTejada BM. Is screening for fetal anomalies
reliable in HIV-infected pregnant women? A multicentre
study. AIDS. 22:2013-2017. I.F.:5,84.
24 Narberhaus A, Segarra-Castells MD, Pueyo-Benito R,
Botet-Mussons F, Junque C. Long-term cognitive dysfunctions in preterm subjects with intraventricular haemorrhage. REV NEUROLOGIA. 47:57-60. I.F.:0,74.
25 Lopez S, Coll O, Durban M, Hernandez S, Vidal R, Suy
A, Moren C, Casademont J, Cardellach F, Mataro D,
Miro O, Garrabou G. Mitochondrial DNA depletion in
oocytes of HIV-infected antiretroviral-treated infertile
women. ANTIVIR THER. 13:833-838. I.F.:4,55.
26 Gratacos E, Antolin E, Lewi L, Martinez JM, HernandezAndrade E, Acosta-Rojas R, Enriquez G, Cabero L, Deprest J. Monochorionic twins with selective intrauterine
growth restriction and intermittent absent or reversed
end-diastolic flow (Type III): feasibility and perinatal
outcome of fetoscopic placental laser coagulation. ULTRASOUND OBST GYN. 31:669-675. I.F.:2,67.
27 Eixarch E, Meler E, Iraola A, Illa M, Crispi F, Hernandez-Andrade E, Gratacos E, Figueras F. Neurodeve-
79
21/10/09 16:16:59
E, Lewi P, Deprest J. The outcome of monochorionic
diamniotic twin gestations in the era of invasive fetal
therapy: a prospective cohort study. AM J OBSTET GYNECOL. 199:-. I.F.:2,92.
40 Lewi L, Lewi P, Diemert A, Jani J, Gucciardo L, VanMieghem T, Done E, Gratacos E, Huber A, Hecher K,
Deprest J. The role of ultrasound examination in the
first trimester and at 16 weeks’ gestation to predict fetal
complications in monochorionic diamniotic twin pregnancies. AM J OBSTET GYNECOL. 199:-. I.F.:2,92.
41 Figueras F, Fernandez S, Hernandez-Andrade E, Gratacos E. Umbilical venous blood flow measurement: accuracy and reproducibility. ULTRASOUND OBST GYN.
32:587-591. I.F.:2,67.
42 Jani J, Cannie M, Sonigo P, Roberts Y, Moreno O, Benachi A, Vaast P, Gratacos E, Nicolaides KH, Deprest J.
Value of prenatal magnetic resonance imaging in the
prediction of postnatal outcome in fetuses with diaphragmatic hernia. ULTRASOUND OBST GYN. 32:793799. I.F.:2,67.
Reviews
1
2
3
4
Carbonell-Estrany X, Bont L, Doering G, Gouyon JB,
Lanari M. Clinical relevance of prevention of respiratory
syncytial virus lower respiratory tract infection in preterm infants born between 33 and 35 weeks gestational
age. EUR J CLIN MICROBIOL. 27:891-899. I.F.:2,31.
Burdio F, Mulier S, Navarro A, Figueras J, Berjano E,
Poves I, Grande L. Influence of approach on outcome in
radiofrequency ablation of liver tumors. SURG ONCOL.
17:295-299. I.F.:1,24.
Done E, Gucciardo L, VanMieghem T, Jani J, Cannie M,
VanSchoubroeck D, Devlieger R, DeCatte L, Klaritsch P,
Mayer S, Beck V, Debeer A, Gratacos E, Nicolaides K,
Deprest J. Prenatal diagnosis, prediction of outcome
and in utero therapy of isolated congenital diaphragmatic hernia. PRENATAL DIAG. 28:581-591. I.F.:1,32.
Coll O, Menendez C, Botet F, Daya R, Carbonell-Estrany
X, Weisman LE, Anceschi MM, Greenough A, Gibss
RS, Ville Y. Treatment and prevention of malaria in
pregnancy and newborn. J PERINAT MED. 36:15-29.
I.F.:1,10.
Multicentrics
1
Murphy KE, Hannah ME, Willan AR, Hewson SA, Ohlsson A, Kelly EN, Matthews SG, Saigal S, Asztalos E,
Ross S, Delisle MF, Amankwah K, Guselle P, Gafni A,
Lee SK, Armson BA. Multiple courses of antenatal corticosteroids for preterm birth (MACS): a randomised
controlled trial. LANCET. 372:2143-2151. I.F.:28,64.
bifida, urogenital and abdominal wall defects (EuroSTEC).
Grant: European Commision, LSHB-CT-2006-037409. Duration: 01/01/2007-31/12/2011.
Gratacos E. MC - EST - Multidisciplinary Research Training
Programme in Fetal Medicine and Health. Grant: European
Commision, MEST-CT-2005-019707. Duration: 01/01/200631/12/2009.
Gratacos E. Evaluation of the brain perfusion/circulation in
growth restricted fetuses and its association with the neurodevelopment after birth. Grant: Thrasher Research Fund,
Thrasher05/02822-0. Duration: 01/09/2005-31/08/2008.
Gratacos E. CIBER-ER. CIBER Enfermedades raras. Grant:
28/07/2006-27/07/2010.
Figueras J. Oxido nítrico exhalado total y nitritos-nitratos e
IL-8 endotraqueales en el recién nacido prematuro ventilado. Relación con la corioamnionitis y la displasia broncopulmonar. Grant: Ministerio Sanidad y Consumo, PI060052.
Duration: 18/10/2006-30/12/2009.
Borrell A. Cribado prenatal del Síndrome de Down mediante test de contingencia en el primer trimestre. Estudio
multicéntrico de aplicación del test combinado seguido del
estudio selectivo de marcadores ecográficos secundarios.
18/10/2006-30/12/2009.
Gratacos E. Perfusión cerebral fetal medida por fracción
sanguínea en movimiento y asociación con desarrollo
neurológico posnatal en fetos hipoxicos por retraso de
crecimiento y gestación gemelar monocorial complicada.
18/10/2006-30/12/2009.
Cararach V. Valoración del impacto de un programa de
intervención precoz basado en la autoidentificación de la
vaginosis bacteriana por la propia gestante por medio de la
medida semanal del pH vaginal. Grant: Ministerio Sanidad y
Gratacos E. Fundació Cerebra (UK). Evaluation of regional
brain perfusion in growth ewstriction and neurological
damage after birth. Grant: FUND. Duration: 01/12/200530/11/2008.
Carbonell X. Evolución y estabilidad de ácidos grasos, vitaminas y factores inmunitarios en la leche materna. Grant:
FIS, AGL 2005-06940. Duration: 01/01/2006-31/12/2008.
80
Coll JO. Paediatric European Network Treatment AIDS and
European Collaborative Study on HIV-infected pregnant women and their children. Grant: European Commision, LSHPCT-2006-018865. Duration: 01/03/2006-28/02/2010.
Gratacos E. IP- Soft tissue engineering for congenital birth
defects in children: new treatment modalities for spina
072-113 AREA3.indd 80
Gratacos E. Ayudas de Incentivación a la participación en
proyectos del espacio Europeo de Investigación. Grant:
Ministerio de Educación y Ciencia, AI- 07/90026. Duration:
01/01/2007-31/12/2008.
Gratacos E. Diseño de un sistema clínico-biológico para
el pronóstico de los pacientes con leucemia linfática crónica. Grant: CLL Global Research Foundation,. Duration:
16/04/2008-31/05/2009.
21/10/09 16:17:01
Thesis
Deprest J, Hoylaerts MF, Gratacos E. Monochorionic Diamniotic Twin Pregnancies: Pregnancy outcome, risk stratification on early ultrasound scan and lessons learnt from
placental examination. Doctorand: Dr. Liesbeth Lewi. Katholieke Universiteit Leuven.
Gratacos E. Evaluación de las alteraciones hemodinámicas
asociadas a las complicaciones de la gestación monocorial,
Palacio M. Marcadores inflamatorios predictores de infección intraamniótica subclínica en gestantes con amenaza
de parto prematuro y bolsa íntegra. Doctorand: Mª Teresa
Cobo Cobo, Universitat de Barcelona.
Patents
Eduard Gratacos, Ivan Amat. Equipo para visión mejorada
por infrarrojo de estructuras vasculares, aplicable para
asistir intervenciones fetoscópicas, laparoscópicas y endoscópicas y proceso de tratamiento de la señal para mejorar
dicha visión.
Gratacos E. Transferencia génica fetal en un modelo
de coneja gestante. Optimización de vectores
retrovirales para una mayor eficiencia, seguridad y
persistencia de la expresión transgénica. Doctorand:
Rafael Moreno Olié.
asociación con lesión neurológica e impacto de la fetoscópia. Doctorand: Begoña Muñoz Avellana, Medicina. Universidad Autónoma de Barcelona.
81
072-113 AREA3.indd 81
21/10/09 16:17:03
Metabolic Regulation and Molecular Disease
Team Members
Metabolic regulation and molecular disease
Team Leader:
■ Josep Carreras
(Facultat de Medicina)
Tel.: 93 402 45 41
Fax: 93 403 58 82
IDIBAPS Members:
■ Joan Aureli Cadefau (Facultat de Medicina)
■ Ferran Climent (Facultat de Medicina)
■ Roser Cussó (Facultat de Medicina)
Collaborators:
Pablo Pérez de la Ossa (Facultat de Medicina)
Guillem Revilla López (Facultat de Medicina)
Christian Bayona (Facultat de Medicina)
Technicians:
Mario Guerrero (Facultat de Medicina)
Rosario Ruiz (Facultat de Medicina)
Anna Belem (Facultat de Medicina)
Doctoral Students:
Helena Raurell (FIS)
Feliu Roset (Facultat de Medicina)
1. Study of rabbit muscle proteome and muscle lesions; metabolic analyses of muscle biopsies.
2. Reversal of metabolic blockade by means of proteins linked to protein transduction domain (PTD).
3. Study of apoptosis in transplanted hearts and their
conservation.
2.Use of biochemical markers to determine muscle
lesions.
3.Repair of metabolic disorders in leukocytes and in
cells of transplanted hearts.
4. Study of transplanted hearts and their conservation.
1. Study of rabbit muscle proteome in fast- and slowtwitch fibres and the modifications caused by work
due to electrostimulation.
Left: Control. Right: Myocytes treated with PTD-beta-galactosidase.
I.F.: 5,34
PublicaTions
Original Articles
1
Cusso R. Marcadores moleculares para el diagnóstico de la
lesión muscular. Grant: Antibodybcn S.L., 07/248. Duration:
28/12/2007-28/12/2009.
82
2
3
072-113 AREA3.indd 82
Repiso A, Andres R, Climent F, Urena JM. Expression
patterns in mouse embryos of neuroleukin/glucose6-phosphate isomerase and autocrine motility factor
receptor. ANAT HISTOL EMBRYOL. 37:380-382. I.F.:0,55.
Guerrero M, Guiu-Comadevall M, Cadefau JA, Parra J,
Balius R, Estruch A, Rodas G, Bedini JL, Cusso R. Fast
and slow myosins as markers of muscle injury. BRIT J
SPORT MED. 42:581-584. I.F.:2,46.
Selivanov VA, DeAtauri P, Centelles JJ, Cadefau J, Parra
J, Cusso R, Carreras J, Cascante M. The changes in the
energy metabolism of human muscle induced by training. J THEOR BIOL. 252:402-410. I.F.:2,32.
Climent F. Corrección de enzimopatías mediante la introducción de proteïnas ligadas a PTD. Grant: Ministerio Sanidad
y Consumo. Duration: 01/03/2006-28/02/2009.
Cusso R. Optimización de entrenamientos aeróbicos y anaeróbicos. Análisis proteómico, transcripcional y del metabolismo energético en músculo esquelético. Grant: Ministerio
Educación y Ciencia. Duration: 01/01/2005-31/12/2008.
21/10/09 16:17:09
Bone Metabolic Disease
Team members
Team Leader:
■ Dra. Núria Guañabens
(Hospital Clínic)
Tel.: 93 227 54 00 (Ext.: 2235)
Bone metabolic disease
IDIBAPS Members:
■ Lluïsa Álvarez (Hospital Clínic)
■ Mª Jesús Martínez de Osaba (Hospital Clínic)
■ José Muñoz Gómez (Hospital Clínic)
■ Pilar Peris (Hospital Clínic)
Collaborators:
Angels Martinez-Ferrer (Hospital Clínic)
Ana Monegal (Hospital Clínic)
Raquel Reyes (Hospital Clínic)
1. Osteoporosis in premenopausal women.
2. Osteoporosis in men.
3. Osteoporosis associated with primary
biliary cirrhosis.
4. Liver transplant osteoporosis.
5. Applicability of biochemical markers
of bone replacement.
Primary culture of human osteoblasts.
I.F.: 14,55
PublicaTions
Original Articles
3
1
Peris P, Martinez-Ferrer A, Monegal A, DeOsaba MJM,
Alvarez L, Ros I, Muxi A, Reyes R, Guanabens N. Aetiology and clinical characteristics of male osteoporosis.
Have they changed in the last few years? CLIN EXP
RHEUMATOL. 26:582-588. I.F.:2,27.
2 Chung PYJ, Beyens G, Guanabens N, Boonen S,
Papapoulos S, Karperien M, Eekhoff M, VanWesenbeeck L, Jennes K, Geusens P, Offeciers E, VanOffel J, Westhovens R, Zmierczak H, Devogelaer
JP, VanHul W. Founder effect in different European
countries for the recurrent P392L SQSTM1 mutation
in Paget’s disease of bone. CALCIFIED TISSUE INT.
83:34-42. I.F.:2,44.
072-113 AREA3.indd 83
4
5
6
Peris P, Ruiz-Esquide V, Monegal A, Alvarez L, DeOsaba
MJM, Martinez-Ferrer A, Reyes R, Guanabens N. Idiopathic osteoporosis in premenopausal women. Clinical
characteristics and bone remodelling abnormalities.
CLIN EXP RHEUMATOL. 26:986-991. I.F.:2,27.
Martinez-Ferrer A, Peris P, Reyes R, Guanabens N.
Intake of calcium, magnesium and sodium through
water: health implications. MED CLIN-BARCELONA.
131:641-646. I.F.:1,34.
DelRio L, Peris P, Jover L, Guanabens N, Monegal A,
DiGregorio S. Men suffer vertebral fractures with similar spinal T-scores to women. CLIN EXP RHEUMATOL.
26:283-287. I.F.:2,27.
Guanabens N, Garrido J, Gobbo M, Piga AM, DelPino
J, Torrijos A, Descalzo MA, Garcia FJB, Cros JRR, Car-
The priority of our group is to research pathogenic
and therapeutic aspects of metabolic diseases of the
bone.
6.Clinical analysis of vertebroplasty.
7.Culturing human osteoblasts, with an analysis of the
effect of cholestasis on survival and cell function.
8.Analysis of skeletal retention of bisphosphonates in
patients with osteoporosis.
83
21/10/09 16:17:14
bonell J, Perez MR, Tornero J, Carmona L. Prevalence
of Paget’s disease of bone in Spain. BONE. 43:10061009. I.F.:3,97.
Peris P. Efecte de la vertebroplàstia percutània en la qualitat
de vida dels pacients amb dolor relacionat amb fractures
vertebrals osteoporòtiques. Comparació amb el tractament
conservador. Grant: Fundació La Marató de TV3. Duration:
01/01/2007-01/01/2010.
Bone metabolic disease
Guanyabens N. Estudio del efecto bifásico de la hormona
paratiroidea (PTH) sobre osteoblastos humanos primarios
en cultivo. Acción sobre el sistema OPG/RANKL y los mar-
cadores de diferenciación osteoblástica RUNX2/CBFA1, osteocalcina y procolágeno tipo I. Grant: Ministerio Sanidad y
84
072-113 AREA3.indd 84
21/10/09 16:17:16
Viral Hepatitis in Immunocompetent and Liver Transplant Patients
Team members
Team Leader:
■ Jose M Sánchez-Tapias
(Hospital Clínic)
Tel.: 93 227 54 99
Collaborators:
Sofia Pérez del Pulgar (CIBERehd)
Gonzalo Crespo (Hospital Clínic)
Graciela Castro (Fundació Clínic)
Doctoral Students:
José A. Carrión (Fundació Clínic)
Jakub Dragun (Marie Curie)
Stella Martínez (Fundació Clínic)
Santseharay Ramírez (IDIBAPS)
Mairene Coto (MAEC-AECI)
Technicians:
Patricia González (CIBERehd)
Laura Mensa (CIBERehd)
Nurses:
Concepció Bartrés (Fundació Clínic)
Investigation of epidemiologic, pathogenic, diagnostic
and therapeutic aspects of infections due to hepatitis
virus in immunocompetent and liver transplant patients.
1. Study of the role of neutralizing antibodies in the kinetics of infection by the hepatitis C virus (HVC) after liver transplant
and implications in the course of recurrence of hepatitis C
The group has prepared a technique that makes it
possible to study the neutralizing potential (in vitro)
of HVC antibodies. This means that we can determine
whether these antibodies modulate the early kinetics
of graft infection and whether this affects the severity
of hepatitis C evaluated a year after transplant.
2.Occult hepatitis B and liver-cell carcinoma
The presence of residual markers of infection by the
hepatitis B virus (HVB), in the absence of the surface
antigen (HBsAg), has been linked by some studies to
a greater predisposition to develop liver diseases and
even liver-cell carcinoma. With the collaboration of the
hepatic oncology group, we will study this hypothesis
in a well-characterized cohort of patients with liver-cell
carcinoma (HBsAg-negative).
072-113 AREA3.indd 85
Viral hepatitis in immunocompetent
and liver transplant patients
IDIBAPS Members:
■ Josep Maria Barrera (Hospital Clínic)
■ Miquel Bruguera (Hospital Clínic)
■ Josep Costa (Hospital Clínic)
■ Xavier Forns (Hospital Clínic)
■ Miquel Navasa (Hospital Clínic)
3.Expression of HVC entry receptors in liver
tissue. Influence on the kinetics of liver
graft infection and on patient outcome
This is a broad project with multiple objectives, which
began last year. The aim is to characterize the expression of the different receptors that HVC uses to enter
the liver cell (CD81, claudin-1, occludin, SRB-1) using
different techniques (flux cytometry, immunofluorescence, western-blot). In the medium term, we are
looking to increase knowledge on the role of these
85
21/10/09 16:17:20
receptors in the kinetics of graft infection following
liver transplant. We will also study the possible role of
immunosuppressant drugs in the expression of CD81,
claudin and SRB-1.
4. Treatment of chronic hepatitis C
Naturally, our group continues to make great efforts to
improve the efficacy and safety of antiviral treatment
in patients with chronic HVC infection. This line of research includes the following different aspects: 1) participation in clinical trials of new antiviral molecules
(both in initial phases and in pre-marketing phases).
2) study of the predictive factors of response to treatment, and design of models that provide a reliable
prediction of treatment results, 3) further study of the
5.Noninvasive diagnosis
of chronic hepatitis C
The objective of this line of research is to validate different models of noninvasive diagnosis of liver damage (basically liver fibrosis) in cohorts of patients infected with HVC. The diagnosis models are based on
the combination of routine laboratory variables, the
combination of different markers of fibrogenesis and
transitory elastometry (ET). Over the next year, the
group will continue to apply new models based on serologic marker and will focus on the study of patients
with hepatitis C after liver transplant.
I.F.: 46,14
PublicaTions
Original Articles
1
2
mechanisms that explain the lack of response and recurrence in antiviral treatment.
3
4
5
6
86
7
8
072-113 AREA3.indd 86
Crespo G, Cervera C, Michelena J, Marco F, Moreno
A, Navasa M. Immune Reconstitution Syndrome After
Voriconazole Treatment for Cryptococcal Meningitis
in a Liver Transplant Recipient. LIVER TRANSPLANT.
14:1671-1674. I.F.:3,75.
Laguno M, Larrousse M, Blanco JL, Leon A, Milinkovic
A, Martinez-Rebozler M, Lonca M, Martinez E, SanchezTapias JM, DeLazzari E, Gatell JM, Costa J, Mallolas
J. Prevalence and clinical relevance of occult hepatitis
B in the fibrosis progression and antiviral response to
INF therapy in HIV-HCV-Coinfected patients. AIDS RES
HUM RETROV. 24:547-553. I.F.:2,02.
Martinez-Bauer E, Forns X, Armelles M, Planas R, Sola
R, Vergara M, Fabregas S, Vega R, Salmeron J, Diago
M, Sanchez-Tapias JM, Bruguera M. Hospital admission is a relevant source of hepatitis C virus acquisition
in Spain. J HEPATOL. 48:20-27. I.F.:6,64.
Dominguez A, Oviedo M, Carmona G, Batalla J, Bruguera M, Salleras L, Plasencia A. Impact and effectiveness of a mass hepatitis A vaccination programme of
preadolescents seven years after introduction. VACCINE. 26:1737-1741. I.F.:3,38.
Dominguez A, Torner N, Barrabeig I, Rovira A, Rius C,
Cayla J, Plasencia E, Minguell S, Sala MR, Martinez A,
Costa J, Mosquera M, Cabezas C. Large outbreak of
measles in a community with high vaccination coverage: Implications for the vaccination schedule. CLIN
INFECT DIS. 47:1143-1149. I.F.:6,75.
Garcia-Cortes M, Borraz Y, Lucena MI, Pelaez G, Salmeron J, Diago M, Martinez-Sierra MC, Navarro JM, Planas R, Soria MJ, Bruguera M, Andrade RJ. Liver injury
induced by “natural remedies”: an analysis of cases
submitted to the Spanish Liver Toxicity Registry. REV
ESP ENFERM DIG. 100:688-695. I.F.:1,09.
Muñoz J, Alonso D, Vilella A, Naniche D, Costa J, Gascon J. Measles in travelers: Are we aware enough?. J
TRAVEL MED. 15:124-125. I.F.:1,05.
Marti J, Charco R, Ferrer J, Calatayud D, Rimola A,
Navasa M, Fondevila C, Fuster J, Garcia-Valdecasas JC.
Optimization of liver grafts in liver retransplantation: A
European single-center experience. SURGERY. 144:762769. I.F.:3,00.
9 Salleras L, Dominguez A, Plans P, Costa J, Cardenosa N,
Torner N, Plasencia A. Seroprevalence of varicella zoster
virus infection in child and adult population of Catalonia
(Spain). MED MICROBIOL IMMUN. 197:329-333. I.F.:1,54.
10 Martinez-Llordella M, Lozano JJ, Puig-Pey I, Orlando G,
Tisone G, Lerut J, Benitez C, Pons JA, Parrilla P, Ramirez P, Bruguera M, Rimola A, Sanchez-Fueyo A. Using
transcriptional profiling to develop a diagnostic test of
operational tolerance in liver transplant recipients. J
CLIN INVEST. 118:2845-2857. I.F.:16,92.
Reviews
1
Castera L, Forns X, Alberti A. Non-invasive evaluation
of liver fibrosis using transient elastography. J HEPATOL. 48:835-847. I.F.:6,64.
Editorials
1
2
Forns X. Diagnosis of liver fibrosis in 2008. GASTROEN
CLIN BIOL. 32:1-3. I.F.:0,85.
Navasa M, Forns X. How accurately and how early can
we predict rapid fibrosis progression in hepatitis C virus-infected patients after liver transplantation?. LIVER
TRANSPLANT. 14:1237-1239. I.F.:3,75.
Forns X. NoE - European Vigilance Network for the Management of Antiviral Drug Resistance. Grant: European
Commision, LSHM-CT-2004-503359. Duration: 01/05/200430/04/2008.
Forns X. Entry Inhibitors for the treatment of HCV Infection.
Grant: European Commision, MRTN-CT-2006-035599. Duration: 01/10/2006-30/09/2010.
Forns X. CIBER de Enfermedades hepáticas y digestivas.
21/10/09 16:17:23
Navasa M. Evolución de la recidiva de la infección por el
virus de la hepatitis C en el traspalnte hepático de donante
vivo. Comparación con el trasplante convencional. Papel de
las lipoproteínas en la cinética y en la infectividad del virus
de la hepatits C. Grant: Ministerio Sanidad y Consumo,
PI050230. Duration: 01/01/2006-30/12/2008.
Thesis
Forns X. Estudio de la compartimetalización del virus de la
hepatitis C (VHC) y su relación con la recidiva de la infección tras el tratamiento antiviral y el trasplante hepático.
01/01/2006-30/12/2008.
Navasa M. Investigación del papel de las lipoproteínas
de alta densidad (HDL) y de los neutrófilos sobre
las infecciones bacterianas en la cirrosis hepática.
Doctorand: María José Ramírez Lázaro. Facultat de
Medicina, UB.
Forns X. Infección por el virus de la hepatitis C: Papel actual
de la transmisión nosocomial de la infección. Factores predictivos de respuesta al tratamiento antiviral. Doctorand:
Eva Martínez Bauer. Facultat de Medicina, UB.
87
072-113 AREA3.indd 87
21/10/09 16:17:25
Pathophysiology and Treatment of Ascites and Renal
Function Disorder in Cirrhosis of the Liver
Team Members
Pathophysiology and treatment of ascites and
renal function disorder in cirrhosis of the liver
Team Leader:
■ Vicente Arroyo (Hospital Clínic)
Tel.: 93 227 57 39
88
IDIBAPS Members:
■ Ramón Bataller (Hospital Clínic)
■ Joan Clària (Hospital Clínic)
■ Javier Fernández-Gómez (Hospital Clínic)
■ Pere Ginès (Hospital Clínic)
■ Mónica Guevara (IDIBAPS)
■ Wladimiro Jiménez (Hospital Clínic)
■ Manuel Morales-Ruiz (Hospital Clínic)
Collaborators:
Jordi Colmenero (Hospital Clínic)
Josefa Ros (FIS-IDIBAPS)
Montserrat Moreno (CIBERehd)
Esther Titos (CIBERehd)
Marco Pavesi (CIBERehd)
Marta López-Parra (MCyT)
Doctoral Students:
Maria Eugenia Baccaro (Fundació Clínic)
Ana González-Périz (MCyT)
Raquell Horrillo (Generalitat de Catalunya)
Marta López-Parra (MCyT)
Marta Martín (Hospital Clínic)
Pedro Melgar (FPI-MEC)
Javier Muñoz (MEC)
André Nazar (Fundació Clínic)
Montserrat Pauta (FPI)
Anna Planagumà (IDIBAPS)
Alessandro Príncipe (Universitat de Bolonia)
Jordi Ribera (CIBERehd)
Sònia Tugués (IDIBAPS)
Eva Urtasun (Fundació Clínic)
Marcos Martínez-Clemente (MEC)
Eva Morán (IDIBAPS)
Juan Acevedo (Hospital Clínic)
Marcella Marinelli (Fundació Clínic)
Technicians:
Montse Bernat (Fundació Clínic)
Cristina Díez (Hospital Clínic)
Carmen Escofet (Hospital Clínic)
Guillermo Fernandez Varó (CIBERehd)
Elena Juez (IDIBAPS)
Vanessa López (Hospital Clínic)
Cristina Millán (IDIBAPS)
Melissa Visser (CIBERehd)
Nurses:
Miriam Castro (CIBERehd)
Raquel Cela (Hospital Clínic)
This is an interdisciplinary group that investigates the
mechanisms and treatment of the inflammation and
liver fibrosis that lead to cirrhosis, and the pathogenesis and treatment of multi-organ complications deriving from established cirrhosis of the liver.
1. Molecular determinants of liver inflammation.
Role of Kupffer cells.
2. Acute bacterial infections in cirrhosis.
3. Pathophysiology and treatment of hepatorenal syndrome and renal failure associated with bacterial
infections.
4. Evaluation of cirrhotic myocardiopathy.
072-113 AREA3.indd 88
Electronic microscopy image of the liver of a patient with hepatic fibrosis
caused by non-alcoholic steatohepatitis. A large fat vesicle is visible in the
interior of a hepatocyte.
21/10/09 16:17:31
5. Relationship between hepatic encephalopathy and
abnormal renal function in cirrhosis.
6. Pathogenesis, clinical implications and treatment of
hyponatremia.
7. Evaluation of different cerebral magnetic resonance
techniques in cirrhotic patients. Relationship with
hepatic encephalopathy.
8. Role of endogenous cannabinoids in the pathophysiology of arterial vasodilation.
9. Application of genomics and gene therapy in liver
dysfunction.
10.Angiogenesis, edema and vascular remodeling in
cirrhosis of the liver.
11.Pathogenesis of liver fibrosis: cellular bases and
identification of new therapeutic strategies.
12.Pathophysiology and treatment of arterial vasodilation.
13.Pathophysiology and treatment of ascites.
14.Artificial liver support systems.
Original Articles
1
072-113 AREA3.indd 89
10 11 12 13 Reviews
1
2
3
4
Gines P, Guevara M. Hyponatremia in cirrhosis: Pathogenesis, clinical significance, and management. HEPATOLOGY. 48:1002-1010. I.F.:10,73.
Arroyo V, Fernandez J, Gines P. Pathogenesis and
treatment of hepatorenal syndrome. SEMIN LIVER DIS.
28:81-95. I.F.:5,81.
Sanyal AJ, Bosch J, Blei A, Arroyo V. Portal hypertension and its complications. GASTROENTEROLOGY.
134:1715-1728. I.F.:11,67.
Gines P, Cardenas A. The management of ascites and
hyponatremia in cirrhosis. SEMIN LIVER DIS. 28:43-58.
I.F.:5,81.
Coll E, Larrousse M, DeLaSierra A, Collado S, Jimenez
W, Cases A. Chronic hypotension in hemodialysis patients: role of functional vascular changes and vasodilator agents. CLIN NEPHROL. 69:114-120. I.F.:1,32.
2 Dominguez M, Rincon D, Abraldes JG, Miquel R, Colmenero J, Bellot P, Garcia-Pagan JC, Fernandez R,
Moreno M, Banares R, Arroyo V, Caballeria J, Gines
P, Bataller R. A New Scoring System for Prognostic
Stratification of Patients With Alcoholic Hepatitis. AM J
GASTROENTEROL. 103:2747-2756. I.F.:6,10.
3 Terg R, Fassio E, Guevara M, Cartier M, Longo C, Lucero R, Landeira C, Romero G, Dominguez N, Munoz A,
Levi D, Miguez C, Abecasis R. Cipirofloxacin in primary
prophylaxis of spontaneous bacterial peritonitis: A randomized, placebo-controlled study. J HEPATOL. 48:774779. I.F.:6,64.
4 Salerno F, Gerbes A, Gines P, Wong F, Arroyo V.
Diagnosis, prevention and treatment of hepatorenal
syndrome in cirrhosis. POSTGRAD MED J. 84:662-670.
I.F.:1,22.
5 Gines P, Wong F, Watson H, Milutinovic S, DelArbol
LR, Olteanu D. Effects of satavaptan, a selective vasopressin V-2 receptor antagonist, on ascites and serum
sodium in cirrhosis with hyponatremia: A randomized
trial. HEPATOLOGY. 48:204-213. I.F.:10,73.
6 Casillas-Ramirez A, Amine-Zaouali M, Massip-Salcedo
M, Padrissa-Altes S, Bintanel-Morcillo M, Ramalho F,
Serafin A, Rimola A, Arroyo V, Rodes J, Rosello-Catafau
J, Peralta C. Inhibition of angiotensin II action protects
rat steatotic livers against ischemia-reperfusion injury.
CRIT CARE MED. 36:1256-1266. I.F.:6,28.
7 Rodriguez-Vilarrupla A, Graupera M, Matei V, Bataller
R, Abraldes JG, Bosch J, Garcia-Pagan JC. Large-conductance calcium-activated potassium channels modulate vascular tone in experimental cirrhosis. LIVER INT.
28:566-573. I.F.:2,56.
8 Botella-Lopez A, DeMadaria E, Jover R, Bataller R,
Sancho-Bru P, Candela A, Compan A, Perez-Mateo M,
Martinez S, Saez-Valero J. Reelin is overexpressed in
the liver and plasma of bile duct ligated rats and its
levels and glycosylation are altered in plasma of humans with cirrhosis. INT J BIOCHEM CELL B. 40:766775. I.F.:4,01.
9 Munoz-Luque J, Ros J, Fernandez-Varo G, Tugues S,
Morales-Ruiz M, Alvarez CE, Friedman SL, Arroyo V,
Jimenez W. Regression of fibrosis after chronic stimu-
lation of cannabinoid CB2 receptor in cirrhotic rats.
J PHARMACOL EXP THER. 324:475-483. I.F.:4,00.
Lopez-Parra M, Titos E, Horrillo R, Ferre N, GonzalezPeriz A, Martinez-Clemente M, Planaguma A, Masferrer J, Arroyo V, Claria J. Regulatory effects of
arachidonate 5-lipoxygenase on hepatic microsomal
TG transfer protein activity and VLDL-triglyceride and
apoB secretion in obese mice. J LIPID RES. 49:25132523. I.F.:4,34.
Martin-Llahi M, Pepin MN, Guevara M, Diaz F, Torre A,
Monescillo A, Soriano G, Terra C, Fabrega E, Arroyo V,
Rodes J, Gines P. Terlipressin and albumin vs albumin
in patients with cirrhosis and hepatorenal syndrome:
A randomized study. GASTROENTEROLOGY. 134:13521359. I.F.:11,67.
Principe A, Melgar-Lesmes P, Fernandez-Varo G, DelArbol LR, Ros J, Morales-Ruiz M, Bernardi M, Arroyo V,
Jimenez W. The hepatic apelin system: A new therapeutic target for liver disease. HEPATOLOGY. 48:11931201. I.F.:10,73.
Lacy AM, Delgado S, Castells A, Prins HA, Arroyo V,
Ibarzabal A, Pique JM. The long-term results of a randomized clinical trial of laparoscopy-assisted versus
open surgery for colon cancer. ANN SURG. 248:1-7.
I.F.:7,45.
I.F.: 77,06
PublicaTions
89
Editorials
1
2
Gines P. Complications of cirrhosis - Foreword. SEMIN
LIVER DIS. 28:1-1. I.F.:5,81.
Cardenas A, Gines P. Predicting mortality in cirrhosis
- Serum sodium helps. NEW ENGL J MED. 359:10601062. I.F.:52,59.
21/10/09 16:17:33
Bataller R. STREP - Development of Innovative Assays and
Locally acting therapies aiming at critical Kinases in hepatic
and renal fibrosis. Grant: European Commision, LSHBCT-2007-036644. Duration: 01/10/2006-30/09/2009.
Arroyo V. Grup de Recerca en Hepatologia Clínica. Grant:
Duration: 19/10/2005-31/12/2008.
Arroyo V. CIBER de Enfermedades hepáticas y digestivas.
Gines P. Complicaciones de la cirrosis en pacientes en candidatos a trasplante hepático. Diseño de nuevas estrategias
para la reducción de la mortalidad en lista de espera de
trasplante hepático. Grant: Ministerio Sanidad y Consumo,
PI050246. Duration: 01/01/2006-30/12/2008.
Guevara M. Eficacia de la administración de albúmina endovenosa sobre la supervivencia y prevención del desarrollo
de la insuficiencia renal en pacientes con cirrosis y sepsis.
Estudio aleatorizado y controlado. Grant: Ministerio Sanidad y Consumo, PI050273. Duration: 01/01/2006-30/12/2008.
Arroyo V. Fibrosis hepática secundaria a esteatohepatitis
no alcohólica: diagnóstico no invasivo, bases patogénicas y
nuevas estrategias terapéuticas. Grant: Ministerio Sanidad y
Guevara M. Estudio Aleatorizado y controlado sobre la eficacia de la albúmina en la prevención de las complicaciones
de pacientes de cirrosis en la lista de espera de trasplante
hepático. Grant: Ministerio Sanidad y Consumo, PI070443.
Duration: 26/11/2007-30/12/2010.
Gines P. Efecto de la hiponatremia sobre la función neuropsicológica en los pacientes con cirrosis. Mecanismos
patogénicos e intervenciones terapéuticas. Grant: Ministerio
Bataller R. Investigación de los mecanismos celulares y
moleculares responsables de la fibrosis hepática inducida
por el virus de la hepatitis C. Grant: Ministerio Educación y
Ciencia, SAF2005-06245. Duration: 15/10/2005-14/10/2008.
Claria J. Participación de los mediadores lipídicos derivados
del ácido araquidónico en el desarrollo y progresión de la
inflamación y esteatosis hepática. Efecto de los ácidos grasos poliinsaturados Omega-3. Grant: Ministerio Educación y
Jimenez W. Fibrosis, disfunción homodinámica y renal y prevención del rechazo en la enfermedad hepática. Evaluación de
nuevas estrategias terapéuticas en modelos experimentales
de cirrosis y trasplante de hígado. Grant: Ministerio Educación
y Ciencia, SAF2006-07053. Duration: 01/10/2006-30/09/2009.
Morales M. Función fisiopatológica de la activación de las
células endoteliales hepáticas en la cirrosis. Posibles implicaciones terapéuticas. Grant: Ministerio Educación y Ciencia, SAF2007-63069. Duration: 01/10/2007-04/10/2010.
Thesis
Morales-Ruiz M. Fisiopatologia de la cel·lula endotelial en la
cirrosi hepàtica. Doctorand: Sonia Tugues Solsona.
Gines P. Estudio de la insuficiencia renal inducida por infecciones bacterrianas distintas de la peritonitis bacteriana
espontánea en pacientes con cirrosis. Doctorand: Carlos
Antonio Rodrigues Terra Filho.
90
072-113 AREA3.indd 90
21/10/09 16:17:35
Hepatic Oncology
Team members
Team Leader:
■ Jordi Bruix (Hospital Clínic)
Tel.: 93 227 98 03
Fax: 93 227 57 92
This multidisciplinary group, internationally known as
he “Barcelona Clínic Liver Cancer (BCLC) Group” carries out clinical research in liver cell carcinoma and in
translational research. The objective is to investigate
both the efficacy of clinical and therapeutic interventions and the mechanisms that regulate the progression of this disease.
At clinical level, we are working on the definition of
new diagnostic tools and, to evaluate the efficacy of
the treatments, we are refining optimum criterial for
indicating radical treatment (surgical resection, transplant, percutaneous approach with injection of alcohol
or thermal ablation) to achieve the greatest efficacy
in terms of both survival and associated morbidity. In
the area of treatment, we evaluate options for improving the efficacy of noncurative treatments for which
we have shown efficacy in increasing survival (arterial chemoembolization, sorafenib). In this regard, we
are developing and leading phase 1, 2 and 3 studies
at international level to determine the efficacy of new
molecular agents. At the same time, we are evaluat-
072-113 AREA3.indd 91
Nurses:
Adela Godoy (Fundació Clínic)
Secretary:
Núria Pérez (Fundació Clínic)
Diana Segarra (CIBERehd)
ing the efficacy of antiangiogenic treatment to prevent
recurrence after surgery or ablation.
In terms of translational research, we are researching
the pathogenesis of liver cell carcinoma, analyzing
new signalling pathways and genomic abnormalities
implicated in the development of the tumor, and identifying new therapeutic targets. An international consortium for genome research on liver cell carcinoma
has been constituted in collaboration with Mount Sinai
Medical School, Harvard University and the Instituto di
Tumori in Milan, Italy, which has consolidated a tissue
bank of enormous importance.
Collaborators:
Loreto Boix (Fundació Clínic)
Juan M. López (IDIBAPS)
Judit Peix (CIBERehd)
Manel Solé (Hospital Clínic)
Victoria Tovar (IDIBAPS)
Jordi Rimola (CDIC)
Marta Burrel (CDIC)
Maria Isabel Real (CDIC)
Lluís Bianchi (CDIC)
Augusto Villanueva (Ciberehd)
Doctoral Students:
Clara Alsinet (IDIBAPS)
Alejandro Forner (MEC)
María Reig (IDIBAPS)
Carlos Rodriguez de Lope (Fundació Clínic)
Helena Cornella (IDIBAPS)
Hepatic oncology
IDIBAPS Members:
■ M. Carmen Ayuso (Hospital Clínic)
■ Concepció Bru (Hospital Clínic)
■ Josep Fuster (Hospital Clínic)
■ Josep M. Llovet (IDIBAPS)
■ Ramon Vilana (Hospital Clínic)
91
Cell line BCLC-9 of hepatocellular carcinoma
with nuclear stain with H-3342.
21/10/09 16:17:39
Associated Group
Translational research on hepatic oncology
■ Llovet, Josep M. (ICMDM)
Hepatic oncology
The group was constituted in 2006 to carry out genomic studies on liver cell carcinoma and identify therapeutic targets and new molecular treatments. We have established two lines of research in the context
of an international consortium (HCC Genome Project), organized by Dr. Llovet and with the participation
of Hospital Clínic-IDIBAPS, Mount Sinai School of Medicine (New York), Dana-Farber/Broad Institute (Boston) and Instituto
di Tumori (Milan): 1. Genomics. Identification of genome alterations in liver cell carcinoma (LCC) and determination of
their implications in diagnosis and treatment. Comprehensive analysis of the study of the transcriptome (oligonucleotide
microarrays) and abnormalities in the genome (SNP arrays). Identification of markers for early diagnosis del CHC.2. Signaling pathways and molecular therapies. Identification of the role of signal transduction pathways in the pathogenesis of
LCC and identification of new therapeutic targets and new molecular treatments. We are currently studying the signalling
pathways of Akt/mTOR, EGFR-Ras-MAPK, IGF and Wnt in human samples, cell lines and experimental animals.
I.F.: 167,42
PublicaTions
Original Articles
1
2
3
4
5
92
6
072-113 AREA3.indd 92
Rodriguez S, Pages M, Castells A, DeJuan C, Bordas
JM, Rimola J, Ayuso JR, Ayuso C. Dark-lumen MR colonography with fecal tagging: a comparison of water
enema and air methods of colonic distension for detecting colonic neoplasms. EUR RADIOL. 18:1396-1405.
I.F.:3,41.
Forner A, Vilana R, Ayuso C, Bianchi L, Sole M, Ayuso
JR, Boix L, Sala M, Varela M, Llovet JM, Bru C, Bruix
J. Diagnosis of hepatic nodules 20 mm or smaller in
cirrhosis: Prospective validation of the noninvasive
diagnostic criteria for hepatocellular carcinoma. HEPATOLOGY. 47:97-104. I.F.:10,73.
Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P,
Minguez B, Leblanc AC, Donovan DJ, Thung SN, Sole
M, Tovar V, Alsinet C, Ramos AH, Barretina J, Roayaie
S, Schwartz M, Waxman S, Bruix J, Mazzaferro V, Ligon
AH, Najfeld V, Friedman SL, Sellers WR, Meyerson M,
Llovet JM. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. CANCER RES.
68:6779-6788. I.F.:7,67.
Hoshida Y, Villanueva A, Kobayashi M, Peix J, Chiang
DY, Camargo A, Gupta S, Moore J, Wrobel MJ, Lerner
J, Reich M, Chan JA, Glickman JN, Ikeda K, Hashimoto
M, Watanabe G, Daidone MG, Roayaie S, Schwartz M,
Thung S, Salvesen HB, Gabriel S, Mazzaferro V, Bruix
J, Friedman SL, Kumada H, Llovet JM, Golub TR. Gene
Expression in Fixed Tissues and Outcome in Hepatocellular Carcinoma. NEW ENGL J MED. 359:1995-2004.
I.F.:52,59.
Schwartz M, Dvorchik I, Roayaie S, Fiel MI, Finkelstein
S, Marsh JW, Martignetti JA, Llovet JM. Liver transplantation for hepatocellular carcinoma: Extension of
indications based on molecular markers. J HEPATOL.
49:581-588. I.F.:6,64.
7
Rimola J, Rodriguez S, Ayuso C. Magnetic resonance
enterography in Crohn’s disease: a new diagnostic
tool?. MED CLIN-BARCELONA. 130:580-584. I.F.:1,34.
8 Berzigotti A, Gilabert R, Abraldes JG, Nicolau C, Bru C,
Bosch J, Garcia-Pagan JC. Noninvasive prediction of
clinically significant portal hypertension and esophageal varices in patients with compensated liver cirrhosis. AM J GASTROENTEROL. 103:1159-1167. I.F.:6,10.
9 Villanueva A, Chiang DY, Newell P, Peix J, Thung S,
Alsinet C, Tovar V, Roayaie S, Minguez B, Sole M, Battiston C, VanLaarhoven S, Fiel MI, DiFeo A, Hoshida Y,
Yea S, Toffanin S, Ramos A, Martignetti JA, Mazzaferro
V, Bruix J, Waxman S, Schwartz M, Meyerson M, Friedman SL, Llovet JM. Pivotal Role of mTOR Signaling
in Hepatocellular Carcinoma. GASTROENTEROLOGY.
135:1972-1983. I.F.:11,67.
10 Yea S, Narla G, Zhao X, Garg R, Tal-Kremer S, Hod E,
Villanueva A, Loke J, Tarocchi M, Akita K, Shirasawa S,
Sasazuki T, Martignetti JA, Llovet JM, Friedman SL. Ras
promotes growth by alternative splicing-mediated inactivation of the KLF6 tumor suppressor in hepatocellular
carcinoma. GASTROENTEROLOGY. 134:1521-1531.
I.F.:11,67.
11 Llovet JM, Ricci S, Mazzaferro V, Hilgard P, Gane E,
Blanc JF, DeOliveira AC, Santoro A, Raoul JL, Forner A,
Schwartz M, Porta C, Zeuzem S, Bolondi L, Greten TF,
Galle PR, Seitz JF, Borbath I, Haussinger D, Giannaris
T, Shan M, Moscovici M, Voliotis D, Bruix J. Sorafenib
in advanced hepatocellular carcinoma. NEW ENGL J
MED. 359:378-390. I.F.:52,59.
Reviews
1
2
Llovet JM, DiBisceglie AM, Bruix J, Kramer BS, Lencioni R, Zhu AX, Sherman M, Schwartz M, Lotze M,
Talwalkar J, Gores GJ. Design and endpoints of clinical
trials in hepatocellular carcinoma. J NATL CANCER I.
100:698-711. I.F.:15,68.
Newell P, Villanueva A, Friedman SL, Koike K, Llovet
JM. Experimental models of hepatocellular carcinoma.
J HEPATOL. 48:858-879. I.F.:6,64.
21/10/09 16:17:42
3
4
5
EditoriaLS
1
2
3
4
Llovet JM, Lok A. Hepatitis B virus genotype and mutants: Risk factors for hepatocellular carcinoma. J NATL
CANCER I. 100:1121-1123. I.F.:15,68.
Bruix J. Liver cancer: An evolving challenge reaching
research maturity. HEPATOLOGY. 47:1103-1104.
I.F.:10,73.
Forner A, Bruix J. Locoregional treatment for hepatocellular carcinoma: From clinical exploration to robust clinical data, changing standards of care. HEPATOLOGY.
47:5-7. I.F.:10,73.
Newell P, Villanueva A, Llovet JM. Molecular targeted
therapies in hepatocellular carcinoma: From pre-clinical
models to clinical trials. J HEPATOL. 49:1-5. I.F.:6,64.
Bruix J. CIBER Enfermedades hepáticas y digestivas. Grant:
28/07/2006-27/07/2010.
Bru C. Integración de las diferentes técnicas de imagen
médica en una única imagen multimodal. Desarrollo de
distintos modelos de aplicación. Angiologia cerebral y
Bruix J. Perfil de expresión génica en lesiones preneoplásicas y en el carcinoma hepatocelular inicial, en la cirrosis por
el virus de la hepatitis c. Aplicación en la detección precoz
y en el diagnostico. Grant: Ministerio Sanidad y Consumo,
PI050150. Duration: 01/01/2006-30/12/2008.
Ayuso C. Utilidad de la resonancia magnética de 3T con
espectroscopia en el diagnóstico y caracterización del carcinoma hepatocelular. Grant: Ministerio Sanidad y Consumo,
PI060132. Duration: 18/10/2006-30/12/2009.
Llovet JM. Papel de la vía de señalización del IGF en el carcinoma hepatocelular (CHC). Terapia molecular in vitro e in
vivo. Grant: Ministerio Educación y Ciencia, SAF2007-61898.
Duration: 01/10/2007-04/10/2010.
Llovet JM. Integrative genomic analysis in hepatocellular carcinoma. Grant: National Institutes of Health,
1R01DK076986-01. Duration: 08/10/2007-31/07/2012.
Thesis
Llovet JM. Activación de la vía de señalizacion de PI3K/
Akt en el carcinoma hepatocelular: Evidencia de su
bloqueo y efecto antineoplásico con un nuevo inhibidor
dual de la tirosin kinasa (AEE788) y un inhibidor de
mTOR (RAD001, everolimus). Doctorand: Augusto
Villanueva Rodríguez. Universidad de Santiago de
Compostela.
Bruix J. Seguridad, eficacia y farmacocinética de la quimioembolización del carcinoma hepatocelular con esferas
liberadoras de adriamicina. Doctorand: Maria Varela Calvo.
cardiológica (TC,RM,SPECT). Grant: Ministerio de Industria Turismo y Comercio, CDTEAM. Duration: 17/01/200618/01/2010.
Hepatic oncology
Villanueva A, Toffanin S, Llovet JM. Linking molecular
classification of hepatocellular carcinoma and personalized medicine: preliminary steps. CURR OPIN ONCOL.
20:444-453. I.F.:3,69.
Llovet JM, Bruix J. Molecular targeted therapies in
hepatocellular carcinoma. HEPATOLOGY. 48:1312-1327.
I.F.:10,73.
Wilhelm SM, Adnane L, Newell P, Villanueva A, Llovet
JM, Lynch M. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and
PDGF receptor tyrosine kinase signaling. MOL CANCER
THER. 7:3129-3140. I.F.:4,80.
93
072-113 AREA3.indd 93
21/10/09 16:17:44
Hepatic Hemodynamics and Portal Hypertension.
Digestive Tract Bleeding due to Rupture of Esophageal Varicose Veins
Team Members
Hepatic hemodynamics and
portal hypertension. Digestive tract bleeding
due to rupture of esophageal varicose veins
Team Leader:
■ Jaume Bosch (Hospital Clínic)
Tel.: 93 227 57 90
Fax: 93 227 93 48
IDIBAPS Members:
■ Ramon Deulofeu (Hospital Clínic)
■ Àngels Escorsell (Hospital Clínic)
■ Mercedes Fernández (IDIBAPS)
■ Joan C. García-Pagán (Hospital Clínic)
■ Mª Rosa Gilabert (Hospital Clínic)
■ Juan González-Abraldes (Hospital Clínic)
■ Carles Nicolau (Hospital Clínic)
■ Carles Piera (Hospital Clínic)
■ Juan Manuel Salmerón (Hospital Clínic
Collaborators:
Aina Rodríguez (Post-doc CIBERehd)
Filippo Schepis (Universidad de Módena)
Andrea de Gottardi (EASL)
Annalisa Berzigotti (Hospital Clínic)
Doctoral Students:
Marta Divi (FIS)
Jordi Gracia (MEC)
Bárbara Laviña (SAF)
Vasilica Matei (Becaria FIS)
Marc Mejías (SAF)
Marcos Pasarín (FIS)
Sebastian Raffa (Fundació Clínic)
Eugeni Rosado (CIBERehd)
To gain further knowledge of the mechanisms responsible for portal hypertension, the main complication
of liver diseases, and develop new treatments for this
syndrome and new noninvasive evaluation methods.
94
1. Factors that regulate liver microcirculation in normal conditions and in cirrhosis by means of perfusion studies in isolated liver and in hepatic sinusoidal endothelial cells.
2. Intrahepatic endothelial dysfunction in cirrhosis.
3. Post-transcription regulation of the activity of endothelial nitric oxide synthase (eNOS). Relevance in
the treatment of portal hypertension.
4. Regulation of the transcription of hepatic sinusoidal
endothelium protecting genes: relevance in the pa-
072-113 AREA3.indd 94
Carolina Tiani (CIBERehd)
Elba Llop (Fundació Clínic)
Eva Erice (CIBERehd)
Chang Pik Eu Jason (HMDP)
Alexandra Flores-Arroyo (Universidad de Guadalajara,
México)
Mª Gabriela Delgado (Fundació Clínic)
Susana Seijó (CIBERehd)
Mario d’Amico (IDIBAPS)
Ranka Vukotic (Universidad de Módena)
Vincenzo La Mura (Fundació Clínic)
Lucía Russo (CIBERehd)
Technicians:
Esther García (CIBERehd)
Héctor García (CIBERehd)
Montse Monclús (Idibaps)
Nurses:
Rosa Sáez (CIBERehd)
thophysiology of portal hypertension and in conservation of the liver ex vivo.
5. Regulation of the development of collateral circulation, hyperdynamic circulation and hepatic fibrogenesis by angiogenic factors.
6.New noninvasive methods for evaluating cirrhosis.
7. Clinical studies of random distribution of new
treatments for portal hypertension.
8. Hepatic vascular diseases.
Layout of a measure of the hepatic venous pressure gradient.
21/10/09 16:17:49
Associated Group
Associated Group
Regulation of hepatic microcirculation in
cirrhosis and hepatic vascular diseases
Angiogenesis in hepatic diseases
■ Garcia-Pagan, Juan Carlos
(ICMDM)
Original Articles
1
2
3
4
5
6
J, Lomena F, Josa M, Pons F, Cid MC. Development
of aortic aneurysm/dilatation during the followup of
patients with giant cell arteritis: A cross-sectional screening of fifty-four prospectively followed patients. ARTH
RHEUM/AR C RES. 59:422-430. I.F.:7,68.
Junyent M, Zambon D, Gilabert R, Nunez I, Cofan M,
Ros E. Carotid atherosclerosis and vascular age in the
assessment of coronary heart disease risk beyond the
Framingham Risk Score. ATHEROSCLEROSIS. 196:803809. I.F.:4,29.
Junyent M, Zambon D, Gilabert R, Cofan M, Nunez I,
Ros E. Carotid atherosclerosis in familial combined
hyperlipidemia associated with the APOB/APOA-1 ratio.
ATHEROSCLEROSIS. 197:740-746. I.F.:4,29.
Junyent M, Gilabert R, Zambon D, Pocovi M, Mallen M,
Cofan M, Nunez I, Civeira F, Tejedor D, Ros E. Femoral
atherosclerosis in heterozygous familial hypercholesterolemia influence of the genetic defect. ARTERIOSCL
THROM VAS. 28:580-586. I.F.:7,22.
Junyent M, Gilabert R, Nunez I, Corbella E, Cofan
M, Zambon D, Ros E. Femoral ultrasound in the as-
072-113 AREA3.indd 95
I.F.: 153,59
sessment of preclinical atherosclerosis. Distribution
of intima-media thickness and frequency of atheroma
plaques in a Spanish community cohort. MED CLINBARCELONA . 131:566-571. I.F.:1,34.
7 Dominguez M, Rincon D, Abraldes JG, Miquel R, Colmenero J, Bellot P, Garcia-Pagan JC, Fernandez R,
8 Rodriguez-Vilarrupla A, Graupera M, Matei V, Bataller
R, Abraldes JG, Bosch J, Garcia-Pagan JC. Large-conductance calcium-activated potassium channels modulate vascular tone in experimental cirrhosis. LIVER INT.
28:566-573. I.F.:2,56.
9 Berzigotti A, Gilabert R, Abraldes JG, Nicolau C, Bru C,
Bosch J, Garcia-Pagan JC. Noninvasive prediction of
clinically significant portal hypertension and esophageal varices in patients with compensated liver cirrhosis. AM J GASTROENTEROL. 103:1159-1167. I.F.:6,10.
10 Coll M, Genesca J, Raurell I, Rodriguez-Vilarrupla A,
Mejias M, Otero T, Oria M, Esteban R, Guardia J, Bosch
J, Martell M. Down-regulation of genes related to the
adrenergic system may contribute to splanchnic vasodilation in rat portal hypertension. J HEPATOL. 49:4351. I.F.:6,64.
11 Abraldes JG, Villanueva C, Banares R, Aracil C, Catalina MV, Garcia-Pagan JC, Bosch J. Hepatic venous
pressure gradient and prognosis in patients with acute
PublicaTions
The objective of our research is
to determine the implication and
regulation of angiogenesis in the
pathophysiology of portal hypertension. In recent
experimental models of portal hypertension, we
have shown that the processes of angiogenesis
or formation of new blood vessels contribute
significantly to two of the most important
components of the pathophysiology of portal
hypertension: formation of portal systemic collateral
vessels and the development of hyperdynamic
splenic circulation. The results of these studies may
provide valuable information for improving our
knowledge of the molecular mechanisms implicated
in the pathophysiology of portal hypertension and
chronic liver diseases - a leading cause of death and
liver transplant in our country and around the world.
We intend that the studies of this project should lead
to the development of new therapeutic approaches
to reducing the morbidity and mortality of patients
suffering from these diseases.
One of the mechanisms responsible for
the development of portal hypertension
and its severe consequences is the increased resistance
to portal flow that occurs in a cirrhotic liver. Part of this
increase is dynamic and susceptible to modification with
drugs. Therefore, better knowledge from experimental
animal models of the cellular, biochemical and molecular mechanisms that regulate this dynamic component
will allow us to design new strategies for treating these
patients. Hepatic vascular diseases, particularly BuddChiari syndrome and non-cirrhotic portal vein thrombosis, are rare causes of portal hypertension. This makes
gaining increased knowledge of the disease, prognosis
and optimization of treatments more difficult. This is of
special relevance as these diseases mainly affect young
people with a potentially long life-expectancy. For some
years, our group has become a reference center for these diseases, which has allowed us to propose new alternative treatments and improve our knowledge.
■ Fernadez Lobato, Mercè
95
21/10/09 16:17:53
12 Area 3 Liver, Digestive System and Metabolism
13 14 15 16 17 18 19 20 96
21 072-113 AREA3.indd 96
variceal bleeding treated with pharmacologic and endoscopic therapy. J HEPATOL. 48:229-236. I.F.:6,64.
Gracia-Sancho J, Lavina B, Rodriguez-Vilarrupla A, Garcia-Caldero H, Fernandez M, Bosch J, Garcia-Pagan JC.
Increased oxidative stress in cirrhotic rat livers: A potential mechanism contributing to reduced nitric oxide
bioavailability. HEPATOLOGY. 47:1248-1256. I.F.:10,73.
Qamar AA, Grace ND, Groszmann RJ, Garcia-Tsao G,
Bosch J, Burroughs AK, Maurer R, Planas R, Escorsell
A, Garcia-Pagan JC, Patch D, Matloff DS, Makuch R.
Platelet count is not a predictor of the presence or
development of gastroesophageal varices in cirrhosis.
HEPATOLOGY. 47:153-159. I.F.:10,73.
Lafuente A, Bernardo M, Mas S, Crescenti A, Aparici
M, Gasso P, Deulofeu R, Mane A, Catalan R, Carne X.
Polymorphism of dopamine D2 receptor (TaqIA, TaqIB,
and-141C Ins/Del) and dopamine degradation enzyme
(COMT G158A, A-278G) genes and extrapyramidal
symptoms in patients with schizophrenia and bipolar
disorders. PSYCHIAT RES. 161:131-141. I.F.:2,30.
Turnes J, Garcia-Pagan JC, Gonzalez M, Aracil C, Calleja JL, Ripoll C, Abraldes JG, Banares R, Villanueva
C, Albillos A, Ayuso JR, Gilabert R, Bosch J. Portal
Hypertension-Related Complications After Acute Portal
Vein Thrombosis: Impact of Early Anticoagulation. CLIN
GASTROENTEROL H. 6:1412-1417. I.F.:5,47.
Gonzalez-Navajas JM, Bellot P, Frances R, Zapater P,
Munoz C, Garcia-Pagan JC, Pascual S, Perez-Mateo M,
Bosch J, Such J. Presence of bacterial-DNA in cirrhosis
identifies a subgroup of patients with marked inflammatory response not related to endotoxin. J HEPATOL.
48:61-67. I.F.:6,64.
Castro-Fornieles J, Deulofeu R, Baeza I, Casula V, Saura
B, Lazaro L, Puig J, Toro J, Bernardo M. Psychopathological and nutritional correlates of plasma homovanillic
acid in adolescents with anorexia nervosa. J PSYCHIATR RES. 42:213-220. I.F.:3,71.
Bosch J, Thabut D, Albiuos A, Carbonell N, Spicak J,
Massard J, D’amico G, Lebrec D, DeFranchis R, Fabricius S, Cai Y, Bendtsen F. Recombinant factor VIIa for
variceal bleeding in patients with advanced cirrhosis:
A randomized, controlled trial. HEPATOLOGY. 47:16041614. I.F.:10,73.
Arena U, Vizzutti F, Abraldes JG, Corti G, Stasi C, Moscarella S, Milani S, Lorefice E, Petrarca A, Romanelli
RG, Laffi G, Bosch J, Marra F, Pinzani M. Reliability of
transient elastography for the diagnosis of advanced
fibrosis in chronic hepatitis C. GUT. 57:1288-1293.
I.F.:10,02.
Kiladjian JJ, Cervantes F, Leebeek FWG, Marzac C, Cassinat B, Chevret S, Cazals-Hatem D, Plessier A, GarciaPagan JC, Murad SD, Raffa S, Janssen HLA, Gardin C,
Cereja S, Tonetti C, Giraudier S, Condat B, Casadevall
N, Fenaux P, Valla DC. The impact of JAK2 and MPL
mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. BLOOD.
111:4922-4929. I.F.:10,90.
Mejias M, Garcia-Pras E, Tiani C, Bosch J, Fernandez M.
The somatostatin analogue octreotide inhibits angiogenesis in the earliest, but not in advanced, stages of
portal hypertension in rats. J CELL MOL MED. 12:16901699. I.F.:6,81.
22 Matei V, Rodriguez-Vilarrupla A, Deulofeu R, GarciaCaldero H, Fernandez M, Bosch J, Garcia-Pagan JC.
Three-day tetrahydrobiopterin therapy increases in
vivo hepatic NOS activity and reduces portal pressure
in CCl4 cirrhotic rats. J HEPATOL. 49:192-197. I.F.:6,64.
23 Garcia-Pagan JC, Heydtmann M, Raffa S, Plessier A,
Murad S, Fabris F, Vizzini G, Abraldes JG, Olliff S, Nicolini A, Luca A, Primignani M, Janssen HLA, Valla D,
Elias E, Bosch J. TIPS for Budd-Chiari syndrome: Longterm results and prognostics factors in 124 patients.
GASTROENTEROLOGY. 135:808-815. I.F.:11,67.
Reviews
1
2
3
4
5
6
7
8
Sanyal AJ, Bosch J, Blei A, Arroyo V. Portal hypertension and its complications. GASTROENTEROLOGY.
134:1715-1728. I.F.:11,67.
Garcia-Pagan JC, Hernandez-Guerra M, Bosch J. Extrahepatic Portal Vein Thrombosis. SEMIN LIVER DIS.
28:282-292. I.F.:5,81.
Bosch J, Abraldes JG, Berzigotti A, Garcia-Pagan JC.
Portal hypertension and gastrointestinal bleeding. SEMIN LIVER DIS. 28:3-25. I.F.:5,81.
Garcia-Tsao G, Bosch J, Groszmann RJ. Portal hypertension and variceal bleeding--unresolved issues. Summary of an American Association for the study of liver
diseases and European Association for the study of the
liver single-topic conference. HEPATOLOGY. 47(5):17641772. I.F.:10,73.
Tiani C, Abraldes JG, Bosch J. Portal hypertension: Preprimary and primary prophylaxis of variceal bleeding.
DIGEST LIVER DIS. 40:318-327. I.F.:1,98.
Berzigotti A, Garcia-Pagan JC. Prevention of recurrent
variceal bleeding. DIGEST LIVER DIS. 40:337-342.
I.F.:1,98.
Bellot P, Garcia-Pagan JC, Abraldes JG, Bosch J. Primary prophylaxis of esophageal variceal bleeding in cirrhosis. GASTROEN CLIN BIOL. 32:532-540. I.F.:0,85.
Garcia-Pagan JC, DeGottardi A, Bosch J. Review article:
the modern management of portal hypertension - primary and secondary prophylaxis of variceal bleeding
in cirrhotic patients. ALIMENT PHARM THERAP. 28:178186. I.F.:3,20.
Editorials
1
Salmeron JM, Benarroch G, Pique JM, Rodes J. Medical personnel’s careers. A useful incentive system as
long as we adhere to its application principles. MED
Bosch J. CIBER de Enfermedades hepáticas y digestivas.
Grant: Ministerio de Ciencia e Innovación, CB06/04/0026.
Duration: 28/07/2006-27/07/2010.
Nicolau C. Evaluación de la Ecografía con contraste para
la cuantificación de la angiogénesis en tumores hepáticos.
Repercusiones clínicas y terapéuticas. Grant: Ministerio
21/10/09 16:17:56
Gonzalez-Abraldes J. Enfermedad hepática por depósito
de grasa y disfunción endotelial sinusoidal. Grant: Ministerio Sanidad y Consumo, PI050519. Duration: 01/01/200601/01/2009.
Garcia-Pagan JC. Mecanismos moleculares de la disfunción
endotelial intrahepática en la cirrosis. Nuevas dianas terapéuticas de la hipertensión portal. Grant: Ministerio Educación y
Bosch J. Disfunción endotelial y actividad eNOs en la cirrosis. Mecanismo, significación y nuevas aplicaciones terapéuticas. Grant: Ministerio Sanidad y Consumo, PI060623.
Duration: 18/10/2006-30/12/2009.
Thesis
Merce Fernadez Lobato. Regulación e implicación de la
angiogénesis en la hipertensión portal y la cirrosis hepática. Grant: Ministerio Educación y Ciencia, SAF2005-05825.
Duration: 15/10/2005-30/11/2008.
Patents
Jaume Bosch, Mercedes Fernandez. Treatment of portal hypertension and conditions related thereof.
Jaume Bosch, Andrea de Gottardi. Catéter percutáneo y
método para medir vasos de presión en vasos sanguíneos.
Gilabert R. Caracterización de la placa de ateroma carotídea
mediante ecografía con potenciador de señal ecográfica.
Comparación con la resonancia magnética con gadolinio y
el estudio histológico. Grant: Ministerio Sanidad y Consumo, PI061329. Duration: 18/10/2006-30/12/2009.
Bosch J, Garcia-Pagan JC. Mecanismos fisiopatológicos
que regulan el aumento de tono vascular en la cirrosis hepática: papel del cofactor de la Enos, la tetrahidrobiopterina.
Premi Extraordinari de Doctorat. Doctorand: Vasilica Matei,
97
072-113 AREA3.indd 97
21/10/09 16:17:58
Inflammatory Bowel Disease
Team Members
Inflammatory bowel disease
Team Leader:
■ Julián Panés (Hospital Clínic)
Tel.: 93 227 54 00 (Ext.: 2779)
Fax: 93 227 93 87
98
IDIBAPS Members:
■ Josep Mª Bordas (Hospital Clínic)
■ Salvadora Delgado (Hospital Clínic)
■ Faust Feu (Hospital Clínic)
■ Glòria Lacima (Hospital Clínic)
■ Josep Llach (Hospital Clínic)
■ Josep M. Piqué (Hospital Clínic)
■ Elena Ricart (Hospital Clínic)
■ Azucena Salas (Hospital Clínic)
■ Miquel Sans (Hospital Clínic)
Collaborators:
Montserrat Aceituno (Hospital Clínic)
Edgar Ayala (Hospital Clínic)
Orlando García (Hospital Clínic)
Salvadora Delgado (Hospital Clínic)
Ingrid Ordás (Hospital Clínic)
Daniel Benítez (CIBERehd)
Doctoral Students:
Marisol Veny (Fundació Clínic)
Maria del Carme Masamunt (Fundació Clínic)
Technicians:
Míriam Esteller (Fundació Clínic)
Jeroni Luna (Fundació Clínic)
Carolina España (Ciberhed)
Rut Mora (Fundació Clínic)
Nurses:
Anna Guerra (Hospital Clínic)
Susana Pinó (Ciberhed)
Marta Gallego (Hospital Clínic)
The strategic objectives of the research group on inflammatory bowel disease include aspects of pathophysiology, diagnosis and treatment of thee processes, specifically, the following:
• Development of new treatment strategies for
Crohn disease and ulcerative colitis, focussing on cellular therapies and on identifying new
therapeutic targets susceptible to modulation by
drugs.
• Increasing knowledge of the genetic and environmental factors responsible for susceptibility and
implicated in the course of the disease in order to
design personalized therapies.
• Optimizing radiologic and biochemical diagnostic
techniques with the aim of adapting treatment to
the needs of each patient and avoiding invasive examinations.
1. Autotransplant of hematopoietic stem cells in Crohn
disease refractory to conventional treatment and
biologic therapy.
072-113 AREA3.indd 98
Cultured intestinal fibroblasts. Vimentin positivity.
2. Evaluation of the efficacy and safety of therapy with
autologous dendritic cells derived from peripheralblood monocytes in refractory Crohn disease.
3. Optimization of magnetic resonance imaging and
ultrasound techniques with contrast medium to
evaluating the extension and severity of the inflammatory lesions in Crohn disease and ulcerative colitis.
4. Evaluation of the prognostic value of radiologic
findings in magnetic resonance imaging for predicting the outcome of the disease and therapeutic response.
21/10/09 16:18:02
5. Characterization of the genetic factors that determine susceptibility and phenotype of Crohn disease
and ulcerative colitis. Construction of genetic diagnostic chips.
6. Study of the environmental factors that affect the
susceptibility and outcome of inflammatory bowel disease.
I.F.: 60,59
PublicaTions
Original Articles
072-113 AREA3.indd 99
11 12 13 14 Reviews
1
Henckaerts L, Figueroa C, Vermeire S, Sans M. The
role of genetics in inflammatory bowel disease. CURR
DRUG TARGETS. 9:361-368. I.F.:4,04.
Editorials
1
2
3
4
Salmeron JM, Benarroch G, Pique JM, Rodes J. Medical personnel’s careers. A useful incentive system as
long as we adhere to its application principles. MED
Reinisch W, Panes J, Lemann M, Schreiber S, Feagan
B, Schmidt S, Sturniolo GC, Mikhailova T, Alexeeva
O, Sanna L, Haas T, Korom S, Mayer H. A Multicenter,
Randomized, Double-Blind Trial of Everolimus Versus
Azathioprine and Placebo to Maintain Steroid-Induced
Remission in Patients With Moderate-to-Severe Active
Crohn’s Disease. AM J GASTROENTEROL. 103:22842292. I.F.:6,10.
Font D, Pique JM, Guerra F, Rodes J. Establishment of
clinical management in the hospital organization. MED
Rodes J, Font D, Trilla A, Pique JM, Gomis R. Scientific
and technical advances in biomedicine: reflection on
clinical management. MED CLIN-BARCELONA. 130:553556. I.F.:1,34.
Lacy AM, Delgado S, Castells A, Prins HA, Arroyo V,
Ibarzabal A, Pique JM. The long-term results of a randomized clinical trial of laparoscopy-assisted versus
open surgery for colon cancer. ANN SURG. 248:1-7.
I.F.:7,45.
2 Rodriguez S, Pages M, Castells A, DeJuan C, Bordas JM,
Rimola J, Ayuso JR, Ayuso C. Dark-lumen MR colonography with fecal tagging: a comparison of water enema
and air methods of colonic distension for detecting colonic neoplasms. EUR RADIOL. 18:1396-1405. I.F.:3,41.
3 Pena-Rossi C, Schreiber S, Golubovic G, Mertz-Nielsen
A, Panes J, Rachmilewitz D, Shieh MJ, Simanenkov
VI, Stanton D, Graffner H. Clinical trial: a multicentre,
randomized, double-blind, placebo-controlled, dosefinding, phase II study of subcutaneous interferon-beta1a in moderately active ulcerative colitis. ALIMENT
PHARM THERAP. 28:758-767. I.F.:3,20.
4 Fernandez-Esparrach G, Bordas JM, Llach J, Lacy A,
Delgado S, Vidal J, Cardenas A, Pellise M, Gines A,
Sendino O, Zabalza M, Castells A. Endoscopic dilation
with Savary-Gilliard bougies of stomal strictures after
laparosocopic gastric bypass in morbidly obese patients. OBES SURG. 18:155-161. I.F.:2,85.
5 Fernandez-Esparrach G, Bordas JM, Pellise M, GimenoGarcia AZ, Lacy A, Delgado S, Cardenas A, Ginies A,
Sendino O, Momblan D, Zabalza M, Llach J. Endoscopic management of early GI hemorrhage after laparoscopic gastric bypass. GASTROINTEST ENDOSC.
67:552-555. I.F.:5,89.
6 Vidal A, Gomez-Gil E, Sans M, Portella MJ, Salamero
M, Pique JM, Panes J. Health-related quality of life in
inflammatory bowel disease patients: The role of psychopathology and personality. INFLAMM BOWEL DIS.
14:977-983. I.F.:4,71.
7 Pellise M, Fernandez-Esparrach G, Cardenas A, Sendino O, Ricart E, Vaquero E, Gimeno-Garcia AZ, DeMiguel
C, Zabalza M, Gines A, Pique JM, Llach J, Castells A.
Impact of wide-angle, high-definition endoscopy in
the diagnosis of colorectal neoplasia: A randomized
controlled trial. GASTROENTEROLOGY. 135:1062-1068.
I.F.:11,67.
8 Lacy AM, Delgado S, Rojas OA, Almenara R, Blasi A,
Llach J. MA-NOS radical sigmoidectomy: report of a
transvaginal resection in the human. SURG ENDOSC.
22:1717-1723. I.F.:2,24.
9 Font D, Gomis R, Trilla A, Bigorra J, Pique JM, Rodes J.
Organization and functioning model of biomedical research structures. Situation and future challenges. MED
10 Vidal O, Soriano-Izquierdo A, Pera M, Elizalde JI, Palacin A, Castells A, Pique JM, Volant A, Metges JP. Positi-
1
ve VEGF immunostaining independently predicts poor
prognosis in curatively resected gastric cancer patients:
Results of a study assessing a panel of angiogenic markers. J GASTROINTEST SURG. 12:1005-1014. I.F.:2,27.
Aceituno M, Garcia-Planella E, Heredia C, Zabona Y,
Feu F, Domenech E, Gassull MA, Panes J. Steroid-refractory ulcerative colitis: Predictive factors of response
to cyclosporine and validation in an independent cohort. INFLAMM BOWEL DIS. 14:347-352. I.F.:4,71.
Herrera S, Bordas JM, Llach J, Gines A, Pellise M,
Fernandez-Esparrach G, Mondelo F, Mata A, Cardenas A,
Castells A. The beneficial effects of argon plasma coagulation in the management of different types of gastric
vascular ectasia lesions in patients admitted for GI hemorrhage. GASTROINTEST ENDOSC. 68:440-446. I.F.:5,89.
Arenas M, Gil F, Gironella M, Hernandez V, Biete A,
Pique JM, Panes J. Time course of anti-inflammatory
effect of low-dose radiotherapy: Correlation with TGFbeta(1) expression. RADIOTHER ONCOL. 86:399-406.
I.F.:4,07.
DelRio AS, Campo R, Llach J, Pons V, Mreish G, Panades A, Parra A. Variation among Endoscopy Units
in the Achievement of the Standards of Colonoscopic
Performance Indicators. HEPATO-GASTROENTEROL.
55:1594-1599. I.F.:0,90.
99
21/10/09 16:18:05
5
Sans M, Castells A. Ulcerative Colitis and Crohn’s Disease Genetics: More Similar Than We Thought?. GASTROENTEROLOGY. 135:1796-1798. I.F.:11,67.
Panes J. NoE - European Molecular Imaging Laboratories.
Grant: European Commision, LSHC-CT-2004-503569. Duration: 01/07/2004-30/06/2009.
Sans M. Development of a new DNA array-based diagnostic
system (IBDchip) to predict clinical course, development
of complications, and response to therapy in patients
with inflammatory bowel disease (IBD). Grant: European
Commision, LSHB-CT-2006-037319. Duration: 01/12/200630/11/2009.
Pique JM. Grup de recerca clínica i experimental de les lesions inflamatòries i neoplàsiques gastrointestinals. Grant:
Duration: 19/10/2005-31/12/2008.
Sans M. Development of a new DNA array-based diagnostic
system (“IBDCHIP”) to predict clinical course, development
of complications, and response to therapy in patients with
Inflammatory Bowel Disease (IBD). Grant: Ministerio Sanidad
y Consumo, AI07/90033. Duration: 26/10/2007-30/12/2009.
Panes J. CIBER de Enfermedades hepáticas y digestivas.
Sans M. Estudio de los principales determinantes moleculares implicados en la fibrosis intestinal en la enfermedad
de Crohn. Evaluación de estrategias de tratamiento anti-fibrogénico. Grant: Ministerio Educación y Ciencia, SAF200500280. Duration: 31/12/2005-31/12/2008.
Panes J. Análisis de expresión génica en la enfermedad
inflamatoria intestinal: relación con el fenotipo,
progresión de la enfermedad y espuesta al tratamiento.
Grant: Ministerio Educación y Ciencia, SAF2006-03074.
Duration: 01/10/2006-30/09/2009.
Salas A. Papel de las integrinas alfa4 en la génesis de la
enfermedad inflamatoria intestinal y valor terapéutico
de su bloqueo mediante pequeñas moléculas. Grant:
01/01/2006-31/12/2008.
Panes J. Desarrollo de un Kit diagnóstico para las
enfermedades inflamatorias mediadas por mecanismos
inmunes (IMID-kit). Grant: Ministerio Educación y Ciencia,
PSE-010000-2006-6. Duration: 01/01/2006-31/12/2009.
Panes J, Cañete J. Desarrollo de un kit diagnóstico
para las enfermedades inflamatorias mediadas por
mecanismos inmunes (IMID-Kit). Subproyecto 1: Estudio
de asociación de genoma completo en las enfermedades
inflamatorias mediadas por mecanismos inmunes. Grant:
Ministerio Educación y Ciencia, PSE-010000-2008-9.
Duration: 01/01/2008-31/12/2009.
Thesis
Panes J. Mecanismos moleculares responsables
del efecto anti-inflamatorio de los probióticos en la
enfermedad inflamatoria Intestinal. Doctorand: Sandra
Milena Angulo Preciador.
Panes J. Efectes antiinflamatoris de la radioteràpia a
dosis baixes en un model experimental d’inflamació
sistèmica. Doctorand: Meritxell Arenas Prat.
100
072-113 AREA3.indd 100
21/10/09 16:18:07
Liver Failure and Cholestasis
Team members
Team Leader:
■ Albert Parés (Hospital Clínic)
Tel.: 93 227 57 53
Fax: 93 451 55 22
Doctoral Students:
Marina Gorga (Fundació Clínic)
Pau Bosch (Fundació Clínic)
1.Epidemiology, natural history and
therapeutic response of chronic
cholestatic diseases in adults
Determine the prevalence and incidence of cholestatic
diseases in adults in Spain and define the factors associated with the form of presentation of primary biliary
cirrhosis, basically the asymptomatic forms. Evaluate the therapeutic response factors and propose new
therapeutic regimens in patients with suboptimal response to ursodeoxycholic acid. Relevance of the AE2
anion exchanger.
acid fractions and their conjugate pairs eliminated by
the MARS system and their relationship with reduced
pruritus.
4. Pathogenesis of osteoporosis and
development of fractures in primary
biliary cirrhosis and other chronic
cholestatic diseases
In collaboration with the Bone Metabolic Disease
group, evaluate the factors involved in the development of fractures in primary biliary cirrhosis and
propose new therapeutic regimens to increase bone
mass. Investigate the repercussion of biliary acids and
bilirubin retained in cholestasis on the development of
bone disease.
5.Artificial liver support
Evaluate the safety and efficacy of different bioartificial
liver procedures and liver support for the treatment of
acute liver failure and acute-phase chronic liver failure.
Randomized, open-ended, prospective study (versus
conventional treatment) with cryopreserved human
liver cells from organs not suitable for transplant.
1. Study of the epidemiology, pathogenesis, diagnosis and treatment of chronic cholestatic diseases in
adults and of autoimmune hepatitis.
2. Discovery of the pathogenetic mechanisms of pruritus and osteoporosis of primary biliary cirrhosis.
3. Definition of the therapeutic potential of different
artificial liver support procedures in liver failure.
Technicians:
Rebeca Quesada (Fundació Clínic)
Liver failure and cholestasis
IDIBAPS Members:
■ Antoni Mas (Hospital Clínic)
2. Diagnosis of autoimmune hepatitis
Design of a new diagnostic procedure for autoimmune
hepatitis by means of peptide mapping - a project that
is being carried out in collaboration with six European
centers and one Israeli center.
101
3. Pruritus in chronic cholestasis and therapeutic response to albumin dialysis:
proteomic analysis
Evaluation of the therapeutic response using albumin dialysis in patients with chronic cholestasis and
refractory pruritus and identification of peptides and
proteins eliminated by the MARS system. Study of the
skin of these patients to identify potential molecules
associated with the pruritus. Evaluation of the biliary
072-113 AREA3.indd 101
Bidimensional gel of plasma from a patient with
primary biliary cirrhosis and refractory pruritus before
MARS treatment.
21/10/09 16:18:13
PublicaTions
Original Articles
Hennes EM, Zeniya M, Czaja AJ, Pares A, Dalekos GN,
Krawitt EL, Bittencourt PL, Porta G, Boberg KM, Hofer
H, Bianchi FB, Shibata M, Schramm C, DeTorres BE,
Galle PR, Mcfarlane I, Dienes HP, Lohse AW. Simplified
criteria for the diagnosis of autoimmune hepatitis. HEPATOLOGY. 48:169-176. I.F.:10,73.
Pares A. Tratamiento del prurito refractario de la colestasis mediante diálisis con albumina. Estudios moleculares.
Pares A. Enfermedades hepáticas autoinmunes. Nuevos
procedimientos diagnósticos mediante mapeo peptídico.
Grant: Instituto de Salud Carlos III, PI07/1318E (E-RARE).
Duration: 01/01/2008-31/12/2010.
Pares A. Enfermedades hepáticas y digestivas. Grant: Instituto de Salud Carlos III, CB06/04/0015. Duration: 28/07/200627/07/2010.
Liver failure and cholestasis
1
I.F.: 10,73
102
072-113 AREA3.indd 102
21/10/09 16:18:15
Mitochondrial Regulation of Cell Death and Steatohepatitis
Team members
Team Leader:
■ José Carlos Fernández-Checa
(IIBB-CSIC)
Tel.: 93 227 57 09
Collaborators:
Laura Conde de la Rosa (CSIC)
Claudia Von Montfort (CSIC)
Laura Llacuna (IDIBAPS)
Anna Moles (FIS)
Joan Montero (McyT)
Raquel Fucho (CIBERehd)
Nuria Matias (MCyT)
Nuria Tarrats (FIS)
Doctoral Students:
Francisco Caballero (FIS)
Anna Fernández (McyT)
Technicians:
Alberto Garcia Martinez (Ciberehd)
Susana Núñez Pozuelo (Ciberehd)
1. Determine intracellular signalling and the role of
mitochondria in cellular susceptibility in inflammation processes, hypoxia and chemotherapy and
their relevance in (hepato) carcinogenesis.
2. Determine the cholesterol-regulating role of sphingolipids in cell death and in liver-cell damage due to
ischemia/reperfusion.
3. Analysis and role of free cholesterol in patients with
nonalcoholic steatohepatitis.
4. Contribution of the physicochemical properties of
the mitochondrial membrane in cell death.
1.Mechanisms of liver-cell damage due to ischemia/
reperfusion and its regulation by means of antioxidant and anti-inflammatory strategies.
2. Regulation of cell death due to mitochondrial oxidative stress and sphingolipids.
3.Regulation of cholesterol homeostasis in patients
and experimental models of nonalcoholic steatohepatitis.
4.Mechanisms responsible for mitochondrial transit
of cholesterol.
5. Role of cholesterol in the response of liver cell carcinoma to chemotherapy.
6.Role of cholesterol and mitochondrial GSH in Alzheimer disease.
7.Contribution of acid sphingomyelinase in hepatic
fibrosis.
Mitochondrial regulation of cell
death and steatohepatitis
IDIBAPS Members:
■ Joan Caballeria (Hospital Clínic)
■ Anna Colell (IIBB-CSIC)
■ Carmen García Ruíz (IIBB-CSIC)
■ Montserrat Marí (IDIBAPS)
■ Albert Morales (IDIBAPS)
Two lines in which we have obtained important results are:
103
1.Identification of mitochondrial
cholesterol as a mechanism of resistance
to chemotherapy in liver cell carcinoma
Mitochondrial dysfunction is one of the characteristics
of tumor cells that results in greater dependence on
aerobic glycolysis, known as the Warburg effect. One
of the mechanisms involved in this process is the accumulation of cholesterol in the mitochondrion, which
reduces the function of electronic transport to phos-
072-113 AREA3.indd 103
21/10/09 16:18:20
Mitochondrial regulation of cell
death and steatohepatitis
phorylative oxidation. Our studies in cells and mouse
models of liver cell carcinoma have shown that cholesterol accumulates in the external and internal mitochondrial membrane due to the overexpression of
a specific transporter, StAR, contributing to greater
resistance to chemotherapy. Reduction of the level of
mitochondrial cholesterol by genetic silencing of StAR
generates sensitivity to the therapeutic action of doxorubicin. These data show that mitochondrial cholesterol may be a new therapeutic target in the treatment of
liver cell carcinoma.
2. Role of the peroxidated cardiolipin in
permeabilization of the mitochondrial
membrane by TNF and Bax
Permeabilization of the mitochondrial membrane is an
essential mechanism in apoptosis as it allows the release of cytochrome c into the cytosol and the assembly
of the apoptosome. However, this mechanism of death induced by TNF is not fully understood. Comparing
intracellular signalling of TNF in conditions of simula-
PublicaTions
ted mitochondrial GSH (GSHm), we have observed a
greater susceptibility to TNF that is not associated with
important changes in the premitochondrial pathway or
in the translocation and oligomerization of Bax in the
mitochondrial membrane, or oxidative changes in the
proteomic profile of the mitochondrion. Only after the
reduction of GSHm do we observe permeabilization
of the mitochondrial membrane despite the incorporation and oligomerization of Bax. The analysis of the
lipid composition reveals peroxidation of cardiolipin
(CLOOH) after treatment with TNF and reduction of
GSHm. The incorporation of CLOOH into the liposome
bilayer shows that its presence increases the permeabilizing action of oligomerized Bax due to the restructuring of the lipid bilayer and induction of the transition
of the lamellar structure to an inverted hexagonal
structure. Our studies therefore show that CLOOH is a
critical determinant in regulating the permeabilization
of the mitochondrial membrane and, therefore, regulation of the death of liver cells, with the implications that
this involves in important liver diseases.
I.F.: 25,45
Original Articles
1
2
3
Dominguez M, Rincon D, Abraldes JG, Miquel R, Colmenero J, Bellot P, Garcia-Pagan JC, Fernandez R,
Mari M, Colell A, Morales A, Caballero F, Moles A,
Fernandez A, Terrones O, Basanez G, Antonsson B,
Garcia-Ruiz C, Fernandez-Checa JC. Mechanism of
mitochondrial glutathione-dependent hepatocellular
susceptibility to TNF despite NF-kappa B activation.
Montero J, Morales A, Llacuna L, Lluis JM, Terrones O,
Basanez G, Antonsson B, Prieto J, Garcia-Ruiz C, Colell
A, Fernandez-Checa JC. Mitochondrial cholesterol contributes to chemotherapy resistance in hepatocellular
carcinoma. CANCER RES. 68:5246-5256. I.F.:7,67.
Fernández-Checa JC. H36071. USC-UCLA Research Center
for Alcoholic Liver and Pancreatic Injury Research Project#1.
Grant: National Institutes of Health - EU, 5P50AA011999-09.
Duration: 01/01/2004-31/12/2008.
104
Caballeria J. Homeostasis del colesterol libre hepático en la
esteatohepatitis no alcohólica. Implicaciones fisiopatológicas y terapéuticas de su regulación. Grant: Ministerio Sanidad y Consumo, PI060085. Duration: 18/10/2006-30/12/2009.
072-113 AREA3.indd 104
Morales A. Esfingolípidos en cáncer hepático y colorectal:
regulación e implicaciones terapéuticas. Grant: Ministerio Sanidad y Consumo, PI060395. Duration: 18/10/200630/12/2009.
Mari M. Catepsinas en la Fibrosis Hepática: Regulación por
TNF. Grant: Ministerio Sanidad y Consumo, PI070193. Duration: 26/11/2007-30/12/2010.
Colell A. Mitocondria, colesterol y beta-amiloide: implicación en la enfermedad de Alzheimer. Grant: Ministerio
García C. Papel del SREBP2 en la susceptibilidad hepatocelular al fator de necrosis tumoral: relvancia en la
esteatohepatitis. Grant: Ministerio Educación y Ciencia,
SAF2005-03943. Duration: 01/10/2006-30/10/2008.
Fernández-Checa JC. Papel de la caveolina 1, STAR y PBR
en el tráfico de colesterol a la mitocondria: relevancia en la
esteatohepatitis y la neurodegeneración en la enfermedad
de Niemann-Pick. Grant: Ministerio Educación y Ciencia,
SAF2006-06780. Duration: 01/01/2007-31/12/2009.
Fernández-Checa JC. Mitochondria, signaling lipids and
alcoholic liver disease. Research Subproject 1. UCLA-USC
Research Center for alcoholic liver and pancreatic diseases.
Grant: National Institute Alcohol Abuse and Alcoholism. Duration: 01/01/2004-31/12/2008.
21/10/09 16:18:22
Liver Transplant and Graft Viability
Team members
Team Leader:
■ Antoni Rimola (Hospital Clínic)
Tel.: 93 227 57 53
Fax: 93 451 55 22
Technicians:
Anna Rodríguez (IDIBAPS)
Xavier Muñoz (CIBERehd)
María Dintel (IDIBAPS)
Nurses:
Pilar Sesé (IDIBAPS)
Investigate clinical aspects pathogenic mechanisms
and therapeutic aspects of liver transplant.
1.Conservation liver damage, with special interest
in lesions due to ischemia/reperfusion in different models: warm ischemia and experimental
transplant in rats with normal grafts, reduced
grafts or steatotic grafts; experimental transplant in pigs with whole or partial grafts or grafts
obtained from asystolic donors; and liver transplant in humans.
2.Immunosuppression with special interest in
three fields: immunologic tolerance to allografts,
determination of biomarkers of the effect of immunosuppressants and identification of populations with different risks of rejection.
072-113 AREA3.indd 105
Collaborators:
Felix Bohne (CIBERehd)
David Calatayud (Hospital Clínic)
Jose Fuster (Hospital Clínic)
Olga Sánchez García (CIBERehd)
Marta Massip (CIBERehd)
Carme Xaus (IDB-CSIC)
Ismael Ibn Ben Mosbah (IDB-CSIC)
Marta López (IDIBAPS)
Doctoral Students:
Marc Martínez Llordella (MEyC)
Isabel Puig-Pey (IDIBAPS)
Lourdes Rafael-Valdivia (Fundació Clínic)
Belinda Martínez (Fundació Clínic)
Araní Casillas (Soc. Catalana de Trasplantament)
Amine Zauali (IDIBAPS)
Susana Padrissa (MCyT)
Isabel Fernández-Monteiro (IDIBAPS)
Mariangeles Bintanel (IDIBAPS)
Liver transplant and graft viability
IDIBAPS Members:
■ Constantino Fondevila (Hospital Clínic)
■ Juan C. García-Valdecasas (Hospital Clínic)
■ Xavier González Argente (Hospital Clínic)
■ Martí Manyalich (Hospital Clínic)
■ Carmen Peralta (IIBB-CSIC)
■ Joan Rosselló-Catafau (IIBB-CSIC)
■ Albert Sánchez Fueyo (Hospital Clínic)
105
American ex vivo perfusion machine with oxygenation for the liver.
The essential elements are a receptacle with the organ, a perfusion
pump, and oxygenator and a heater. Bile from the perfused liver can be
seen coming out of the graft.
21/10/09 16:18:25
I.F.: 42,78
PublicaTions
Original Articles
1
Liver transplant and graft viability
2
3
4
5
6
Martinez-Llordella M, Lozano JJ, Puig-Pey I, Orlando G,
Tisone G, Lerut J, Benitez C, Pons JA, Parrilla P, Ramirez P, Bruguera M, Rimola A, Sanchez-Fueyo A. Using
transcriptional profiling to develop a diagnostic test of
operational tolerance in liver transplant recipients. J
CLIN INVEST. 118:2845-2857. I.F.:16,92.
Casillas-Ramirez A, Amine-Zaouali M, Massip-Salcedo
M, Padrissa-Altes S, Bintanel-Morcillo M, Ramalho F,
Serafin A, Rimola A, Arroyo V, Rodes J, Rosello-Catafau
J, Peralta C. Inhibition of angiotensin II action protects
rat steatotic livers against ischemia-reperfusion injury.
CRIT CARE MED. 36:1256-1266. I.F.:6,28.
Massip-Salcedo M, Zaouah MA, Padrissa-Altes S, Casiflas-Ramirez A, Rodes J, Rosello-Catafau J, Peralta C.
Activation of peroxisome proliferator-activated receptor-alpha inhibits the injurious effects of adiponectin
in rat steatotic liver undergoing ischemia-reperfusion.
HEPATOLOGY. 47:461-472. I.F.:10,73.
Fondevila C, Shen XD, Tsuchihashi S, Uchida Y, Freitas
MC, Ke B, Busuttil RW, Kupiec-Weglinski JW. The membrane attack complex (C5b-9) in liver cold ischemia and
reperfusion injury. LIVER TRANSPLANT. 14:1133-1141.
I.F.:3,75.
Orlando G, Manzia T, Baiocchi L, Sanchez-Fueyo A, Angelico M, Tisone G. The Tor Vergata weaning off immunosuppression protocol in stable HCV liver transplant
patients: The updated follow up at 78 months. TRANSPL IMMUNOL . 20:43-47. I.F.:2,09.
Bruguera M. Búsqueda de marcadores inmunológicos de
tolerancia en el transplante hepático. Grant: Ministerio
Fondevila C. Estudio de la perfusión normotérmica como
método de preservación en el trasplante hepático de donante a corazón parado e el cerdo. Grant: Ministerio Sanidad y
Roselló J. Papel del sistema renina-angiotensina en el trasplante hepático experimental con injerto de tamaño reducido. Grant: Ministerio Educación y Ciencia, SAF2005-00385.
Duration: 07/10/2005-07/10/2008.
Sanchez A. Affording Recovery in StrokeCentre coordinador: Charité - Universitaetsmedizin Berlin. Grant: Charité
- Universitaetsmedizin Berlin, 201024. Duration: 01/03/200828/02/2013.
Garcia-Valdecasas JC. Curso Dr. Valdecasas. Grant: Fundació Clínic per a la Recerca Biomèdica. Duration: 01/01/200831/12/2100.
Carmen Peralta. Mecanismos de protección del precondicionamiento isquémico en el injerto esteatosico. Grant:
Instituto de Salud Carlos III, PI060021. Duration: 18/10/200630/12/2009.
Carmen Peralta. Preservación del injerto hepático. Grant:
Agencia de Gestión de Ayudas Universitarias, SGR200500781. Duration: 01/01/2006-31/12/2008.
Roselló J. Mejora de las soluciones de preservación para
trasplante hepático. Grant: Ministerio de Asuntos Exteriores. Duration: 01/01/2007-31/12/2009.
Patents
Manyalich M. European Living Donation and Public
Health. Grant: European Commision, 2006211. Duration:
01/05/2007-31/10/2009.
Carmen Peralta, Joan Roselló-Catafau, Ismail Ben . Solución aquosa para la preservación de tejidos y órganos.
Sanchez A. IP: Reprogramming the Immune System for the
Establishment of Tolerance. Grant: European Commision,
512090. Duration: 01/09/2007-28/02/2010.
Constantino Fondevila, Angel Ruiz, Juan Carlos GarcíaValdecasas. Dispositivo para la preservación de un injerto
hepático en condiciones de normotermia.
106
072-113 AREA3.indd 106
21/10/09 16:18:28
Gastrointestinal and Pancreatic Oncology
Team members
Team Leader:
■ Antoni Castells (Hospital Clínic)
Tel.: 93 227 54 18
Fax: 93 227 93 87
Mª Dolores Giráldez (Hospital Clínic)
María López-Cerón Pinilla (Fundació Clínic)
Josep Maria Roig Camacho (CIBERehd, Hospital Clínic)
Doctoral Students:
Victòria Gonzalo (Hospital Clínic)
Oriol Sendino (Hospital Clínic)
Mariana Rickmann (Hospital Clínic)
Nurses:
Teresa Ocaña (Hospital Clínic)
Cristina Rodríguez de Miguel (Fundació Clínic)
Anna Serradesanferm Fabregas (IDIBAPS)
Technicians:
Jennifer Muñoz (CIBERehd, Hospital Clínic)
Georgina Ramirez Ramal (Fundació Clínic)
Increase knowledge regarding the mechanisms involved in the development and progression of premalignant and malignant gastrointestinal and pancreatic lesions in order to establish new diagnostic, therapeutic
and/or preventive strategies.
The activity of the Research Group on Gastrointestinal and Pancreatic Oncology is divided into four areas
and these areas are divided into different lines of research:
1. Pathophysiology of colorectal cancer
• Hereditary forms of colorectal cancer,
screening and surveillance
•Genetic susceptibility to colorectal cancer
•Epigenetics of colorectal cancer
2. Pathophysiology of pancreatic cancer
• Implication of microRNA in pancreatic cancer
• Epithelial-mesenchymal transition in local
and metastatic spread of pancreatic cancer
Collaborators:
Francesc Balaguer (Hospital Clínic)
Glòria Fernández (Hospital Clínic)
Pere Gambús(Hospital Clínic)
Eva Vaquero (Hospital Clínic)
Virginia Alonso Espinaco (CIBERehd, Hospital Clínic)
Meritxell Gironella Cos (CIBERehd. Hospital Clínic)
Gastrointestinal and pancreatic oncology
IDIBAPS Members:
■ Juan Ramon Ayuso (Hospital Clínic)
■ Sergi Castellví (Fundació Clínic)
■ José Ignacio Elizalde (Hospital Clínic)
■ Laureano Fernández-Cruz (Hospital Clínic)
■ Àngels Ginès(Hospital Clínic)
■ Isabel González (IDIBAPS)
■ Antonio Lacy (Hospital Clínic)
■ Salvador Navarro (Hospital Clínic)
■ Maria Pellisé (Hospital Clínic)
107
3. Research and innovation in endoscopy
• Endoscopic ultrasound
• Advanced diagnostic techniques
• Endoscopic therapies
Microsatellite instability analysis.
072-113 AREA3.indd 107
4. Research and innovation in surgery
• Surgery of colorectal cancer
• Surgery of pancreatic cancer
21/10/09 16:18:33
PublicaTions
Original Articles
1
108
Sanjuan A, Escaramis G, Ayuso JR, Roman SM, Torne A,
Ordi J, Lejarcegui JA, Pahisa J. Role of magnetic resonance imaging and cause of pitfalls in detecting myometrial invasion and cervical involvement in endometrial
cancer. ARCH GYNECOL OBSTET. 278:535-539. I.F.:0,67.
2 Lacy AM, Delgado S, Castells A, Prins HA, Arroyo V,
Ibarzabal A, Pique JM. The long-term results of a randomized clinical trial of laparoscopy-assisted versus open
surgery for colon cancer. ANN SURG. 248:1-7. I.F.:7,45.
3 Rodriguez S, Pages M, Castells A, DeJuan C, Bordas
JM, Rimola J, Ayuso JR, Ayuso C. Dark-lumen MR colonography with fecal tagging: a comparison of water
enema and air methods of colonic distension for detecting colonic neoplasms. EUR RADIOL. 18:1396-1405.
I.F.:3,41.
4 Forner A, Vilana R, Ayuso C, Bianchi L, Sole M, Ayuso
5 Turnes J, Garcia-Pagan JC, Gonzalez M, Aracil C, Calleja JL, Ripoll C, Abraldes JG, Banares R, Villanueva
C, Albillos A, Ayuso JR, Gilabert R, Bosch J. Portal
Hypertension-Related Complications After Acute Portal
Vein Thrombosis: Impact of Early Anticoagulation. CLIN
GASTROENTEROL H. 6:1412-1417. I.F.:5,47.
6 Fernandez-Esparrach G, Bordas JM, Llach J, Lacy A,
Delgado S, Vidal J, Cardenas A, Pellise M, Gines A,
Sendino O, Zabalza M, Castells A. Endoscopic dilation
with Savary-Gilliard bougies of stomal strictures after
laparosocopic gastric bypass in morbidly obese patients. OBES SURG. 18:155-161. I.F.:2,85.
7 Fernandez-Esparrach G, Bordas JM, Pellise M, GimenoGarcia AZ, Lacy A, Delgado S, Cardenas A, Ginies A,
Sendino O, Momblan D, Zabalza M, Llach J. Endoscopic management of early GI hemorrhage after laparoscopic gastric bypass. GASTROINTEST ENDOSC.
67:552-555. I.F.:5,89.
8 Pellise M, Fernandez-Esparrach G, Cardenas A, Sendino O, Ricart E, Vaquero E, Gimeno-Garcia AZ, DeMiguel
C, Zabalza M, Gines A, Pique JM, Llach J, Castells A.
Impact of wide-angle, high-definition endoscopy in
the diagnosis of colorectal neoplasia: A randomized
controlled trial. GASTROENTEROLOGY. 135:1062-1068.
I.F.:11,67.
9 Lacy AM, Delgado S, Rojas OA, Almenara R, Blasi A,
Llach J. MA-NOS radical sigmoidectomy: report of a
transvaginal resection in the human. SURG ENDOSC.
22:1717-1723. I.F.:2,24.
10 Vidal O, Soriano-Izquierdo A, Pera M, Elizalde JI, Palacin A, Castells A, Pique JM, Volant A, Metges JP.
Positive VEGF immunostaining independently predicts
poor prognosis in curatively resected gastric cancer
patients: Results of a study assessing a panel of angiogenic markers. J GASTROINTEST SURG. 12:1005-1014.
I.F.:2,27.
072-113 AREA3.indd 108
I.F.: 144,61
11 Herrera S, Bordas JM, Llach J, Gines A, Pellise M,
Fernandez-Esparrach G, Mondelo F, Mata A, Cardenas
A, Castells A. The beneficial effects of argon plasma
coagulation in the management of different types of
gastric vascular ectasia lesions in patients admitted for
GI hemorrhage. GASTROINTEST ENDOSC. 68:440-446.
I.F.:5,89.
12 Tomlinson IPM, Webb E, Carvajal-Carmona L, Broderick P, Howarth K, Pittman AM, Spain S, Lubbe S,
Walther A, Sullivan K, Jaeger E, Fielding S, Rowan A,
Vijayakrishnan J, Domingo E, Chandler I, Kemp Z, Qureshi M, Farrington SM, Tenesa A, Prendergast JGD,
Barnetson RA, Penegar S, Barclay E, Wood W, Martin
L, Gorman M, Thomas H, Peto J, Bishop DT, Gray R,
Maher ER, Lucassen A, Kerr D, Evans DGR, Schafmayer C, Buch S, Volzke H, Hampe J, Schreiber S, John
U, Koessler T, Pharoah P, VanWezel T, Morreau H, Wijnen JT, Hopper JL, Southey MC, Giles GG, Severi G,
Castellvi-Bel S, Ruiz-Ponte C, Carracedo A, Castells A,
Forsti A, Hemminki K, Vodicka P, Naccarati A, Lipton
L, Ho JWC, Cheng KK, Sham PC, Luk J, Agundez JAG,
Ladero JM, DeLaHoya M, Caldes T, Niittymaeki I, Tuupanen S, Karhu A, Aaltonen L, Cazier JB, Campbell H,
Dunlop MG, Houlston RS. A genome-wide association
study identifies colorectal cancer susceptibility loci on
chromosomes 10p14 and 8q23.3. NAT GENET. 40:623630. I.F.:25,56.
13 Bessa X, Balleste B, Andreu M, Castells A, Belosillo B,
Balaguer F, Castellvi-Bel S, Paya A, Jover R, Alenda
C, Tito L, Martinez-Villacampa M, Vilella A, Xicola RM,
Pons E, Llor X. A prospective, multicenter, populationbased study of BRAF mutational analysis for lynch
syndrome screeningand. CLIN GASTROENTEROL H.
6:206-214. I.F.:5,47.
14 Sendino O, Pellise M, Ghita G, Sole M, Rimola J, Gines
A. Aspergillus mediastinitis diagnosed by EUS-guided
FNA. GASTROINTEST ENDOSC. 67:153-153. I.F.:5,89.
15 Morinigo R, Vidal J, Lacy AM, Delgado S, Casamitjana
R, Gomis R. Circulating peptide YY, weight loss, and
glucose homeostasis after gastric bypass surgery in
morbidly obese subjects. ANN SURG. 247:270-275.
I.F.:7,45.
16 Balmana J, Balaguer F, Castellvi-Bel S, Steyerberg EW,
Andreu M, Llor X, Jover R, Castells A, Syngal S. Comparison of predictive models, clinical criteria and molecular tumour screening for the identification of patients
with Lynch syndrome in a population-based cohort of
colorectal cancer patients. J MED GENET. 45:557-563.
I.F.:5,54.
17 Dar AA, Zaika A, Piazuelo MB, Correa P, Koyama T, Belkhiri A, Washington K, Castells A, Pera M, El-Rifai W.
Frequent overexpression of Aurora Kinase A in upper
gastrointestinal adenocarcinornas correlates with potent antiapoptotic functions. CANCER. 112:1688-1698.
I.F.:4,63.
18 Fernandez-Cruz L, Blanco L, Cosa R, Rendon H. Is
laparoscopic resection adequate in patients with neuroendocrine pancreatic tumors?. WORLD J SURG.
32:904-917. I.F.:1,78.
21/10/09 16:18:35
1
Giradez MD, Castellvi-Bel S, Balaguer F, Gonzalo V,
Ocana T, Castells A. Lynch syndrome in colorectal
cancer patients. EXPERT REV ANTICANC. 8:573-583.
I.F.:1,99.
Castells A. Cribado del cáncer colorrectal en población de
riesgo intermedio: estudio multicéntrico, aleatorizado y
controlado en el que se compara la prueba de detección
de sangre oculta en heces mediante método inmunológico
y la colonoscopia. Grant: Fundación de la Asociación Española Contra el Cáncer (AECC), AECC_07/185. Duration:
07/05/2007-06/05/2010.
Castells A. CIBER de Enfermedades Hepáticas y Digestivas.
Castellvi S. Polimorfismos en genes candidatos involucrados en cáncer colorrectal familiar: caracterización de
componentes genéticos comunes y de baja penetrancia
de susceptibilidad para el desarrollo y predicción de la
respuesta al tratamiento del cáncer colorrectal. Grant:
Ministerio Sanidad y Consumo, PI050071. Duration:
01/01/2006-30/12/2008.
Gines A. Ultrasonografía endoscópica con o sin punción
aspirativa, tomografía computarizada multidetector y resonancia magnética en el estudio de extensión locorregional
del cáncer de recto. Estudio prospectivo y comparativo.
Grant: Instituto de Salud Carlos III, PI06/90464. Duration:
01/01/2007-30/12/2008.
Castells A. Hipermetilación de la región promotora de los
genes MLH1, MGMT, CDKN2A, RASSF1A, CDX1 y SFRP1
en mucosa colorrectal no tumoral como factor favorecedor del desarrollo del cáncer colorrectal. Grant: Ministerio
Castellvi S. Canvi de senyalització del receptor CD95 durant
l’adquisició de quimioresistència en càncer de cólon. Grant:
Fundación de la Asociación Española Contra el Cáncer
(AECC), AECC_07_009. Duration: 16/02/2008-15/02/2010.
Editorials
1
2
Sans M, Castells A. Ulcerative Colitis and Crohn’s Disease Genetics: More Similar Than We Thought?. GASTROENTEROLOGY. 135:1796-1798. I.F.:11,67.
Castells A. MYH-Associated Polyposis: Adenomas and
Hyperplastic Polyps, Partners in Crime?. GASTROENTEROLOGY. 135:1857-1859. I.F.:11,67.
Castellvi S. Caracterización clínica, histológica y molecular
del cáncer colorrectal diagnosticado antes de los 50 años.
Grant: Fundación de Investigación Médica Mutua Madrileña, 08/246. Duration: 21/07/2008-20/07/2010.
Multicentrics
Pellise M. Técnicas de endoscopia avanzada para la optimización del manejo de los pacientes con enfermedades
colorrectales. Grant: Instituto de Salud Carlos III, PI07/90174.
Duration: 31/01/2008-30/12/2009.
1
Thesis
Phitayakorn R, Delaney CP, Reynolds HL, Champagne
BJ, Heriot AG, Neary P, Senagore AJ. Standardized
algorithms for management of anastomotic leaks and
related abdominal and pelvic abscesses after colorectal
surgery. WORLD J SURG. 32:1147-1156. I.F.:1,78.
072-113 AREA3.indd 109
Reviews
19 Fernandez-Cruz L, Cosa R, Blanco L, Lopez-Boado MA,
Astudillo E. Pancreatogastrostomy With Gastric Partition
After Pylorus-Preserving Pancreatoduodenectomy Versus Conventional Pancreatojejunostomy A Prospective
Randomized Study. ANN SURG. 248:930-938. I.F.:7,45.
20 Pittman AM, Webb E, Carvajal-Carmona L, Howarth K,
DiBernardo MC, Broderick P, Spain S, Walther A, Price
A, Sullivan K, Twiss P, Fielding S, Rowan A, Jaeger E,
Vijayakrishnan J, Chandler I, Penegar S, Qureshi M,
Lubbe S, Domingo E, Kemp Z, Barclay E, Wood W, Martin L, Gorman M, Thomas H, Peto J, Bishop T, Gray R,
Maher ER, Lucassen A, Kerr D, Evans GR, VanWezel T,
Morreau H, Wijnen JT, Hopper JL, Southey MC, Giles
GG, Severi G, Castellvi-Bel S, Ruiz-Ponte C, Carracedo
A, Castells A, Forsti A, Hemminki K, Vodicka P, Naccarati A, Lipton L, Ho JWC, Cheng KK, Sham PC, Luk
J, Agundez JAG, Ladero JM, DeLaHoya M, Caldes T,
Niitymaki I, Tuupanen S, Karhu A, Aaltonen LA, Cazier
JB, Tomlinson IPM, Houlston RS. Refinement of the
basis and impact of common 11q23.1 variation to the
risk of developing colorectal cancer. HUM MOL GENET.
17:3720-3727. I.F.:7,81.
21 Vidal J, Ibarzabal A, Romero F, Delgado S, Momblan
D, Flores L, Lacy A. Type 2 diabetes mellitus and the
metabolic syndrome following sleeve gastrectomy in
severely obese subjects. OBES SURG. 18:1077-1082.
I.F.:2,85.
22 Balaguer F, Balmana J, Castellvi-Bel S, Steyerberg
EW, Andreu M, Llor X, Jover R, Syngal S, Castells A.
Validation and extension of the PREMM1,2 model in a
population- based cohort of colorectal cancer patients.
109
Castells A, Castellvi S. Caracterització i identificació de les
formes hereditàries de càncer colorectal. Doctorand: Francesc Balaguer Prunés. Universitat de Barcelona.
21/10/09 16:18:37
Diabetes: Metabolic and Molecular Networks
Team Members
Diabetes: Metabolic and molecular networks
Team Leader:
■ Ramon Gomis (IDIBAPS)
Tel.: 93 227 98 84
Fax: 93 451 66 38
IDIBAPS Members:
■ M. Carmen Carmona (IDIBAPS)
■ Roser Casamitjana (Hospital Clínic)
■ Ignacio Conget (Hospital Clínic)
■ Enric Esmatjes (Hospital Clínic)
■ Jorge Ferrer (Hospital Clínic)
■ Rosa Gasa (IDIBAPS)
■ Perla Kaliman (IDIBAPS)
■ Anna Novials (IDIBAPS)
■ Marcelina Parrizas (IDIBAPS)
■ Joan Marc Servitja (IDIBAPS)
■ Josep Vidal (Hospital Clínic)
Collaborators:
Sílvia Barceló (CIBERDEM)
Sílvia Casas (IDIBAPS)
María José Coves (Fundació Clínic)
Marga Gimenez (Hospital Clínic)
Miguel Angel Maestro (CIBERDEM)
Mercè Martí (Fundació Clínic)
Belén Nadal (Universitat de Barcelona)
Takao Nammo(IDIBAPS)
Alexandra Felicia Hanzu (IDIBAPS)
Rebeca Fernández (CIBERDEM)
Sandra Rebuffat (CIBERDEM)
Maud Soty (Fundació Clínic)
Laura Brugnara (CIBERDEM)
Doctoral Students:
Jordi Altirriba (Fundació Clínic)
Marta Amigó (Fundació Clínic)
Laura Haba (Fundació Clínic)
Maria Lucas (Fundació Clínic)
110
1. Investigate the molecular determinants of the pancreatic beta cell that may play a role in the etiopathogenesis of diabetes, with special emphasis on
those involved in the processes of apoptosis and
cell regeneration.
2. Investigate the determinants of cell plasticity in diabetes and obesity: effect of different treatments in
humans and experimental animals.
3. Investigate the molecular and metabolic mechanisms in increased cardiovascular risk in diabetes
and obesity.
072-113 AREA3.indd 110
Esther Llagostera (Universitat de Barcelona)
Núria Palau (Fundació Clínic)
Dimitri Petrov (IDIBAPS)
Myriam Solar (Fundació Clínic)
Joris Van Arensbergen(IDIBAPS)
Lisa Cadavez (Fundació Clínic)
Joana Duarte (Fundació Clínic)
Miriam Ejarque (IDIBAPS)
Fabian Pardo (Fundació Clínic)
Gemma Pujadas (Fundació Clínic)
Montse Visa (Fundació Clínic)
Technicians:
Carlos Castaño (IDIBAPS)
Yaiza Esteban (CIBERDEM)
Ainhoa García (CIBERDEM)
Vanessa Grau (CIBERDEM)
Marta Julià (CIBERDEM)
Sandra Piquer (CIBERDEM)
Lidia Sanchez (IDIBAPS)
Javier García (CIBERDEM)
Nurses:
Judith Viaplana (IDIBAPS)
Mercè Lara (Fundació Clínic)
Dieticians:
Serafín Murillo (CIBERDEM)
Principal Lines
of Research
1. Analysis of the transcription circuits that regulate
the beta cell population and their function.
2. Description of the modulating effects of the transcription factors neuroD1 and neurogenin3 in embryonic pancreas development.
3.Description of the molecular pathways involved in
the antiobesity and antidiabetic effects of tungstate
in experimental animals.
4. Determine the role of kinases and phosphatases in
diabetes and obesity.
21/10/09 16:18:42
2D-DIGE analysis of brown adipose tissue. 2-D gel of
adipose tissue, followed by bioinformatics analyses
(Ingenuity), revealing the role of PGC-1 alpha in the
action of the tungstate, validate using real-time PCR.
7. Impact of normoglycemia in endothelial
dysfunction: use of therapies involving
insulin pumps.
Associated Group
Pancreatic islets: biomarkers and function
■ Gomis, Ramon (IDIBAPS)
The group of Dr. Ramon Gomis carries out research on the physiology of the pancreatic islet and adipose
tissue, and on the causes that lead to dysfunction in these tissues. A central aspect of these studies is the
determination of the molecular mechanisms implicated in the balance of the cell mass, both in embryo
development and in adult age, with special emphasis on the processes of cell regeneration and apoptosis.
Emerging Group
Genomic programming of beta cells and
diabetes
Molecular and metabolic abnormalities in
diabetes
■ Ferrer, Jorge (ICMDM)
This team focuses on the study of genomic programming of beta cells and
diabetes.
■ Novials, Anna (IDIBAPS)
The main line of research of the group
of Dr. Novials focuses on determining
the molecular, genetic and critical environmental factors in the dysfunction and destruction of
pancreatic beta cells in type-2 diabetes.
I.F.: 103,68
PublicaTions
Original Articles
1
2
Benito B, Conget I, Bosch X, Heras M, Ordonez J, Sionis A, Diaz G, Esmatjes E. Intensive insulin therapy in
non-diabetic patients with myocardial infarction and
hyperglycemia. INSUCOR study. MED CLIN-BARCELONA. 130:601-605. I.F.:1,34.
DeLaSierra A, Gorostidi M, Marin R, Redon J, Banegas
JR, Armario P, Puig JG, Zarco J, Llisterri JL, Sanchis C,
Abarca B, Palomo V, Gomis R, Otero A, Villar F, Honorato J, Tamargo J, Lobos JM, Macias-Nunez J, Sarria A,
Aranda P, Ruilope LM. Evaluation and management of
hypertension in Spain. A consensus guide. MED CLINBARCELONA. 131:104-116. I.F.:1,34.
072-113 AREA3.indd 111
Emerging Group
5. Investigate the genetic and cellular determinants involved in the formation of amylin deposits and the
associated beta cell dysfunction.
6.Determine the role of DMPK in the development of resistance to insulin and in other metabolic disorders.
3
Casals G, Ordi J, Creus M, Fabregues F, Casamitjana R,
Quinto L, Campo E, Balasch J. Osteopontin and alpha
(v) beta (3) integrin expression in the endometrium of
infertile and fertile women. REPROD BIOMED ONLINE.
16:808-816. I.F.:2,84.
4 Fernandez-Esparrach G, Bordas JM, Llach J, Lacy
A, Delgado S, Vidal J, Cardenas A, Pellise M, Gines
A, Sendino O, Zabalza M, Castells A. Endoscopic
dilation with Savary-Gilliard bougies of stomal
strictures after laparosocopic gastric bypass in
morbidly obese patients. OBES SURG. 18:155-161.
I.F.:2,85.
5 Font D, Gomis R, Trilla A, Bigorra J, Pique JM, Rodes J.
Organization and functioning model of biomedical re-
111
21/10/09 16:18:47
6
7
8
9
10 11 12 13 14 15 16 112
17 072-113 AREA3.indd 112
search structures. Situation and future challenges. MED
Morinigo R, Vidal J, Lacy AM, Delgado S, Casamitjana R,
Gomis R. Circulating peptide YY, weight loss, and glucose homeostasis after gastric bypass surgery in morbidly
obese subjects. ANN SURG. 247:270-275. I.F.:7,45.
Vidal J, Ibarzabal A, Romero F, Delgado S, Momblan
D, Flores L, Lacy A. Type 2 diabetes mellitus and the
metabolic syndrome following sleeve gastrectomy in
severely obese subjects. OBES SURG. 18:1077-1082.
I.F.:2,85.
Halperin I, Nicolau J, Casamitjana R, Sesmilo G, SerraPrat M, Palomera E, Puig-Domingo M. A short acute
octreotide test for response prediction of long-term
treatment with somatostatin analogues in acromegalic
patients. HORM METAB RES. 40:422-426. I.F.:2,25.
Casas S, Novials A, Reimann F, Gomis R, Gribble FM.
Calcium elevation in mouse pancreatic beta cells
evoked by extracellular human islet amyloid polypeptide involves activation of the mechanosensitive ion
channel TRPV4. DIABETOLOGIA. 51:2252-2262. I.F.:5,82.
Reviriego J, Gomis R, Maranes JP, Ricart W, Hudson P,
Sacristan JA. Cost of severe hypoglycaemia in patients
with type 1 diabetes in Spain and the cost-effectiveness
of insulin lispro compared with regular human insulin in preventing severe hypoglycaemia. INT J CLIN
PRACT. 62:1026-1032. I.F.:1,59.
Marzo N, Ortega S, Stratmann T, Garcia A, Rios M,
Gimenez A, Gomis R, Mora C. Cyclin-dependent kinase
4 hyperactivity promotes autoreactivity in the immune
system but protects pancreatic beta cell mass from autoimmune destruction in the nonobese diabetic mouse
model. J IMMUNOL. 180:1189-1198. I.F.:6,07.
Fernandez-Egea E, Bernardo M, Parellada E, Justicia
A, Garcia-Rizo C, Esmatjes E, Conget I, Kirkpatrick B.
Glucose abnormalities in the siblings of people with
schizophrenia. SCHIZOPHR RES. 103:110-113. I.F.:4,24.
Lugo-Garcia L, Nadal B, Gomis R, Petit P, Gross R, Lajoix AD. Human Pancreatic Islets Express the Purinergic
P2Y(11) and P2Y(12) receptors. HORM METAB RES.
40:827-830. I.F.:2,25.
Gasa R, Mrejen C, Lynn FC, Skewes-Cox P, Sanchez L,
Yang KY, Lin CH, Gomis R, German MS. Induction of
pancreatic islet cell differentiation by the neurogeninneuroD cascade. DIFFERENTIATION. 76:381-391.
I.F.:2,90.
Davies M, Lavalle-Gonzalez F, Storms F, Gomis R. Initiation of insulin glargine therapy in type 2 diabetes
subjects suboptimally controlled on oral antidiabetic
agents: results from the AT.LANTUS trial. DIABETES
OBES METAB. 10:387-399. I.F.:3,44.
Davies M, Sinnassamy P, Storms F, Gomis R. Insulin
glargine-based therapy improves glycemic control in
patients with type 2 diabetes sub-optimally controlled
on premixed insulin therapies. DIABETES RES CLIN PR.
79:368-375. I.F.:1,82.
Barcelo-Batllori S, Kalko SG, Esteban Y, Moreno S, Carmona MC, Gomis R. Integration of DIGE and bioinformatics analyses reveals a role of the antiobesity agent
tungstate in redox and energy homeostasis pathways
in brown adipose tissue. MOL CELL PROTEOMICS.
7:378-393. I.F.:9,43.
18 Vila L, Legaz G, Barrionuevo C, Espinel ML, Casamitjana R, Muñoz J, Serra-Prat M, Puig-Domingo M. Iodine
status and thyroid volume changes during pregnancy:
Results of a survey in Aran Valley (Catalan Pyrenees). J
ENDOCRINOL INVEST. 31:851-855. I.F.:2,02.
19 Esmatjes E, Jimenez A, Diaz G, Mora M, Casamitjana
R, DeNanclares GP, Castano L, Ricart MJ. Neonatal
Diabetes With End-Stage Nephropathy Pancreas transplantation decision. DIABETES CARE. 31:2116-2117.
I.F.:7,85.
20 Gimenez M, Nicolau J, Vidal J, Casamitjana R, Conget
I. Phenotype changes at the onset of type 1 diabetes in
young adults from a Mediterranean area throughout
the last decade. ACTA DIABETOL. 45:87-90. I.F.:1,62.
21 Brotons C, DeLaFiguera M, Franch J, Aristegui I, Azeredo RR, Garcia M, Gomis R. Prediction of glucose and
insulin resistance disorders by using anthropometric
parameters of central adiposity: PRED-IR study. MED
22 Gigoux V, Clerc P, Sanchez D, Coll MG, Corominola H,
Leung-Theung-Long S, Penicaud L, Gomis R, Seva C,
Fourmy D, Dufresne M. Reg genes are CCK2 receptor
targets in ElasCCK2 mice pancreas. REGUL PEPTIDES.
146:88-98. I.F.:2,42.
23 Fernandez-Real JM, Lopez-Bermejo A, Ropero AB,
Piquer S, Nadal A, Bassols J, Casamitjana R, Gomis R,
Arnaiz E, Perez I, Ricart W. Salicylates increase insulin
secretion in healthy obese subjects. J CLIN ENDOCR
METAB. 93:2523-2530. I.F.:5,49.
24 Saiz A, Blanco Y, Sabater L, Gonzalez F, Bataller L, Casamitjana R, Ramio-Torrenta L, Graus F. Spectrum of
neurological syndromes associated with glutamic acid
decarboxylase antibodies: diagnostic clues for this association. BRAIN. 131:2553-2563. I.F.:8,57.
25 Luco RF, Maestro MA, Sadoni N, Zink D, Ferrer J. Targeted deficiency of the transcriptional activator Hnf1
alpha alters subnuclear positioning of its genomic targets. PLOS GENET. 4:-. I.F.:8,72.
26 DelPrato S, Blonde L, Martinez L, Goke B, Woo V, Millward
A, Gomis R, Canovatchel B, Strack T, Lawrence D, Freemantle N. The effect of the availability of inhaled insulin on
glycaemic control in patients with Type 2 diabetes failing
on oral therapy: Exubera as a therapeutic option on insulin
initiation and improvement in glycaemic control in clinical
practice trial. DIABETIC MED. 25:662-670. I.F.:2,97.
27 Rueda S, Fernandez-Fernandez C, Romero F, DeOsaba
MJM, Vidal J. Vitamin D, PTH, and the metabolic syndrome in severely obese subjects. OBES SURG. 18:151154. I.F.:2,85.
Reviews
1
Kaliman P, Llagostera E. Myotonic dystrophy protein
kinase (DMPK) and its role in the pathogenesis of myotonic dystrophy 1. CELL SIGNAL. 20:1935-1941. I.F.:4,15.
Editorials
1
21/10/09 16:18:49
Ferrer J. Collaborative European Effort to Develop Diabetes Diagnosis. Grant: Desconocida, 07/338. Duration:
01/08/2007-31/07/2012.
Ferrer J. IP - Beta Cell Programming for Treatment of Diabetes. Grant: European Commision, LSHB-CT-2005-512145.
Duration: 01/04/2005-30/03/2010.
Esmatjes E. Efectos del by-pass gástrico sobre la presión
arterial y la disfunción endotelial en personas con obesidad
grave. Grant: Ministerio Sanidad y Consumo, PI070124. Duration: 26/11/2007-30/12/2010.
Gomis R. REDIMET - Red de Diabetes y Enfermedades Metabólicas Asociadas. Grant: Ministerio Sanidad y Consumo,
RD06/0015/0000. Duration: 01/01/2007-30/06/2008.
Ferrer J. REDIMET - Red de Diabetes y Enfermedades Metabólicas Asociadas. Grant: Ministerio Sanidad y Consumo,
RD06/0015/0026. Duration: 01/01/2007-30/06/2008.
Ferrer J. Control epigenético de la diferenciación de las células beta. Grant: Ministerio Educación y Ciencia, SAF200500850. Duration: 31/12/2005-31/12/2008.
Gomis R. Banco Nacional de ADN - Nodo de Metabólicas.
Grant: Genoma-España, 06/409. Duration: 01/10/200630/09/2009.
Gomis R. Dianes moleculares inducidas por tungstato en la
obesidad. Grant: Ministerio Educación y Ciencia, SAF200607382. Duration: 01/10/2006-30/09/2011.
Gomis R. Diabetis i alteracions metabòliques. Investigació
cel·lular i molecular en diabetis i obesitat. Grant: Comissionat per a Universitats i Recerca, 2005SGR00019. Duration:
19/10/2005-31/12/2008.
Kaliman P. Identificación de vias de señalización molecular
reguladas por DMPK (Myotonic Dystrophy Protein Kinase)
y su papel en el desarrollo de las alteraciones metabólicas asociadas a la Distrofia Miotónica. Grant: Ministerio
Ferrer J. Programació genòmica de les cèl·lules beta i
diabetis. Grant: Comissionat per a Universitats i Recerca,
2005SGR00532. Duration: 19/10/2005-31/12/2008.
Gasa R. Funció del factor de transcripció math6 en la diferenciació de les cèl·lules endocrines del pàncrees. Grant:
Desconocida, ACD_07_001. Duration: 01/06/2007-30/11/2008.
Gomis R. Coordination action on the aetiology, pathology
and prediction of type 1 diabetes in Europe. Grant: Ministerio Sanidad y Consumo, AI07/90016. Duration: 26/10/200730/12/2008.
Gasa R. Estudio del papel del factor de transcripción
MATH6, diana potencial de neurogenina3, en la diferenciación endocrina del páncreas. Grant: Ministerio Educación y
Ciencia, BFU2005-06080. Duration: 31/12/2005-31/12/2008.
Ferrer J. Analysis of the plasticity of pancreatic duct cells.
Grant: Juvenile Diabetes Res. Foundation, 26-2008-633. Duration: 01/08/2008-31/07/2010.
Gomis R. Diabetes y enfermedades metabólicas. Grant:
Instituto de Salud Carlos III, CB07/08/0009. Duration:
01/01/2008-31/12/2011.
Novials A. Estudio de los factores implicados en la amiloidogenesis pancreática de la Diabetes Mellitus tipo 2:
Análisis del efecto molecular de la mutación -132 G/A del
promotor del gen de la amilina en la célula B-pancreática.
Grant: Instituto de Salud Carlos III, PI051215. Duration:
12/04/2008-30/12/2008.
Gomis R. Coordination Action on the Aetiology, pathology and prediction of type 1 diabetes in Europe. Grant:
01/06/2004-31/05/2008.
Ferrer J. IP - Functional genomics of pancreatic beta cells
and of tissues involved in control of the endocrine pancreas
for prevention and treatment of type 2 diabetes. Grant:
01/03/2006-28/02/2010.
hipoglucemias recurrentes y severas. Grant: Ministerio
Thesis
Servitja JM. Estudio de la respuesta del islote pancreático
a la hipoxia: papel de HIF-1. Grant: Ministerio Educación y
Ciencia, BFU2006-09072. Duration: 01/10/2006-30/09/2009.
Vidal J. Mecanismos de resolución de la diabetes tipo 2
tras bypass gástrico en pacientes con obesidad grave.
18/10/2006-30/12/2009.
Vidal J. Señales gastrointestinales y del tejido adiposo en la
obesidad grave en un modelo quirúrgico de pérdida de peso.
Doctorand: Rosa Morínigo Moizé. Universitat de Barcelona.
113
Gomis R. Cèl•lules estrellades pancreàtiques: implicació en
el procés de transdiferenciació cel•lular endocrina i caracterització del seu secretoma. Doctorand: Maria Lucas Gil.
Conget I. Sistemas de infusión subcutánea continua de
insulina y de monitorización continua de la glucosa en
la diabetes de tipo 1. Efecto sobre el perfil de riesgo
cardiovascular de los pacientes con control lábil por
072-113 AREA3.indd 113
21/10/09 16:18:51
114-153 AREA4.indd 114
21/10/09 16:00:57
Area 4
Clinical and Experimental Neurosciences
Neuropharmacology and Experimental Neuropathology . . . . . . . . . . . . . . . . . . . . . . . 116
Degenerative and Autoimmune Diseases of the Nervous System . . . . . . . . . . . 120
Neurophysiology and Functional Studies of the Nervous System . . . . . . . . . . . 124
Secondary Lesions due to Chronic Alcohol Consumption:
Muscular Pathology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 127
Cell Biology of Pathologic Processes . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 131
Biological Bases of Psychiatric Disorders and Nuclear Psychiatry . . . . . . . . . . . 134
Neuropsychology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 142
Systems Neuroscience . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 146
Neurobiology unit . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 148
Cerebral Ischemia: Clinical and Experimental Studies . . . . . . . . . . . . . . . . . . . . . . . . . . . . 150
Molecular neurobiology (IDIBAPS virtual team at the
UB faculty of biology) . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 152
Image: Microscope view of neuron cells
114-153 AREA4.indd 115
21/10/09 16:00:59
Neuropharmacology and Experimental Neuropathology
Team Members
Area 4 Clinical and Experimental Neurosciences
Neuropharmacology and
experimental neuropathology
Team Leader:
■ Guadalupe Mengod (IIBB-CSIC)
Tel.: 93 363 83 23
Fax: 93 636 83 01
116
IDIBAPS Members:
■ Albert Adell (IIBB-CSIC)
■ Francesc Artigas (IIBB-CSIC)
■ Analia Bortolozzi (IDIBAPS)
■ Anna Castañé (IIBB-CSIC)
■ Pau Celada (IDIBAPS)
■ Roser Cortés (IIBB-CSIC)
■ Rosa Cristòfol (IIBB-CSIC)
■ Sebastià Pons (IIBB-CSIC)
■ Eduard Rodriguez Farré (IIBB-CSIC)
■ Coral Sanfeliu (IIBB-CSIC)
■ Josep Saura (Facultat de Medicina UB)
■ Joan Serratosa (IIBB-CSIC)
■ Carme Solà (IIBB-CSIC)
■ Cristina Suñol (IIBB-CSIC)
■ Josep Maria Tusell (IIBB-CSIC)
■ Mª Teresa Vilaró (IIBB-CSIC)
Collaborators:
Francisco Campos (CIBERESP)
Marcelo Farina (IIBB-CSIC)
Elisabet Reyes (CIBERNED)
Elisenda Rodríguez Vargas (IIBB-CSIC)
Noemí Santana (CIBERSAM)
Valentina Ghisi (CSIC)
Tamara Romón (IDIBAPS)
Tony Valente (IDIBAPS)
Doctoral Students:
Julián de Almeida (FPI-MCyT)
Rubén Álvarez (FPI-MCyT)
Mercedes Barzi (FPI-IDIBAPS)
Jordi Berenger (CSIC)
Raúl Borne (CSIC)
Victor Briz (FPI-IDIBAPS)
Aroa Ejarque (FPI-IDIBAPS)
Mireia Galofré (IIBB-CSIC)
Yoelvis García (Marató TV3-IDIBAPS)
Silvia García (FPI-GenCat)
Núria Gresa (I3P-CSIC)
Emily Johansson (FPI-CSIC)
Lucila Kargieman (FPI-CSIC)
Xavier López Gil (I3P-CSIC)
Laia Lladó (JAE-CSIC)
Pilar Mancera (Marató TV3-IDIBAPS)
Mercè Masana (I3P-CSIC)
Joan Salvador Ardid (IDIBAPS)
Cristina Sanabra (FPI-IDIBAPS)
Marco Straccia (JAE-CSIC)
Pablo Vázquez (FPU-CSIC)
Anna García (FPI-IDIBAPS)
Giuseppe Mocci (JAE-CSIC)
Rocío Rodríguez-Minguela (CIBERNED)
Susana Revilla (FPU-MICINN)
Eva Troyano (FPI-CSIC)
Aina Palou (IDIBAPS)
Technicians:
Francisca V. Calderón (IIBB-CSIC)
Leticia Campa (IIBB-CSIC)
Jésica López (RETICS)
Rocío Martín-Álvarez (IIBB – CSIC)
Anghara Menéndez (IDIBAPS)
Albert Parull (IIBB-CSIC)
Sara Sánchez-Redondo (CIBERESP)
Verónica Paz (CIBERSAM)
Silvia Serrano (CIBERNED)
Noemí Jurado (CSIC)
To learn more about the pathophysiologic mechanisms
of neurologic and psychiatric diseases and processes
of neurotoxicity and ageing in the CNS in order to
identify new cell and functional targets and propose
new therapies.
1. Neurochemistry and pharmacology group
Francesc Artigas (IIBB-CSIC)
2.Group on mechanisms of neurotoxicity
and neurodegeneration
Cristina Suñol (IIBB-CSIC)
3.Group on control of neuron proliferation
Sebastià Pons (IIBB-CSIC)
4.Cell neurobiology group
Dr. Joan Serratosa (IIBB-CSIC)
5. Molecular neuropharmacology group
Dra. Guadalupe Mengod(IIBB-CSIC)
114-153 AREA4.indd 116
21/10/09 16:01:04
Associated Group
Neurochemistry and
neuropharmacology group
■ Artigas, Francesc (CSIC)
The group studies the neuronal circuits
responsible for the pathophysiology and
treatment of depression and schizophrenia, with special emphasis on the prefrontal cortex. We
also study neurotransmission and its atomic, cellular and
molecular bases implicated in neurodegenerative and psychiatric diseases, in order to identify and characterize new
sites of therapeutic action.
Associated Group
Group on mechanisms of
neurotoxicity and neurodegeneration
The group performs studies of cytotoxicity, oxidative stress, synaptic functions
and proteomics to determine abnormal
targets in processes of toxicity and ageing in the CNS. It
also focuses on neuroprotection strategies and the development of in vitro methods to predict neurotoxicity.
Senile plaques,
neurons, astrocytes
and microglia in
the hippocampus
of a patient with
Alzheimer disease.
Associated Group
Molecular neuropharmacology group
Associated Group
Cell neurobiology group
■ Serratosa, Joan (CSIC)
The principal objective of our research
group is to obtain information that can
help us to develop new strategies for
preventing neurodegenerative lesions that occur in the
presence of chronic glial activation. To achieve this, we
use different animal and cell models. Our hypothesis is
that different factors (cell receptors, transcription factors
and other proteins) that, in normal conditions, control the
response of glial cells but are altered in neurodegenerative
diseases and that, if they can be manipulated, may make it
possible to inhibit glial activation/neuroinflammation and
the neurotoxicity that this causes. In summary, our objectives are aimed at studying the role of glial cells (specifically
astrocytes and microglia) in neuroinflammation.
114-153 AREA4.indd 117
■ Mengod, Guadalupe (CSIC)
The group studies neurotransmission
and its anatomic, cellular and molecular
aspects implicated in neurodegenerative
diseases with an inflammatory component. The aim is to
identify and characterize new sites of therapeutic action.
Associated Group
Group on control of neuron proliferation
Clinical and Experimental Neurosciences Area 4
■ Suñol, Cristina (CSIC)
117
■ Pons, Sebastián (CSIC)
This group focuses on describing the mechanisms involved in the regulation of neuron proliferation; more specifically, it studies the molecules that oppose proliferation
induced by the Sonic Hedgehog oncogene in granular
brain cells.
21/10/09 16:01:07
I.F.: 72,86
PublicaTions
Original Articles
1
118
Bal-Price AK, Sunol C, Weiss DG, VanVliet E, Westerink
RHS, Costa LG. Application of in vitro neurotoxicity testing
for regulatory purposes: Symposium III summary and research needs. NEUROTOXICOLOGY. 29:520-531. I.F.:3,01.
2 Reyes-Irisarri E, Perez-Torres S, Miro X, Martinez E,
Puigdomenech P, Palacios JM, Mengod G. Differential
distribution of PDE4B splice variant mRNAs in rat brain
and the effects of systemic administration of LPS in
their expression. SYNAPSE. 62:74-79. I.F.:2,52.
3 SaenzDelBurgo L, Cortes R, Mengod G, Zarate J, Echevarria E, Salles J. Distribution and neurochemical characterization of neurons expressing GIRK channels in
the rat brain. J COMP NEUROL. 510:581-606. I.F.:3,92.
4 DeAlmeida J, Palacios JM, Mengod G. Distribution of
5-HT and DA receptors in primate prefrontal cortex:
implications for pathophysiology and treatment.. PROG
BRAIN RES. 172:101-115. I.F.:2,01.
5 Garcia-Matas S, Gutierrez-Cuesta J, Coto-Montes A, Rubio-Acero R, Diez-Vives C, Camins A, Pallas M, Sanfeliu
C, Cristofol R. Dysfunction of astrocytes in senescenceaccelerated mice SAMP8 reduces their neuroprotective
capacity. AGING CELL. 7:630-640. I.F.:5,85.
6 Marin C, Aguilar E, Mengod G, Cortes R, RodriguezOroz MC, Obeso JA. Entacapone potentiates the
long-duration response but does not normalize levodopa-induced molecular changes. NEUROBIOL DIS.
32:340-348. I.F.:4,38.
7 Pertusa A, Garcia-Matas S, Marnmeri H, Adell A,
Rodrigo T, Mallet J, Cristfol R, Sarkis C, Sanfeliu C.
Expression of GDNF transgene in astrocytes improves
cognitive deficits in aged rats. NEUROBIOL AGING.
29:1366-1379. I.F.:5,61.
8 Garcia DA, Vendrell I, Galofre M, Sunol C. GABA released from cultured cortical neurons influences the
modulation of t-[S-35]butylbicyclophosphorothionate
binding at the GABA(A) receptor Effects of thymol. EUR
J PHARMACOL . 600:26-31. I.F.:2,38.
9 Slevin M, Krupinski J, Mitsios N, Perikleous C, Cuadrado E, Montaner J, Sanfeliu C, Luque A, Kumar S,
Kumar P, Gaffney J. Leukaemia inhibitory factor is overexpressed by ischaemic brain tissue concomitant with
reduced plasma expression following acute stroke.
EUR J NEUROL. 15:25-33. I.F.:2,58.
10 Moreno M, Canadas F, Cardona D, Sunol C, Campa L,
Sanchez-Amate MC, Flores P, Sanchez-Santed F. Longterm monoamine changes in the striatum and nucleus
accumbens after acute chlorpyrifos exposure. TOXICOL
LETT. 176:162-167. I.F.:2,83.
11 Lopez-Gimenez JF, Vilaro MT, Milligan G. Morphine
Desensitization, Internalization, and Down-Regulation
of the mu Opioid Receptor Is Facilitated by Serotonin
5-Hydroxytryptamine(2A) Receptor Coactivation. MOL
PHARMACOL. 74:1278-1291. I.F.:3,62.
12 Kargieman L, Santana N, Mengod G, Celada P, Artigas
F. NMDA Antagonist and Antipsychotic Actions in Cortico-subcortical Circuits. NEUROTOX RES. 14:129-140.
I.F.:5,23.
114-153 AREA4.indd 118
13 Scorza MC, Meikle MN, Hill XL, Richeri A, Lorenzo D,
Artigas F. Prefrontal cortex lesions cause only minor
effects on the hyperlocomotion induced by MK-801
and its reversal by clozapine. INT J NEUROPSYCHOPH.
11(4):519-532. I.F.:4,90.
14 DeAlmeida J, Mengod G. Serotonin 1A receptors in
human and monkey prefrontal cortex are mainly expressed in pyramidal neurons and in a GABAergic
interneuron subpopulation: implications for schizophrenia and its treatment. J NEUROCHEM. 107:488-496.
I.F.:4,45.
15 DeVera N, Martinez E, Sanfeliu C. Spermine induces
cell death in cultured human embryonic cerebral cortical neurons through N-methyl-D-aspartate receptor
activation. J NEUROSCI RES. 86:861-872. I.F.:3,27.
16 Carreno M, Gil-Nagel A, Sanchez JC, Elices E, Serratosa
JM, Salas-Puig J, Villanueva V, Porcel J. Strategies to
detect adverse effects of antiepileptic drugs in clinical
practice. EPILEPSY BEHAV. 13:178-183. I.F.:2,10.
17 Sunol C, Babot Z, Fonfria E, Galofre M, Garcia D, Herrera N, Iraola S, Vendrell I. Studies with neuronal cells:
From basic studies of mechanisms of neurotoxicity to
the prediction of chemical toxicity. TOXICOL IN VITRO.
22:1350-1355. I.F.:2,19.
18 Castane A, Artigas F, Bortolozzi A. The absence of 5-HT1A
receptors has minor effects on dopamine but not serotonin release evoked by MK-801 in mice prefrontal cortex.
PSYCHOPHARMACOLOGY. 200:281-290. I.F.:3,56.
19 Celada P, Puig MV, Diaz-Mataix L, Artigas F. The hallucinogen DOI reduces low-frequency oscillations in
rat prefrontal cortex: Reversal by antipsychotic drugs.
BIOL PSYCHIAT. 64:392-400. I.F.:8,46.
Sanfeliu C. Counteracting Alzheimer’s disease progession:
effects of early-environmental treatments on the tripletransgenic 3xTgAD mic. Grant: Fundació Marató TV3,
62931. Duration: 14/03/2007-13/03/2010.
Serratosa J. Excitotoxic mechanisms, neuroinflammatory
response and seric factors in experimental and human amyotrophyc lateral esclerosis. Grant: Fundació Marató TV3,
63031. Duration: 02/03/2007-01/03/2010.
Celada MP. Modulación de los circuitos cortico-mesencefálicos por receptores 5-HT1A. Relevancia en la acción terapéutica de los fármacos antipsicóticos. Grant: Ministerio Sanidad
Adell A. Alteraciones de las conexiones de la corteza prefrontal en el modelo de esquizofrenia de antagonismo
NMDA. Sitio de acción y mecanismo de los fármacos antipsicóticos. Grant: Ministerio Sanidad y Consumo, PI070111.
Duration: 26/11/2007-30/12/2010.
Artigas F. REM-TAP - Red de Enfermedades Mentales y Trastornos Afectivos y Psicóticos. Grant: Ministerio Sanidad y
Consumo, RD06/0011/0009. Duration: 01/01/2007-30/06/2008.
21/10/09 16:01:10
Artigas F. Monoaminergic neurotransmission in prefrontal
cortex: Target for augmentation strategies in schizophrenia.
Grant: SENYFundació - Schizophrenia Research Foundation,
SenyFund_07_002. Duration: 22/05/2007-21/05/2010.
Suñol C. Optimization and pre-validation of an in vitro test
strategy for predicting human acute toxicity (A-Cute-Tox).
Grant: European Commission, LSHB-CT-2004-512051. Duration: 01/01/2005-31/12/2009.
Rodríguez E. Grup de Recerca Consolidat. Farmacologia i
Toxicologia. Grant: Comissionat per a Universitats i Recerca, 2005SGR00826. Duration: 17/10/2005-17/10/2008.
Mengod G. CIBERNED Centro de Investigación Biomédica
en Red sobre Enfermedades Neurodegenerativas. Grant:
Ministerio de Sanidad y Consumo, CB06/05/0012. Duration:
01/01/2007-31/12/2009.
Artigas F. Grup de Recerca Consolidat. Neuroquímica i
Neurofarmacología. Grant: Comissionat per a Universitats i
Recerca, 2005SGR00758. Duration: 18/10/2005-18/10/2008.
Mengod G. AMPC y neuroinflamación: identificación de moléculas implicadas en la regulación de los niveles de AMPC
en la esclerosis múltiple y en la encefalomielitis alérgica experimental. Grant: Ministerio Educación y Ciencia, SAF200610243. Duration: 01/10/2006-30/09/2009.
Rodríguez E. Neurotoxicidad de agentes ambientales, exposición de la población y salud pública. CIBER Epidemiología
y Salud Pública (CIBERESP). Grant: Instituto de Salud Carlos
III, CB06/02/0024. Duration: 01/12/2006-01/12/2009.
Sanfeliu C. Red temática de investigación cooperativa en
envejecimiento y fragilidad (RETICEF). Grant: Ministerio
Sanidad y Consumo, RD06/0013/1004. Duration: 01/01/200831/12/2010.
Artigas F. Centros de Investigación Biomédica en Red, Salud
Mental. Grant: Instituto de Salud Carlos III, CB07/09/0034.
Duration: 01/01/2008-31/12/2009.
Saura J. ¿Es C/EBPbeta una diana para atenuar la respuesta
neuroinflamatoria asociada a enfermedades neurodegenerativas? Grant: Ministerio Sanidad y Consumo, PI070455.
Duration: 01/01/2008-31/12/2010.
Sanfeliu C. Molecular Imaging of atherosclerosis. Grant: European Commission. Duration: 08/01/2007-31/12/2009.
Thesis
Sanfeliu C. Mecanismos de envejecimiento cerebral: papel
de GSK3beta/CDK5 y de las sirtuinas en cultivos de neuronas y astrocitos. Grant: Ministerio Educación y Ciencia,
SAF2006-13092-C02-02. Duration: 01/10/2006-30/09/2009.
Serratosa J. Papel de la proteina P21CIP1 en la respuesta
inflamatoria glial. Implicación en los procesos neurodegenerativos relacionados con la enfemedad de Alzheimer.
Grant: Ministerio Sanidad y Consumo, PIO50658. Duration:
23/12/2005-30/12/2008.
Suñol C. Identificación de dianas celulares y funcionales
alteradas en procesos de neurotoxicidad inducida por contaminanres amnbientales y biocidas en cultivos neuronales.
30/10/2006-30/10/2009.
Saura J, Serratosa J. C/EBPs en la activación glial. Doctorand: Aroa Ejarque Ortiz.
Pons S. Bases moleculares del antagonismo entre Shh y
BMP2 en celulas granulares de cerebelo. Doctorand: Ruben
Alvarez Rodriguez. Universitat de Barcelona.
Salles J, Cortes R. Canales regulados por proteínas G heterotriméricas (GIRK): Localización y regulación farmacológica de su expresión en sistema nervioso central de rata.
Doctorand: Laura Sáenz del Burgo Martínez. Universitat del
País Basc.
Artigas F, Cortes R. Proyecciones de la corteza prefrontal
a los núcleos monoaminérgicos del mesencéfalo: vías y
receptores implicados. Doctorand: Pablo Vázquez Borsetti.
Pons S. Bases moleculares de la interacción entre “sonic
hedgehog” y las “bone morphogenetic proteins. Grant:
Ministerio Educación y Ciencia, BFU2005 01599. Duration:
01/01/2006-31/12/2008.
Artigas F. Modulación serotoninérgica de la corteza prefrontal: relevancia en el tratamiento de la depresión y
la esquizofrenia. Grant: Ministerio Educación y Ciencia,
SAF2007-62378. Duration: 01/10/2007-04/10/2010.
119
114-153 AREA4.indd 119
21/10/09 16:01:13
Degenerative and Autoimmune Diseases of the Nervous System
Team Members
Degenerative and autoimmune
diseases of the nervous system
Team Leader:
■ Francesc Graus (Hospital Clínic)
Tel.: 93 227 57 85
Fax: 93 227 57 83
IDIBAPS Members:
■ Mario Ezquerra (ISC3, Hospital Clínic)
■ Conxita Marín (IDIBAPS)
■ Maria Josep Martí (Hospital Clínic)
■ José Luís Molinuevo (Hospital Clínic)
■ Esteban Muñoz (Hospital Clínic)
■ Albert Saiz (Hospital Clínic)
■ Eduardo Tolosa (Hospital Clínic)
■ Francesc Valldeoriola (Hospital Clínic)
Collaborators:
Yolanda Blanco (Hospital Clínic)
Albert LLadó (Hospital Clínic)
Raquel Sánchez-Valle (Hospital Clínic)
Lorena Rami (Juan de La Cierva)
Lidia Sabater (PNSEURONET)
Doctoral Students:
Beatriz Bosch (Hospital Clínic)
Claudia Caprile (Fundació Clinic)
Yaroslau Compta (Hospital Clínic)
Carles Gaig (ISC3, Hospital Clínic)
Amparo Villar (Hospital Clínic)
Claudia Moreno (Fundació Carolina)
Technicians:
Esther Aguilar (Fundació Clínic)
Mercè Bonastre (CIBERNED)
Eva Caballero (Grup Suport Generalitat)
Manuel Fernández (Fundació Clínic)
Guadalupe Fernandez (Fundació Clinic)
Maria Teresa Buongiorno (Fundació Clínic)
Ana Camara (Fundació Clínic)
Lucia Moreno (Fundació Clínic)
To develop research projects with results that can be
applied in the short term to improve diagnosis and
treatment of degenerative and autoimmune neurologic diseases. A large part of the lines of research
are linked to clinical research protocols of the Hospital
Clínic neurology department.
120
1. Genetic analysis, biologic markers and experimental
therapies in Parkinson and other movement disorders.
Studies of genetics and expression in parkinsonism.
2. Study of the pathophysiologic mechanisms involved
in Parkinson disease and other movement disorders
in in vivo and in vitro experimental models.
3. Study of autoimmune mechanisms of multiple sclerosis and neurologic diseases related to cancer.
4. Genetic studies and studies of diagnostic and predictive markers of Alzheimer disease, other dementias and multiple sclerosis. Experimental neuroimaging studies in normal and pathologic ageing.
114-153 AREA4.indd 120
Characterization of a lesion of the substantia nigra in an experimental
Parkinson model after administration of the neurotoxin 6-hydroxydopamine
(6-OHDA) to the rat. C. Marin, G. Soria, E. Aguilar.
21/10/09 16:01:17
Associated Group
Parkinson disease and movement disorders
■ Tolosa, Eduardo (ICN)
We have consolidated the genetic line in degenerative diseases, particularly Parkinson disease. This year, we
have carried out or published several studies on expression in the brain of genes potentially implicated in progressive supranuclear paralysis (isoforms of tau, CRHR1, IMP5, cdk5, GSK3, and saitohin). We have also determined the frequency of the most common mutations of the gene LRRK2 in patients with Parkinson who visited our department,
and in parkinsonisms of the Neurologic Tissue Bank.
Original Articles
1
2
3
5
6
7
8
114-153 AREA4.indd 121
10 11 12 13 14 15 16 17 18 Ramirez-Ruiz B, Marti MJ, Tolosa E, Falcon C, Bargallo
N, Valldeoriola F, Junque C. Brain Response to Complex Visual Stimuli in Parkinson’s Patients with Hallucinations: A Functional Magnetic Resonance Imaging
Study. MOVEMENT DISORD. 23:2335-2343. I.F.:3,21.
Martinez-Rodriguez JE, Munteis E, Carreno M, Blanco
Y, Roquer J, Abanades S, Graus F, Saiz A. Cannabis use
in Spanish patients with multiple sclerosis: Fulfilment
of patients’ expectations?. J NEUROL SCI. 273:103-107.
I.F.:2,32.
Ferrer A, Bosch F, Villamor N, Rozman M, Graus F,
Gutierrez G, Mercadal S, Campo E, Rozman C, LopezGuillermo A, Montserrat E. Central nervous system
involvement in mantle cell lymphoma. ANN ONCOL.
19:135-141. I.F.:4,88.
Molina-Porcel L, Llado A, Rey MJ, Molinuevo JL,
Martinez-Lage M, Esteve FX, Ferrer I, Tolosa E, Blesa R.
Clinical and pathological heterogeneity of neuronal intermediate filament inclusion disease. ARCH NEUROLCHICAGO. 65:272-275. I.F.:5,78.
Saiz A, Blanco Y, Berenguer J, Gomez-Choco M, Carreras E, Arbizu T, Graus F. Clinical outcome 6 years after
autologous hematopoietic stem cell transplantation in
multiple sclerosis. NEUROLOGIA. 23:405-407. I.F.:0,83.
Llado A, Sanchez-Valle R, Rey MJ, Ezquerra M, Tolosa
E, Ferrer I, Molinuevo JL. Clinicopathological and genetic correlates of frontotemporal lobar degeneration and
corticobasal degeneration. J NEUROL. 255:488-494.
I.F.:2,48.
Gerstner ER, Abrey LE, Schiff D, Ferreri AJM, Lister
A, Montoto S, Tsang R, Thiel E, Graus F, Behringer
D, Illerhaus G, Weaver S, Wen P, Voloschin A, Harris
NL, Batchelor TT. CNS Hodgkin lymphoma. BLOOD.
112:1658-1661. I.F.:10,90.
Marin C, Aguilar E, Bonastre M. Effect of locus coeruleus denervation on levodopa-induced motor fluctuations in hemiparkinsonian rats. J NEURAL TRANSM.
115:1133-1139. I.F.:2,67.
Bartres-Faz D, Serra-Grabulosa JM, Sun FT, Sole-Padulles C, Rami L, Molinuevo JL, Bosch B, Mercader JM,
Bargallo N, Falcon C, Vendrell P, Junque C, D’esposito
M. Functional connectivity of the hippocampus in elderly
with mild memory dysfunction carrying the APOE epsilon 4 allele. NEUROBIOL AGING. 29:1644-1653. I.F.:5,61.
Ibarretxe-Bilbao N, Ramirez-Ruiz B, Tolosa E, Marti
MJ, Valldeoriola F, Bargallo N, Junque C. Hippocampal
4
M, Marco F, Mensa J. Effect of antimicrobial therapy on
mortality in 377 episodes of Enterobacter spp. bacteraemia. J ANTIMICROB CHEMOTH. 62:397-403. I.F.:4,04.
Saldana M, Pujols L, Mullol J, Roca-Ferrer J, Cardozo
A, Aguilar E, Bonastre M, Marin C. Relevance of COX-2
gene expression in dementia with Lewy bodies associated with Alzheimer pathology. MOVEMENT DISORD.
23:804-810. I.F.:3,21.
Saiz A, Blanco Y, Sabater L, Gonzalez F, Bataller L, Casamitjana R, Ramio-Torrenta L, Graus F. Spectrum of
neurological syndromes associated with glutamic acid
decarboxylase antibodies: diagnostic clues for this association. BRAIN. 131:2553-2563. I.F.:8,57.
Marin C, Aguilar E, Mengod G, Cortes R, RodriguezOroz MC, Obeso JA. Entacapone potentiates the
long-duration response but does not normalize levodopa-induced molecular changes. NEUROBIOL DIS.
32:340-348. I.F.:4,38.
Olanow CW, Hauser RA, Jankovic J, Langston W, Lang
A, Poewe W, Tolosa E, Stocchi F, Melamed E, Eyal E,
Rascol O. A Randomized, Double-Blind, Placebo-Controlled, Delayed Start Study to Assess Rasagiline as a
Disease Modifying Therapy in Parkinson’s Disease (The
ADAGIO Study): Rationale, Design, and Baseline Characteristics. MOVEMENT DISORD. 23:2194-2201. I.F.:3,21.
Sabater L, Xifro X, Saiz A, Alberch J, Graus F. Analysis
of antibodies to neuronal surface antigens in adult opsoclonus-myoclonus. J NEUROIMMUNOL. 196:188-191.
I.F.:2,92.
Morer A, Lazaro L, Sabater L, Massana J, Castro J,
Graus F. Antineuronal antibodies in a group of children
with obsessive-compulsive disorder and Tourette syndrome. J PSYCHIATR RES. 42:64-68. I.F.:3,71.
Cabrera-Gomez J, Saiz-Hinarejos A, Graus F, GonzalezQuevedo A, Rodriguez-Rojas R, Quevedo-Sotolongo L,
Real-Gonzalez Y, Grass-Fernandez D, Cristofol-Corominas M, Rodriguez-Cordero M, Robinson-Agramonte M,
Infante-Velazquez E, Cabrera-Nunez A, Ugarte-Sanchez
C, Jordan-Gonzalez J, DeLaNuez JG, Garcia-Lahera J,
Tellez R, Baez-Martin M, Romero-Garcia K. Brain magnetic resonance imaging findings in acute relapses of
neuromyelitis optica spectrum disorders. MULT SCLER.
14:248-251. I.F.:3,26.
9
I.F.: 147,03
PublicaTions
121
21/10/09 16:01:21
19 Degenerative and autoimmune
20 21 22 Area 4 Clinical and Experimental Neurosciences
23 24 25 26 27 28 122
29 114-153 AREA4.indd 122
head atrophy predominance in Parkinson’s disease
with hallucinations and with dementia. J NEUROL.
255:1324-1331. I.F.:2,48.
Ezquerra M, Campdelacreu J, Gaig C, Compta Y, Munoz
E, Marti MJ, Valldeoriola F, Tolosa E. Lack of association of APOE and tau polymorphisms with dementia
in Parkinson’s disease. NEUROSCI LETT. 448:20-23.
I.F.:2,09.
Kumru H, Iranzo A, Carrasco E, Valldeoriola F, Marti MJ,
Santamaria J, Tolosa E. Lack of effects of pramipexole
on REM sleep behavior disorder in Parkinson disease.
SLEEP. 31:1418-1421. I.F.:4,34.
Haugarvoll K, Rademakers R, Kachergus JM, Nuytemans
K, Ross OA, Gibson JM, Tan EK, Gaig C, Tolosa E, Goldwurm S, Guidi M, Riboldazzi G, Brown L, Walter U, Benecke R, Berg D, Gasser T, Theuns J, Pals P, Cras P, DeDeyn
PP, Engelborghs S, Pickut B, Uitti RJ, Foroud T, Nichols
WC, Hagenah J, Klein C, Samii A, Zabetian CP, Bonifati V,
VanBroeckhoven C, Farrer MJ, Wszolek ZK. Lrrk2 R1441C
parkinsonism is clinically similar to sporadic Parkinson
disease. NEUROLOGY. 70:1456-1460. I.F.:6,01.
Blanco Y, Compta Y, Graus F, Saiz A. Midbrain lesions
and paroxysmal dysarthria in multiple sclerosis. MULT
SCLER. 14:694-697. I.F.:3,26.
Rami L, Caprile C, Gomez-Anson B, Sanchez-Valle
R, Monte GC, Bosch B, Molinuevo JL. Naming is associated with left temporal pole metabolite levels in
neurodegenerative diseases. DEMENT GERIATR COGN.
25:212-217. I.F.:2,64.
Graus F, Saiz A, Lai M, Bruna J, Lopez F, Sabater L,
Blanco Y, Rey MJ, Ribalta T, Dalmau J. Neuronal surface antigen antibodies in limbic encephalitis - Clinicalimmunologic associations. NEUROLOGY. 71:930-936.
I.F.:6,01.
Rami L, Serradell M, Bosch B, Caprile C, Sekler A, Villar
A, Canal R, Molinuevo JL. Normative data for the Boston Naming Test and the Pyramids and Palm Trees Test
in the elderly Spanish population. J CLIN EXP NEUROPSYC. 30:1-6. I.F.:1,69.
Gaig C, Iranzo A, Tolosa E, Vilaseca I, Rey MJ, Santamaria J. Pathological description of a non-motor variant
of multiple system atrophy. J NEUROL NEUROSUR PS.
79:1399-1400. I.F.:3,86.
Healy DG, Falchi M, O’sullivan SS, Bonifati V, Durr A,
Bressman S, Brice A, Aasly J, Zabetian CP, Goldwurm
S, Ferreira JJ, Tolosa E, Kay DM, Klein C, Williams DR,
Marras C, Lang AE, Kwszolek Z, Berciano J, Schapira
AHV, Lynch T, Bhatia KP, Gasser T, Lees AJ, Wood NW.
Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson’s disease: a casecontrol study. LANCET NEUROL. 7:583-590. I.F.:10,17.
Grimm SA, Mccannel CA, Omuro AMP, Ferreri AJM, Blay
JY, Neuwelt EA, Siegal T, Batchelor T, Jahnke K, Shenkier TN, Hall AJ, Graus F, Herrlinger U, Schiff D, Raizer J,
Rubenstein J, Laperriere N, Thiel E, Doolittle N, Iwamoto
FM, Abrey LE. Primary CNS lymphoma with intraocular
involvement International PCNSL Collaborative Group
Report. NEUROLOGY. 71:1355-1360. I.F.:6,01.
Llado A, Anton-Aguirre S, Villar A, Rami L, Molinuevo JL. Psychological impact of the diagnosis
of Alzheimer’s disease. NEUROLOGIA. 23:294-298.
I.F.:0,83.
30 Frauscher B, Iranzo A, Hogi B, Casanova-Molla J, Salamero M, Gschliesser V, Tolosa E, Poewe W, Santamaria
J. Quantification of electromyographic activity during
REM sleep in multiple muscles in REM sleep behavior
disorder. SLEEP. 31:724-731. I.F.:4,34.
31 Kollensperger M, Geser F, Seppi K, Stampfer-Kountchev M, Sawires M, Scherfler C, Boesch S, Mueller J,
Koukouni V, Quinn N, Pellecchia MT, Barone P, Schimke
N, Dodel R, Oertel W, Dupont E, Ostergaard K, Daniels
C, Deuschl G, Gurevich T, Giladi N, Coelho M, Sampaio C, Nilsson C, Widner H, DelSorbo F, Albanese A,
Cardozo A, Tolosa E, Abele M, Klockgether T, Kamm C,
Gasser T, Djaldetti R, Colosimo C, Meco G, Schrag A,
Poewe W, Wenning GK. Red flags for multiple system
atrophy. MOVEMENT DISORD. 23:1093-1099. I.F.:3,21.
32 Gaig C, Ezquerra M, Marti MJ, Valldeoriola F, Munoz E,
Llado A, Rey MJ, Cardozo A, Molinuevo JL, Tolosa E.
Screening for the LRRK2 G2019S and codon-1441 mutations in a pathological series of parkinsonian syndromes and frontotemporal lobar degeneration. J NEUROL
SCI. 270:94-98. I.F.:2,32.
33 Sabater L, Titulaer M, Saiz A, Verschuuren J, Gure AO,
Graus F. SOX1 antibodies are markers of paraneoplastic Lambert-Eaton myasthenic syndrome. NEUROLOGY.
70:924-928. I.F.:6,01.
34 Costa J, Valls-Sole J, Valldeoriola F, Rumia J. Subcortical interactions between somatosensory stimuli of
different modalities and their temporal profile. J NEUROPHYSIOL. 100:1610-1621. I.F.:3,68.
35 Martinez-Martin P, Tolosa E, Hernandez B, Badia X.
Validation of the “QUICK” questionnaire - A tool for
diagnosis of “Wearing-Off’ in patients with Parkinson’s
disease. MOVEMENT DISORD. 23:830-836. I.F.:3,21.
36 Sabater L, Bataller L, Suarez-Calvet M, Saiz A, Dalmau
J, Graus F. ZIC antibodies in paraneoplastic cerebellar
degeneration and small cell lung cancer. J NEUROIMMUNOL. 201:163-165. I.F.:2,92.
Reviews
1
2
Poewe W, Gauthier S, Aarsland D, Leverenz JB, Barone
P, Weintraub D, Tolosa E, Dubois B. Diagnosis and management of Parkinson’s disease dementia. INT J CLIN
PRACT. 62:1581-1587. I.F.:1,59.
Valls-Sole J, Compta Y, Costa J, Valldeoriola F, Rumia
J. Human central nervous system circuits examined
through the electrodes implanted for deep brain stimulation. CLIN NEUROPHYSIOL. 119:1219-1231. I.F.:2,47.
Editorials
1
Graus F, Saiz A. Limbic encephalitis. NEUROLOGY.
70:500-501. I.F.:6,01.
Multicentrics
1
Polman CH, Kappos L, Freedman MS, Edan G, Hartung
HP, Miller DH, Montalban X, Barkhof F, Selmaj K, Uitdehaag BMJ, Dahms S, Bauer L, Pohl C, Sandbrink R.
Subgroups of the BENEFIT study: Risk of developing
MS and treatment effect of interferon beta-1b. J NEUROL. 255:480-487. I.F.:2,48.
21/10/09 16:01:24
2
3
Hallett M, Evinger C, Jankovic J, Stacy M, Valls J, Tolosa E. Update on blepharospasm - Report from the
BEBRF International Workshop. NEUROLOGY. 71:12751282. I.F.:6,01.
Aziz NA, VanDerBurg JMM, Landwehrmeyer GB, Brundin P, Stijnen T, Roos RAC, Tolosa E. Weight loss in
Huntington disease increases with higher CAG repeat
number. NEUROLOGY. 71:1506-1513. I.F.:6,01.
Tolosa E. Genetic and environment factors influencing disease expression in Parkinson’s disease caused by LRRK2
mutations. Clinical and imaging studies in LRRK2 mutation
carriers without parkinsonism. Grant: Fundació Marató TV3,
061130/31. Duration: 02/03/2007-01/03/2010.
Tolosa E. Grup de recerca de malalties neurològiques. Grant: Comissionat per a Universitats i Recerca,
2005SGR00856. Duration: 19/10/2005-31/12/2008.
Marin C. Papel de las proyecciones dopaminérgicas extraestriatales y de los mecanismos compensatorios talámicos en
el desarrollo de las complicaciones motoras inducidas por
levodopa en el parkinsonismo experimental. Grant: Ministerio Sanidad y Consumo, PI050094. Duration: 01/01/200630/12/2008.
Saiz A. Análisis de anticuerpos contra antígenos de membrana, y su efecto patogénico, en enfermedades desmielinizantes: esclerosis múltiple y neuromielitis óptica.
18/10/2006-30/12/2009.
Valldeoriola F. Estudio de la enervación simpática cardíaca a
través de gammagrafía con 123I-MIBG en la enfermedad de
parkinson, parkinsonismo vascular y en pacientes con mutaciones del gen LRRK2. Grant: Ministerio Sanidad y Consumo, PI070426. Duration: 26/11/2007-30/12/2010.
Martí MJ. Combined use of neuropsychological, biochemical, and neuroimaging biomarkers for assessment of risk
of dementia in Parkinson disease. Grant: Fundació Marató
TV3, 60510. Duration: 06/02/2007-05/02/2010.
Tolosa E. Enfermedades neurodegenerativas. Grant: Ministerio Sanidad y Consumo, CB06/05/0018. Duration:
28/07/2007-27/07/2011.
123
114-153 AREA4.indd 123
21/10/09 16:01:26
Neurophysiology and Functional Studies of the Nervous System
Team Members
Neurophysiology and functional
studies of the nervous system
Team Leader:
■ Josep Valls Solé (Hospital Clínic)
Tel.: 93 227 54 13
Fax: 93 227 57 83
IDIBAPS Members:
■ Mar Carreño (Hospital Clínic)
■ Xavier Gasull (Facultat de Medicina)
■ Arcadi Gual (Facultat de Medicina)
■ Alejandro Iranzo (Hospital Clínic)
■ Miguel Morales (IDIBAPS)
■ Joan Santamaria (Hospital Clínic)
Collaborators:
Antonio Donaire (Hospital Clínic)
Jordi Palés (Facultat de Medicina)
Xavier Sala Blanch (Hospital Clínic)
Lilian Enríquez-Barreto (Facultat de Medicina UB)
Doctoral Students:
Elena Abad (Facultat de Medicina)
Germán Cuesto Gil (IDIBAPS)
We want to increase scientific knowledge on functional
aspects of the nervous system, integrating as much as
possible the basic and clinical aspects and using mainly neurophysiologic techniques. In the clinical aspect,
the principal objectives are the characterization of the
neurophysiologic aspects of motor control and pain,
and the pathophysiologic aspects of disease that produce sleep disorders, episodes of epilepsy and others,
including all entities with neuropathic pain. In the basic
aspect, the principal aspects are the characterization
of the cellular physiologic mechanisms both in ocular
physiology, and in mechanisms that play a role in neuron hyperexcitability in neuropathic pain and exploration of the modulation of synaptic transmission.
124
1. Role of subcortical motor systems in the execution
of movements, maintaining posture and reflex control. Study of the circuits of the startle reaction to
auditory or somatosensory stimuli. Prepulse phenomena.
2. Physiology and pathophysiology of neuropathic
pain. Study of nociceptive evoked potentials. Autonomic reflex actions to nociceptive stimulation. Perception and awareness of sensations.
114-153 AREA4.indd 124
Enrique Emilio Syriani (Facultat de Medicina)
Hatice Kumru (Hospital Clínic)
Gisela Lorente (Facultat de Medicina)
Iratxe Maestro (Hospital Clínic)
Monica Serradell (Hospital Clínic)
Astrid Tulleuda (Facultat de Medicina)
Joao Costa (Hospital Clínic)
Maaike Begeman (Hospital Clinic)
Jordi Casanova (Hospital Clinic)
Technicians:
Olga Sierra Bernat (IDIBAPS)
Jéssica Marquez (IDIBAPS)
Merche Morales (Marató de TV3)
Associated Group
Neurophysiology
■ Gasull, Xavier (FM_UB)
In the field of neurophysiology, the
group is interested in understanding
the functions of different ion channels
and of the cytoskeleton in the regulation of different
cellular processes. In particular, at the neuron level, we
study potassium channels implicated in the generation
of hyperexcitability in nociceptive neurons and their
relationship with neuropathic pain. In hippocampal
neurons, we study the mechanisms that play a role in
synaptogenesis and spinogenesis. In trabecular cells
that regulate the flow of aqueous humor in the eye, we
study the role of the cytoskeleton and of different ion
channels in the function of these cells and their relationship with the pathophysiology of glaucoma.
3.Study sound and its disorders in different diseases.
Numbness. Multiple sound latency tests. Restless
leg syndrome. Periodic movements of the legs during sleep.
4.Epileptic phenomena and their treatment. Status
epilepticus. Monitoring epileptic episodes. Video-
21/10/09 16:01:32
EEG and epidural register. Recording episodes
using functional magnetic resonance imaging.
5. Neurone synaptogenesis and spinogenesis.
6. Characterization of ion channels implicated in neuron hyperexcitability in sensory neurons. Implications in neuropathic pain.
7. Physiology of the evaluation of the aqueous humor
and pathophysiology of glaucoma. Ocular disease
of ageing. Physiology of the cells of the trabecular
meshwork of the eye.
PublicaTions
Original Articles
1
2
4
5
6
7
8
9
114-153 AREA4.indd 125
10 Abad E, Lorente G, Gavara N, Morales M, Gual A, Gasull X. Activation of store-operated Ca2+ channels in
trabecular meshwork cells. INVEST OPHTH VIS SCI.
49:677-686. I.F.:3,53.
11 Kofler M, Muller J, Rinnerthaler-Weichbold M, Valls-Sole J. Laterality of auditory startle responses in humans.
CLIN NEUROPHYSIOL. 119:309-314. I.F.:2,47.
12 Pales J, Gual A. Medical education in Spain: current
status and new challenges. MED TEACH. 30:365-369.
I.F.:1,23.
13 Kumru H, Soto O, Casanova J, Valls-Sole J. Motor cortex excitability changes during imagery of simple reaction time. EXP BRAIN RES. 189:373-378. I.F.:2,03.
14 Fernandez S, Carreno M, Casanova J, Donaire A. Nonconvulsive status with hemianopsia and ictal headaches: an uncommon manifestation of parieto-occipital
epilepsy. NEUROLOGIA. 23:184-187. I.F.:0,83.
15 Maestro L, Carreno M, Donaire A, Rumia J, Conesa
G, Bargallo N, Falcon C, Setoain X, Pintor L, Boget
T. Oroalimentary automatisms induced by electrical
stimulation of the fronto-opercular cortex in a patient
without automotor seizures. EPILEPSY BEHAV. 13:410412. I.F.:2,10.
16 Syriani E, Gomez-Cabrero A, Bosch M, Moya A, Abad
E, Gual A, Gasull X, Morales M. Profilin induces lamellipodia by growth factor-independent mechanism. FASEB J. 22:1581-1596. I.F.:6,79.
17 Carreno M. Recognition of nonepileptic events. SEMIN
NEUROL. 28:297-304. I.F.:1,74.
18 Kofler M, Valls-Sole J, Fuhr P, Schindler C, Zaccaria BR,
Saltuari L. Sensory modulation of voluntary and TMSinduced activation in hand muscles. EXP BRAIN RES.
188:399-409. I.F.:2,03.
19 Schestatsky P, Llado-Carbo E, Casanova-Molla J,
Alvarez-Blanco S, Valls-Sole J. Small fibre function in
patients with meralgia paresthetica. PAIN. 139:342-348.
I.F.:5,25.
20 Queralt A, Valls-Sole J, Castellote JM. The effects of a
startle on the sit-to-stand manoeuvre. EXP BRAIN RES.
185:603-609. I.F.:2,03.
3
Kumru H, Vidal J, Kofler M, Benito J, Garcia A, VallsSole J. Exaggerated auditory startle responses in patients with spinal cord injury. J NEUROL. 255:703-709.
I.F.:2,48.
Carreno M, Gil-Nagel A, Sanchez JC, Elices E, Serratosa
JM, Salas-Puig J, Villanueva V, Porcel J. Strategies to
detect adverse effects of antiepileptic drugs in clinical
practice. EPILEPSY BEHAV. 13:178-183. I.F.:2,10.
Martinez-Rodriguez JE, Munteis E, Carreno M, Blanco
Y, Roquer J, Abanades S, Graus F, Saiz A. Cannabis use
in Spanish patients with multiple sclerosis: Fulfilment
of patients’ expectations?. J NEUROL SCI. 273:103-107.
I.F.:2,32.
Kumru H, Iranzo A, Carrasco E, Valldeoriola F, Marti MJ,
Santamaria J, Tolosa E. Lack of effects of pramipexole
on REM sleep behavior disorder in Parkinson disease.
SLEEP. 31:1418-1421. I.F.:4,34.
Gaig C, Iranzo A, Tolosa E, Vilaseca I, Rey MJ, Santamaria J. Pathological description of a non-motor variant
of multiple system atrophy. J NEUROL NEUROSUR PS.
79:1399-1400. I.F.:3,86.
Frauscher B, Iranzo A, Hogi B, Casanova-Molla J, Salamero M, Gschliesser V, Tolosa E, Poewe W, Santamaria
Costa J, Valls-Sole J, Valldeoriola F, Rumia J. Subcortical interactions between somatosensory stimuli of
different modalities and their temporal profile. J NEUROPHYSIOL. 100:1610-1621. I.F.:3,68.
Serranova T, Valls-Sole J, Munoz E, Genis D, Jech R,
Seeman P. Abnormal corticospinal tract modulation of
the soleus H reflex in patients with pure spastic paraparesis. NEUROSCI LETT. 437:15-19. I.F.:2,09.
Pales J, Gual A, Gomar C, Estrach MT. Acquisition of
learning outcomes by students from the Medical School
of the University of Barcelona (Catalonia, Spain): A student survey. MED TEACH. 30:693-698. I.F.:1,23.
I.F.: 61,01
Graphic representation of the analysis of signals (Fourier rapid transform)
obtained in a polysomnography study of a patient with sleep apnea.
Top channel: EEG frequency bands recorded using occipital electrodes
with auricular reference (O1-A1). Waking alpha activity (initial yellow band
at around 10 Hz), which gives rise to slowed activity when the patient falls
asleep, with occasional interruptions. Middle channel: Electro-oculogram
(EOG), with periods of higher signal power, corresponding to REM or
wakefulness. Bottom channel: Finger oxyhemoglobin saturation with
drops below the normal baseline values during a period of sleep apnea in
the REM phase at the end of the graph.
125
21/10/09 16:01:35
21 Queralt A, Weerdesteyn V, VanDuijnhoven HJR, Castellote JM, Valls-Sole J, Duysens J. The effects of an
auditory startle on obstacle avoidance during walking.
J PHYSIOL-LONDON. 586:4453-4463. I.F.:4,58.
Gual A. Grup de Recerca Consolidat. Laboratori de Neurofisiologia i Biomembranes. Grant: Comissionat per a
Universitats i Recerca, 2005SGR00980. Duration: 22/12/200522/12/2008.
Reviews
Valls J. Intervencions sobre els components sensorial i
emocional de les respostes a estímuls de dolor en pacients
amb dolor neuropàtic crònic. Grant: Fundació La Marató de
TV3. Duration: 01/01/2007-31/12/2009.
1
2
Valls-Sole J, Compta Y, Costa J, Valldeoriola F, Rumia
J. Human central nervous system circuits examined
through the electrodes implanted for deep brain stimulation. CLIN NEUROPHYSIOL. 119:1219-1231. I.F.:2,47.
Valls-Sole J, Kumru H, Kofler M. Interaction between
startle and voluntary reactions in humans. EXP BRAIN
RES. 187:497-507. I.F.:2,03.
Multicentrics
1
Hallett M, Evinger C, Jankovic J, Stacy M, Valls J, Tolosa E. Update on blepharospasm - Report from the
BEBRF International Workshop. NEUROLOGY. 71:12751282. I.F.:6,01.
Valls J. Neurofisiologia del dolor, epilèpsia, son i control
motor (NEDESC). Grant: Comissionat per a Universitats i
Recerca, 2005SGR00394. Duration: 19/10/2005-31/12/2008.
Iranzo A. Marcadores pronósticos del desarrollo de una
enfermedad neurodegenerativa en pacientes afectos del
trastorno de conducta durante el sueño REM idiopático.
01/01/2006-30/12/2008.
Valls J. Intervencions sobre els components sensorial i
emocional de les respostes a estímuls de dolor en pacients
amb dolor neuropàtic crònic (Interventions on emotional
responses to pain stimuli in patients with chronic neuropathic pain). Grant: Fundació La Marató de TV3, 71930. Duration: 25/02/2008-24/02/2011.
Morales M. Synaptic recovery. A new therapy in Alzheimer
Disease. Grant: Fundación CIEN. Proyecto Alzheimer Reina
Sofia. Duration: 01/01/2008-31/12/2011.
Valls J. Mecanismos fisiopatológicos en la cronificación
del dolor neuropático y en el origen del síndrome regional
complejo. Grant: INstituto de Salud Carlos III, PI080266. Duration: 31/12/2008-30/12/2011.
Thesis
Gasull X, Gual A. Caracterización de la entrada de calcio
capacitativa en las células trabeculares. Doctorand: Elena
Abad Adan, Universitat de Barcelona.
Gasull X. Canales de leakage en enuronas DRG implicados
en la generación de hiperexitabilidad y dolor neuropático: caracterización electrofisiológica. Grant: Ministerio Educación y
Ciencia, BFU2005-01572/BFI. Duration: 22/12/2005-22/12/2008.
126
114-153 AREA4.indd 126
21/10/09 16:01:38
Secondary Lesions due to Chronic Alcohol Consumption: Muscular Pathology
Team members
Team Leader:
■ Álvaro Urbano Márquez
(Hospital Clínic)
Tel.: 93 227 55 39
Fax: 93 227 55 39
Collaborators:
Emilia Antunez (Facultat de Medicina)
Xavier Bosch (Hospital Clínic)
Jordi Casademont (Hospital de St. Pau)
1. Study of the pathologic mechanisms of alcohol on
organic cells and the disease it causes at the neurologic and cardiocirculatory level.
2. Importance of alcohol in intracytosolic calcium
transport.
3. Effect of alcohol on the development of arteriosclerosis.
4. Prognosis of alcoholic myocardiopathy and its most
suitable treatment.
5. Study of muscular and myocardial apoptosis with
chronic alcohol consumption.
6. Study of the pathophysiology of muscular diseases,
particularly in muscular immunohistochemical, immunogenetic and angiogenic changes (prognostic
factors) of inflammatory myopathies.
7. Study of metabolic myopathies, particularly glucogenesis and myoadenylate-deaminase deficit.
8. Study of myocardial regeneration in alcoholic myocardiopathy.
9. Clinical and functional repercussion of chronic fatigue syndrome.
114-153 AREA4.indd 127
Technicians:
Esther Tobias (Facultat de Medicina)
Mireia Nicolàs (CIBERER)
Mercedes Morales (Marató TV3)
Núria Vila (CIBEROBN)
10.Study of the effects of moderate wine consumption
and the Mediterranean diet in the prevention of cardiovascular diseases.
11.Study of mitochondrial myopathies in adults and
secondary mitochondrial involvement in different
pathologic and toxic situations.
12.Study of the pathophysiologic mechanisms implicated in the development of systemic vasculitis.
Doctoral Students:
Rosas Casas (PREDIMED)
Ana García Martínez (SAF08)
Glòria Garrabou (CIBERER)
Esther Lozano (SAF08)
Mari Pau Mena (PREDIMED)
Marta Segarra (Marató TV3)
Mònica Vázquez (PREDIMED)
Constanza Morén (FIPSE)
Georgina Espígol (PostMIR ISCIII)
Marc Corbera (Marató TV3)
Sergio Prieto (SAF08)
Ester Planas (SAF08)
Anna Sandra Hernàndez (Hospital Clínic)
Jordi Casanova (PostMIR ISCIII)
Gemma Chiva (PREDIMED)
Nasiruddin Khan (FPU)
Montserrat Butjosa (Hospital Clínic)
Secondary lesions due to chronic
alcohol consumption: muscular pathology
IDIBAPS Members:
■ Francesc Cardellach (Hospital Clínic)
■ Ramón Estruch (Hospital Clínic)
■ Joaquin Fernández (Hospital Clínic)
■ Josep M. Grau (Hospital Clínic)
■ Ferran Masanes (Hospital Clínic)
■ Oscar Miró (Hospital Clínic)
■ José Maria Nicolás (Hospital Clínic)
■ Emilio Sacanella (Hospital Clínic)
Our future challenges are:
1. To learn more about the action of alcohol on signal
translation and apoptosis at muscular and myocardial level and the influence of possible alterations to
mitochondrial DNA and the mitochondrial respiratory
chain on degenerative diseases such as Alzheimer, inflammatory myopathies and due to inclusion bodies.
2. To learn more about the prognostic factors of dermatomyositis for early detection of cases that require more
vigorous treatments (anti-TNF, gammaglobulins).
3. To characterize the clinical and morphologic aspect of metabolic myopathies (glucogenesis and
MDA deficiency).
127
21/10/09 16:01:42
4. To study sarcopenia in the geriatric population.
5. To learn more about mitochondrial toxicity of
antiretroviral drugs and of CO.
6. Proteomic studies on the mechanisms of skeletal
and cardiac muscle tissue damage due to exposure
to alcohol.
7. Study of the regeneration of myocardial cells using
stem cells in the myocardium of chronic alcoholic
patients.
I Research Group on Muscle/Mitochondrial
Function:
1. Histologic, histochemical and immunohistochemical study of myopathies
2. Study of mitochondrial functionalism
3. Study of mitochondrial diseases with special emphasis on biochemical and genetic studies in different cellular substrates.
4. Analysis of respiration and mitochondrial DNA in
muscle, fatty tissue and lymphocytes in HIV patients
and patients being treated with antiretroviral drugs.
5. Effect of smoking, carbon monoxide and neuroleptic agents on mitochondrial function.
6. Mitochondrial function in sepsis.
3.Creation of a questionnaire to evaluate the quality
of life in patients with giant cell arteritis (international study).
4. Expression of angiogenic and antiangiogenic factors as prognostic indicators of dermatomyositis.
IIIAlcohol-induced disease:
1.We are investigating the relationship between alcohol and arterial hypertension; the course of alcoholic myocardiopathy, the role of phenol derivatives of
wine and alcohol as factors that influence the appearance of atherosclerosis; the effect of nicotine
and ageing on mitochondrial respiration; and the
presence of growth factors and adhesion molecules
in angiogenesis, apoptosis, myocardiopathy and alcoholic myopathy.
2.Study of the effects of moderate wine consumption,
the Mediterranean diet and other products rich in
polyphenols in the primary prevention of cardiovascular disease.
3.Proteomic studies in skeletal and cardiac muscle in
the context of the pathogenesis of tissue damage
due to exposure to alcohol.
II Vascular inflammation:
1. Expression of cytokines and growth factors in inflammatory lesions of blood vessels and their relationship with phenotype expression, complications
and outcome of systemic vasculitis.
2. Study of the interactions between lymphocytes,
the endothelium and the extracellular matrix in the
development and perpetuation of vascular inflammation and in the mechanisms that play a role in
vascular occlusion and regeneration.
Intense myocardial focal capture of myostatin in the
microcardiocyte interconnection area. Cardiac biopsy of a
56-year-old patient with alcoholic dilated myocardiopathy.
Immune staining with human myosin. MO x 200 magnification.
I.F.: 66,47
PublicaTions
Original Articles
1
2
128
3
114-153 AREA4.indd 128
Cibeira MT, Rozman M, Segarra M, Lozano E, Rosinol
L, Cid MC, Filella X, Blade J. Bone marrow angiogenesis and angiogenic factors in multiple myeloma
treated with novel agents. CYTOKINE. 41:244-253.
I.F.:2,17.
RHEUM/AR C RES. 59:422-430. I.F.:7,68.
Lozano E, Segarra M, Garcia-Martinez A, HernandezRodriguez J, Cid MC. Imatinib mesylate inhibits in vitro
and ex vivo biological responses related to vascular occlusion in giant cell arteritis. ANN RHEUM DIS. 67:15811588. I.F.:6,41.
4
5
6
Dambrava PG, Torres A, Valles X, Mensa J, Marcos
Zazpe I, Sanchez-Tainta A, Estruch R, Lamuela-Raventos RM, Schroder H, Salas-Salvado J, Corella D, Fiol
M, Gomez-Gracia E, Aros F, Ros E, Ruiz-Gutierrez V,
Iglesias P, Conde-Herrera M, Martinez-Gonzalez MA.
A large randomized individual and group intervention
conducted by registered dietitians increased adherence
to Mediterranean-type diets: The PREDIMED study. J
AM DIET ASSOC. 108:1134-1144. I.F.:3,01.
Sanchez-Tainta A, Estruch R, Bullo M, Corella D, Gomez-Gracia E, Fiol M, Algorta J, Covas MI, Lapetra J,
Zazpe I, Ruiz-Gutierrez V, Ros E, Martinez-Gonzalez MA.
Adherence to a Mediterranean-type diet and reduced
prevalence of clustered cardiovascular risk factors in a
21/10/09 16:01:46
7
8
10 11 13 14 15 16 114-153 AREA4.indd 129
Urbano A. Identification and Validation of Alcohol Biomarker Signatures by Proteomics (Subaward nº 08004000-R82301). Grant: Thomas Jefferson University,
1R01AA016210-01. Duration: 15/05/2006-30/04/2009.
Grau J. Grup de Recerca Muscular. Grant: Comissionat
per a Universitats i Recerca, 2005SGR00300. Duration:
19/10/2005-31/12/2008.
Miro O. enzima Q como profilaxis y tratamiento de la disfunción mitocondrial asociada.. Grant: Fundación para la
Investigación y la Prevención del Sida en España, 36572/06.
Duration: 21/11/2006-30/12/2008.
Estruch R. Balance beneficio / riesgo del contenido en polifenoles y alcohol del vino: bases científicas de los efectos
del consumo moderado de vino sobre el sistema cardiovascular. Grant: Ministerio Educación y Ciencia, AGL200614228-C03-01. Duration: 01/10/2006-30/09/2009.
Estruch R. Efectos de tomate procesado casero sobre los
biomarcadores inflamatorios relacionados con la arteriosclerosis. Grant: Ministerio Educación y Ciencia, AGL200766638-C02-02. Duration: 01/12/2007-30/11/2010.
Estruch R. Fisiotatología de la obesidad y nutrición. Grant:
28/07/2006-27/07/2010.
Masanes F. Sarcopenia y discapacidad en el anciano. Factores predictivos y evolutivos. Grant: Ministerio Sanidad y
Nicolas JM. Marcadores biológicos del fracaso multiorgánico en el shock séptico. Grant: Ministerio Sanidad y Consumo, PI050164. Duration: 01/01/2006-30/12/2008.
Miro O. Comparación de dos metodologías diferentes
para la difusión de la enseñanza de la reanimación cardiopulmonar básica durante la escolarización obligatoria.
26/11/2007-30/12/2010.
Estruch R. Bases biológicas de los Efectos Protectores de la
Dieta Mediterránea en la Enfermedad Cardiovascular: Efectos sobre la adiposidad, hormonas relacionadas y marcadores de inflamación. Grant: Ministerio Sanidad y Consumo,
PI070473. Duration: 26/11/2007-30/12/2010.
12 17 Muñoz J, Vilella A, Domingo C, Nicolas JM, DeOry F,
Corachan M, Tenorio A, Gascon J. Yellow fever-associated viscerotropic disease in Barcelona, Spain. J TRAVEL
MED. 15:202-205. I.F.:1,05.
9
cohort of 3204 high-risk patients. EUR J CARDIOV PREV
R. 15:589-593. I.F.:2,22.
Salas-Salvado J, Garcia-Arellano A, Estruch R, Marquez-Sandoval F, Corella D, Fiol M, Gomez-Gracia E,
Vinoles E, Aros F, Herrera C, Lahoz C, Lapetra J, Perona
JS, Munoz-Aguado D, Martinez-Gonzalez M, Ros E.
Components of the mediterranean-type food pattern
and serum inflammatory markers among patients at
high risk for cardiovascular disease. EUR J CLIN NUTR.
62:651-659. I.F.:2,33.
Salas-Salvado J, Fernandez-Ballart J, Ros E, MartinezGonzalez MA, Fito M, Estruch R, Corella D, Fiol M,
Gomez-Gracia E, Aros F, Flores G, Lapetra J, LamuelaRaventos R, Ruiz-Gutierrez V, Bullo M, Basora J, Covas
MI. Effect of a Mediterranean Diet Supplemented With
Nuts on Metabolic Syndrome Status One-Year Results
of the PREDIMED Randomized Trial. ARCH INTERN
MED . 168:2449-2458. I.F.:8,39.
Lopez S, Coll O, Durban M, Hernandez S, Vidal R, Suy
A, Moren C, Casademont J, Cardellach F, Mataro D,
Miro O, Garrabou G. Mitochondrial DNA depletion in
oocytes of HIV-infected antiretroviral-treated infertile
women. ANTIVIR THER. 13:833-838. I.F.:4,55.
Salgado E, Antolin A, Rodriguez D, Bragulat E, Sanchez
M, Miro O. Failure of a special winter programme aimed to alleviate negative effects of winter overload on
an emergency department. MED CLIN-BARCELONA.
130:286-291. I.F.:1,34.
Paiva B, Vidriales MB, Cervero J, Mateo G, Perez JJ,
Montalban MA, Sureda A, Montejano L, Gutierrez NC,
DeCoca AG, Heras ND, Mateos MV, Lopez-Berges MC,
Garcia-Boyero R, Galende J, Hernandez J, Palomera L,
Carrera D, Martinez R, DeLaRubia J, Martin A, Blade J,
Lahuerta JJ, Orfao A, Miguel JFS. Multiparameter flow
cytometric remission is the most relevant prognostic
factor for multiple myeloma patients who undergo autologous stem cell transplantation. BLOOD. 112:40174023. I.F.:10,90.
Negredo E, Garrabou G, Puig J, Lopez S, Moren C, Bellido R, Ayen R, Cardellach F, Miro O, Clotet B. Partial
immunological and mitochondrial recovery after reducing didanosine doses in patients on didanosine and
tenofovir-based regimens. ANTIVIR THER. 13:231-240.
I.F.:4,55.
Galicia M, Nogue S, To-Figueras J, Echarte JL, Iglesias
ML, Miro O. Poisoning by liquid ecstasy (GHB) in hospital emergency departments of Barcelona: a 2-years
study. MED CLIN-BARCELONA. 130:254-258. I.F.:1,34.
Lluis M, Nogue S, Miro O. Severe acute poisoning due
to a glufosinate containing preparation without mitochondrial involvement. HUM EXP TOXICOL. 27:519524. I.F.:1,34.
Alentorn-Geli E, Padilla J, Moras G, Haro CL, FernandezSola J. Six Weeks of Whole-Body Vibration Exercise Improves Pain and Fatigue in Women with Fibromyalgia. J
ALTERN COMPLEM MED. 14:975-981. I.F.:1,53.
Roura E, Andres-Lacueva C, Estruch R, Bilbao MLM,
Izquierdo-Pulido M, Lamuela-Raventos RM. The effects
of milk as a food matrix for polyphenols on the excretion profile of cocoa (-)-epicatechin metabolites in
healthy human subjects. BRIT J NUTR. 100:846-851. I.F.:2,34.
129
Miro O. Estudio experimental y clínico de la implicación
del metabolismo de las pirimidinas en la patogénesis de la
redistribución de la grasa corporal asociada a la infección
por el VIH-1 y al tratamiento antirretroviral. Grant: FUND,
FIPSE36572/06. Duration: 21/11/2006-30/12/2008.
21/10/09 16:01:48
Thesis
Estruch R, Sacanella E. Efecte dels polifenols de la dieta en
els marcadors inflamatoris predictors d’arteriosclerosi. Doctorand: Vàzquez Agell, Mònica.
Fernandez-Sola J, Moras G. Tratamiento sintomático del
dolor musculoesquelético crónico (fibromialgia) a través de
vibraciones mecánicas. Doctorand: Eduard Alentorn Geli.
Estruch R. Efecto de la dieta mediterránea en la respuesta
inflamatoria de la pared arterial que interviene en la formación/estabilidad de la placa de ateroma. Doctorand: Mari
Pau Mena Jaramillo.
Cardellach F, Miro O. Mecanismes fisiopatològics de lesió mitocondrial secundària: antiretrovirals, antibiòtics, antipsicòtics
i monòxid de carboni. Doctorand: Glòria Garrabou Tornos.
130
114-153 AREA4.indd 130
21/10/09 16:01:51
Cell Biology of Pathologic Processes
Team members
Team Leader:
■ Jordi Alberch
Tel.: 93 403 52 85
Doctoral Students:
Empar Crespo (FIS)
Inés Fernández-Ulibarri (UB)
Albert Giralt (FPI, MEC)
Francisco Lázaro-Diéguez (UB)
Paola Paoletti (High Q Foundation)
Daniel del Toro (FPU, MEC)
Noelia Urbán (CIRIT)
Olga Carretón (UB)
Laura Rué (UB)
Enric Gutiérrez (CIRIT)
Laia Salcedo (FPI, Fundació Clínic)
Javier Selva (UB)
Technicians:
Cristina Herranz (CIBER)
Ana López (CIBER)
Maite Muñoz (Facultat de Medicina)
Ingrid Vila (CIBERNED)
1. Study of the cellular and molecular bases of mechanisms that regulate neuron death in neurodegenerative diseases, identifying intracellular pathways
that protect the specific populations of neurons affected in these diseases. Our final objective is to
identify new targets for the treatment of neurodegenerative diseases of the basal ganglia.
2. Determination of the molecular mechanisms implicated in the interaction of the cytoskeleton with the
system of cellular endomembranes (in particular,
the Golgi apparatus), and structural and functional
support in membrane traffic and cell motility. We
also want to see how this interaction is altered, and
by which mechanism(s), by toxic agents such as alcohol.
3. Characterization of the mechanisms of neuron differentiation of stem cells of different origins. Our
objective is to identify different extrinsic and intrinsic factors that contribute to neural differentiation
with the aim of using stem cells for cell replacement
therapies.
1. Molecular bases of the interaction of the actin dynamic with the Golgi apparatus and secretor traffic.
2.Role of diacylglycerol and phosphatidic acid in the
formation of transport vesicles and in the structural
organization of the Golgi apparatus.
3. Study of transport to the blood brain barrier (BBB)
of functionalized nanoparticles that carry bound antibodies or therapeutic peptides.
4.Study of the implication of neurotrophic factors and
pathophysiology and treatment of neurodegenerative diseases of the basal ganglia.
5. Study of the role of mutated huntingtin in dopaminergic and glutamatergic signalling in models of
Huntingdon disease.
6.Study of intracellular signal cascades implicated in
the degeneration of striatal neurons in Huntingdon
disease.
7. Study of the mechanisms of differentiation of
embryo or adult stem cells into neurons for cell
therapy in neurodegenerative diseases such as
Huntingdon.
114-153 AREA4.indd 131
Collaborators:
Begoña Caneda (RETICS, IDIBAPS)
Silvia Gines (Facultat de Medicina)
Raquel Martín (CIBER)
Susana Eva Martínez (Facultat de Medicina)
Bet Sarri (Fundació Clínic)
Xavier Xifro (IDIBAPS)
Verónica Brito (High Q Foundation)
Miriam Esgleas (CIBERNED)
Ana Saavedra (UB)
Susana Granell (IDIBAPS)
Cell biology of pathologic processes
IDIBAPS Members:
■ Josep M. Canals (Facultat de Medicina)
■ Gustavo Egea (Facultat de Medicina)
■ Esther Perez (Facultat de Medicina)
131
23/10/09 10:38:34
Associated Group
Membrane traffic
■ Egea, Gustavo (FM_UB)
The objective of this group is to understand the principles that control and
regulate the transport of membrane
components (lipids and proteins) within the cells. In
particular, we investigate the interaction of the transport intermediaries (vesicles and tubules) with the actin
cytoskeleton and its associated proteins and regulators,
such as myosins and Rho GTPase. We also analyze
how lipid homeostasis participates in the organization
of membrane traffic and in the formation of transport
intermediaries. Finally, we want to know the pathophysiologic bases by which ethanol alters the functioning of
nerve cells.
I.F.: 48,29
PublicaTions
Original Articles
1
Colocalization of optineurin (red) and Golgi (green) in neuronal precursors.
The nucleus is stained with Topro-3 (blue).
2
3
4
5
6
132
7
8
114-153 AREA4.indd 132
Sabater L, Xifro X, Saiz A, Alberch J, Graus F. Analysis
of antibodies to neuronal surface antigens in adult opsoclonus-myoclonus. J NEUROIMMUNOL. 196:188-191.
I.F.:2,92.
Gavalda N, Perez-Navarro E, Garcia-Martinez JM, Marco S, Benito A, Alberch J. Bax deficiency promotes an
up-regulation of Bim(EL) and Bak during striatal and
cortical postnatal development, and after excitotoxic
injury. MOL CELL NEUROSCI. 37:663-672. I.F.:3,99.
Xifro X, Garcia-Martinez JM, DelToro D, Alberch J,
Perez-Navarro E. Calcineurin is involved in the early
activation of NMDA-mediated cell death in mutant huntingtin knock-in striatal cells. J NEUROCHEM. 105:15961612. I.F.:4,45.
Marin MP, Tomas M, Esteban-Pretel G, Megias L, LopezIglesias C, Egea G, Renau-Piqueras J. Chronic ethanol
exposure induces alterations in the nucleocytoplasmic transport in growing astrocytes. J NEUROCHEM.
106:1914-1928. I.F.:4,45.
Lazaro-Dieguez F, Knecht E, Egea G. Clearance of a Hirano body-like F-actin aggresome generated by jasplakinolide. AUTOPHAGY. 4:717-720. I.F.:4,66.
Torres-Peraza JF, Giralt A, Garcia-Martinez JM, Pedrosa
E, Canals JM, Alberch J. Disruption of striatal glutamatergic transmission induced by mutant huntingtin
involves remodeling of both postsynaptic density and
NMDA receptor signaling. NEUROBIOL DIS. 29:409-421.
I.F.:4,38.
Paoletti P, Vila I, Rife M, Lizcano JM, Alberch J, Gines
S. Dopaminergic and glutamatergic signaling crosstalk
in Huntington’s disease neurodegeneration: The role of
p25/cyclin-dependent kinase 5. J NEUROSCI. 28:1009010101. I.F.:7,49.
Lazaro-Dieguez F, Aguado C, Mato E, Sanchez-Ruiz Y,
Esteban I, Alberch J, Knecht E, Egea G. Dynamics of
an F-actin aggresome generated by the actin-stabilizing toxin jasplakinolide. J CELL SCI. 121:1415-1425.
I.F.:6,38.
9 Martin-Ibanez R, Unger C, Stromberg A, Baker D, Canals JM, Hovatta O. Novel cryopreservation method for
dissociated human embryonic stem cells in the presence of a ROCK inhibitor. HUM REPROD. 23:2744-2754.
I.F.:3,54.
10 Calvo-Garrido J, Carilla-Latorre S, Lazaro-Dieguez F,
Egea G, Escalante R. Vacuole membrane protein 1 is an
endoplasmic reticulum protein required for organelle
biogenesis, protein secretion, and development. MOL
BIOL CELL. 19:3442-3453. I.F.:6,03.
Alberch J. Development of neuroprotectve strategies with
BDNF in Huntington’s Disease. Grant: Fundació Marató TV3,
62010. Duration: 15/02/2007-14/02/2010.
Egea G. Interacción estructural y funcional entre el citoesqueleto de actina y el aparato de golgi. Grant: Ministerio
Educación y Ciencia, BFU2006-00867/BMC. Duration:
01/10/2006-30/09/2009.
Canals JM. Red de Terapia Celular. Grant: Ministerio Sanidad y Consumo, RD06/0010/0006. Duration: 01/01/200731/12/2010.
Canals JM. Diferenciación de células madre (troncales)
hacia neuronas GABAérgicas: utilización en terapia substitutiva en enfermedades neurodegenerativas de los ganglios
basales. Grant: Ministerio Educación y Ciencia, SAF200604202. Duration: 01/10/2006-30/09/2009.
Alberch J. Grup de Recerca Consolidat. Fisiopatologia
de les malalties neurodegeneratives. Grant: Comissionat
21/10/09 16:02:00
per a Universitats i Recerca, 00981. Duration: 01/01/200401/01/2008.
Alberch J. Estudio de los mecanismos de acción del BDNF
como agente neuroprotector en la enfermedad de Huntington. Grant: Ministerio Educación y Ciencia, SAF2005-1335.
Duration: 01/01/2005-01/01/2008.
Perez E. Estudio de mecanismos moleculares implicados en
la vulnerabilidad. Grant: Instituto de Salud, PI071183. Duration: 15/10/2007-14/09/2010.
Egea G. Nanotecnologías en Biomedicina. Grant: Ministerio
de Ciencia e Innovación (MICINN), CONSOLIDER-INGENIO
2010-0012. Duration: 01/01/2006-31/12/2010.
Thesis
Alberch J. Programa CIBER. Enfermedades Neurodegenerativas. Grant: Ministerio de Sanidad y Consumo,
CB06/05/0054. Duration: 01/01/2007-31/12/2010.
Egea G. El papel del diacilglicerol en el tráfico de membranas en la zona entre el retículo endoplasmático y el complejo de Golgi. Doctorand: Ines Fernández-Ulibarri.
Egea G. Implicación de los filamentos de actina en la arquitectura, homeostasis y tráfico de salida del aparato de Golgi. Doctorand: Francisco Lázaro-Diéguez.
Canals JM. Convenio entre la Universidad Autonoma de
Barcelona y Institución/Empresa; Obtención de ratones
transgénicos. Construcción de DNA o transgén DN-Helios y
la cepa de ratón C57BI6-SJL. Grant: Fundació Clínic per a la
Recerca Biomèdica, 08/178. Duration: 28/05/2008-15/12/2008.
133
114-153 AREA4.indd 133
21/10/09 16:02:03
Biological Bases of Psychiatric Disorders and Nuclear Psychiatry
Team Members
Biological bases of psychiatric
disorders and nuclear psychiatry
Team Leader:
■ Miguel Bernardo
(Hospital Clínic)
Tel.: 93 227 55 47
Fax: 93 227 55 48
IDIBAPS Members:
■ Antonio Benabarre (Hospital Clínic)
■ Josefina Castro (Hospital Clínic)
■ Rosa Catalán (Hospital Clínic)
■ Cristobal Gastó (Hospital Clínic)
■ Antoni Gual (Hospital Clínic)
■ Fernando Gutierrez (Hospital Clínic)
■ Amalia Lafuente (TU)
■ Luisa Lázaro (Hospital Clínic)
■ Francisco J. Lomeña (Hospital Clínic)
■ Rocío Martín-Santos (Hospital Clínic)
■ Anabel Martínez-Arán (Hospital Clínic)
■ Guillem Masana (Hospital Clínic)
■ Eduard Parellada (Hospital Clínic)
■ Luis Pintor (Hospital Clínic)
■ Mercè Torra (Hospital Clínic)
■ Manuel Valdés (Hospital Clínic)
■ Eduard Vieta (Hospital Clínic)
Collaborators:
Inmaculada Baeza (Hospital Clínic)
Jordi Blanch (Hospital Clínic)
Francesc Colom (Fundació Clínic)
Mercè Comes (Hospital Clínic)
Nuria Cruz (IDIBAPS)
Emili Fernandez-Egea (Hospital Clínic)
Jose Manuel Goikolea (Hospital Clínic)
Ester Gómez (Hospital Clínic)
Joana Guarch (Hospital Clínic)
Teodoro Marcos (Hospital Clínic)
Sergi Mas Herrero (Associat)
Victor Navarro (Hospital Clínic)
Joan de Pablo (Hospital Clínic)
Rafael Penadés (Hospital Clínic)
Maria Reinares(CIBERSAM)
Nuria Segarra (IDIBAPS)
Jose Toro (Hospital Clínic)
Carla Torrent (CIBERSAM)
Elena de la Serna (CIBERSAM)
Patricia Gasso (Fundació Clínic)
Eva Baillés (Fundació Clínic)
Montse Batllé (IDIBAPS)
Fabian Bravo (IDIBAPS)
Piero Castro Loli (Fund. Clinic)
Anna Crescenti (FI, Generalitat)
Joan Jou (IDIBAPS)
Caterina Mar Bonning (IDIBAPS)
Anna Sanahuja (IDIBAPS)
José Sánchez-Moreno (CIBERSAM)
Marc Walther (IDIBAPS)
Carolina Franco (Hospital Clinic)
Isabella Pachiarotti (CIBERSAM)
Adriane R. Rosa (Fundació Clínic)
Marc Valentí (IDIBAPS)
Clemente Garcia-Rizo (Hospital Clínic)
Andrea Murru (Fundació Clinic)
Brisa Sole (IDIBAPS)
Technicians:
M Alicia Durán (Fundació Clínic)
Rosa Maria Palaus (Fundació Clínic)
Nurses:
Azucena Justicia (CIBERSAM)
Statistician:
Josep Maria Bari (Fundació Clínic)
134
Our group studies severe psychiatric disorders in
its neurobiologic and therapeutic aspects, with six
lines of research: bipolar disorders, schizophrenia
and depression-anxiety, child psychiatry and psychology, psychiatric intervention in medical disease
and alcoholism.
• The
114-153 AREA4.indd 134
bipolar disorders program principally investigates the neurobiologic and anatomical-functional
mechanisms implicated in the development of the
disease (genetics, neuromodulators, hormonal factors and neuroimaging) and its relapses, the clinical
course and its neuropsychological consequences,
21/10/09 16:02:07
114-153 AREA4.indd 135
cipal lines are the following: Prospective transversal
study of alcoholism; follow-up of a cohort of 850 patients who began treatment in 1987 in the Catalan
Network of Drug Addictions; screening instruments
and early-detection techniques and short counselling
in risk drinkers in hospitals and in primary health care;
evaluation and prognosis of alcoholic patients who
are candidates for liver transplant; treatment of smoking in alcoholic patients; and evaluation of European
alcohol policies and their impact on public health.
•The objectives of the depression line include implementing new psychopathologic and biologic endophenotype methods in major depression. Development of methods for analyzing the mechanism of
action of antidepressants by means of the platelet
model of depression (developed together with the
hemostasis group led by Prof. Ginés Escolar), research of neurotrophic factors (BDNF) in depressive
patients and research into factors that condition the
residual symptoms of major depression.
The main lines of research of the Clínic research group
on Child Psychiatry and Psychology are the following:
•Schizophrenia and bipolar disorder: Study and follow-up of early psychotic episodes, cognitive rehabilitation in adolescent patients with schizophrenia,
study of children and adolescents with a high genetic risk of schizophrenia and bipolar disorder due
to being children of patients with these disorders,
study of prodromal symptoms of psychotic disorders in children and adolescents and study of the
safety and tolerance of antipsychotic drugs in adolescents.
•Anorexia and bulimia nervosa and obsessive-compulsive disorder: Study of the common and differential
abnormalities (genetic, neuropsychologic and neuroimaging) of anorexia nervosa and of obsessive-compulsive disorder, study of new therapeutic approaches
(psychologic and pharmacologic) for bulimia and anorexia nervosa, study of autoimmune abnormalities in
obsessive-compulsive disorder and in anorexia.
•Addictive behavior: Analysis of the percentage of
patients seen by a child psychiatry department for
different diseases, who also present toxic substance
use, abuse or dependence, study of the efficacy of
the efficacy of drug treatments and new therapies,
and psychological interventions for early detection
and prevention of relapses, increased adherence to
treatment and improved efficacy of the therapeutic
strategies for bipolar disorder. The strategic objectives are to investigate the causes and the mechanisms implicated in the etiopathogenesis of bipolar
disorder and to investigate new treatments to improve the outcome of this disease.
•The schizophrenia program focuses on the study of
early schizophrenic episodes and resistant and comorbid schizophrenia by means of functional neuroimaging (SPECT of cerebral perfusion and receptors,
PET and fMRI). We have performed studies on sensory and cognitive neuroactivation with neuropsychologic tests of frontal activation and studies on the
occupation of dopaminergic receptors, and studies on
the presynaptic dopaminergic function. We have also
studied plasma metabolites of dopamine as biologic
indicators of relapse in a prospective, transversal follow-up study and a study of response to treatment.
We have studied the role of schizophrenia in the development of cardiovascular and metabolic diseases
and, secondarily, the role of antipsychotic drugs. We
have studied the pharmacogenetics of antipsychotic drugs to evaluate the efficacy and safety of these
drugs depending on individual genetic characteristics. Specifically, we analyzed the pharmacogenetics
of the extrapyramidal effects caused by treatment
with antipsychotics, polymorphisms associated with
the risk of schizophrenia and new pharmacogenetic
methods for their implantation in clinical and hospital
care. We have initiated a psychoeducation project that
will roll out new ways of exchanging and transmitting
knowledge, with the support of new technologies, rigorous content and appropriate communication. The
new Forumclinic website is an interactive program
with the objective of increasing patient autonomy in
terms of their health.
•The Alcoholism Unit is a reference standard in Catalonia in the area of the treatment of alcohol dependency.
We are one of the main research groups in Spain and
are currently trying to consolidate a leading position
in Europe in the area of short interventions to reduce
drinking in at-risk drinkers. Several lines of research
are being carried out y the Alcoholism Unit. The prin-
Voxel-based morphometry analysis in the group of patients with schizophrenia.
135
21/10/09 16:02:10
new multimodal treatment approaches to addictive
behavior in adolescents.
• Autistic disorders: Study of the efficacy of new psychologic and drug therapies in these disorders and
study of the neuropsychologic profile in children
with autistic disorders with high functioning and
the relationship with clinical variables.
The line of psychiatric intervention in medical disease has focused on researching knowledge of psychiatric disorders that occur in the main neurologic
diseases: dementia, multiple sclerosis, epilepsy,
Parkinson disease and Huntingdon disease. Study
of psychiatric pathology and psychological aspects
associated with medical and surgical hospital processes: transplants, delirium, psychiatric problems
in medical patients admitted to a general hospital,
evaluation of predictive variables and factors associated with suicide in the general hospital. We also
study the biologic markers and therapeutic aspects
of major depression.
We have also studied personality disorders: the structure of diagnostic systems, relationship with adaptation to the environment and validation of new models
and instruments.
Websites relating to the team:
ForumClinic
www.forumclinic.org
Network of Centers for Biomedical Research
on Mental Health (CiberSAM)
www.cibersam.es
Associated Group
Schizophrenia
■ Bernardo, Miquel (ICN)
Our group, the Clínic Schizophrenia Group (GEC), was recognized as a consolidated research group
(2005SGR00223) by DURSI in 2005. It has an interdisciplinary team formed by psychiatrists, psychologists and neuropsychologists, nurses, nuclear medicine specialists, pharmacologists, toxicologists and
biochemists linked to Hospital Clínic and the University of Barcelona. This is a group of researchers that form part of the
Clínic Schizophrenia Program (PEC) and disorders relating to schizophrenia. IT is a program of clinical care, research
and teaching both at hospital and outpatient level, which includes different care and research protocols aimed at responding to problems posed by schizophrenia and it brings together the different departments of Hospital Clínic, Barcelona. In 2007, it was a group of the network on Mental Diseases: emotional and psychotic disorders (REMTAP) and in
2008, it also formed part of the groups that made up the Network of Centers for Biomedical Research on Mental Health
(CiberSAM) (www.cibersam.es). The Clínic Schizophrenia Group investigates early episodes of schizophrenia, early schizophrenia in childhood/adolescence and resistant and comorbid schizophrenia. The principal lines of research are physical health, neurobiology and neuropsychopharmacology in schizophrenia, with a professional from each of these areas
under the coordination of Dr. M Bernardo. Another line of research is early schizophrenia in children and adolescents,
a population with a high risk of schizophrenia, this line is carried out in close collaboration with the child psychiatry
department of Hospital Clínic, directed by Dr. Castro, together with Dr. Baeza, Lázaro and Dr. Sánchez-Gistau (Study on
high genetic risk of schizophrenia).
Emerging Group
Depression Group
■ Gasto, Cristobal (ICN)
136
Our group has specialized in researching the neurobiologic bases and clinical indicators of depression associated
with the therapeutic response and course of this disease. It is estimated that depression afflicts 10% of people during their lives. This disease is currently one of the biggest health problems, particularly due to its slow, and often
incomplete, resolution. The disease interferes significantly with the normal functioning of the person and their families and has an
associated risk of suicide of greater than 10%. The project of the World Health Organization (WHO) for 2020 considers that depression will be the second cause of disability after cardiovascular diseases. In Europe, it is calculated that some thirty million people
suffer some form of depression, with an annual cost of 100 billion euro. Our group works actively on the early detection, treatment
and comorbidity (medical and psychiatric) of this disease. The genetic and neuroendocrine markers that we are investigating have
led to an improved understanding of the pathophysiologic mechanisms of depression. Also, several researchers of the group are
actively working on the design of new drug and psychotherapeutic strategies, individually and with the group.
114-153 AREA4.indd 136
21/10/09 16:02:13
Associated Group
Research group on Child Psychiatry and Psychology
■ Castro, Josefina (ICN)
Associated Group
The Clínic research group on child psychiatry and psychology works within the child psychiatry and psychology department, which has patient care, research and teaching aspects. All of these aspects are clearly interrelated in order to provide better care with standardized protocols and evaluation, undergraduate and postgraduate teaching and to allow both clinical research and research with genetics, neuroimaging and neurobiology groups. The group
is mostly made up of members of the child psychiatry and psychology department but is part of the Institut d’Investigacions
Biomèdiques August Pi i Sunyer (IDIBAPS) in the group on biological bases of psychic disorder (coordinator, M. Bernardo), in
the CiberSAM (Network of Centers for Biomedical Research on Mental Health) of the Carlos III Health Institute, in the Hospital
Clínic group coordinated by Dr. M. Bernardo. It was also part of the Network of Early Episodes in Children and Adolescents in
the Mental Disease Network (REMTAP) of the same institute. It also carries out important collaborations with the Adult Psychiatric Department of Hospital Clínic (particularly for schizophrenia, bipolar disorder and addictive behavior). The objectives of the
research are to study the manifestations, causes and treatment of the most severe and/or prevalent disorders that appear at these ages: Schizophrenia and Bipolar Disorder, Anorexia and Bulimia Nervosa, Obsessive-Compulsive Disorder, Autistic Disorders
and Addictive Behavior. At the same time, it is carrying out another line in relation the efficacy and safety of psychiatric drugs in
children and adolescents, and area that is underdeveloped in relation to knowledge in adult patients.
Bipolar disorders
■ Vieta, Eduard (ICN)
I.F.: 193,78
PublicaTions
Original Articles
1
2
3
Pareto D, Aguiar P, Pavia J, Gispert JD, Cot A, Falcon
C, Benabarre A, Lomena F, Vieta E, Ros D. Assessment
of SPM in perfusion brain SPECT studies. A numerical
simulation study using bootstrap resampling methods.
IEEE T BIO-MED ENG. 55:1849-1853. I.F.:1,62.
Parellada E, Lomena F, Font M, Pareto D, Gutierrez F,
Simo M, Fernandez-Egea E, Pavia J, Ros D, Bernardo
M. Fluordeoxyglucose-PET study in first-episode schizophrenic patients during the hallucinatory state, after
remission and during linguistic-auditory activation.
NUCL MED COMMUN. 29:894-900. I.F.:1,30.
11:193-200. I.F.:1,91.
114-153 AREA4.indd 137
4
5
6
7
Mezones-Holguin E, Blumel JE, Huezo M, Vargas R, Castro J, Cordova W, Valenzuela G, Castelo-Branco C. Impact
of diabetes mellitus on the sexuality of Peruvian postmenopausal. GYNECOL ENDOCRINOL. 24:470-474. I.F.:1,17.
symptoms in patients with schizophrenia and bipolar disorders. PSYCHIAT RES. 161:131-141. I.F.:2,30.
Castro-Fornieles J, Deulofeu R, Baeza I, Casula V, Saura
B, Lazaro L, Puig J, Toro J, Bernardo M. Psychopathological and nutritional correlates of plasma homovanillic
acid in adolescents with anorexia nervosa. J PSYCHIATR RES. 42:213-220. I.F.:3,71.
Fernandez-Egea E, Bernardo M, Parellada E, Justicia
A, Garcia-Rizo C, Esmatjes E, Conget I, Kirkpatrick B.
The bipolar disorders program essentially investigates the neurobiologic and anatomical-functional mechanisms implicated in the development of the disease, its clinical course, comorbidity with other diseases, the neurocognitive mechanisms involved, and the search for new drug, biophysical and psychosocial
treatments to improve outcome and quality of life of the patients. Our group has been a pioneer in characterizing the
associated neurocognitive dysfunction, developing new drug treatments and in the implementation of psychoeducational
techniques aimed at both patients and their families. The result of this research and innovation, is that the main international diagnostic and therapeutic guidelines take these contributions and recommend their application to clinical practice.
Our program collaborates actively with other IDIBAPS groups, with CiberSAM groups and with European and international
research centers to obtain multicenter projects with a particular translational and innovative bent.
137
21/10/09 16:02:16
8
9
10
11
12
13
14
15
16
17
138
18
19
114-153 AREA4.indd 138
Glucose abnormalities in the siblings of people with
schizophrenia. SCHIZOPHR RES. 103:110-113. I.F.:4,24.
Morer A, Lazaro L, Sabater L, Massana J, Castro J,
Graus F. Antineuronal antibodies in a group of children
with obsessive-compulsive disorder and Tourette syndrome. J PSYCHIATR RES. 42:64-68. I.F.:3,71.
Maestro L, Carreno M, Donaire A, Rumia J, Conesa G,
Bargallo N, Falcon C, Setoain X, Pintor L, Boget T. Oroalimentary automatisms induced by electrical stimulation
of the fronto-opercular cortex in a patient without automotor seizures. EPILEPSY BEHAV. 13:410-412. I.F.:2,10.
Lafuente A, Bernardo M, Mas S, Crescenti A, Aparici M,
Gasso P, Goti J, Sanchez V, Catalan R, Carne X. -141C
Ins/Del polymorphism of the dopamine D2 receptor
gene is associated with schizophrenia in a Spanish population. PSYCHIAT GENET. 18:122-127. I.F.:2,26.
Bowden C, Gogus A, Grunze H, Haggstrom L,
Rybakowski J, Vieta E. A 12-week, open, randomized
trial comparing sodium valproate to lithium in patients
with bipolar I disorder suffering from a manic episode.
INT CLIN PSYCHOPHARM. 23:254-262. I.F.:3,26.
Castro-Fornieles J, Bargallo N, Lazaro L, Andres S,
Falcon C, Plana MT, Junque C. A cross-sectional and
follow-up voxel-based morphometric MRI study in adolescent anorexia nervosa. J PSYCHIATR RES. 43:331340. I.F.:3,71.
Vieta E, Cruz N, Garcia-Campayo J, DeArce R, Crespo
JM, Valles V, Perez-Blanco J, Roca E, Olivares JM,
Morinigo A, Fernandez-Villamor R, Comes M. A doubleblind, randomized, placebo-controlled prophylaxis trial
of oxcarbazepine as adjunctive treatment to lithium in
the long-term treatment of bipolar I and II disorder. INT
J NEUROPSYCHOPH . 11:445-452. I.F.:4,90.
Vieta E, Nieto E, Autet A, Rosa AR, Goikolea JM, Cruz
N, Bonet P. A long-term prospective study on the outcome of bipolar patients treated with long-acting injectable risperidone. WORLD J BIOL PSYCHIA. 9:219-224.
I.F.:1,69.
Sanchez-Moreno J, Villagran JM, Gutierrez JR, Camacho M, Ocio S, Palao D, Querejeta I, Gascon J, Sanchez
G, Vieta E. Adaptation and validation of the Spanish
version of the Mood Disorder Questionnaire for the
detection of bipolar disorder. BIPOLAR DISORD. 10:400412. I.F.:4,44.
Castro-Fornieles J, Parellada M, Soutullo CA, Baeza I,
Gonzalez-Pinto A, Graell M, Paya B, Moreno D, DeLaSerna E, Arango C. Antipsychotic treatment in child
and adolescent first-episode psychosis: A longitudinal
naturalistic approach. J CHILD ADOL PSYCHOP. 18:327336. I.F.:3,14.
Gasso P, Bernardo M, Mas S, Crescenti A, Garcia C, Parellada E, Lafuente A. Association of A/G Polymorphism
in Intron 13 of the Monoamine Oxidase B Gene with
Schizophrenia in a Spanish Population. NEUROPSYCHOBIOLOGY. 58:65-70. I.F.:1,99.
DeCid R, Fonseca F, Gratacos M, Gutierrez F, MartinSantos R, Estivill X, Torrens M. BDNF variability in
opioid addicts and response to methadone treatment:
preliminary findings. GENES BRAIN BEHAV. 7:515-522.
I.F.:3,53.
Segarra N, Bernardo M, Valdes M, Caldu X, Falcon C,
Rami L, Bargallo N, Parramon G, Junque C. Cerebellar
20 21 22 23 24 25 26 27 28 29 30 31 32 deficits in schizophrenia are associated with executive
dysfuntion. NEUROREPORT. 19:1513-1517. I.F.:2,16.
Lazaro L, Caldu X, Junque C, Bargallo N, Andres S, Morer A, Castro-Fornieles J. Cerebral activation in children
and adolescents with obsessive-compulsive disorder
before and after treatment: A functional MRI study. J
PSYCHIATR RES. 42:1051-1059. I.F.:3,71.
Andres S, Lazaro L, Salamero M, Boget T, Penades R,
Castro-Fornieles J. Changes in cognitive dysfunction
in children and adolescents with obsessive-compulsive
disorder after treatment. J PSYCHIATR RES. 42:507-514.
I.F.:3,71.
VanRiel WG, Vieta E, Martinez-Aran A, Haro JM,
Bertsch J, Reed C, VanOs J. Chronic mania revisited:
factors associated with treatment non-response during
prospective follow-up of a large European cohort (EMBLEM). WORLD J BIOL PSYCHIA. 9(4):313-320. I.F.:1,69.
Diaz R, Castro-Fornieles J, Serrano L, Gonzalez L, Calvo
R, Goti J, Kaminer Y, Gual A. Clinical and research utility of Spanish Teen-Addiction Severity Index (T-ASI).
ADDICT BEHAV. 33:188-195. I.F.:1,75.
Rami L, Goti J, Ferrer J, Marcos T, Salamero M, Bernardo M. Cognitive functions after only one ECT session: A
controlled study. PSYCHIAT RES. 158:389-394. I.F.:2,30.
Navarro V, Gasto C, Torres X, Masana G, Penades
R, Guarch J, Vazquez M, Serra M, Pujol N, Pintor L,
Catalan R. Continuation/maintenance treatment with
nortriptyline versus combined nortriptyline and ECT in
late-life psychotic depression: A two-year randomized
study. AM J GERIAT PSYCHIAT. 16:498-505. I.F.:3,50.
Crescenti A, Mas S, Gasso P, Parellada E, Bernardo M,
Lafuente A. CYP2D6*3, *4, *5 and *6 polymorphisms
and antipsychotic-induced extrapyramidal side-effects
in patients receiving antipsychotic therapy. CLIN EXP
PHARMACOL P. 35:807-811. I.F.:2,04.
Brugue E, Colom F, Sanchez-Moreno J, Cruz N, Vieta E.
Depression subtypes in bipolar I and II disorders. PSYCHOPATHOLOGY. 41:111-114. I.F.:1,44.
Bombin I, Arango C, Mayoral M, Castro-Fornieles J,
Gonzalez-Pinto A, Gonzalez-Gomez C, Moreno D, Parellada M, Baeza I, Graell M, Otero S, Saiz PA, PatinoGarcia A. DRD3, but not COMT or DRD2, genotype
affects executive functions in healthy and first-episode
psychosis adolescents. AM J MED GENET B. 147B:873879. I.F.:4,22.
Goodwin GM, Anderson I, Arango C, Bowden CL,
Henry C, Mitchell PB, Nolen WA, Vieta E, Wittchen HU.
ECNP consensus meeting. Bipolar depression. Nice,
March 2007. EUR NEUROPSYCHOPHARM. 18:535-549.
I.F.:4,43.
Mas S, Gasso P, Crescenti A, Parellada E, Bernardo M,
Lafuente A. Effect of polymorphisms of the cathecol-Omethyltransferase on schizophrenia risk in a Spanish
population. MED CLIN-BARCELONA . 131:761-764.
I.F.:1,34.
Vieta E, Suppes T, Eggens I, Persson I, Paulsson B,
Brecher M. Efficacy and safety of quetiapine in combination with lithium or divalproex for maintenance of
patients with bipolar I disorder (international trial 126).
J AFFECT DISORDERS. 109:251-263. I.F.:3,14.
Vieta E, T’joen C, Mcquade RD, Carson WH, Marcus RN,
Sanchez R, Owen R, Nameche L. Efficacy of adjunctive
21/10/09 16:02:19
33 34 36 37 39 40 41 42 43 114-153 AREA4.indd 139
38 44 Tabares-Seisdedos R, Balanza-Martinez V, SanchezMoreno J, Martinez-Aran A, Salazar-Fraile J, Selva-Vera
G, Rubio C, Mata I, Gomez-Beneyto M, Vieta E. Neurocognitive and clinical predictors of functional outcome
in patients with schizophrenia and bipolar I disorder at
one-year follow-up. J AFFECT DISORDERS. 109:286299. I.F.:3,14.
45 Martinez-Aran A, Torrent C, Tabares-Seisdedos R, Salamero M, Daban C, Balanza-Martinez V, Sanchez-Moreno
J, Goikolea JM, Benabarre A, Colom F, Vieta E. Neurocognitive impairment in bipolar patients with and without history of psychosis. J CLIN PSYCHIAT. 69:233-239. I.F.:5,06.
46 Mur M, Portella MJ, Martinez-Aran A, Pifarre J, Vieta E.
Neuropsychological profile in bipolar disorder: a preliminary study of monotherapy lithium-treated euthymic
bipolar patients evaluated at a 2-year interval. ACTA
PSYCHIAT SCAND. 118:373-381. I.F.:3,78.
47 Vieta E, Panicali F, Goetz I, Reed C, Comes M, Tohen
M. Olanzapine monotherapy and olanzapine combination therapy in the treatment of mania: 12-week
results from the European Mania in Bipolar Longitudinal Evaluation of Medication (EMBLEM) observational
study. J AFFECT DISORDERS. 106:63-72. I.F.:3,14.
48 Tohen M, Vieta E, Goodwin GM, Sun B, Amsterdam JD,
Banov M, Shekhar A, Aaronson ST, Bardenstein L, Grecu-Gabos I, Tochilov V, Prelipceanu D, Oliff HS, Kryzhanovskaya L, Bowden C. Olanzapine Versus Divalproex
Versus Placebo in the Treatment of Mild to Moderate
Mania: A Randomized, 12-Week, Double-Blind Study.
J CLIN PSYCHIAT. 69:1776-1789. I.F.:5,06.
49 Femandez-Egea E, Miller B, Bernardo M, Donner T,
Kirkpatrick B. Parental history of Type 2 diabetes in
patients with nonaffective psychosis. SCHIZOPHR RES.
98:302-306. I.F.:4,24.
50 Herrero MJ, Domingo-Salvany A, Torrens M, Brugal
MT, Gutierrez F. Personality profile in young current regular users of cocaine. SUBST USE MISUSE. 43:13781394. I.F.:1,23.
51 Catafau AM, Penengo MM, Nucci G, Bullich S, Corripio
I, Parellada E, Garcia-Ribera C, Gomeni R, Merlo-Pich
E. Pharmacokinetics and time-course of D-2 receptor
occupancy induced by atypical antipsychotics in stabilized schizophrenic patients. J PSYCHOPHARMACOL .
22:882-894. I.F.:3,78.
52 Rosa AR, Andreazza AC, Kunz M, Gomes F, Santin
A, Sanchez-Moreno J, Reinares M, Colom F, Vieta E,
Kapczinski F. Predominant polarity in bipolar disorder:
Diagnostic implications. J AFFECT DISORDERS. 107:4551. I.F.:3,14.
53 Brissos S, Dias VV, Carita AI, Martinez-Aran A. Quality
of life in bipolar type I disorder and schizophrenia in
remission: Clinical and neurocognitive correlates. PSYCHIAT RES. 160:55-62. I.F.:2,30.
54 Suppes T, Hirschfeld RM, Vieta E, Raines S, Paulsson
B. Quetiapine for the treatment of bipolar II depression:
Analysis of data from two randomized, double-blind,
placebo-controlled studies. WORLD J BIOL PSYCHIA.
9:198-211. I.F.:1,69.
55 Cruz N, Vieta E, Comes M, Haro JM, Reed C, Bertsch
J. Rapid-cycling bipolar I disorder: Course and
treatment outcome of a large sample across Europe.
J PSYCHIATR RES. 42:1068-1075. I.F.:3,71.
35 aripiprazole to either valproate or lithium in bipolar
mania patients partially nonresponsive to valproate/
lithium monotherapy: A placebo-controlled study.
AM J PSYCHIAT. 165:1316-1325. I.F.:9,13.
Valenti M, Benabarre A, Garcia-Amador M, Molina O,
Bernardo M, Vieta E. Electroconvulsive therapy in the
treatment of mixed states in bipolar disorder. EUR PSYCHIAT. 23:53-56. I.F.:1,88.
Kotzalidis GD, Pacchiarotti I, Manfredi G, Savoja V, Torrent C, Mazzarini L, Tatarelli C, Amann B, DiMarzo S,
Sanchez-Moreno J, Sani G, Girardi P, Colom F, Vieta E.
Ethical questions in human clinical psychopharmacology: should the focus be on placebo administration?.
J PSYCHOPHARMACOL. 22:590-597. I.F.:3,78.
Tabares-Seisdedos R, Mata I, Escamez T, Vieta E, LopezIlundain JM, Salazar J, Selva G, Balanza V, Rubio C,
Martinez-Aran A, Valdes-Sanchez L, Geijo-Barrientos E,
Martinez S. Evidence for association between structural
variants in lissencephaly-related genes and executive deficits in schizophrenia or bipolar patients from a Spanish
isolate population. PSYCHIAT GENET. 18:313-317. I.F.:2,26.
Rosa AR, Franco C, Martinez-Aran A, Sanchez-Moreno
J, Salamero M, Valenti M, Tabares-Seisdedos R, Gonzalez-Pinto A, Kapczinski F, Vieta E. Functional impairment and previous suicide attempts in bipolar disorder.
ACTA NEUROPSYCHIATR. 20:300-306. I.F.:1,21.
Berk M, Ng F, Wang WV, Tohen M, Lubman DI, Vieta
E, Dodd S. Going up in smoke: Tobacco smoking is
associated with worse treatment outcomes in mania. J
AFFECT DISORDERS. 110:126-134. I.F.:3,14.
Gonzalez-Pinto A, Vega P, Ibanez B, Mosquera F, Barbeito S, Gutierrez M, DeAzua SR, Ruiz I, Vieta E. Impact of
cannabis and other drugs on age at onset of psychosis.
J CLIN PSYCHIAT. 69:1210-1216. I.F.:5,06.
Reinares M, Colom F, Sanchez-Moreno J, Torrent C,
Martinez-Aran A, Comes M, Goikolea JM, Benabarre
A, Salamero M, Vieta E. Impact of caregiver group psychoeducation on the course and outcome of bipolar
patients in remission: a randomized controlled trial.
BIPOLAR DISORD. 10:511-519. I.F.:4,44.
Navines R, Martin-Santos R, Gomez-Gil E, DeOsaba
MJM, Gasto C. Interaction between serotonin 5-HT1A
receptors and beta-endorphins modulates antidepressant response. PROG NEURO-PSYCHOPH . 32:18041809. I.F.:2,80.
Mur M, Portella MJ, Martinez-Aran A, Pifarre J, Vieta E.
Long-term stability of cognitive impairment in bipolar
disorder: A 2-year follow-up study of lithium-treated
euthymic bipolar patients. J CLIN PSYCHIAT. 69:712719. I.F.:5,06.
Guarch J, Marcos T, Salamero M, Gasto C, Blesa R.
Mild cognitive impairment: a risk indicator of later
dementia, or a preclinical phase of the disease?.
INT J GERIATR PSYCH. 23:257-265. I.F.:2,20.
Sanjuan J, Martin-Santos R, Garcia-Esteve L, Carot JM,
Guillamat R, Gutierrez-Zotes A, Gornemann I, Canellas
F, Baca-Garcia E, Jover M, Navines R, Valles V, Vilella
E, DeDiego Y, Castro JA, Ivorra JL, Gelabert E, Guitart
M, Labad A, Mayoral F, Roca M, Gratacos M, Costas J,
VanOs J, DeFrutos R. Mood changes after delivery: role
of the serotonin transporter gene. BRIT J PSYCHIAT.
193:383-388. I.F.:5,45.
139
21/10/09 16:02:21
56 Pino O, Guilera G, Rojo JE, Gomez-Benito J, Bernardo
M, Crespo-Facorro B, Cuesta MJ, Franco M, MartinezAran A, Segarra N, Tabares-Seisdedos R, Vieta E, Purdon SE, Diez T, Rejas J. Spanish version of the Screen
for Cognitive Impairment in Psychiatry (SCIP-S): Psychometric properties of a brief scale for cognitive evaluation in schizophrenia. SCHIZOPHR RES. 99:139-148.
I.F.:4,24.
57 VanRossum I, Haro JM, Tenback D, Boomsma M, Goetz
I, Vieta E, VanOs J. Stability and treatment outcome of
distinct classes of mania. EUR PSYCHIAT. 23:360-367.
I.F.:1,88.
58 Vieta E, Sanchez-Moreno J, Lahuerta J, Zaragoza S.
Subsyndromal depressive symptoms in patients with
bipolar and unipolar disorder during clinical remission.
J AFFECT DISORDERS. 107:169-174. I.F.:3,14.
59 Walther M, Montse B, Silvia M, Gemma N, Antoni G.
Teaching hospital staff about hazardous drinking: The
effect of a single intervention. ALCOHOL ALCOHOLISM.
43:51-52. I.F.:2,09.
60 Patino-Garcia A, Santos JL, Paya B, Parellada M, Bombin I, Sierrasesumaga L, Castro-Fornieles J, Baeza
I, Gonzalez-Pinto A, Graell M, Moreno DM, RapadoCastro M, Arango C. The genetic contribution to first
psychotic episodes in children and adolescents of the
child and adolescent first-episode psychosis study. PSYCHIAT GENET. 18:151-152. I.F.:2,26.
61 Torrent C, Vieta E, Garcia-Garcia M. Validation of the
Barcelona Bipolar Eating Disorder Scale for Bipolar Patients with Eating Disturbances. PSYCHOPATHOLOGY.
41:379-387. I.F.:1,44.
62 Vieta E, Bobes J, Ballesteros J, Gonzalez-Pinto A, Luque
A, Ibarra N. Validity and reliability of the Spanish versions of the Bech-Rafaelsen’s mania and melancholia
scales for bipolar disorders. ACTA PSYCHIAT SCAND.
117:207-215. I.F.:3,78.
63 Gutierrez F, Navines R, Navarro P, Garcia-Esteve L, Subira
S, Torrens M, Martin-Santos R. What do all personality
disorders have in common? Ineffectiveness and uncooperativeness. COMPR PSYCHIAT. 49:570-578. I.F.:1,86.
Reviews
1
2
140
3
4
5
114-153 AREA4.indd 140
Lopez-Munoz F, Garcia-Garcia P, Saiz-Ruiz J, Mezzich
JE, Rubio G, Vieta E, Alamo C. A bibliometric study of
the use of the classification and diagnostic systems in
psychiatry over the last 25 years. PSYCHOPATHOLOGY.
41:214-225. I.F.:1,44.
Fountoulakis KN, Vieta E, Bouras C, Notaridis G, Giannakopoulos P, Kaprinis G, Akiskal H. A systematic
review of existing data on long-term lithium therapy:
neuroprotective or neurotoxic?. INT J NEUROPSYCHOPH. 11:269-287. I.F.:4,90.
Kapczinski F, Vieta E, Andreazza AC, Frey BN, Gomes
FA, Traniontina J, Kauer-Sant’anna M, Grassi-Oliveira
R, Post RM. Allostatic load in bipolar disorder: Implications for pathophysiology and treatment. NEUROSCI
BIOBEHAV R. 32:675-692. I.F.:8,15.
Vieta E, Suppes T. Bipolar II disorder: arguments for
and against a distinct diagnostic entity. BIPOLAR DISORD. 10:163-178. I.F.:4,44.
Goodwin GM, Martinez-Aran A, Glahn DC, Vieta E. Cog-
nitive impairment in bipolar disorder: Neurodevelopment
or neurodegeneration? An ECNP expert meeting report.
EUR NEUROPSYCHOPHARM. 18:787-793. I.F.:4,43.
6 Ghaemi SN, Bauer M, Cassidy F, Malhi GS, Mitchell P,
Phelps J, Vieta E, Youngstrom E. Diagnostic guidelines
for bipolar disorder: a summary of the International
society for bipolar disorders diagnostic guidelines task
force report. BIPOLAR DISORD. 10:117-128. I.F.:4,44.
7 Balanza-Martinez V, Rubio C, Selva-Vera G, MartinezAran A, Sanchez-Moreno J, Salazar-Fraile J, Vieta E,
Tabares-Seisdedos R. Neurocognitive endophenotypes
(Endophenocognitypes) from studies of relatives of bipolar disorder subjects: A systematic review. NEUROSCI BIOBEHAV R. 32:1426-1438. I.F.:8,15.
8 Martinez-Aran A, Vieta E, Chengappa KNR, Gershon S,
Mullen J, Paulsson B. Reporting outcomes in clinical
trials for bipolar disorder: a commentary and suggestions for change. BIPOLAR DISORD. 10:566-579. I.F.:4,44.
9 Daban C, Martinez-Aran A, Cruz N, Vieta E. Safety
and efficacy of Vagus Nerve Stimulation in treatmentresistant depression. A systematic review. J AFFECT
DISORDERS. 110:1-15. I.F.:3,14.
10 Fountoulakis KN, Vieta E. Treatment of bipolar disorder:
a systematic review of available data and clinical perspectives. INT J NEUROPSYCHOPH. 11:999-1029. I.F.:4,90.
11 Torrent C, Amann B, Sanchez-Moreno JS, Colom F, Reinares M, Comes M, Rosa AR, Scott J, Vieta E. Weight
gain in bipolar disorder: pharmacological treatment as
a contributing factor. ACTA PSYCHIAT SCAND. 118:418. I.F.:3,78.
12 Tandon R, Belmaker RH, Gattaz WF, Lopez-Bor JJ,
Okasha A, Singh B, Stein DJ, Olie JP, Fleischhacker
WW, Moeller HJ, Vieta E. World Psychiatric Association
Pharmacopsychiatry section statement on comparative
effectiveness of antipsychotics in the treatment of schizophrenia. SCHIZOPHR RES. 100:20-38. I.F.:4,24.
Editorials
1
2
3
Vieta E. Antidepressants in bipolar depression. ACTA
PSYCHIAT SCAND. 118:335-336. I.F.:3,78.
Vieta E. Overcoming the current approach in bipolar
disorder research: towards DSM-V and beyond. J PSYCHOPHARMACOL. 22:406-407. I.F.:3,78.
Gual A. Translational research: A necessary and difficult step forward in the addictions field. ADDICTION.
103:1065-1066. I.F.:4,01.
Multicentrics
1
Moller HJ, Baldwin DS, Goodwin G, Kasper S, Okasha
A, Stein DJ, Tandon R, Versiani M, Vieta E. Do SSRIs or
antidepressants in general increase suicidality? WPA
section on pharmacopsychiatry: consensus statement.
EUR ARCH PSY CLIN N. 258:3-23. I.F.:2,81.
Bernardo M. Diabetes in Neuropsychiatric Disorders.
(subaward nº 07-20846A1. Grant: National Institutes of
Health - EU, 1R01DK069265-01A1 S02078-. Duration:
01/04/2005-31/03/2010.
21/10/09 16:02:24
Bernardo M. Grup Esquizofrenia Clínic (GEC). Grant: Comissionat per a Universitats i Recerca, 2005SGR00223. Duration: 19/10/2005-31/12/2008.
Vieta E. Funcionamiento y discapacidad en los trastornos
afectivos. Grant: Ministerio Sanidad y Consumo, PI050206.
Duration: 01/01/2006-30/12/2008.
Gutierrez F. Una taxonomía con base empírica para los
transtornos de la personalidad: reorganización factorial
del Eje II (DSM-IV). Grant: Ministerio Sanidad y Consumo,
PI070033. Duration: 26/11/2007-30/12/2010.
Castro J. Características psicopatológicas, neuropsicológicas y de neuroimagen comunes y diferenciales en niños
y adolescentes hijos de pacientes con esquizofrenia o con
transtorno bipolar. Grant: Ministerio Sanidad y Consumo,
PI070066. Duration: 26/11/2007-30/12/2010.
Penades R. Análisis de los efectos del tratamiento de rehabilitación cognitiva en la esquizofrenia mediante técnicas de
neuroimagen funcional. Grant: Ministerio Sanidad y Consumo, PI070258. Duration: 26/11/2007-30/12/2010.
Vieta E. REM-TAP - Red de Enfermedades Mentales y
Trastornos Afectivos y Psicóticos. Grant: Ministerio Sanidad y Consumo, RD06/0011/0005. Duration: 01/01/200730/06/2008.
Bernardo M. REM-TAP - Red de Enfermedades Mentales
y Trastornos Afectivos y Psicóticos. Grant: Ministerio Sa-
Gual T. Public health interventions to reduce the harm done
by alcohol. Grant: Ministerio Educación y Ciencia, SAF200729421-E. Duration: 10/04/2007-10/04/2008.
Bernardo M. Contrato para la formacion y perfeccionamiento del Personal Investigador postdoctorales. Grant: Ministerio de Sanidad y Comsumo, FIS CD07/00117. Duration:
01/01/2007-31/12/2009.
Penades R. Eficacia de un tratamiento de rehabilitación
cognitiva en adolescentes con trastornos del espectro de
la esquizofrenia. Grant: Ministerio de Sanidad y Consumo.
Duration: 01/01/2008-31/12/2009.
Bernardo M. Centro de investigacion biomedica en red en
salud mental (CIBERSAM). Grant: Instituto de Salud Carlos III, CB07/09/0005. Duration: 01/01/2008-31/12/2011.
Gual T. Standardizing Measurement of Alcohol Related
Troubles. Grant: Instytut Psychiatrii i Neurologii (IPIN),
2007308. Duration: 01/09/2008-31/08/2010.
Vieta E. Salud Mental. Grant: Instituto de Salud Carlos III,
CB07/09/0004. Duration: 01/01/2008-31/12/2011.
Thesis
Lafuente A. Estudio de asociación de polimorfismos en
los genes COMT, MAO-A, MAO-B y DAT con el riesgo de
esquizofrenia y de aparición de efectos extrapiramidales en
pacientes tratados con antipsicóticos. Doctorand: Patricia
Gasso Astorga.
Lazaro L. Estudio de la relación clínica y genética entre un
subgrupo de pacientes con anorexia nerviosa y pacientes
con trastorno obsesivo compulsivo en niños y adolescentes. Grant: Ministerio Sanidad y Consumo, PI070350. Duration: 26/11/2007-30/12/2010.
Gasto C. Análisis de los niveles plasmáticos de BDNF y
de interleukin 1beta en depresión y estudio de su relación
con el funcionamiento del eje HHA como modelo de rasgo
predictor de respuesta al tratamiento. Grant: Ministerio
Educación y Ciencia, SAF2005-07852-C02-02. Duration:
31/12/2005-31/12/2008.
Bernardo M. Polimorfismos MAO A(T941G), MAO B (intron
13 A/G), COMT (-A278G), ACE (I/D), CYP2D6(*3,*4,*5,*6) y
CYP1A2 (*1C, *1F). Grant: Ministerio Sanidad y Consumo,
PI060182. Duration: 18/10/2006-30/12/2009.
nidad y Consumo, RD06/0011/0006. Duration: 01/01/200730/06/2008.
141
114-153 AREA4.indd 141
21/10/09 16:02:27
Neuropsychology
Team Members
Neuropsychology
Team Leader:
■ Carme Junqué
Tel.: 93 403 44 46
Fax: 93 403 92 98
IDIBAPS Members:
■ Núria Bargalló (Hospital Clínic)
■ David Bartrés-Faz (Facultat de Medicina)
■ Teresa Boget (Hospital Clínic)
■ Teodor Marcos (Hospital Clínic)
■ José M. Mercader (Hospital Clínic)
■ Manuel Salamero (Hospital Clínic)
■ Josep M. Serra (Universitat de Barcelona)
■ Pere Vendrell (Facultat de Medicina)
Collaborators:
Ana Narberhaus (Facultat de Psicología)
Dolors Segarra (Facultat de Psicología)
Beatriz Carrillo (Juan de la Cierva. MICINN)
142
Doctoral Students:
Davinia Fernández (MEC)
Naroa Ibarretxe (MEC)
Giusi Rametti (MEC)
Sara Soria (MEC)
Joana B. Pereira (MICINN)
Leire Zubiaurre (MICINN)
Eider Martinez de Arenaza (MICINN)
Cleofé Peña (APIF)
Eva Palacios (IDIBAPS)
Nuria Segarra (UB)
Roser Sala (Becari projecte)
Technicians:
Silvia Juanes (CIBERNED)
Study of the consequences of cerebral lesions and
dysfunctions in behavior and cognition. The preferred
technique for carrying out our research is magnetic
resonance imaging in its structural and functional applications. We have a neuroimaging analysis laboratory with different high-performance workstations
equipped with software for processing medical images: ANALYZE, BRAIN-VOYAGER, BRAIN VISA, DTISTUDIO, SPM.
1.Neuropsychology and neuroimaging
in ageing in degenerative diseases
Changes caused by transcranial electrical stimulation
to cerebral activation and memory. Cognitive deterioration patterns in relation to abnormalities of the grey
matter and cerebral connectivity in Parkinson disease,
Alzheimer disease and mild cognitive deterioration.
Contribution of the cognitive and cerebral reserve to
the level of deterioration.
In Parkinson disease, we have found that patients without dementia have reduced grey matter that selectively
affects the top of the hippocampus; in patients with dementia, this reduction is also observed in the posterior
114-153 AREA4.indd 142
MRI coronal slices showing a regional reduction in the grey
matter (yellow and red images) in patients with Parkinson
disease. There is a clear predominance of atrophy in the anterior
part of the hippocampus, with conservation of the medial part.
21/10/09 16:02:31
PublicaTions
Original Articles
1
2
3
4
Narberhaus A, Segarra D, Caldiu X, Gimenez M, Pueyo R, Botet F, Junque C. Corpus callosum and prefrontal functions in adolescents with history of very
preterm birth. NEUROPSYCHOLOGIA. 46:111-116.
I.F.:3,63.
Narberhaus A, Segarra-Castells MD, Pueyo-Benito R,
Botet-Mussons F, Junque C. Long-term cognitive dysfunctions in preterm subjects with intraventricular haemorrhage. REV NEUROLOGIA. 47:57-60. I.F.:0,74.
Soria-Pastora S, Gimenez M, Narberhaus A, Falcon C,
Botet F, Bargallo N, Mercader JM, Junque C. Patterns
of cerebral white matter damage and cognitive impairment in adolescents born very preterm. INT J DEV
NEUROSCI. 26:647-654. I.F.:3,61.
Gimenez M, Soria-Pastor S, Junque C, Caldu X, Narberhaus A, Botet F, Bargallo N, Falcon C, Mercader JM.
Proton Magnetic Resonance Spectroscopy Reveals Medial Temporal Metabolic Abnormalities in Adolescents
114-153 AREA4.indd 143
3.Dysfunctions of the frontobasal system
and memory disorders
Dysfunctions of the frontoparietal systems associated with dyscalculia. Potential use of fMRI in identifying memory dysfunctions associated with the hippocampus.
In this line, we have shown that deficits of episodic
memory and visual memory are preclinical manifestations of dementia in subjects who subjectively complain of memory loss. On the other hand, working
memory, which reflects frontal dysfunctions, does not
seem to have any prognostic value.
Within the different measurements of verbal fluency,
which is a task traditionally considered to be prefrontal, we have found that the ability to classify (cluster
formation) is more predictive of conversion to Alzheimer in subjects with mild cognitive deterioration than
the ability to change and the total number of words
mentioned. This finding is of considerable clinical interest in the application of batteries of neuropsychological tests.
I.F.: 80,12
With History of Preterm Birth. PEDIATR RES. 64:572577. I.F.:2,84.
5 Vidal A, Gomez-Gil E, Sans M, Portella MJ, Salamero
M, Pique JM, Panes J. Health-related quality of life in
inflammatory bowel disease patients: The role of psychopathology and personality. INFLAMM BOWEL DIS.
14:977-983. I.F.:4,71.
6 Ramirez-Ruiz B, Marti MJ, Tolosa E, Falcon C, Bargallo N, Valldeoriola F, Junque C. Brain Response to
Complex Visual Stimuli in Parkinson’s Patients with
Hallucinations: A Functional Magnetic Resonance
Imaging Study. MOVEMENT DISORD. 23:2335-2343.
I.F.:3,21.
7 Bartres-Faz D, Serra-Grabulosa JM, Sun FT, Sole-Padulles C, Rami L, Molinuevo JL, Bosch B, Mercader JM,
Bargallo N, Falcon C, Vendrell P, Junque C, D’esposito
M. Functional connectivity of the hippocampus in elderly with mild memory dysfunction carrying the APOE
epsilon 4 allele. NEUROBIOL AGING. 29:1644-1653.
I.F.:5,61.
2.Cerebral plasticity
Long-term consequences of brain damage. Study of
the cerebral response to language in patients in a vegetative or minimum-response state. Structural and
functional connectivity associated with diffuse axon
damage. Abnormal gyrification, cerebral connectivity
and cerebral thickness in premature children with periventricular leukomalacia.
In this line, we have found that functional MRI makes it
possible to detect language perception skills preserved
in some trauma patients in a chronic vegetative state
and patients with minimal response. Furthermore, we
have identified patterns of cerebral hypoactivation
during working-memory tasks, caused by diffuse axon
damage, as well as its partial reversibility with clinical
improvement and cognitive treatment.
In studies of prematurely-born adolescents, we have
identified regions of the white matter that partly explain
the alterations in the speed of mental processing. We
have also found that magnetic resonance spectroscopy
is a complementary technique to cerebral volumetry
for observing long-term sequelae of the hippocampus
linked to learning deficiencies. We have also shown that
the genu of the corpus callosum is fundamentally linked
to prefrontal abnormalities whereas the splenium reflects vocabulary-acquisition deficiencies.
Neuropsychology
region. We have also found that abnormal declarative
memory correlates to the loss of grey matter in the top
of the hippocampus. Functional magnetic resonance
imaging studies have shown a reduction in the activity
of the prefrontal cortex in patients with visual hallucinations during face-perception tasks, suggesting an alteration of the attention mechanisms in these patients.
The most significant finding in ageing and cognitive
deterioration in early-stage Alzheimer disease (AD) was
from a study with functional magnetic resonance imaging, showing that people with cognitive disorder, an advanced age and who are carriers of the e4 allele of the
E apolipoprotein, present increased functional connectivity of the hippocampus with other cortical and subcortical regions during a visual learning task. Because
this variant represents a risk factor for AD, these results
indicate that in preclinical stages of the disease, carriers of this allele over-activate neuronal networks in an
attempt to compensate for the degenerative processes.
In the area of cognitive deterioration and small-vessel
cerebrovascular disease, we were able to show from
an analysis of structural MRI that cases with more than
one lacunar stroke had more widespread damage to the
white matter in comparison with patients who had only
suffered one lacunar stroke.
143
21/10/09 16:02:34
8
9
Neuropsychology
10 11 12 Area 4 Clinical and Experimental Neurosciences
13 14 15 16 17 18 144
19 20 114-153 AREA4.indd 144
Ibarretxe-Bilbao N, Ramirez-Ruiz B, Tolosa E, Marti
MJ, Valldeoriola F, Bargallo N, Junque C. Hippocampal
head atrophy predominance in Parkinson’s disease
with hallucinations and with dementia. J NEUROL.
255:1324-1331. I.F.:2,48.
Frauscher B, Iranzo A, Hogi B, Casanova-Molla J, Salamero M, Gschliesser V, Tolosa E, Poewe W, Santamaria
Maestro L, Carreno M, Donaire A, Rumia J, Conesa
Castro-Fornieles J, Bargallo N, Lazaro L, Andres S,
Falcon C, Plana MT, Junque C. A cross-sectional and
follow-up voxel-based morphometric MRI study in adolescent anorexia nervosa. J PSYCHIATR RES. 43:331340. I.F.:3,71.
Segarra N, Bernardo M, Valdes M, Caldu X, Falcon
C, Rami L, Bargallo N, Parramon G, Junque C. Cerebellar deficits in schizophrenia are associated with
executive dysfuntion. NEUROREPORT. 19:1513-1517.
I.F.:2,16.
Lazaro L, Caldu X, Junque C, Bargallo N, Andres S, Morer A, Castro-Fornieles J. Cerebral activation in children
and adolescents with obsessive-compulsive disorder
before and after treatment: A functional MRI study. J
PSYCHIATR RES. 42:1051-1059. I.F.:3,71.
Andres S, Lazaro L, Salamero M, Boget T, Penades R,
Castro-Fornieles J. Changes in cognitive dysfunction
in children and adolescents with obsessive-compulsive
disorder after treatment. J PSYCHIATR RES. 42:507-514.
I.F.:3,71.
Rami L, Goti J, Ferrer J, Marcos T, Salamero M, Bernardo M. Cognitive functions after only one ECT session: A
controlled study. PSYCHIAT RES. 158:389-394. I.F.:2,30.
Rosa AR, Franco C, Martinez-Aran A, Sanchez-Moreno
J, Salamero M, Valenti M, Tabares-Seisdedos R, Gonzalez-Pinto A, Kapczinski F, Vieta E. Functional impairment and previous suicide attempts in bipolar disorder.
ACTA NEUROPSYCHIATR. 20:300-306. I.F.:1,21.
Reinares M, Colom F, Sanchez-Moreno J, Torrent C,
Martinez-Aran A, Comes M, Goikolea JM, Benabarre
A, Salamero M, Vieta E. Impact of caregiver group psychoeducation on the course and outcome of bipolar
patients in remission: a randomized controlled trial.
BIPOLAR DISORD. 10:511-519. I.F.:4,44.
Guarch J, Marcos T, Salamero M, Gasto C, Blesa R.
Mild cognitive impairment: a risk indicator of later
dementia, or a preclinical phase of the disease?. INT J
GERIATR PSYCH. 23:257-265. I.F.:2,20.
Martinez-Aran A, Torrent C, Tabares-Seisdedos R,
Salamero M, Daban C, Balanza-Martinez V, SanchezMoreno J, Goikolea JM, Benabarre A, Colom F, Vieta E.
Neurocognitive impairment in bipolar patients with and
without history of psychosis. J CLIN PSYCHIAT. 69:233239. I.F.:5,06.
Sanchez-Carrion R, Fernandez-Espejo D, Junque C,
Falcon C, Bargallo N, Roig T, Bernabeu M, Tormos JM,
21 22 23 24 25 26 Vendrell P. A longitudinal fMRI study of working memory in severe TBI patients with diffuse axonal injury.
NEUROIMAGE. 43:421-429. I.F.:5,46.
Fernandez-Espejo D, Junque C, Vendrell P, Bernabeu M,
Roig T, Bargallo N, Mercader JM. Cerebral response to
speech in vegetative and minimally conscious states
after traumatic brain injury. BRAIN INJURY. 22:882-890.
I.F.:1,25.
Fagundo AB, Lopez S, Romero M, Guarch J, Marcos
T, Salamero M. Clustering and switching in semantic
fluency: predictors of the development of Alzheimer’s
disease. INT J GERIATR PSYCH. 23:1007-1013.
I.F.:2,20.
Sanchez-Carrion R, Gomez PV, Junque C, FernandezEspejo D, Falcon C, Bargallo N, Roig-Rovira T, Ensenat-Cantallops A, Bernabeu M. Frontal hypoactivation
on functional magnetic resonance imaging in working
memory after severe diffuse traumatic brain injury. J
NEUROTRAUM. 25:479-494. I.F.:3,64.
Bargallo N. Functional magnetic resonance: New applications in epilepsy. EUR J RADIOL. 67:401-408. I.F.:1,92.
Grau-Olivares M, Arboix A, Bartres-Faz D, Junque C.
Higher severity of frontal periventricular white matter
and basal ganglia hyperintensities in first-ever lacunar
stroke with multiple silent lacunes. EUR J NEUROL.
15:1002-1005. I.F.:2,58.
Moncayo FLG, Requena GC, Perez FJ, Salamero M,
Sanchez N, Sirgo A. Psychological adjustment and
prevalence of psychiatric disorders in cancer patients.
MED CLIN-BARCELONA. 130:90-92. I.F.:1,34.
Bargallo N. Usefulness of ictal functional MRI in localization of epileptogenic area in patients with refractory focal
epilepsy. Grant: Fundació Marató TV3, 60910. Duration:
15/02/2007-14/02/2010.
Bargallo N. Papel de la resonancia magnética funcional
ictal en la localización del area epileptogena en pacientes
con epilepsia focal farmacoresistente. Grant: Ministerio
Salamero M. Desarrollo y validación en una nueva escala
de somnolencia de aplicación clínica. Grant: Ministerio
Junqué C. Bases cerebrales estructurales y funcionales de
los deficit neuropsicologicos asociados a la prematuridad.
Junqué C. Grup de Neuropsicologia. Grant: Comissionat
22/12/2005-22/12/2008.
Serra JM. Bases neuroanatómicas y neurofuncionales de
la discalculia del desarrollo. Grant: Ministerio Educación
y Ciencia, SEJ2005-08704/PSIC. Duration: 31/10/200530/10/2008.
21/10/09 16:02:37
Junqué C. Distinció de la Generalitat de Catalunya per a la
Promoció de la Recerca Universitària. Grant: Generalitat de
Catalunya, UNI/2001/2004. Duration: 31/12/2004-31/12/2010.
Bargallo N. Red española de investigación en patología
infecciosa (REIPI). Grant: Instituto de Salud Carlos III,
RD06/0008/1013. Duration: 29/02/2008-31/12/2010.
Bartres D. Patrones de activación y conectividad funcional
en resonancia magnética funcional en el deterioro cognitivo
leve de tipo amnésico. Relación con la evolución clínica y
otras variables pronóstico. Grant: Ministerio de Educación y
Junque C, Vendrell P. Alteración y recuperación
de la activación cerebral durante tareas de
memoria de trabajo en pacientes con traumatismo
craneoencefálico grave y difuso. Doctorand: Rocio
Sánchez-Carrón Abascal.
Junque C. Anomalías de la estructura y función del hipocampo en la esquizofrenia en relación a los déficits de
memoria declarativa. Doctorand: Giuseppina Rametti.
Bartres D, Arboix A. Neuropsychological and
structural b
rain correlates of lacunar infarcts.
Doctorand: Marta Grau Olivares.
Neuropsychology
Junqué C. Aplicación de la resonancia magnética estructural y funcional al estudio del estado vegetativo y el estado
de mínima conciencia en los traumatismos craneo encefálicos. Grant: Ministerio Educación y Ciencia, SAF 2007-66077.
Duration: 01/01/2008-31/12/2010.
Thesis
145
114-153 AREA4.indd 145
21/10/09 16:02:39
Systems Neuroscience
Team Members
Systems neuroscience
Team Leader:
■ Maria Victoria Sánchez Vives
(ICREA-IDIBAPS)
Tel.: 93 227 5400 (ext 4302)
IDIBAPS Members:
■ Albert Compte (IDIBAPS)
■ David Robbe (Ramón y Cajal IDIBAPS)
Collaborators:
Rita de Almeida (IDIBAPS)
Francesca Barbieri (IDIBAPS)
Jorge Brotons Mas (IDIBAPS)
Daniel Perez Marcos (IDIBAPS)
Ramón Reig (IDIBAPS)
Vanessa Fernandez Descalzo (IDIBAPS)
Xavier Palomer
Maria Cano Colino
Thomas Gener
Daniel Jercog
Diego López
Maria Pérez Zabalza
David Gómez Cabrero (MICINN)
Marcel Ruíz
Salvador de la Torre
Doctoral Students:
Juan Abolafia
Technicians:
Lorena Perez
•Effect of cannabinoids on high-voltage axes.
•Use of virtual reality in neurosciences in the context
The increasing amount of knowledge on synaptic
physiology and physiology of cerebral circuits, together with the development of new instruments for
recording, analyzing and modeling the activity of a
large number of neurons has provided access to one
of the major challenges pending in neuroscience: understanding the relationship between the activity of
the neuron population and behavioral performance.
The objective of the systems neuroscience group is to
approach this challenge by combining experimental
studies of networks of basal, hippocampal and cortical
ganglia with a theoretical focus.
of the EVENT lab (Virtual Environments in Neurosciences and Technology) in collaboration with Mel
Slater (University of Barcelona).
In summary, we have three major lines of action:
• Mechanisms of generation and control of electrical
146
activity in neuronal networks, specifically in the cerebral cortex.
• Hippocampal and subicular mechanisms of spatial
processing.
• Mechanisms of synchronization of neuron activity
in cortical networks.
• Mechanisms of distributed cortical networks implicated in selective attention, working memory and
executive control.
• Simple motor coding (head movement, pulling levers) by means of striatal groups.
• Mechanism of information transfer between networks.
114-153 AREA4.indd 146
1.Cortical networks and EVENT lab
(Virtual Environments in Neurosciences
and Technology). Led by Dr. Maria Victòria
Sánchez (IDIBAPS)
Neuronal activity and the cellular and synaptic properties that determine and give form to the activity of
the emerging population (spontaneous or invoked)
generated by neuronal networks. At the same time,
this activity has effects on the network, as it regulates
relevant mechanisms such as synaptic plasticity. We
are interested in different aspects of the activity generated: the mechanisms that regulate it, the information
coded and the consequences of the presence of this
activity for the network.
The impact of different cellular processes (for example,
activation of the ion channel) on the resulting activity
in the network tends to be nonintuitive and unpredictable, which requires using a theoretic and experimental approach.
With regard to the information coded by the activity
of the network, we have worked on different sensory
modes (visual, tactile, auditory) and are currently especially interested in the spacial processing that occurs in the hippocampal complex.
21/10/09 16:02:44
Finally, the integration of the cortical information that
gives rise to body representation and the combination
of brain-computer interfaces and virtual reality to understand these processes is another line of research
by our group as part of the EVENT lab (http://www.
event-lab.org).
http://www.sanchez-vives.org
http://complab.fcrb.es
PublicaTions
Original Articles
1
2
3
Winograd M, Destexhe A, Sanchez-Vives MV. Hyperpolarization-activated graded persistent activity in the prefrontal
cortex. P NATL ACAD SCI USA. 105:7298-7303. I.F.:9,60.
Sanchez-Vives MV, Descalzo VF, Reig R, Figueroa N,
Compte A. Rhythmic Spontaneous Activity in the Piriform Cortex. CEREB CORTEX. 18(5):1179-1192. I.F.:6,52.
Compte A, Reig R, Descalzo VF, Harvey MA, Puccini
GD, Sanchez-Vives MV. Spontaneous High-Frequency
(10-80 Hz) Oscillations during Up States in the Cerebral
Cortex In Vitro. J NEUROSCI. 28:13828-13844. I.F.:7,49.
Compte A. Mecanismos y función de la actividad oscilatoria
rápida en redes neuronales de la corteza cerebral. Grant:
Ministerio Educación y Ciencia, BFU2006-11999. Duration:
01/10/2006-30/09/2009.
Robbe D. Dynamic of Neuronal Network Interactions in the
basal Ganglia. Grant: European Comission, 230976. Duration: 01/09/2008-31/08/2012.
114-153 AREA4.indd 147
Surprisingly, the excellent description of the anatomical
characteristics of the basal ganglia (BG) has led to two
opposing models of the type of processing that takes
place in the BG. In the first model, the BG have been
modeled as independent information-processing channels, whereas in the second model, they are thought
to act as integrators of cortical input. To approach this
controversy, we use electrophysiologic recording techniques, (silica probes, tetrodes) during specific motor
tasks, in combination with advanced analytical tools
and drug perturbation (cannabinoids).
http://neuro.fcrb.es/BasalGangLab/RobbeLab/Welcome.html
I.F.: 23,61
Sanchez-Vives MV. Funcionalidad de la corteza cerebral
a través del análisis de la actividad rítmica espontánea
en distintas áreas corticales. Grant: Ministerio de Educación y Ciencia, BFU2007-31070-E. Duration: 02/09/200801/09/2009.
Sanchez-Vives MV. IP: Presence: Research Encompassing Sensory Enhancement, Neuroscience, CerebralComputer Interfaces and ApplicationsCentre coordinador:
Universitat Politecnica de Catalunya. Grant: Universitat
Politècnica de Catalunya-Docència, 27731. Duration:
01/01/2008-31/12/2010.
Sanchez-Vives MV. Synthetic Forager. Grant: Universitat
Pompeu Fabra, 217148. Duration: 15/01/2008-14/01/2011.
3. Physiology of networks of basal ganglia
and regulation by means of cannabinoids.
Led by Dr. David Robbe (IDIBAPS)
The principal objective of the laboratory is to understand
how cognitive and motor-sensitive (cortical) information
is processed in the basal ganglia, a group of subcortical
nuclei essential to motor coordination and habit forming, and implicated in Parkinson disease and addiction.
Systems neuroscience
2. Theoretical neurobiology of cortical
networks. Led by Dr. Albert Compte (IDIBAPS)
Our research is aimed at determining the mechanisms
that operate in the cortical microcircuit to carry out
computations relevant to behavior. The tools we use
are models of cortical networks run on computers,
which seek biologic plausibility, and technically sophisticated data-analysis tools. We work on two levels
in parallel: we model the activity observed in in vitro
preparations to understand and quantify the mechanisms in the neurons and in the microcircuit, and we
study the physiological bases of cognitive skills such
as working memory and selective attention.
147
Sanchez-Vives MV, Compte A. Estudi de tècniques
avançades de modelització i estimulació neuronalModalitat Projectes en Recerca Industrial i Desenvolupament
Experimental - Projectes Comuns. Grant: STARLAB
BARCELONA, S.L., RD08-2-0013. Duration: 15/07/200815/07/2010.
21/10/09 16:02:47
Neurobiology unit
Team Members
Neurobiology unit
Team Leader:
■ Ramon Trullàs (IIBB-CSIC)
Tel.: 93 363 83 03
Fax: 93 363 83 24
IDIBAPS Members:
■ Nicole Mahy (Facultat de Medicina)
Collaborators:
Marta Enguita (IIBB-CSIC)
Kevin Clayton (IIBB-CSIC)
Manuel Rodríguez (Facultat de Medicina)
Marco Pugliese (Facultat de Medicina)
M. Alba Abad (IIBB-CSIC)
Petar Podlesniy (IIBB-CSIC)
Joan Espinosa (Facultad de Medicina)
148
Doctoral Students:
Montse Batlle (Facultat de Medicina)
Lluís Benítez (IIBB-CSIC)
Javier Ortega (Facultat de Medicina)
Technicians:
Carmen Andrade (Facultat de Medicina)
Nuria Serra (IIBB-CSIC)
To investigate molecular mechanisms of excitotoxic
neuron death and apoptotic death with the aim of
identifying new therapeutic-intervention targets for
the treatment of neurodegenerative diseases. Another
objective is to understand the mechanisms that regulate neurogenesis in the adult brain in experimental
models and in human neurodegenerative diseases.
1. Investigation of the biochemical mechanisms that
produce excitotoxic neuron death. This project posits that inhibition of phospholipid synthesis is a
key mechanism in neuron death caused by overactivation of glutamatergic receptors.
2. Investigation of the function of neuronal pentraxin 1
during programmed neuronal death with the hypothesis that inhibiting the expression of this gene
may provide a new treatment for chronic neurodegenerative disorders.
3. Study of the mechanism by which the KATP channel modifies microglial activation and thereby characterize in vitro and in vivo the neuroprotector and
neurotoxic effect of microglia in situations of brain
damage by activation and blocking of this channel.
4. Investigation of the role of the glia in mechanisms
of neurogenesis associated with chronic neurodegeneration in the adult brain hippocampus.
114-153 AREA4.indd 148
Double immune staining of BrdU with GFAP and IB4 showing, respectively,
astrocytes and microglia that have proliferated as a result of the excitotoxic
lesion in the hippocampus of an adult rat. Bar: 10 micrometers.
5. Investigation of the efficacy and safety of anti-Abeta immune therapy as a treatment for Alzheimer
disease.
We have shown that excitotoxic hippocampal damage
induces the migration of neuroblasts from the subventricular region to the injured hippocampus, thereby
generating neurogenesis independent of that of the
hippocampus itself. Also, in certain conditions of excitotoxicity, we have shown that the microglia may
present neuroprotective activity and that this activity
can be controlled by means of the activity of the KATP
channels.
In studies carried out in primary cultures of cortical
neurons, we have also shown that the reduction of
the expression of neuronal pentraxin 1 by interference
with its RNA causes a very marked increase in the
number of excitor synapses. Furthermore, in studies
21/10/09 16:02:54
carried out in models of Alzheimer disease, we have
confirmed that neuronal pentraxin 1 causes loss of
synapses, damage to neurites and apoptotic neurotox-
icity. These results indicate that reducing the quantity
of neuronal pentraxin 1 may impede the reduction in
synaptic contacts that occurs in Alzheimer disease.
I.F.: 4,22
PublicaTions
Original Articles
1
Mahy N. Grup de neuroquímica FM. Grant: Comissionat
19/10/2005-31/12/2008.
Trullas R. Influencia de la pentraxina neuronal 1 y de su
regulación por la quinasa GSK3 sobre la degeneración
neurítica y la muerte neuronal apoptótica en modelos de
Alzheimer. Grant: Ministerio Educación y Ciencia, SAF200501167. Duration: 31/12/2005-31/12/2008.
Neurobiology unit
Gozzelino R, Sole C, Llecha N, Segura MF, Moubarak
RS, Iglesias-Guimarais V, Perez-Garcia MJ, Reix S,
Zhang J, Badiola N, Sanchis D, Rodriguez-Alvarez J,
Trullas R, Yuste VJ, Comella JX. BCL-X-L regulates
TNF-alpha-mediated cell death independently of NF-kappa B, FLIP and IAPs. CELL RES. 18:1020-1036. I.F.:4,22.
Mahy N. Dinámica de las células progenitoras del SNC relacionada con el proceso neurodegenerativo hipocampal
en la rata adulta. Correlación con la neurodegenración hipocampal humana. Grant: Ministerio Educación y Ciencia,
SAF2005-04314. Duration: 01/10/2005-01/10/2008.
Mahy N. Validación del efecto neuroprotector de la glibenclamida en la isquemia cerebral. Grant: Ministerio de
Educación y Ciencia Y CIENCIA, PET2007-0450. Duration:
12/09/2008-11/09/2010.
Thesis
Mahy N. Validación del efecto neuroprotector de la glibenclamida en la isquemia cerebral. Grant: Neurotec Pharma
S.L., 07/247. Duration: 05/07/2007-25/06/2008.
Trullas R. La pentraxina neuronal 1 i la toxicitat sinàptica
en la malaltia d’Alzheimer. Doctorand: Maria Alba Abad
Fernández.
Trullas R. Enfermedades neurodegenerativas. Grant: Ministerio Sanidad y Consumo, CB06/05/0050. Duration:
28/07/2006-27/07/2010.
149
114-153 AREA4.indd 149
21/10/09 16:02:57
Cerebral Ischemia: Clinical and Experimental Studies
Team Members
Cerebral ischemia: clinical and
experimental studies
Team Leader:
■ Anna M. Planas (IIBB-CSIC)
Tel.: 93 363 83 27
150
IDIBAPS Members:
■ Luisa Camon (IIBB-CSIC)
■ Nuria de Vera (IIBB-CSIC)
■ Ángel Chamorro (Hospital Clínic)
■ Carles Justicia (Beatriu de Pinós, IDIBAPS)
■ Emili Martínez (IIBB-CSIC)
■ Valérie Petegnief (IIBB-CSIC)
■ Esther Pozas (Ramón y Cajal, IDIBAPS)
■ Tomàs Santalucia (IDIBAPS)
Collaborators:
Víctor Obach (Hospital Clínic)
Marta Vargas (Hospital Clínic)
Roser Gorina (IDIBAPS)
Fernando Pérez Asensio (Juan de la Cierva, CSIC)
Ester Verdaguer (Juan de la Cierva, IDIBAPS)
Álvaro Cervera (FIS, Hospital Clínic)
Guadalupe Soria (contracte I3P, CSIC)
Leonardo J. Márquez (IIBB-CSIC)
Luca Maggioni (IDIBAPS)
Study of cerebrovascular disease from the clinical and
basic research perspective, with special emphasis on inflammation and the immune response and on the application of neuroimaging techniques. The end objective is
to develop therapeutic strategies for treating stroke.
Doctoral Students:
Sergi Amaro (FIS)
Miriam Font Nieves de la Vega (MEC)
Manuel Gómez-Choco (Fundació Clínic)
Anna Serra (IDIBAPS)
Xabier Urra (FIS)
Álvaro Cervera (Hospital Clínic)
Isabel Pérez de Puig (IDIBAPS)
Rebeca Medina (IIBB-CSIC)
Technicians:
Noelia Montoya (IDIBAPS)
Francisca Ruiz (IDIBAPS)
in experimental animals, anatomic and functional
parameters of the brain lesion, including the immune response.
5.Signals implicated in neuronal death and survival in ischemia: Role of endoplasmic reticulum stress and molecular regulation of hypoxia-inducible factor (HIF-1a).
6.Neuron repair and neurogenesis in cerebral ischemia: Effect of inflammation on neurogenesis.
1. Immunologic mechanisms implicated in the course
of ischemic stroke and in the appearance of infectious complications. Study of inflammatory responses and innate immunity to stroke. Genetic aspects
of the immune response.
2. Identification of new antioxidant treatments in
stroke. Preclinical studies of the protective effects of
these treatments and of the mechanisms involved.
Design and execution of a phase IIb study of the administration of uric acid in stroke treated with rtPA.
3.Use of intra-arterial rescue treatments with rt-PA in
patients previously treated with intravenous rt-PA
and selected using multimodal imaging techniques.
4. Neuroimaging in cerebral ischemia: Application of
imaging techniques using magnetic resonance (MR)
for noninvasive in vivo monitoring in patients and,
114-153 AREA4.indd 150
Study of a rat brain using MRI. A) Map of fractional anisotropy ultrasound
providing information on the magnitude of anisotropy in the fibers of the white
matter and showing the brain anatomy of the control rat in coronal slices in
three different levels of the brain. B) Color maps of the same sections of brain,
providing information on the 3-dimensional orientation of the white-matter
fibers, using diffusion tensor imaging (DTI). C) Coronal slices of the fractional
anisotropy map of an animal 7 days after occlusion of the middle cerebral artery
for 90 minutes. D) Color map in the same sections of the ischemic brain.
21/10/09 16:03:02
I.F.: 39,47
PublicaTions
Original Articles
1
Petegnief V. Muerte celular programada en la isquemia cerebral: implicación del estres del retículo endoplásmico.
23/12/2005-30/12/2008.
2
4
5
7
8
9
Reviews
1 Hacke W, Chamorro A, Cervera A, Obach V. Guidelines for management of ischaemic stroke and transient ischaemic attack 2008 - The European Stroke
Organisation (ESO) Executive Committee and the
ESO Writing Committee. CEREBROVASC DIS . 25:457507. I.F.:2,53.
2 Endres M, Engelhardt B, Koistinaho J, Lindvall O,
Meairs S, Mohr JP, Planas A, Rothwell N, Schwaninger
M, Schwab ME, Vivien D, Wieloch T, Dirnagl U. Improving outcome after stroke: Overcoming the translational
roadblock. CEREBROVASC DIS. 25:268-278. I.F.:2,53.
114-153 AREA4.indd 151
Santalucía T. La muerte neuronal retardada en la isquemia cerebral: mecanismos moleculares y celulares. Grant: M
inisterio
Educación y Ciencia, SAF2005-05793-CO2-02. Duration:
30/10/2005-30/10/2008.
Planas A. Neuroreparació i neurogènesis desprès de l’ictus.
Grant: Generalitat de Catalunya, CIDEM. Duration: 01/04/200731/12/2009.
Planas A. Diagnostic for Molecular Imaging. European Network
of Excellence. Grant: European Community. Sixth Framework
Programme (Life Sciences, genomics and biotechnology for
health), LSHB-CT-2005-512146. Duration: 01/04/2005-30/03/2010.
Planas A. La muerte neuronal retardada en la isquemia cerebral: mecanismos moleculares y celulares. Grant: Ministerio Educación y Ciencia, SAF2005-05793-CO2-01. Duration:
01/10/2006-31/12/2008.
Planas A. Grup de Qualitat de la CIRIT: Equip d’isquèmia cerebral del IDIBAPS. Grant: Generalitat de Catalunya (Agaur-Grup
Consolidat). Duration: 01/01/2006-31/12/2009.
Chamorro A. Estudios clínicos y experimentales de la respuesta inmune en el infarto cerebral isquémico. Grant: Ministerio
Sanidad y Consumo (FIS). Duration: 01/01/2007-31/12/2009.
Planas A. Affording recovery in Stroke (ARISE). Grant: European Community. Seventh Framework Programme (Life Sciences). Duration: 01/04/2008-01/03/2013.
6
Planas A. La muerte neuronal retardada en la isquemia cerebral focal transitoria: implicación de la respuesta de estres y de
la muerte programada. Perspectivas de tratamiento. Grant: Ministerio Educación y Ciencia, SAF2005-05793-CO2-01. Duration:
10/10/2005-30/10/2008.
Cerebral ischemia: clinical and
experimental studies
3
DeVera N, Martinez E, Sanfeliu C. Spermine induces cell
death in cultured human embryonic cerebral cortical
neurons through N-methyl-D-aspartate receptor activation. J NEUROSCI RES. 86:861-872. I.F.:3,27.
Weber R, Ramos-Cabrer P, Justicia C, Wiedermann D,
Strecker C, Sprenger C, Hoehn M. Early prediction of
functional recovery after experimental stroke: Functional
magnetic resonance imaging, electrophysiology, and
behavioral testing in rats. J NEUROSCI. 28:1022-1029.
I.F.:7,49.
Martinez-Revelles S, Jimenez-Altayo F, Caracuel L,
Perez-Asensio FJ, Planas AM, Vila E. Endothelial dysfunction in rat mesenteric resistance artery after transient middle cerebral artery occlusion. J PHARMACOL
EXP THER. 325:363-369. I.F.:4,00.
Serra-Perez A, Verdaguer E, Planas AM, Santalucia T.
Glucose promotes caspase-dependent delayed cell
death after a transient episode of oxygen and glucose
deprivation in SH-SY5Y cells. J NEUROCHEM. 106:12371247. I.F.:4,45.
Carolei A, Chamorro A, Laloux P, Leys D, Rother J,
Sander D, Stansby G, Weimar C. Identification and
management of polyvascular disease in patients with
noncardioembolic ischaemic stroke. INT J STROKE.
3:237-248. I.F.:1,92.
Justicia C, Ramos-Cabrer P, Hoehn M. MRI detection of
secondary damage after stroke - Chronic iron accumulation in the thalamus of the rat brain. STROKE. 39:15411547. I.F.:6,30.
Petegnief V, Font-Nieves M, Martin ME, Salinas M,
Planas AM. Nitric oxide mediates NMDA-induced persistent inhibition of protein synthesis through dephosphorylation of eukaryotic initiation factor 4E-binding
protein 1 and eukaryotic initiation factor 4G proteolysis.
BIOCHEM J. 411:667-677. I.F.:4,01.
Soria G, Wiedermann D, Justicia C, Ramos-Cabrer P,
Hoehn M. Reproducible imaging of rat corticothalamic
pathway by longitudinal manganese-enhanced MRI (LMEMRI). NEUROIMAGE. 41:668-674. I.F.:5,46.
Gomez-Choco M, Obach V, Urra X, Amaro S, Cervera
A, Vargas M, Chamorro A. The response to IV rt-PA in
very old stroke patients. EUR J NEUROL. 15:253-256.
I.F.:2,58.
Pozas E. Neurogenesis endógena e inflamación en la isquemia
cerebral en modelos experimentales murinos y en pacientes
con ictus. Grant: Ministerio de Sanidad y Consumo (FIS),
PI070917. Duration: 01/01/2008-31/12/2010.
Thesis
151
Planas A. La via JAK/STAT como a mediadora de respostes a
l’estrès oxidatiu, la inflamació i la inmunitat innata en astròcits.
Premi extraordinari. Doctorand: Roser Gorina Méndiz (Universitat de Barcelona)
Planas A. Les tècniques d’imatge en l’estudi de la isquèmia
cerebral experimental. Doctorand: Santi Rojas Codina. Universitat de Barcelona.
21/10/09 16:03:04
Molecular neurobiology (IDIBAPS virtual team at the UB faculty of biology)
Team Members
Molecular neurobiology (IDIBAPS
virtual team at the UB faculty of biology)
Team Leader:
■ Dr. Rafael Franco Fernández
(Facultat de Biologia, UB)
Tel.: 93 402 12 08
152
Collaborators:
Enric I. Canela (Facultat de Biologia, UB)
Antoni Cortés (Facultat de Biologia, UB)
M. Carme Lluís (Facultat de Biologia, UB)
Josepa Mallol (Facultat de Biologia, UB)
Vicent Casadó (Facultat de Biologia, UB)
Francisco Ciruela (Facultat de Biologia, UB)
Doctoral Students:
Daniel Marcelino (Facultat de Biologia, UB)
Paulina Carriba (Facultat de Biologia, UB)
Laia Canela (Facultat de Biologia, UB)
José María Martínez (Facultat de Biologia, UB)
Carla Ferrada (Facultat de Biologia, UB)
Aroa Soriano (Facultat de Biologia, UB)
Gemma Navarro (Facultat de Biologia, UB)
Jorge Gandía (Facultat de Biologia, UB)
We promote multidisciplinary basic research involving
biochemistry, molecular and cellular biology and immunology. One of the global objectives is the study of
the molecular mechanisms implicated in communication between neurons and between neurons and glia,
in pathologic and nonpathologic conditions of the CNS.
The other objective is to discover the existence and function of neuromodulator and neurotransmitter receptors
in the cardiac system and in the immune synapse.
These research activities are carried out in close collaboration with different international working groups.
Following are some of the more solid collaborations of
the team: In the US, the groups of Dr. Sergi Ferré and
Amina Woods of the National Institutes of Drug Abuse
(NIDA/NIH, EUA) and Dr. Dave Roberts, of North Carolina University, with whom we study the heteromerization of neurotransmitter and neuromodulator receptors and the role of heteromers in neurologic diseases
and drug addiction. We have also recently established
a collaboration with the Curing Huntingdon Disease
Initiatives (CHDI) Foundation. In Europe, we have a
very active collaboration with Dr Bob Leurs of the Vrije University of Belgium, with whom we collaborate
on the study of histamine receptors as modulators of
dopaminergic and adenosinergic transmission, and
with the groups of Dr. Kjell Fuxe of the Karolinska Institute in Stockholm and Dr. Luigi Agnati of the University of Modena, with whom we study the consequences
114-153 AREA4.indd 152
Jordi Bonaventura (Facultat de Biologia, UB)
Eduard Gracia (Facultat de Biologia, UB)
Estefanía Moreno (Facultat de Biologia, UB)
Laia Barceló (Facultat de Biologia, UB)
Technicians:
Jasmina Jiménez Cano (Facultat de Biologia, UB)
of heteromerization of receptors in neurodegenerative
diseases, in plasticity and memory.
In Spain, we collaborate with many groups, both inside
and outside of IDIBAPS, on the study of receptors implicated in the CNS, on the study of adenosine receptors
in the cardiovascular system, and on the study of new
mechanisms that play a role in the immune synapse.
1.Physiologic functions of the heteromers of the neuron membrane
2.Identification of new heteromers in the central nervous system.
3.Research on receptor heteromers as therapeutic
targets in Parkinson, schizophrenia, Alzheimer and
drug addiction.
4.Identification of new receptor-protein interactions
of special relevance in neuron function.
5. Synthesis and evaluation of new drug molecules that
interact with heteromers of membrane receptors.
6.Genomic techniques for studying neurologic and
neuropsychiatric diseases.
7.Molecular bases of neuronal plasticity. Learning
and memory.
8. Neuroimmunology. Identification and characterization of neurotransmissor receptors in lymphocytes.
9.Identification of new receptor-protein interactions
in the cardiovascular system.
21/10/09 16:03:08
I.F.: 35,90
PublicaTions
Original Articles
1
Franco R. Receptors estriatals d’histamina H3 en el control
de l’activitat motora i com a diana de la malaltia de Parkinson. Grant: Fundació La Marató de TV3, 060110. Duration:
01/01/2007-01/01/2009.
2
3
5
6
7
Reviews
1
Franco R, Casado V, Cortes A, Perez-Capote K, Mallol
J, Canela E, Ferre S, Lluis C. Novel pharmacological
targets based on receptor heteromers. BRAIN RES REV.
58:475-482. I.F.:6,48.
114-153 AREA4.indd 153
Franco R. Interrelaciones moleculares y funcionales entre
receptores CB1, D2, y A2A en el estriado. Grant: Ministerio
Franco R. Grup de Recerca Consolidat. Neurobiologia Molecular. Grant: Comissionat per a Universitats i Recerca,
2005SGR00711. Duration: 30/11/2005-31/12/2009.
Franco R. Heteromerización de los receptores acoplados
a proteína G, excitotoxicidad neuronal y enfermedades
neurodegenerativas. Grant: Ministerio Educación y Ciencia,
SAF2005-00903. Duration: 31/10/2005-31/12/2008.
Franco R. Receptores Estriatales de Histamina H3 en el
control de la actividad motora y como diana terapeútica
en la enfermedad de Parkinson. Grant: Ministerio Educación y Ciencia, SAF2006-05481. Duration: 01/01/200631/12/2009.
Franco R. Enfermedades Neurodegenerativas. CIBERNED. Area 2: Fisiopatología de los circuitos neuronales y
formas clínicas de la enfermedad de Parkinson. Implicaciones diagnósticas y terapéuticas. Grant: Ministerio de
Sanidad y Consumo, CIBERNED. Duration: 01/01/200731/12/2009.
Franco R. Evaluación de la adenosina desaminasa como
molécula coestimuladora de la actividad linfocitaria en
una vacuna terapéutica del VIH. Grant: Fundación para la
investigación y la prevención del SIDA en España (FIPSE),
36750/08. Duration: 01/01/2008-31/12/2010.
4
Gandia J, Galino J, Amaral OB, Soriano A, Lluis C,
Franco R, Ciruela F. Detection of higher-order G proteincoupled receptor oligomers by a combined BRET-BiFC
technique. FEBS LETT. 582:2979-2984. I.F.:3,26.
Marcellino D, Carriba P, Filip M, Borgkvist A, Frankowska
M, Bellido I, Tanganelli S, Muller CE, Fisone G, Lluis C, Agnati LF, Franco R, Fuxe K. Antagonistic cannabinoid CB1/
dopamine D-2 receptor interactions in striatal CB1/D-2
heteromers. A combined neurochemical and behavioral
analysis. NEUROPHARMACOLOGY. 54:815-823. I.F.:3,22.
Carriba P, Navarro G, Ciruela F, Ferre S, Casado V, Agnati L, Cortes A, Mallol J, Fuxe K, Canela EI, Lluis C,
Franco R. Detection of heteromerization of more than
two proteins by sequential BRET-FRET. NAT METHODS.
5:727-733. I.F.:15,48.
Navarro G, Carriba P, Gandia J, Ciruela F, Casado V,
Cortes A, Mallol J, Canela EI, Lluis C, Franco R. Detection of Heteromers Formed by Cannabinoid CB1, Dopamine D-2, and Adenosine A(2A) G-Protein-Coupled
Receptors by Combining Bimolecular Fluorescence
Complementation and Bioluminescence Energy Transfer. THESCIENTIFICWORLDJO. 8:1088-1097. I.F.:0,88.
Gracia E, Cortes A, Meana JJ, Garcia-Sevilla J, Herhsfield MS, Canela EI, Mallol J, Lluis C, Franco R, Casado
V. Human adenosine deaminase as an allosteric modulator of human A(1) adenosine receptor: abolishment
of negative cooperativity for [H-3](R)-pia binding to the
caudate nucleus. J NEUROCHEM. 107:161-170. I.F.:4,45.
Ferrada C, Ferre S, Casado V, Cortes A, Justinova Z, Barnes C, Canela EI, Goldberg SR, Leurs R, Lluis C, Franco
R. Interactions between histamine H-3 and dopamine
D-2 receptors and the implications for striatal function.
NEUROPHARMACOLOGY. 55:190-197. I.F.:3,22.
Gandia J, Lluis C, Ferre S, Franco R, Ciruela F. Light
resonance energy transfer-based methods in the study
of G protein-coupled receptor oligomerization. BIOESSAYS. 30:82-89. I.F.:5,40.
Molecular neurobiology (IDIBAPS
virtual team at the UB faculty of biology)
Heteromerization of A2A adenosine and CB1 cannabinoid
receptors in living cells. The HEK293 cells are cotransfected
with the human A2A receptor fused to renilla luciferase
(A2A-Rluc) and/or with human CB1 receptor fused to yellow
fluorescent protein (CB1-YFP). A. Confocal microscopy
image of cells overexpressing A2A-Rluc (left panel), identified
using a mouse anti-A2A antibody and a secondary antibody
conjugated to cyanine-3, and cells overexpressing CB1-YFP
(right panel), detected due to their own fluorescence. B.
Saturation curve of BRET in cells that co-express constant
and physiologic quantities of A2A-Rluc and increasing
quantities in the physiologic interval of CB1-YFP (squares) or
of the negative control CD4-YFP (circles) or a mixture of cells
transfected only with A2A-Rluc or CB1-YFP (triangles). C.
Diagram showing the bases of the BRET technique, showing
that the emission energy on adding the R-luc substrate
can only be transmitted to the protein fused to YPF if the 2
proteins are interacting at molecular level.
153
Franco R. Generation of Stable Cell lines containing adenosine A2A receptors in heterodimer conformations. Screening for A2A/ A1 heterodimer-selective antagonists and
Implications for the treatment of Huntington Disease. Grant:
Curing Huntington Disease Iniciative Fundation (CHDI). Duration: 01/01/2008-31/12/2009.
21/10/09 16:03:11
154-193 AREA5.indd 154
21/10/09 15:43:49
Area 5
Oncology and Hematology
Biologic Markers in Oncology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 156
Human and Experimental Functional Oncomorphology . . . . . . . . . . . . . . . . . . . . . . . . 158
Diagnosis and Therapy in Oncology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 163
Molecular Genetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 166
Genetics . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 168
Melanoma: Imaging, Genetics and Immunology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 171
Transplant of Hemopoietic Precursors . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 174
Hemato-Oncology . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 177
Pathophysiology and Molecular Bases in Hematology . . . . . . . . . . . . . . . . . . . . . . . . . . 182
Hemotherapy-Hemostasis . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 185
Image: 3d concept of bloodcell
154-193 AREA5.indd 155
21/10/09 15:43:50
Biologic Markers in Oncology
Team Members
Area 5 Oncology and Hematology
Biologic markers in oncology
Team Leader:
■ Antonio M. Ballesta
(Hospital Clínic - Faculty of Medicine)
Tel.: 93 227 55 18
156
IDIBAPS Members:
■ Xavier Filella (Hospital Clínic)
■ Rafael Molina (Hospital Clínic - Faculty of Medicine)
Collaborators:
C. Aparicio (Hospital Clínic)
F. Coca (Hospital Clínic)
Amàlia Lafuente (Faculty of Medicine)
M. Portas (Hospital Clínic)
S. Román (Hospital Clínic)
M. Sasot (Hospital Clínic)
The task of this group lies mainly in the area of applied clinical research and is carried out in collaboration with different clinical groups within and outside
Hospital Clínic, Barcelona.
1. Circulating tumor markers. Fine tuning of new techniques for studying biologic markers that are the
peripheral expression of malignant tumors. Study of the utility of proPSA in diagnosing prostate
cancer. Evaluation of new tumor markers such as
the following: Mesomark, of use in mesothelioma;
Mammoglobulin for breast cancer and Thymidine
kinase for lung tumors. Comparison of the clinical
application of isoforms of the antigen associated
with non-small cell carcinoma and evaluation of
isoforms of S-100 and their implication in the study
of malignant melanoma.
2. Consolidation of diagnostic guides on tumor markers for clinical use Collaboration with European
and American groups to agree and publish clinical
guidelines. Diffusion of these guidelines at national
level, via the Commission of Cancer Biologic Markers, created by members of the group, within the
Scientific Committee of the Spanish Society of Biochemistry and Molecular Disease.
3. Incorporation of a quantitative technique for detecting circulating cells of epithelial tumors (CEC) and
improvement of the methods for obtaining them,
154-193 AREA5.indd 156
Doctoral Students:
S. Mas (Post-doctoral, Fundació Bosch i Gimpera))
A. Crescenti (Pre-doctoral, Generalitat de Catalunya)
P. Gasso (Pre-doctoral, Generalitat de Catalunya)
Technicians:
M. Sánchez (Fundació Bosch i Gimpera)
separating them and quantifying them by means
of mNMRI of cytokine 19. Evaluation of the clinical
interest of this methodology in breast and prostate
cancer. Study of oncogenes and suppressor genes
by means of PCP-SSCP (ras and p53) techniques
and methylation studies in p16 and p14.
4. Chemosensitivity of human tumors. Investigation
of biologic factors linked to chemosensitivity. In this
area, we are working on enzyme factors associated
with the metabolism of glutathione (GST), oncogenes in tissue and serum and different circulating tumor markers with polymorphism in TS or XRCC1.
We incorporate the CEC technique in the study of the
response to systemic treatments (hormone therapy
and chemotherapy) in advanced breast tumors.
5.Apoptosis. We are consolidating the line of research centered on the study of genes linked to the
mechanisms of apoptosis (p53, BAX and BCL-2). In
this section, we have initiated a new line of experimental in vitro work, testing possible indicators of
apoptosis in the HT-29 cell line.
6.Investigation of implementation of cytokines in the
development and progression of cancer. We have
consolidated our research on the clinical utility of
cytokines in patients with cancer. The line is developed with a preference for hematologic and urologic
cancers.
7. Markers used in pharmacogenetics. Study of genetic
polymorphism implicated in drug metabolism and
targets. This line focuses particularly on predicting
the safety and efficacy of antineoplastic drugs. In the
past year, we have prepared high-performance genotyping techniques such as minisequencing-SBE.
21/10/09 15:43:55
I.F.: 24,70
PublicaTions
Original Articles
1
2
4
5
8
9
Molina R. STREP - Multiparametric Quantum Dot Bioassay
for Point of Care Diagnosis. Grant: European Commision,
LSHB-CT-2007-037933. Duration: 01/01/2007-31/12/2009.
Oncology and Hematology Area 5
6
7
Biologic markers in oncology
3
Marti J, Cervera C, Filella X, Marin JL, Almela M, Gatell JM, Moreno A. Inflammatory response in elderly
patients with bacteremia. ENFERM INFEC MICR CL.
26:146-149. I.F.:1,10.
Menendez R, Cavalcanti M, Reyes S, Mensa J, Martinez R, Marcos MA, Filella X, Niederman M, Torres A.
Markers of treatment failure in hospitalised community
acquired pneumonia. THORAX. 63:447-452. I.F.:6,23.
Domingo-Domenech J, Fernandez PL, Filella X, Martinez-Fernandez A, Molina R, Fernandez E, Alcaraz A,
Codony J, Gascon P, Mellado B. Serum HER2 extracellular domain predicts an aggressive clinical outcome
and biological PSA response in hormone-independent
prostate cancer patients treated with docetaxel. ANN
ONCOL. 19:269-275. I.F.:4,88.
CEA, SCC and NSE. TUMOR BIOL . 29:371-380. I.F.:2,48.
Holdenrieder S, Molina R, Gion M, Gressner A, Troalen
F, Auge JM, Zancan M, Wycislo M, Stieber P. Alternative antibody for the detection of CA125 antigen: a
European multicenter study for the evaluation of the
analytical and clinical performance of the Access (R)
OV Monitor assay on the UniCel (R) Dxl 800 Immunoassay System. CLIN CHEM LAB MED. 46:588-599. I.F.:1,74.
Molina R, Gion M, Gressner A, Troalen F, Auge JM,
Holdenrieder S, Zancan M, Wycislo M, Stieber P. Alternative antibody for the detection of CA15-3 antigen: a
European multicenter study for the evaluation of the
analytical and clinical performance of the Access (R) BR
Monitor assay on the UniCel (R) Dxl 800 Immunoassay
System. CLIN CHEM LAB MED. 46:612-622. I.F.:1,74.
Stieber P, Molina R, Gion M, Gressner A, Troalen F, Holdenrieder S, Auge JM, Zancan M, Wycislo M, Jarrige
V. Alternative antibody for the detection of CA19-9 antigen: a European multicenter study for the evaluation
of the analytical and clinical performance of the Access
(R) GI Monitor assay on the UniCel (R) Dxl 800 Immunoassay System. CLIN CHEM LAB MED. 46:600-611.
I.F.:1,74.
Casals G, Filella X, Auge JM, Bedini JL. Impact of Ultrasensitive Cardiac Troponin I Dynamic Changes in the
New Universal Definition of Myocardial Infarction. AM
J CLIN PATHOL. 130:964-968. I.F.:2,63.
157
154-193 AREA5.indd 157
21/10/09 15:44:02
Human and Experimental Functional Oncomorphology
Team Members
Human and experimental
functional oncomorphology
Team Leader:
■ Elías Campo Güerri (Hospital Clínic)
Tel.: 93 227 54 50
Fax: 93 227 57 17
IDIBAPS Members:
■ Llúcia Alós (Hospital Clínic)
■ Virginia Amador (IDIBAPS)
■ Silvia M. Beà (Fundació Clínic)
■ Josep Antoni Bombí (Hospital Clínic)
■ Antoni Cardesa (Hospital Clínic)
■ Pedro Luis Fernández (Hospital Clínic)
■ Lluis Hernández Pous (Fundació Clínic)
■ Pedro Jares (IDIBAPS)
■ Carme Mallofré (Hospital Clínic)
■ Antonio Martínez Pozo (Hospital Clínic)
■ Alfons Nadal (Hospital Clinic)
■ Antonio Palacín (Hospital Clínic)
■ Antonio Postigo (ICREA - IDIBAPS)
■ José Francisco Ramírez (Hospital Clínic)
■ Teresa María Ribalta (Hospital Clínic)
■ Manel Solé (Hospital Clínic)
Collaborators:
Rosa Miquel Morera (Hospital Clínic)
Ester Sánchez Tilló (IDIBAPS)
Doctoral Students:
Olga Balaguer Ponz (IDIBAPS)
Julia Calvo Castillo (Fundació Clínic)
Laura Conde del Campo (Fundació Clínic)
Ana Enjuanes Guardiola (IDIBAPS)
Verònica Fernández Pascual (Fundació Clínic)
Alba Navarro López (MCyT)
Anna Petit Montserrat (Hospital Clinic)
Itziar Salaverria Frigola (Universitat de Barcelona)
Cristina Royo Moreno (MCyT)
Raquel Bermudo Gascón (IDIBAPS)
Technicians:
Laura Gelabert Blesa (Fundació Clínic)
Iracema Nayach Monte (Fundació Clínic)
Laura Pla Rodríguez (Fundació Clínic)
Miriam Prieto Beato (Fundació Clínic)
Montse Sánchez Reina (Fundació Clínic)
1. Identification of genetic and molecular mechanisms
implicated in the development and progression of
human cancers.
2. Development of strategies to transfer to clinical practice the knowledge generated by the basic research
on human tumors. Identification of parameters that
allow a better diagnosis and prognosis of cancer and
the identification of possible therapeutic targets.
158
1.Lymphoid tumors
a)Study of the abnormal molecular mechanisms
linked to the cell cycle, genome instability and
profiles of transcriptional expression implicated
in the development and progression of these tumors, and biomarkers with clinical relevance.
b)Functional study of the molecular factors that may
contribute to tumor pathogenesis and that, therefore, may be candidates for developing new therapeutic targets.
154-193 AREA5.indd 158
Image of M-FISH of a metaphase representing of a MINO cell line derived
from a mantle cell lymphoma. The image shows a triploid karyotype
altered with the cryptic translocation t(11;14)(q13;q32) (yellow arrow) and
2 Y chromosomes (green arrow) (from the article Genes Chromosomes
and Cancer 47(12):1086-1097, 2008).
2.Solid tumors
a)Study of the molecular mechanisms of invasion
and metastasis, profiles of transcriptional expression implicated in the development and progres-
21/10/09 15:44:05
sion of different human tumors in relation to the
development, biologic aggressiveness (adhesion
molecules) and therapeutic options. Principally
prostate and breast tumors as tumors with hor-
monal influence, and neoplasias of the airways,
including tumors of the head and neck.
b)Study of the possible criteria of therapeutic response and prognosis of neurologic tumors.
Associated Group
Molecular pathology of solid tumors
■ Fernandez, Pedro Luis (CDB)
The group dedicated to the study of the progression of solid tumors has focused on different types of tumor,
including urologic, breast, nerve-line and head and neck tumors. In urologic tumors, we have finished a microarray analysis of transcriptome profiles of prostate cancer, obtaining a signature for 7 highly discriminating
genes for the disease. This has been validated using PT-PCR and immunohistochemistry and has also been patented. Also in
urology, we have used FISH to study the diagnostic utility of genome abnormalities in urine samples of seminal vesicle carcinoma, the expression of mTOR, PDGF A and B in kidney tumors and, finally, c-kit mutations in these latter tumors. In terms of neural tumors, we have carried out a study in glial tumors on the correlations of the phenotype and the therapeutic response with
loss of alleles in chromosomes 1p and 19q, analyzed by microsatellite PCR and FISH. In head and neck tumors, we have studied
the role of the mutating phenotype in laryngeal cancer in young patients.
Emerging Group
Transcriptional regulation of gene expression
■ Postigo, Antonio (IDIBAPS)
I.F.: 299,08
PublicaTions
Original Articles
1
2
3
RHEUM/AR C RES. 59:422-430. I.F.:7,68.
Grau JJ, Caballero M, Monzo M, Munoz-Garcia C, DomingoDomenech J, Navarro A, Conill C, Campayo M, Bombi JA.
Dihydropyrimidine dehydrogenases and cytidine-deaminase gene polymorphisms as outcome predictors in resected
gastric cancer patients treated with fluoropyrimidine adjuvant chemotherapy. J SURG ONCOL. 98:130-134. I.F.:2,38.
Diagnostic efficacy of bone scintigraphy, magnetic
resonance imaging, and positron emission tomography
RESON IMAGING. 27:625-628. I.F.:2,21.
154-193 AREA5.indd 159
4
5
6
7
8
Aleu AC, Popescu D, Pomes J, Palacin A. Long-standing pain in a 25-year-old patient with a non-diagnosed
cervical osteoblastoma: a case report. ARCH ORTHOP
TRAUM SU. 128:567-571. I.F.:0,91.
Rigol M, Solanes N, Sionis A, Galvez C, Martorell J,
Rojo I, Brunet M, Ramirez J, Roque M, Roig E, PerezVilla F, Barquin L, Pomar JL, Sanz G, Heras M. Effects
of cyclosporine, tacrolimus and sirolimus on vascular
changes relate to immune response. J HEART LUNG
TRANSPL. 27:416-422. I.F.:3,09.
Rigol M, Solanes N, Roque M, Farre J, Batle M, Roura
Cells: An Experimental Study. TRANSPL P . 40:36193622. I.F.:1,03.
Arrizabalaga P, Sole M, Abellana R, Ascaso C. Renal
expression of adhesion molecules in Anca-associated
disease. J CLIN IMMUNOL. 28:411-419. I.F.:2,89.
The group investigates transcriptional mechanisms of gene expression during cell differentiation and cancer. In these studies,
we use two members of the ZEB family, ZEB1/deltaEF1 and ZEB2/SIP1, as a molecular model; these play a role in regulating genes implicated in different cellular signalling pathways and pathophysiologic processes. The projects currently in progress aim
to clarify the role of these proteins in cell differentiation in different tissues. The group currently has one postdoctoral member
(Dr. Ester Sánchez Tilló).
159
21/10/09 15:44:07
9
10 11 12 Area 5 Oncology and Hematology
13 14 15 16 17 160
18 154-193 AREA5.indd 160
ONCOL. 19:269-275. I.F.:4,88.
Almendros I, Carreras A, Ramirez J, Montserrat JM, Navajas D, Farre R. Upper airway collapse and reopening
induce inflammation in a sleep apnoea model. EUR
RESPIR J. 32:399-404. I.F.:5,35.
CEA, SCC and NSE. TUMOR BIOL . 29:371-380. I.F.:2,48.
P, Ramirez J, Torres A, Augusti C, Martínez-Olondris P.
Transbronchial needle aspiration in the study of mediastinal lymph nodes: Yield and cost-effectiveness.
Peinado VI, Paris R, Ramirez J, Roca J, RodriguezRoisin R, Barbera JA. Expression of BKCa channels in
human pulmonary arteries: Relationship with remodeling and hypoxic pulmonary vasoconstriction. VASC
PHARMACOL . 49:178-184. I.F.:2,37.
Iglesias M, Jungebluth P, Petit C, Matute MP, Rovira I,
Martinez E, Catalan M, Ramirez J, Macchiarini P. Extracorporeal lung membrane provides better lung protection
than conventional treatment for severe postpneumonectomy noncardiogenic acute respiratory distress syndrome. J THORAC CARDIOV SUR. 135:1362-U300. I.F.:3,35.
Civico S, Agell N, Hernandez L, Campo E, Bachs O, Balasch J. Increased messenger ribonucleic acid expression of the cyclin-dependent kinase inhibitor p27(Kip1)
in cleavage-stage human embryos exhibiting developmental arrest. FERTIL STERIL. 89:1557-1562. I.F.:3,17.
Casals G, Ordi J, Creus M, Fabregues F, Casamitjana
R, Quinto L, Campo E, Balasch J. Osteopontin and
alpha(v)beta(3) integrin expression in the endometrium
of infertile and fertile women. REPROD BIOMED ONLINE. 16:808-816. I.F.:2,84.
Forner A, Vilana R, Ayuso C, Bianchi L, Sole M, Ayuso
Chiang DY, Villanueva A, Hoshida Y, Peix J, Newell P,
Minguez B, Leblanc AC, Donovan DJ, Thung SN, Sole
M, Tovar V, Alsinet C, Ramos AH, Barretina J, Roayaie
S, Schwartz M, Waxman S, Bruix J, Mazzaferro V, Ligon
AH, Najfeld V, Friedman SL, Sellers WR, Meyerson M,
Llovet JM. Focal gains of VEGFA and molecular classification of hepatocellular carcinoma. CANCER RES.
68:6779-6788. I.F.:7,67.
Villanueva A, Chiang DY, Newell P, Peix J, Thung S,
Alsinet C, Tovar V, Roayaie S, Minguez B, Sole M, Battiston C, VanLaarhoven S, Fiel MI, DiFeo A, Hoshida Y,
Yea S, Toffanin S, Ramos A, Martignetti JA, Mazzaferro
V, Bruix J, Waxman S, Schwartz M, Meyerson M, Friedman SL, Llovet JM. Pivotal Role of mTOR Signaling
in Hepatocellular Carcinoma. GASTROENTEROLOGY.
135:1972-1983. I.F.:11,67.
19 Vidal O, Soriano-Izquierdo A, Pera M, Elizalde JI, Palacin A, Castells A, Pique JM, Volant A, Metges JP. Positive VEGF immunostaining independently predicts poor
prognosis in curatively resected gastric cancer patients:
Results of a study assessing a panel of angiogenic markers. J GASTROINTEST SURG. 12:1005-1014. I.F.:2,27.
20 Sendino O, Pellise M, Ghita G, Sole M, Rimola J, Gines
A. Aspergillus mediastinitis diagnosed by EUS-guided
FNA. GASTROINTEST ENDOSC. 67:153-153. I.F.:5,89.
21 Fernandez-Real JM, Lopez-Bermejo A, Ropero AB,
Piquer S, Nadal A, Bassols J, Casamitjana R, Gomis R,
Arnaiz E, Perez I, Ricart W. Salicylates increase insulin
secretion in healthy obese subjects. J CLIN ENDOCR
METAB. 93:2523-2530. I.F.:5,49.
22 Ferrer A, Bosch F, Villamor N, Rozman M, Graus F,
19:135-141. I.F.:4,88.
23 Graus F, Saiz A, Lai M, Bruna J, Lopez F, Sabater L,
Blanco Y, Rey MJ, Ribalta T, Dalmau J. Neuronal surface antigen antibodies in limbic encephalitis - Clinicalimmunologic associations. NEUROLOGY. 71:930-936.
I.F.:6,01.
24 Castella M, Garcia-Valentin A, Pereda D, Colli A, Martinez A, Martinez D, Ramirez J, Mulet J. Anatomic
aspects of the atrioventricular junction influencing
radiofrequency Cox maze IV procedures. J THORAC
CARDIOV SUR. 136:419-423. I.F.:3,35.
25 Perez-Galan P, Roue G, Lopez-Guerra M, Nguyen M,
Villamor N, Montserrat E, Shore GC, Campo E, Colomer D. BCL-2 phosphorylation modulates sensitivity
to the BH3 mimetic GX15-070 (Obatoclax) and reduces
its synergistic interaction with bortezomib in chronic
lymphocytic leukemia cells. LEUKEMIA. 22:1712-1720.
I.F.:6,92.
26 Roue G, Lopez-Guerra M, Milpied P, Perez-Galan P,
Villamor N, Montserrat E, Campo E, Colomer D. Bendamustine Is Effective in p53-Deficient B-Cell Neoplasms
and Requires Oxidative Stress and Caspase-Independent Signaling. CLIN CANCER RES . 14:6907-6915.
I.F.:6,25.
27 Morente MM, Fernandez PL, DeAtava E. Biobanking:
old activity or young discipline?. SEMIN DIAGN PATHOL. 25:317-322. I.F.:1,67.
28 Zidar N, Gale N, Kojc N, Volavsek M, Cardesa A, Alos L,
Hofler H, Blechschmidt K, Becker KF. Cadherin-catenin
complex and transcription factor Snail-1 in spindle cell
carcinoma of the head and neck. VIRCHOWS ARCH.
453:267-274. I.F.:2,03.
29 Salaverria I, Zettl A, Bea S, Hartmann EM, Dave SS,
Wright GW, Boerma EJ, Kluin PM, Ott G, Chan WC,
Weisenburger DD, Lopez-Guillermo A, Gascoyne RD,
Delabie J, Rimsza LM, Braziel RM, Jaffe ES, Staudt LM,
Mueller-Hermelink HK, Campo E, Rosenwald A. Chromosomal alterations detected by comparative genomic
hybridization in subgroups of gene expression-defined
Burkitt’s lymphoma. HAEMATOL-HEMATOL J. 93:13271334. I.F.:5,52.
30 Bermudo R, Abia D, Ferrer B, Nayach I, Benguria A,
Zaballos A, DelRey J, Miro R, Campo E, Martinez-A C,
Ortiz AR, Fernandez PL, Thomson TM. Co-regulation
21/10/09 15:44:09
31 32 34 35 37 38 39 154-193 AREA5.indd 161
36 40 Baro C, Salido M, Espinet B, Astier L, Domingo A, Granada I, Milla F, Carrio A, Costa D, Luno E, Hernandez
JM, Campo E, Florensa L, Ferrer A, Salar A, Bellosillo B,
Besses C, Serrano S, Sole F. New chromosomal alterations in a series of 23 splenic marginal zone lymphoma
patients revealed by Spectral Karyotyping (SKY). LEUKEMIA RES. 32:727-736. I.F.:2,56.
41 Lenz G, Davis RE, Ngo VN, Lam L, George TC, Wright
GW, Dave SS, Zhao H, Xu WH, Rosenwald A, Ott G,
Muller-Hermelink HK, Gascoyne RD, Connors JM,
Rimsza LM, Campo E, Jaffe ES, Delabie J, Smeland EB,
Fisher RI, Chan WC, Staudt LM. Oncogenic CARD11
mutations in human diffuse large B cell lymphoma.
SCIENCE. 319:1676-1679. I.F.:26,37.
42 Garcia-Herrera A, Colomo L, Camos M, Carreras J,
Balague O, Martinez A, Lopez-Guillermo A, Estrach T,
Campo E. Primary cutaneous small/medium CD4(+)
T-cell lymphomas: A heterogeneous group of tumors
with different clinicopathologic features and outcome.
J CLIN ONCOL. 26:3364-3371. I.F.:15,48.
43 Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H,
Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M,
Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle
A, May L, Gascoyne RD, Connors JM, Troen G, Holte
H, Kvaloy S, Dierickx D, Verhoef G, Delabie J, Smeland
EB, Jares P, Martinez A, Lopez-Guillermo A, Montserrat
E, Campo E, Braziel RM, Miller TP, Rimsza LM, Cook
JR, Pohlman B, Sweetenham J, Tubbs RR, Fisher RI,
Hartmann E, Rosenwald A, Ott G, Muller-Hermelink
HK, Wrench D, Lister TA, Jaffe ES, Wilson WH, Chan
WC, Staudt LM. Stromal Gene Signatures in Large-BCell Lymphomas. NEW ENGL J MED . 359:2313-2323.
I.F.:52,59.
44 O’shea D, O’riain C, Taylor C, Waters R, Carlotti E, Macdougall F, Gribben J, Rosenwald A, Ott G, Rimsza LM,
Smeland EB, Johnson N, Campo E, Greiner TC, Chan
WC, Gascoyne RD, Wright G, Staudt LM, Lister TA, Fitzgibbon J. The presence of TP53 mutation at diagnosis
of follicular lymphoma identifies a high-risk group of
patients with shortened time to disease progression
and poorer overall survival. BLOOD. 112:3126-3129.
I.F.:10,90.
33 analysis of closely linked genes identifies a highly recurrent gain on chromosome 17q25.3 in prostate cancer.
BMC CANCER . 8:-. I.F.:2,71.
Hartmann E, Fernandez V, Moreno V, Valls J, Hernandez
L, Bosch F, Abrisqueta P, Klapper W, Dreyling M, Hoster
E, Muller-Hermelink HK, Ott G, Rosenwald A, Campo E.
Five-Gene Model to Predict Survival in Mantle-Cell Lymphoma Using Frozen or Formalin-Fixed, Paraffin-Embedded Tissue. J CLIN ONCOL. 26:4966-4972. I.F.:15,48.
Fernandez V, Jares P, Salaverria I, Gine E, Bea S, Aymerich M, Colomer D, Villamor N, Bosch F, Montserrat
E, Campo E. Gene expression profile and genomic
changes in disease progression of early-stage chronic lymphocytic leukemia. HAEMATOL-HEMATOL J.
93:132-136. I.F.:5,52.
Enjuanes A, Benavente Y, Bosch F, Martin-Guerrero
I, Colomer D, Perez-Alvarez S, Reina O, Ardanaz MT,
Jares P, Garcia-Orad A, Pujana MA, Montserrat E, DeSanjose S, Campo E. Genetic Variants in Apoptosis and
Immunoregulation-Related Genes Are Associated with
Risk of Chronic Lymphocytic Leukemia. CANCER RES .
68:10178-10186. I.F.:7,67.
Salaverria I, Bea S, Lopez-Guillermo A, Lespinet V, Pinyol M, Burkhardt B, Lamant L, Zettl A, Horsman D, Gascoyne R, Ott G, Siebert R, Delsol G, Campo E. Genomic
profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell
lymphomas. BRIT J HAEMATOL. 140:516-526. I.F.:4,49.
Montoto S, Moreno C, Domingo-Domenech E, Estany
C, Oriol A, Altes A, Besalduch J, Pedro C, Gardelia S,
Escoda L, Asensio A, Vivancos P, Galan P, DeSevilla AF,
Ribera JM, Briones J, Colomer D, Campo E, Montserrat E, Lopez-Guillermo A. High clinical and molecular
response rates with fludarabine, cyclophosphamide
and mitoxantrone in previously untreated patients
with advanced stage follicular lymphoma. HAEMATOLHEMATOL J. 93:207-214. I.F.:5,52.
Ruano Y, Mollejo M, Camacho FI, DeLope AR, Fiano C,
Ribalta T, Martinez P, Hernandez-Moneo JL, Melendez B.
Identification of survival-related genes of the phosphatidylinositol 3 ‘-kinase signaling pathway in glioblastoma
multiforme. CANCER . 112:1575-1584. I.F.:4,63.
Schraders M, Jares P, Bea S, Schoenmakers EFPM,
VanKrieken JHJM, Campo E, Groenen PJTA. Integrated
genomic and expression profiling in mantle cell lymphoma: identification of gene-dosage regulated candidate genes. BRIT J HAEMATOL. 143:210-221. I.F.:4,49.
Lenz G, Wright GW, Emre NCT, Kohlhammer H, Dave
SS, Davis RE, Carty S, Lam LT, Shaffer AL, Xiao WM,
Powell J, Rosenwald A, Ott G, Muller-Hermelink HK,
Gascoyne RD, Connors JM, Campo E, Jaffe ES, Delabie
J, Smeland EB, Rimsza LM, Fisher RI, Weisenburger DD,
Chan WC, Staudt LM. Molecular subtypes of diffuse large B-cell lymphoma arise by distinct genetic pathways.
P NATL ACAD SCI USA. 105:13520-13525. I.F.:9,60.
Salaverria I, Espinet B, Carrio A, Costa D, Astier L,
Slotta-Huspenina J, Quintanilla-Martinez L, Fend F, Sole
F, Colomer D, Serrano S, Miro R, Bea S, Campo E. Multiple Recurrent Chromosomal Breakpoints in Mantle
Cell Lymphoma Revealed by a Combination of Molecular Cytogenetic Techniques. GENE CHROMOSOME
CANC. 47:1086-1097. I.F.:4,53.
Reviews
1
2
Jares P, Campo E. Advances in the understanding of
mantle cell lymphoma. BRIT J HAEMATOL. 142:149165. I.F.:4,49.
VanKrieken JHJM, Jung A, Kirchner T, Carneiro F,
Seruca R, Bosman FT, Quirke P, Flejou JF, Hansen TP,
DeHertogh G, Jares P, Langner C, Hoefler G, Ligtenberg
M, Tiniakos D, Tejpar S, Bevilacqua G, Ensari A. KRAS
mutation testing for predicting response to anti-EGFR
therapy for colorectal carcinoma: proposal for an European quality assurance program. VIRCHOWS ARCH.
453:417-431. I.F.:2,03.
161
Editorials
1
Trullas JC, Sanchez M, Sole M, Mirapeix E. Wife of 50
years with infiltrates. MED CLIN-BARCELONA. 131:699709. I.F.:1,34.
21/10/09 15:44:12
2
Bea S, Campo E. Secondary genomic alterations in
non-Hodgkin’s lymphomas: tumor-specific profiles with
impact on clinical behavior. HAEMATOL-HEMATOL J.
93:641-645. I.F.:5,52.
Postigo A. Transcriptional Regulation of Gene Expression
during Cell Differentiation and Oncogenic Transformation.
Grant: European Commision, MIRG-CT-2006-040985. Duration: 01/10/2006-30/09/2008.
Campo E. Molecular mechanisms associated with clinical
progression and drug resistance in MCL. Grant: Lymphoma
Research Foundation, 2005 LRF MCL. Duration: 15/08/200514/08/2008.
Campo E. Molecular Signatures to Improve Diagonosis
and Outcome Prediction in NHL. Grant: National Institutes
of Health - EU, 5U01CA114778-03. Duration: 31/07/2007-31/05/2008.
Campo E. CA - Archive’s Tissues: Improving Molecular
Medicine Research and Clinical Practice. Grant: European
Commision, LSHG-CT-2007-037211. Duration: 01/03/2007-28/02/2009.
Jares P. Identification of Tumor Supressor Genes, Epigenetic Portrait, and Genotyping of Mantle Cell Lymphomas.
Grant: Lymphoma Research Foundation, 07/168. Duration:
01/05/2007-30/04/2010.
Fernandez PL. New molecules for diagnosis and therapy in
prostate and breast cancers. Modulation of tumor growth
by the chemokine CX3CL1 (fractalkine). Grant: Fundació Marató TV3, 53131. Duration: 15/12/2005-14/12/2008.
Campo E. Oncomorfologia funcional humana i experimental. Grant: Comissionat per a Universitats i Recerca,
2005SGR00870. Duration: 19/10/2005-31/12/2008.
Postigo A. Regulación de la Cadherina e y de la capacidad
invasiva/metastica de tumores epieliales por la familia ZEB
de represores transcripcionales. Grant: Ministerio Educación y Ciencia, BFU2007-60302/BMC. Duration: 01/10/200704/10/2010.
Postigo A. Regulación transcripcional de la expresión génica durante la diferenciación celular y la transformación
oncogénica. Grant: Fundació La Caixa, BM06-057. Duration:
13/11/2006-12/11/2009.
162
Cardesa A. Mecanismos moleculares de inactivación del enzima metiltioadenosina fosforilasa (MTAP) en el carcinoma
escamoso de laringe. Grant: Fundacion Mutua Madrileña,
FundMM_501016. Duration: 04/10/2005-03/10/2008.
Hernandez L. Análisis por microarrays de los genes dianas
de los microrna alterados en su dosis génica en linfomas de
células del manto. Grant: Ministerio Sanidad y Consumo,
PI050224. Duration: 01/01/2006-30/12/2008.
Cardesa A. Análisis de la firma metastática en el carcinoma
escamoso de la laringe. Grant: Ministerio Sanidad y Consumo, PI060189. Duration: 18/10/2006-30/12/2009.
Campo E. Red temática de investigación cooperativa de cáncer. Grant: Ministerio Sanidad y Consumo,
RD06/0020/0039. Duration: 01/01/2007-31/12/2010.
Fernandez PL. Análisis de perfiles transcripcionales y alteraciones genómicas estructurales en la progresión de
carcinomas de próstata y explantes tumorales. Evaluación
de potenciales marcadores con aplicabilidad. Grant: Ministerio Educación y Ciencia, SAF2005-05109-C02-02. Duration:
31/12/2005-31/12/2008.
Campo E. Alteraciones genómicas en el desarrollo y progresión de neoplasias linfoides. Identificación de posibles genes implicados y evaluación de su relevancia clínica. Grant:
31/12/2005-31/12/2008.
Campo E. Ayuda complementaria al proyecto europeo:
European Mantle Cell Lymphoma Network: Translational
determination of molecular prognostic factors and pharmacogenomics in a European interdisciplinary collaboration.
Grant: Ministerio Educación y Ciencia, SAF2006-28392-E.
Duration: 02/02/2007-01/02/2008.
Campo E. Linfoma difuso de células grandes: búsqueda
de nuevos marcadores pronósticos en la era rituximabchop. Grant: Asociación Española Contra el Cáncer (AECC),
AECC_07_011. Duration: 16/02/2008-15/08/2009.
Thesis
Mallofre C. Expressió de KIT i PDGFR en tumors de cèl•lules
renals: discussió del seu paper com a possibles dianes terapèutiques. Doctorand: A. Petit.
Campo E. Diferenciación plasmocelular en linfomas agresivos: Señalización, factores de transcripción y alteraciones
citogenéticas. Doctorand: O. Balagué Ponz.
Campo E. Caracterización Citogenética y molecular de los
linfomas No-Hodgkin Humanos (Estudio de la inestabilidad
genómica en linfoma de células del manto. Doctorand: I.
Salaverria.
Campo E. Análisis de los mecanismos moleculares implicados en el desarrollo y progresión de los linfomas de célula
B pequeña. Doctorand: V. Fernández.
Fernandez PL. Análisis integrado de perfiles transcriptómicos y protéicos en la progresión de las neoplasias de
la próstata. Aplicaciones en el diagnóstico. Grant: Ministerio Educación y Ciencia, PET2005_0660_01. Duration:
19/12/2006-18/12/2008.
154-193 AREA5.indd 162
21/10/09 15:44:14
Diagnosis and Therapy in Oncology
Team members
Team Leader:
■ Francesca Pons (Hospital Clínic)
Tel.: 93 227 54 82
Fax: 93 451 81 37
Collaborators:
Sebastián Capurro (Hospital Clínic)
Francesc Casas (Hospital Clínic)
Carmen De Juan (Hospital Clínic)
Lluís Donoso Bach (Hospital Clínic)
Blanca Farrús (Hospital Clínic)
Mario Pagés (Hospital Clínic)
Teresa Pujol (Hospital Clínic)
Sonia Rodríguez (Hospital Clínic)
Angels Rovirosa (Hospital Clínic)
Marcelo Sánchez (Hospital Clínic)
Gorane Santamaría (Hospital Clínic)
Eugènia Verger (Hospital Clínic)
Àfrica Muxí (Hospital Clínic)
Pilar Paredes (Hospital Clínic)
Francisco Lomeña (Hospital Clínic)
Javier Pavía (Hospital Clínic)
Diagnosis and therapy in oncology
IDIBAPS Members:
■ Albert Biete (Hospital Clínic)
■ Carles Conill (Hospital Clínic)
■ David Fuster (Hospital Clínic)
■ Marià Monzó (University of Barcelona)
■ Xavier Setoain (Hospital Clínic)
■ Martín Velasco (Hospital Clínic)
■ Sergi Vidal-Sicart (Hospital Clínic)
1. To develop techniques to improve diagnosis and
evaluation of outcome and response to therapy in
cancer patients.
2. To develop and apply new therapies in oncology.
1. Molecular studies of embryo and tumor
cells: applications in pharmacogenetics
We carry out two types of study: one analyzes and
compares patterns of microRNAs in embryo tissues
and the other, using allele discrimination, analyzes the
polymorphic profiles (SNPs) in cancer patients with
the aim of selecting more specific treatments.
2. Effects of synchrotron radiation
on cancer cells
In this study, which is carried out in conjunction with
the UAB, we compare the biologic action of synchrotron radiation (currently, the Grenoble synchrotron
until the Alba unit is started at the UAB) with conventional x-rays used in radiotherapy. We also study effectiveness by sensitizing the cell with nanoparticles
of gold and cisplatin.
154-193 AREA5.indd 163
Axial slices of 2 PET-CT studies in a patient with locally advanced breast
cancer, obtained before (top images) and after (bottom images) receiving
treatment with neoadjuvant chemotherapy.
3.Irradiation of ganglial metastasis
of melanoma
We study the role of postoperative irradiation of ganglial metastases of melanoma in locoregional control
of the disease.
163
4.Diagnostic imaging of breast cancer
We carry out two types of study. One type uses 10G
thick-needle aspiration biopsies to improve presurgical diagnosis of breast lesions, especially in those that
21/10/09 15:44:18
present microcalcifications; the aim is to reduce the
number of surgical biopsies for diagnosis to a minimum. The other study evaluates the response to neoadjuvant chemotherapy in breast cancer by means of
breast MRI.
5. Gammagraphy detection
of the sentinel ganglion
Lymphogammagraphy and subsequent use of an external detection probe during surgery to locate and remove the sentinel ganglion. This technique is relevant
164
in 75% of unnecessary lymphadenectomies. The use
of a portable gamma camera during surgery provides
additional advantages.
6.Application of positron-emission
tomography (PET-CT) in oncology
We carry out PET studies for staging and monitoring
the response to treatment in different types of tumor,
including lymphomas, breast cancer and digestive
tract tumors. We aim to use an intraoperative PET
probe to improve detection of tumors.
I.F.: 86,77
PublicaTions
Original Articles
8
1
RHEUM/AR C RES. 59:422-430. I.F.:7,68.
2 Grau JJ, Caballero M, Monzo M, Munoz-Garcia C,
ONCOL. 98:130-134. I.F.:2,38.
3 Conill C, Setoain X, Colomo L, Palacin A, CombaliaAleu A, Pomes J, Marruecos J, Vargas M, Maurel J.
RESON IMAGING. 27:625-628. I.F.:2,21.
BLOOD. 112:4337-4342. I.F.:10,90.
5 Muxi A, Paredes P, Mont L, Setoain FJ, Duch J, Fuertes S, Ortin J, Diaz-Infante E, Pons F. Left ventricular
function and visual phase analysis with equilibrium
radionuclide angiography in patients with biventricular device. EUR J NUCL MED MOL I. 35:912-921.
I.F.:4,10.
6 Bergua C, Torregrosa JV, Fuster D, Gutierrez-Dalmau A,
Oppenheimer F, Campistol JM. Effect of Cinacalcet on
hypercalcemia and bone mineral density in renal transplanted patients with secondary hyperparathyroidism.
7 Paredes P, Vidal-Sicart S, Zanon G, Roe N, Rubi S,
Lafuente S, Pavia J, Pons F. Radioguided occult lesion
localisation in breast cancer using an intraoperative
portable gamma camera: first results. EUR J NUCL
MED MOL I. 35:230-235. I.F.:4,10.
154-193 AREA5.indd 164
9
10 11 12 13 14 15 Arenas M, Gil F, Gironella M, Hernandez V, Biete A,
Pique JM, Panes J. Time course of anti-inflammatory
effect of low-dose radiotherapy: Correlation with TGFbeta(1) expression. RADIOTHER ONCOL. 86:399-406.
I.F.:4,07.
Maestro L, Carreno M, Donaire A, Rumia J, Conesa
Colomer R, Monzo M, Tusquets I, Rifa J, Baena JM,
Barnadas A, Calvo L, Carabantes F, Crespo C, Munoz M,
Llombart A, Plazaola A, Artells R, Gilabert M, Lloveras
B, Alba E. A single-nucleotide polymorphism in the
aromatase gene is associated with the efficacy of the
aromatase inhibitor letrozole in advanced breast carcinoma. CLIN CANCER RES. 14:811-816. I.F.:6,25.
Giralt J, Regadera JP, Verges R, Romero J, DeLaFuente
I, Biete A, Villoria J, Cobo JM, Guarner F. Effects of
probiotic Lactobacillus casei DN-114 001 in prevention
of radiation-induced diarrhea: Results from multicenter,
randomized, placebo-controlled nutritional trial. INT J
RADIAT ONCOL. 71:1213-1219. I.F.:4,29.
Ramirez N, Bandres E, Navarro A, Pons A, Jansa S, Moreno I, Martinez-Rodenas F, Zarate R, Bitarte N, Monzo
M, Garcia-Foncillas J. Epigenetic events in normal colonic mucosa surrounding colorectal cancer lesions. EUR
J CANCER . 44:2689-2695. I.F.:4,45.
Navarro A, Gaya A, Martinez A, Urbano-Ispizua A, Pons
A, Balague O, Gel B, Abrisqueta P, Lopez-Guillermo A,
Artells R, Montserrat E, Monzo M. MicroRNA expression profiling in classic Hodgkin lymphoma. BLOOD.
111:2825-2832. I.F.:10,90.
Monzo M, Navarro A, Bandres E, Artells R, Moreno I,
Gel B, Ibeas R, Moreno J, Martinez F, Diaz T, Martinez
A, Balague O, Garcia-Foncillas J. Overlapping expression of microRNAs in human embryonic colon and
colorectal cancer. CELL RES. 18:823-833. I.F.:4,22.
Fuster D, Duch J, Paredes P, Velasco M, Munoz M,
Santamaria G, Fontanillas M, Pons F. Preoperative
staging of large primary breast cancer with [F-18]
fluorodeoxyglucose positron emission tomography/
computed tomography compared with conventional
imaging procedures. J CLIN ONCOL. 26:4746-4751.
I.F.:15,48.
21/10/09 15:44:20
Setoain FJ. Development and validation of an automatic
dose injection system for ictal spect in epiilepsy. Grant: Fundació Marató TV3, 60610. Duration: 06/02/2007-05/02/2010.
Setoain FJ, Carreño M, Donaire A. Validación de un sistema de inyección automática de una dosis radiactiva para
realizar el SPECT ictal de epilepsia. Grant: Ministerio Sanidad y Consumo, PI060077. Duration: 18/10/2006-30/12/2009.
Fuster D. Utilidad de la tomografía por Emisión de Positrones con Tomografía Computerizada Integrada (PET/TC) en la
estadificación inicial y en la monitorización de la respuesta
a la quimioradioterapia neoadyuvante del adenocarcinoma
gástrico. Grant: Ministerio Sanidad y Consumo, PI070270.
Duration: 26/11/2007-30/12/2010.
Thesis
Monzo M. Análisis comparativo de la expresión de miRNAs
en el desarrollo embrionario del colon, el cáncer colorectal
y el linfoma de Hodgkin. Doctorand: Alfons Naverro Ponz.
Monzo M. Estudi del gen Sonic Hedgehog (Shh) i del gens
de la familia CEACAM durant l’embriogènesis del còlon
humà i la seva implicació en el desenvolupament del cáncer
colorectal. Doctorand: Rosa Artells Prats.
Biete A. Efectos antiinflamatorios de la radioterapia a dosis
bajas en un modelo de enfermedad crónica intestinal.
Doctorand: Meritxell Arenas Prats.
Pons F. Valoración de la PET-TC (Tomografía de Emisión de
Positrones-Tomografía Computarizada) de baja dosis sin
utilización de contraste radiológico como única exploración
de imagen para la estadificación y re-estadificación de los
linfomas. Grant: Ministerio Sanidad y Consumo, PI070277.
Duration: 26/11/2007-30/12/2010.
Santamaria G. Resonancia magnética dinámica del carcinoma in situ de mama: utilidad en la planificación del tratamiento quirúrgico y relación de la captación neoplásica con
la microvascularización tumoral y la expresión del factor
de permeabilidad vascular. Grant: Sociedad Española de
Radiología Médica S, SERAM_08_001. Duration: 01/04/200831/10/2010.
Monzó M. Detección y cuantificación de marcadores Stem
mediante análisis de Micro-RNA (MIRNA) en pacientes con
cáncer de pulmón y en tejido embrionario pulmonar humano. Grant: Ministerio Sanidad y Consumo, PI060087. Duration: 18/10/2006-30/12/2009.
Pons F. Red temática de investigación cooperativa de cáncer. Grant: Ministerio Sanidad y Consumo, RD06/0020/0038.
Duration: 01/01/2007-31/12/2010.
165
154-193 AREA5.indd 165
21/10/09 15:44:23
Molecular Genetics
Team Members
Molecular genetics
Team Leader:
■ Cristóbal Mezquita
(UB-Faculty of Medicine)
Tel.: 93 402 45 18
Fax: 93 403 52 79
IDIBAPS Members:
■ Jovita Mezquita (UB-Faculty of Medicine)
■ Rafael Oliva (Hospital Clínic and UB-Faculty
of Medicine)
■ Josep Oriola (Hospital Clínic and UB-Faculty
of Medicine)
Collaborators:
Betlem Mezquita (UB-Faculty of Medicine)
José Manuel Vidal (UB-Faculty of Medicine)
Juan Martínez (Fundació Clínic)
Josep Lluís Ballescà (Hospital Clínic)
Rubén Azpiazu (Fundació Clinic)
Judit Castillo (Fundació Clinic)
Technicians:
Montserrat Pau (UB-Faculty of Medicine)
Doctoral Students:
Sara de Mateo (Fundació Clínic)
Meritxell Jodar (Fundació Clinic)
The research group is made up of the Gene Expression and Cancer laboratory (www.physiolgenet.com)
and the Human Genetics laboratory (www.ub.edu/humangen). Our research works within the current physiologic paradigm: the study of mechanisms of gene expression as a new approach to the study of the body’s
functions. At present, our work is aimed at proteomic
and molecular characterization of spermatozoa from
infertile patients and controls, and the study of the
mechanisms involved in angiogenesis and in the invasive mechanisms of tumor cells.
The group has traditionally worked on mechanisms of
gene expression and differentiation of the spermatogenic
germinal line and, more recently, on the mechanisms involved in angiogenesis and the invasion of tumor cells.
166
In 2008, we identified several proteins present in increased or reduced levels in asthenozoospermic patients in comparison to controls (Martinez-Heredia et
al., 2008; Oliva et al., 2008). These results provide important clues that lead to the identification of the causes
of male infertility, currently unknown in most patients.
Worthy of mention is the contribution of our group in
launching the proteomic information portal Human
Proteinpedia (Mathivanan et al., 2008). Also relevant is
the fact that we have managed to identify a polymor-
154-193 AREA5.indd 166
Principal changes in the structure of chromatin during spermatogenesis
and in the initial phases of development. The spermatozoon has the
potential to transmit epigenetic information through the methylation
protein to the different genes, by means of the differential distribution of
genes to the regions associated with nucleohistone and nucleoprotamine,
and through the proteome transmitted to the oocyte (Oliva et al.,
Proteomics 2009; 9:1004-17).
21/10/09 15:44:31
phism in the promotor region of the protamine 1 gene
that behaves as a risk factor of abnormal morphology
in spermatozoa (Gázquez et al., 2008). In the coming
years, we aim to achieve detailed characterization of
the functions of new proteins identified in line with the
development of the current project (BFU2006-03479).
One of the important challenges is to determine the
basic mechanisms in the nucleic histone nucleic protamine transition during sperm creation and how
abnormalities in this transition can lead to abnormal
epigenetic information in the spermatozoon. Another
challenge will be the translation of important observations from basic research to clinical practice.
In relation to the mechanisms of tumor invasion, the
principal challenge will be to determine the mechanisms involved in regulating gene expression of the
new family of truncated intracellular forms of the molecule VEGFR-1, which we have characterized in our
laboratory.
Original Articles
1
Mezquita C. Effects of reversible proteasome inhibitors on
the mechanisms involved in inflammatory and remodelling
responses in asthma. Grant: Fundació Marató TV3, 40631.
Duration: 21/01/2005-20/01/2008.
2
Reviews
1
Oliva R, Martinez-Heredia J, Estanyol JM. Proteomics
in the study of the sperm cell composition, differentiation and function. SYST BIOL REPROD MED. 54:23-36.
I.F.:0,81.
Oliva R. Grup de Genètica Humana. Grant: Comissionat
19/10/2005-31/12/2008.
Oliva R. Proteómica del espermatozoide en pacientes
infértiles, en modelos knock-out y mecanismo de la transición nucleohistona nucleoprotamina. Grant: Ministerio
Educación y Ciencia, BFU2006-03479. Duration: 01/10/200630/09/2009.
Thesis
Oliva R. Caracterització proteòmica de l’espermatozoide
humà. Proteïnes diferencials trobades en pacients astenozoospèrmics. Doctorand: Juan Martínez Heredia. Facultat de
Medicina, Universitat de Barcelona.
Patents
Cristina Gazquez, Rafael Oliva, Josep Oriola. Method for the
diagnosis of male infertility.
3
Gazquez C, Oriola J, DeMateo S, Vidal-Taboada
JM, Ballesca JL, Oliva R. A common protamine 1
promoter polymorphism (-190 c -> A) correlates
with abnormal sperm morphology and increased
protamine P1/P2 ratio in infertile patients. J
ANDROL. 29:540-548. I.F.:2,33.
Queralt R, Madrigal I, Vallecillos MA, Morales C,
Ballesca JL, Oliva R, Soler A, Sanchez A, Margarit
E. Atypical XX male with the SRY gene located
at the long arm of chromosome 1 and a 1qter
microdeletion. AM J MED GENET A. 146A:13351340. I.F.:2,44.
Martinez-Heredia J, DeMateo S, Vidal-Taboada JM,
Ballesca JL, Oliva R. Identification of proteomic
differences in asthenozoospermic sperm samples.
HUM REPROD. 23:783-791. I.F.:3,54.
Molecular genetics
I.F.: 8,31
PublicaTions
167
154-193 AREA5.indd 167
21/10/09 15:44:33
Genetics
Team Members
Genetics
Team Leader:
■ Montserrat Milà (Hospital Clínic)
Tel.: 93 2275400 ext.2784
Fax: 932275697
IDIBAPS Members:
■ Anna Carrió (Hospital Clínic)
■ Carmen Herrero (Hospital Clínic)
■ Mario Lecha (Hospital Clínic)
■ Ester Margarit (Hospital Clínic)
■ Aurora Sánchez (Hospital Clínic)
■ Anna Soler (Hospital Clínic)
■ Jordi To-Figueras (Hospital Clínic)
Collaborators:
Cèlia Badenas (Hospital Clínic)
Jordi Bruguera (Fundació Clínic)
Research in this area is aimed at characterizing genetic diseases in their clinical, cytogenetic and molecular aspects.
Each line has the strategic objectives set out by the
research projects that support it, hence the MR study
and identification of cryptic chromosome imbalance
is currently based on the application of high-performance array technology. The FXTAS study is aimed at
identifying a biologic marker that allows us to carry
out presymptomatic diagnosis of FXTAS in patients
carrying the permutation in the FMR1 gene. In porphyria, the strategic objective is to gain better knowledge
of the genotype-phenotype correlation: biochemical
and clinical expression.
Irene Mademont
Irene Madrigal (CIBERER)
Carmen Morales (Hospital Clínic)
Laia Rodriguez Revenga (CIBERER)
Mar Xunclà (Fundació Clínic)
cription of affected patients, men and women) and
molecular aspects (DNA, RNA, miRNA and FMRP)
and the characterization of the expression of the recently described ASFMR1 gene (antisense FMR1).
3.Detection of cryptic chromosome imbalance and
identification of new phenotypes using cytogenetic-molecular techniques. One is in the area if prenatal diagnosis and the other in postnatal diagnosis.
We aim to characterize chromosome imbalances in
fetuses with congenital abnormalities and normal
karyotype by using CGH arrays.
168
1.Identification of the genetic bases of mental retardation (MR) of genetic origin, both syndromal and nonsyndromal, using new MLPA, CGH and array technologies. Application of new technologies to different
MR groups will allow us to establish new molecular
bases of MR. We also aim to define the involvement
of CNV with uncertain clinical significance in MR.
2. FXTAS (Fragile X Tremor Ataxia Syndrome), a new
type of cerebellar ataxy associated with some carriers of the permutation of the fragile x chromosome syndrome (SFX). This line aims to improve
knowledge of FXTAS in its clinical aspects (des-
154-193 AREA5.indd 168
New missense mutations in the UROD protein detected in patients with
late-onset cutaneous porphyria . (Badenas, To-Figueras, Phillips et al,
Clinical Genetics, in press 2009).
21/10/09 15:44:38
4. Study of the genotype-phenotype correlation in porphyria. This line aims to advance in the study of iron
status markers (hepcidin) in patients with different
types of porphyria, particularly PCT. To further stu-
dy acute-phase proteins (pre-albumin, transferrin,
insulin growth factor 1 [IGF-1]) as possible markers
of the severity of acute intermittent porphyria and
to continue participating in the EPNET network.
I.F.: 33,89
PublicaTions
Original Articles
2
3
5
6
7
8
154-193 AREA5.indd 169
10 11 12 13 Grants for Research in Progress
To-Figueras J. European Porphyria Network: providing
better healthcare for patients and their families. Grant:
European Commision, PHEA 2006107. Duration: 01/04/200731/03/2010.
Mila M. Clinical and molecular study of fxtas syndrome (fragile X tremor Ataxia Syndrome). Grant: Fundació Marató
TV3, 60810. Duration: 30/01/2007-29/01/2010.
4
Soler A, Morales C, Badenas C, Rodriguez-Revenga
L, Carrio A, Margarit E, Costa D, Borrell A, Gonce A,
Mila M, Sanchez A. A retrospective and theoretical
evaluation of rapid methods for detecting chromosome
abnormalities and their implications on genetic counseling based on a series of 3868 CVS diagnoses. FETAL
DIAGN THER. 23:126-131. I.F.:0,84.
Morales C, Sanchez A, Bruguera J, Margarit E, Borrell A,
Borobio V, Soler A. Cytogenetic study of spontaneous
abortions using semi-direct analysis of chorionic villi
samples detects the broadest spectrum of chromosome
abnormalities. AM J MED GENET A. 146A:66-70. I.F.:2,44.
Salaverria I, Espinet B, Carrio A, Costa D, Astier L,
CANC. 47:1086-1097. I.F.:4,53.
Baro C, Salido M, Espinet B, Astier L, Domingo A, Granada I, Milla F, Carrio A, Costa D, Luno E, Hernandez
JM, Campo E, Florensa L, Ferrer A, Salar A, Bellosillo B,
Besses C, Serrano S, Sole F. New chromosomal alterations in a series of 23 splenic marginal zone lymphoma
patients revealed by Spectral Karyotyping (SKY). LEUKEMIA RES. 32:727-736. I.F.:2,56.
Queralt R, Madrigal I, Vallecillos MA, Morales C, Ballesca JL, Oliva R, Soler A, Sanchez A, Margarit E. Atypical
XX male with the SRY gene located at the long arm of
chromosome 1 and a 1qter microdeletion. AM J MED
GENET A. 146A:1335-1340. I.F.:2,44.
Torrioli MG, Vernacotola S, Peruzzi L, Tabolacci E, Mila
M, Militerni R, Musumeci S, Ramos FJ, Frontera M,
Sorge G, Marzullo E, Romeo G, Vallee L, Veneselli E,
Cocchi E, Garbarino E, Moscato U, Chiurazzi P, D’iddio
S, Calvani M, Neri G. A double-blind, parallel, multicenter comparison of L-acetylcarnitine with placebo on
the attention deficit hyperactivity disorder in fragile X
syndrome boys. AM J MED GENET A. 146A:803-812.
I.F.:2,44.
Remenyik E, Lecha M, Badenas C, Koszo F, Vass V,
Herrero C, Varga V, Emri G, Balogh A, Horkay I. Childhood-onset mild cutaneous porphyria with compound
heterozygotic mutations in the uroporphyrinogen decarboxylase gene. CLIN EXP DERMATOL. 33:602-605.
I.F.:1,52.
Gamez J, Corbera-Bellalta M, Mila M, Lopez-Lisbona
R, Boluda S, Ferrer I. Chorea-ballism associated with
familial amyotrophic lateral sclerosis. A clinical, genetic, and neuropathological study. MOVEMENT DISORD.
23:434-438. I.F.:3,21.
Carrera C, Puig S, Llambrich A, Palou J, Lecha M, Massi
D, Malvehy J. Development of a human in vivo method
to study the effect of ultraviolet radiation and Sunscreens in melanocytic nevi. DERMATOLOGY. 217:124136. I.F.:1,89.
Rodriguez-Revenga L, Madrigal I, Alegret M, Santos M,
Mila M. Evidence of depressive symptoms in fragileX syndrome premutated females. PSYCHIAT GENET.
18:153-155. I.F.:2,26.
Julia M, Mascaro JM, Guilabert A, Navarra E, Ferrando
J, Herrero C. Sclerodermiform linear lupus erythematosus: A distinct entity or coexistence of two autoinimune diseases?. J AM ACAD DERMATOL. 58:665-667.
I.F.:2,90.
Rodriguez-Revenga L, Santos MM, Sanchez A, Pujol
M, Gomez-Anson B, Badenas C, Jimenez D, Madrigal
I, Mila M. Screening for FXTAS in 95 Spanish patients
negative for Huntington disease. GENET TEST. 12:135138. I.F.:1,22.
Sunyer J, Aivarez-Pedrerol M, To-Figueras J, Ribas-Fito
N, Grimalt JO, Herrero C. Urinary porphyrin excretion
in children is associated with exposure to organochlorine compounds. ENVIRON HEALTH PERSP. 116:14071410. I.F.:5,64.
Genetics
1
9
Mila M. Caracterización y estudio de la implicación de
las variaciones en número de copia en pacientes con
retraso mental ligado a cromosoma X. Grant: Fundación
Ramón Areces, Areces_06_001. Duration: 25/06/200724/06/2010.
Soler A. Detección de desequilibrios cromosómicos submicroscópicos y su correlación con el fenotipo fetal mediante la aplicación de técnicas de citogenética molecular
en el diagnóstico prenatal de malformaciones fetales.
01/01/2006-30/12/2008.
169
To-Figueras J. Estudio bioquímico y genético de familias
con porfiria cutánea tarda tipo II en Catalunya. Grant: Ministerio Sanidad y Consumo, PI060150. Duration: 18/10/200630/12/2009.
21/10/09 15:44:40
Herrero C. Biochemical and molecular genetics studies on
porphyria cutanea tarda and erythropoietic protoporphyria.
Grant: Ministerio de Educación y Ciencia, HH2006-0012. Duration: 01/01/2007-30/06/2009.
Genetics
Sanchez A. Caracterización de desequilibrios cromosómicos, análisis de los puntos de rotura en reordenamientos
aparentes equilibrados e identificación de cromosomas
marcadores mediante microdisección cromosómica y
posterior análisis con técnicas de array-CGH y/o. Grant:
Ministerio Sanidad y Consumo, PI070385. Duration:
26/11/2007-30/12/2010.
170
154-193 AREA5.indd 170
21/10/09 15:44:42
Melanoma: Imaging, Genetics and Immunology
Team members
Team Leader:
■ Susana Puig (Hospital Clínic)
Tel.: 93 2275400 ext 2891
Fax: 93 227 54 38
Antoni Vilalta (Hospital Clínic)
José Palou (Hospital Clínic)
Doctoral Students:
Francisco Cuellar (CONACYD)
Zighe Ogbah (Fundació Clínic)
Joan Anton Puig (Fundació Clínic)
Gabriel Salerni (Fundació Clínic)
Technicians:
Remedios Cervera (Fundació Clínic)
Dani Gabriel (Fundació Clínic)
Pablo Iglesias (Fundació Clínic)
Jordi Milà (Hospital Clínic)
Luchi Millan (Hospital Clínic)
1. Development of noninvasive imaging techniques
for diagnosing melanoma.
2.Study of the genetic bases of susceptibility to melanoma and in photocarcinogenesis of melanoma.
3. Development of strategies for studying melanoma
and skin cancer treatments: target-specific molecular therapies, immunologic therapies and photoprotection therapies.
4. Application of AI systems for evaluating complex
data in melanoma, combining image data and epidemiologic, clinical and molecular data.
5. Development of humanized skin models in mice for
photoprotection and photocarcinogenesis studies.
The principal lines of research that we carry out and
some of the most relevant results obtained recently
are the following:
1.Dermatoscopy and digital dermatoscopy
In dermatoscopy, we are studying the diagnostic criteria of different entities that are not yet well characterized, the correlations with other imaging techniques,
the impact on care of at-risk patients and the relation-
154-193 AREA5.indd 171
ship between dermatoscopy and the patient’s genetic
profile. In digital dermatology, we are analyzing the
use of total body maps and digital dermatoscopy in
monitoring at-risk patients.
Collaborators:
Paula Aguilera (Hospital Clínic)
Pedro Arguís (Hospital Clínic)
Celia Badenas (Hospital Clínic)
Cristina Carrera (Hospital Clínic)
Antonio Campo (Hospital Clínic)
Carlos Conill (Hospital Clínic)
Melinda González (Fundació Clínic)
Ramon Rull (Hospital Clínic)
Marcelo Sánchez (Hospital Clínic)
Sergi Vidal (Hospital Clínic)
Ramón Vilana (Hospital Clínic)
Pedro Zaballos (Hospital Sant Pau
i Santa Tecla, Tarragona)
Teresa Castel (Hospital Clínic)
Melanoma: Imaging, genetics and immunology
IDIBAPS Members:
■ Josep Malvehy (Hospital Clínic)
■ Ramón Vilella (Hospital Clínic)
171
1.1.Definition of new dermatoscopic criteria for different dermatologic processes (dermatofibroma,
angiokeratoma, botryomycoma and blue nevus).
1.2. Development of dermatoscopy for implementation in primary care, anatomical pathology and
dermatology (development of combined dermato-
21/10/09 15:44:48
scopic clinical algorithms for identifying difficultto-diagnose melanomas).
1.3.Combined dermatoscopy and ECO of the primary
tumor for preoperative estimation of Breslow.
2. In vivo confocal microscopy
Description of new algorithms, study of the course
of the lesions, new classifications and use in telemedicine.
2.1. Definition of criteria in nodular melanoma.
2.2. Creation of an algorithm for differential diagnosis
of melanocytic and nonmelanocytic lesions.
2.3.Characterization of pigmented basal cell carcinoma.
2.4.Study of the use of confocal microscopes for the
correct treatment of achromatic or poorly defined
lesions (definition of surgical margins or control
of recurrences).
3.Genetic epidemiology
Study of genes conferring susceptibility to melanoma
in family melanoma and sporadic melanoma. Study
of nevus genes and risk of melanoma. Study of pigmentation genes and risk of melanoma. Identification
of new genes and new mechanisms of susceptibility in
melanoma using a genome-wide scan.
3.1.Studies of penetration and phenotype expression
in patients and families carrying known mutations
in CDKN2A and p14arf.
3.2.Study of the effect of polymorphisms un the MC1R
gene as a modifier gene and low-penetration gene
for melanoma risk and in clinical and dermatoscopic aspects of melanomas.
3.3.Study of polymorphisms in c9orf14 in patients
and controls (>100 nevus vs <20 nevus) as a
susceptibility gene for nevus.
4.Study of the mechanisms involved in
carcinogenesis and photocarcinogenesis
in melanoma
Analysis of oral photoprotection. Study of genetic interaction (CDKN2A, MC1R)/environment (RUV) in risk
of melanoma.
4.1.Study of the influence of ultraviolet radiation
(UVA, UVB, UVA/UVB) on the dermatoscopic, histologic and immunohistochemical characteristics
of melanocytic nevus.
4.2.Dermatoscopic and genetic characterization of
the different Clark nevus in dysplastic nevus syndrome in relation to polymorphisms in c9orf14.
4.3.Research on somatic mutations of NRAS, BRAF,
genome amplifications of several oncogenes and
genome loss of 9p21 (MLPA) in melanoma.
4.4.Studies of expression of metastatic microdisease
(Tyr, MAGE, MART) in sentinel ganglia.
5.Development of therapeutic vaccines
and other new therapeutic strategies
for melanoma
5.1.Incorporation of TNF in hyperthermal perfusion
treatment of limbs.
5.2.Establishment of the bases for optimizing the generation, antigen loading and maturation of dendritic cells for therapeutic use.
5.3.Start of adaptation to good manufacturing practice (GMP) conditions in the “white laboratory” of
the group’s current lines.
6.Evaluation of the immune response
to melanoma
6.1.Study of IL10 and other cytokines in the response
to immune treatment.
I.F.: 64,71
PublicaTions
Original Articles
1
2
172
3
154-193 AREA5.indd 172
Teixe T, Nieto-Blanco P, Vilella R, Engel P, Reina M,
Espel E. Syndecan-2 and-4 expressed on activated primary human CD4(+) lymphocytes can regulate T cell
activation. MOL IMMUNOL. 45:2905-2919. I.F.:3,74.
Carrera C, Puig S, Llambrich A, Palou J, Lecha M, Massi
D, Malvehy J. Development of a human in vivo method to
study the effect of ultraviolet radiation and Sunscreens in
melanocytic nevi. DERMATOLOGY. 217:124-136. I.F.:1,89.
Harland M, Goldstein AM, Kukalizch K, Taylor C, Hogg
D, Puig S, Badenas C, Gruis N, TerHuurne J, Bergman
W, Hayward NK, Stark M, Tsao H, Tucker MA, Landi
MT, Scarra GB, Ghiorzo P, Kanetsky PA, Elder D, Mann
GJ, Holland EA, Bishop DT, Bishop JN. A comparison
of CDKN2A mutation detection within the Melanoma
Genetics Consortium (GenoMEL). EUR J CANCER.
44:1269-1274. I.F.:4,45.
4
5
Brown KM, Macgregor S, Montgomery GW, Craig DW,
Zhao ZZ, Iyadurai K, Henders AK, Homer N, Campbell
MJ, Stark M, Thomas S, Schmid H, Holland EA, Gillanders EM, Duffy DL, Maskiell JA, Jetann J, Ferguson M,
Stephan DA, Cust AE, Whiteman D, Green A, Olsson
H, Puig S, Ghiorzo P, Hansson J, Demenais F, Goldstein
AM, Gruis NA, Elder DE, Bishop JN, Kefford RF, Giles
GG, Armstrong BK, Aitken JF, Hopper JL, Martin NG,
Trent JM, Mann GJ, Hayward NK. Common sequence
variants on 20q11.22 confer melanoma susceptibility.
NAT GENET. 40:838-840. I.F.:25,56.
Menzies SW, Kreusch J, Byth K, Pizzichetta MA,
Marghoob A, Braun R, Malvehy J, Puig S, Argenziano G, Zalaudek I, Rabinovitz HS, Oliviero M, Cabo H,
Ahlgrimm-Siess V, Avramidis M, Guitera P, Soyer HP,
Ghigliotti G, Tanaka M, Perusquia AM, Pagnanelli G,
Bono R, Thomas L, Pellacani G, Langford D, Piccolo D,
Terstappen K, Stanganelli I, Llambrich A, Johr R. Der-
21/10/09 15:44:51
6
7
8
10 11 12 Grants for Research in Progress
Puig S. NoE - Genetic and environmental risk factors for
melanoma: translation into behavioural change. Grant:
01/12/2005-30/11/2010.
Badenas C. Polimorfismos en genes candidatos involucrados en melanoma maligno: caracterización de componentes
genéticos comunes y de baja penetrancia de susceptibilidad
para el desarrollo y predicción de la respuesta al tratamiento. Grant: Ministerio Sanidad y Consumo, PI050302. Duration: 01/01/2006-30/12/2008.
Puig S. Identificación de genes de nevogenicidad y riesgo a
melanoma. Implicaciones en la prevención y en el pronóstico del melanoma. Grant: Ministerio Sanidad y Consumo,
PI060265. Duration: 18/10/2006-30/12/2009.
13 moscopic Features in 202 Melanocytic Lesions. ARCH
DERMATOL. 144:1597-1608. I.F.:2,85.
14 Segura S, Pellacani G, Puig S, Longo C, Bassoli S, Guitera P, Palou J, Menzies S, Seidenari S, Malvehy J. In
Vivo Microscopic Features of Nodular Melanomas Dermoscopy, Confocal Microscopy, and Histopathologic
Correlates. ARCH DERMATOL. 144:1311-1320. I.F.:2,85.
15 Zalaudek I, Kittler H, Marghoob AA, Balato A, Blum
A, Dalle S, Ferrara G, Fink-Puches R, Giorgio CM,
Hofmann-Wellenhof R, Malvehy J, Moscarella E, Puig
S, Scalvenzi M, Thomas L, Argenziano G. Time required
for a complete skin examination with and without dermoscopy. ARCH DERMATOL. 144:509-513. I.F.:2,85.
9
moscopic evaluation of amelanotic and hypomelanotic
melanoma. ARCH DERMATOL. 144:1120-1127. I.F.:2,85.
Zaballos P, Llambrich A, Puig S, Malvehy J. Dermoscopic findings of pilomatricomas. DERMATOLOGY.
217:225-230. I.F.:1,89.
Zaballos P, Puig S, Llambrich A, Malvehy J. Dermoscopy of dermatofibromas. ARCH DERMATOL. 144:75-83.
I.F.:2,85.
Cuellar F, Vilalta A, Puig S, Palou J, Zaballos P, Malvehy
J. Dermoscopy of early recurrent basal cell carcinoma.
ARCH DERMATOL. 144:1254-E1. I.F.:2,85.
Zaballos P, Rodero J, Pastor L, Vives JM, Puig S, Malvehy J. Dermoscopy of lichenoid regressing solar lentigines. ARCH DERMATOL. 144:284-284. I.F.:2,85.
Sorolla A, Yeramian A, Dolcet X, PerezDeSantos AM,
Llobet D, Schoenenberger JA, Casanova JM, Soria X,
Egido R, Llombart A, Vilella R, Matias-Guiu X, Marti
RM. Effect of proteasome inhibitors on proliferation
and apoptosis of human cutaneous melanoma-derived
cell lines. BRIT J DERMATOL. 158:496-504. I.F.:3,50.
Zalaudek I, Giacomel J, Cabo H, DiStefani A, Ferrara
G, Hofmann-Wellenhof R, Malvehy J, Puig S, Stolz W,
Argenziano G. Entodermoscopy: A new tool for diagnosing skin infections and infestations. DERMATOLOGY.
216:14-23. I.F.:1,89.
Garrido-Rios AA, Carrera C, Puig S, Aguilera P, Salerni G, Malvehy J. Homogeneous Blue Pattern in an
Acral Congenital Melanocytic Nevus. DERMATOLOGY.
217:315-317. I.F.:1,89.
Pellacani G, Longo C, Malvehy J, Puig S, Carrera C,
Segura S, Bassoli S, Seidenari S. In Vivo Confocal
Microscopic and Histopathologic Correlations of Der-
173
154-193 AREA5.indd 173
21/10/09 15:44:53
Transplant of Hemopoietic Precursors
Team Members
Team Leader:
■ Enric Carreras (Hospital Clínic)
Tel.: 93 227 54 28
Fax: 93 227 54 84
174
IDIBAPS Members:
■ Francesc Fernández-Avilés (Hospital Clínic)
■ Pedro Marín (Hospital Clínic)
■ Carmen Martínez Muñoz (Hospital Clínic)
■ Montserrat Rovira (Hospital Clínic)
Collaborators:
Anna Gaya (Hospital Clínic)
Josep Mensa (Hospital Clínic)
Alfons Navarro (Faculty of Medicine)
Laura Rosiñol (Hospital Clínic)
Marià Monzó (Faculty of Medicine UB)
Dr. Maribel Díaz Ricart (Hospital Clínic)
After two decades successfully developing lines of
clinical research, in recent years our group has begun to develop basic and translational research lines.
As we do not have our own research facilities, all the
projects to date have been carried out thanks to the
collaboration with other research groups at the hospital (immunology department, hemostasis department)
and the faculty of medicine (human anatomy department). Our objective for the coming years is to obtain
our own research space in one of the new research
centers being developed, expand our collaboration to
other research groups, particularly all those that allow
us to develop the line that we consider most relevant
looking to the future - cellular therapy. We therefore
aim to begin lines of research on antitumor, anti-infectious and cell immune modulation cellular therapy.
Finally, we intend to develop an important line of research in pharmacokinetics, pharmacodynamics and
pharmacogenomics of immune modulators, and the
development of in vitro predictive models of graftversus-host disease.
Technicians:
M. Teresa Lahosa (Fundació Clínic)
Anna Mantecon (Fundació Clínic)
Nuria Montfort (Hospital Clínic)
Marta Palomo de Udaeta (Fundació Clínic)
Ariadna Domènech (Fundació Clínic)
tosus), primary myelofibrosis or nocturnal paroxystic
hemoglobinuria, which have never been treated with
HPT but may benefit from this therapeutic modality.
b)Evaluation of new sources of precursors
(high-complexity HPT)
The lack of compatible siblings for all patients receiving HPT is encouraging the development of transplants
from unrelated donors or umbilical cord blood. We are
the most active group in the country in carrying out
these highly complex procedures, which make up 30%
of our activity.
Lines of clinical research
a)Evaluations of new HPT indications.
Treatment of diseases such as amyloidosis, POEMS
syndrome, scleromyxedema, autoimmune diseases
(multiple sclerosis, Crohn disease, lupus erythema-
154-193 AREA5.indd 174
Expression of VCAM-1, ICAM-1, and E-selectin on the surface of
endothelial cells. The micrographs (x320) show the single layer of
endothelial cells in the presence of control serum (A, D) of de patients
14 days after autogenic HPT (B, E) and 21 days after allogenic HPT (C, F).
The bar diagrams show the gold density (pixels/µm2) corresponding to the
expression of VCAM-1, ICAM-1, and E-selectin in autogenic HPT (panel i)
and allogenic HPTA (panel ii). BB&MT (in press).
21/10/09 15:44:59
Lines of basic and translational research
a)Study of post-HPT complications due
to endothelial dysfunction
Different complications appear shortly after HPT, such
as veno-occlusive disease, capillary rupture syndrome,
thrombotic microangiopathy, graft-versus-host syndrome and idiopathic pneumonia, appear to have their
origin in endothelial dysfunction. The project aims to
characterize this dysfunction to subsequently try to
find effective forms of prevention/treatment. This line
of research has two FIS grants and a grant from the
German José Carreras Foundation.
b)Study of post-HPT immune reconstitution
Once immune reconstitution has been characterized in
bone-marrow, peripheral-blood and low-density HPT,
we intend to evaluate immune reconstitution in umbilical-cord blood, which is currently unknown.
c)Study of the impact of gene polymorphism
in HPT complications and results
Once the we have shown the impact of variants of
mannan-binding-lectin on the incidence of fungal infections, variants of the NOD2/CARD15 genes on survival and the incidence of obliterating bronchiolitis
and, more recently, the variants of the genes NLRP2
and NLRP3 on survival of HPT, we intend to continue
with this line of research by evaluating new polymorphisms that may affect the course of HPT.
d)Study of new techniques aimed at early diagnosis
of HPT infections.
Following advances in early diagnosis of fungal diseases (galactomannan antigen, TACAR) and viral diseases (PCR and CMV antigenemia in all herpes virus
and other pathogens) that have made it possible to
improve patient care, we intend to continue evaluating new diagnostic techniques (quantitative PCR by
means of VEB, application of PCR to tissue samples,
biologic markers in bronchoalveolar lavage, evaluation of infections by means of PET scan).
Original Articles
1
Sintes J, Romero X, Marin P, Terhorst C, Engel P. Differential expression of CD150 (SLAM) family receptors by
human hematopoietic stem and progenitor cells. EXP
HEMATOL. 36:1199-1204. I.F.:3,15.
BLOOD. 112:4337-4342. I.F.:10,90.
3 Saiz A, Blanco Y, Berenguer J, Gomez-Choco M, Carreras E, Arbizu T, Graus F. Clinical outcome 6 years
after autologous hematopoietic stem cell transplantation in multiple sclerosis. NEUROLOGIA. 23:405407. I.F.:0,83.
4 Navarro A, Gaya A, Martinez A, Urbano-Ispizua A, Pons
111:2825-2832. I.F.:10,90.
5 Monzo M, Navarro A, Bandres E, Artells R, Moreno
I, Gel B, Ibeas R, Moreno J, Martinez F, Diaz T, Martinez A, Balague O, Garcia-Foncillas J. Overlapping
154-193 AREA5.indd 175
6
7
8
9
expression of microRNAs in human embryonic
colon and colorectal cancer. CELL RES. 18:823-833.
I.F.:4,22.
Rosinol L, Perez-Simon JA, Sureda A, DeLaRubia J,
DeArriba F, Lahuerta JJ, Gonzalez JD, Diaz-Mediavilla
J, Hernandez B, Garcia-Frade J, Carrera D, Leon A, Hernandez M, Abellan PF, Bergua JM, Miguel JS, Blade J.
A prospective PETHEMA study of tandem autologous
transplantation versus autograft followed by reducedintensity conditioning allogeneic transplantation in
newly diagnosed multiple myeloma. BLOOD. 112:35913593. I.F.:10,90.
Gaya A, Urbano-Ispizua A, Fernandez-Aviles F, Salamero O, Roncero JM, Rovira M, Martinez C, Talarn C,
Granell M, Carreras E, Montserrat E. Anemia associated
with impaired erythropoietin secretion after allogeneic
stem cell transplantation: Incidence, risk factors, and
response to treatment. BIOL BLOOD MARROW TR.
14:880-887. I.F.:3,80.
Moreno-Romero JA, Fernandez-Aviles F, Carreras E,
Rovira M, Martinez C, Mascaro JM. Imatinib as a potential treatment for sclerodermatous chronic graft-vs-host
disease. ARCH DERMATOL. 144:1106-1109. I.F.:2,85.
Avendano A, Sales-Pardo I, Marin L, Marin P, Petriz J.
Oxidative burst assessment and neutrophil-platelet
complexes in unlysed whole blood. J IMMUNOL METHODS . 339:124-131. I.F.:1,95.
I.F.: 61,54
PublicaTions
c)Evaluation of new transplant modalities
• Autogenic HPT in domiciliary regimen (only program in Europe, awarded on several occasions by
the scientific and health-care institutions), a modality we intend to extend to domiciliary allogenic
HPT.
• Intraosseous umbilical-cord blood transplant, an innovative modality being analyzed by two European
centers.
d)Studies aimed at the prevention and treatment
if the principal complications of HPT
• Prevention and treatment of graft-versus-host disease with new agents (anti-IL-2 receptor antibodies, new globulins, antimyocytics, alemtuzumab
and cell therapy using mesenchymal cells). Participation in several multicenter studies.
• Evaluation of the efficacy of new antibacterial, antiviral and antifungal agents. Participation in several
international studies.
175
21/10/09 15:45:01
Carreras E. Transplantament de progenitores hemopoètics
(TPH). Grant: Comissionat per a Universitats i Recerca,
2005SGR00675. Duration: 19/10/2005-31/12/2008.
Urbano A. Estudio farmacogenómico en 326 pacientes
afectos de leucemia mieloblástica aguda tratados con
quimioterapai y trasplante de médula ósea. Diseño de un
tratamiento adaptado a los polimorfismos génicos del
paciente. Grant: Fundació La Caixa, BM05-219-0. Duration:
15/09/2005-31/12/2008.
Carreras E. Disfunción endotelial en el trasplante de progenitores hematopoyéticos: caracterización biológica y papel
en las principales complicaciones precoces post-trasplante.
01/01/2006-30/12/2008.
Urbano A. Efecto de la influencia de la variabilidad genética individual en la respuesta al tratamiento y pronóstico
en 700 pacientes afectos de leucemia aguda y linfoma de
Hodgkin. Grant: Ministerio Sanidad y Consumo, PI050209.
Duration: 01/01/2006-30/12/2008.
10 Fouillard L, Labopin M, Gratwohl A, Gluckman E, Frassoni F, Beelen DW, Willemze R, Montserrat E, Blaise
D, Atienza AI, Sierra J, Santos M, Gorin NC, Rocha V.
Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors of outcomes
for adults transplanted in first complete remission.
HAEMATOL-HEMATOL J. 93:834-841. I.F.:5,52.
11 DeLarrea CF, Cibeira MT, Rovira M, Rosinol L, Esteve
J, Blade J. Spontaneous rupture of the spleen as immediate complication in autologous transplantation
for primary systemic amyloidosis. EUR J HAEMATOL.
80:182-184. I.F.:2,16.
12 Troke P, Aguirrebengoa K, Arteaga C, Ellis D, Heath CH,
Lutsar I, Rovira M, Nguyen Q, Slavin M, Chen SCA.
Treatment of scedosporiosis with voriconazole: Clinical
experience with 107 patients. ANTIMICROB AGENTS
CH. 52:1743-1750. I.F.:4,39.
176
154-193 AREA5.indd 176
21/10/09 15:45:03
Hemato-Oncology
Team members
Team Leader:
■ Prof. Emili Montserrat
(Hospital Clínic)
Tel.: 93 227 54 75
Fax: 93 227 98 11
Hemato-Oncology
IDIBAPS Members:
■ Joan Bladé (Hospital Clínic)
■ Francesc Bosch (Hospital Clínic)
■ Francisco Cervantes (Hospital Clínic)
■ Jordi Esteve (Hospital Clínic)
■ Armando López-Guillermo (Hospital Clínic)
Gonzalo Gutierrez (Hospital Clínic)
Carol Moreno (Fundació Clínic)
Collaborators:
Mª Teresa Cibeira (Hospital Clínic)
Anna Gaya (Hospital Clínic)
Eva Giné (Hospital Clínic)
Benet Nomdedeu (Hospital Clínic)
Laura Rosiñol Dachs (Hospital Clínic)
Montserrat Torrebadell (Hospital Clínic)
Pau Abrisqueta (Hospital Clínic)
The fundamental strategic objectives of our team include clinical, applied and basic research in hematooncology.
1. Lymphoproliferative syndromes
(lymphomas and chronic lymphatic
leukemia)
1.1. Lymphomas:
• Investigation of the mechanisms of progression of
the disease.
• Study of the minimal residual disease and its clinical significance.
• Genome profiles of the different types of lymphoma
and their clinical significance (in collaboration with
the National Cancer Institute (USA) and the Leukemia Lymphoma Molecular Profiling Project, LLMPP).
• New prognostic models in T-cell lymphomas (collaboration in international studies, particularly the
International T-cell Lymphomas Project. University
of Nebraska) and follicular lymphoma.
• Value of PET in evaluating the response of lymphomas and CLL.
• Gene profile of Hodgkin lymphoma.
• Clinical trials in phase I-II with new drugs (bevacizumab, bortezomib, anti-CD40, Aplidine, GA101, etc) and
154-193 AREA5.indd 177
international phase-III clinical trials to establish new
indications in lymphomas (PRIMA and ZAR studies).
1.2. Chronic lymphoid leukemias:
•Mechanisms of progression of the disease.
•Biology of ZAP-70 in relation to BCR.
•Analysis of CLL in transformation.
•Influence of cell microenvironment on the disease.
•Study of immune abnormalities and immune reconstitution in chronic lymphatic leukemia (CLL Global
Foundation Project).
•Evaluation of cell proliferation in CLL.
•Study of autoimmune phenomena.
•Imaging studies in CLL.
•Multiparameter analysis of outcome factors in CLL.
•Clinical trials in phase I/II and III.
2.Multiple myeloma and other monoclonal
gammopathies
•Studies of the role of angiogenesis inhibitors in the
treatment of multiple myeloma - Clinical-biologic
studies of the mechanisms of progression of monoclonal gammopathy of uncertain significance and
quiescent myeloma - Phase I, II and III clinical trials with new drugs (thalidomide, bortezomib, lenalidomide, histone deacetylase inhibitors, Aplidine,
anti-IL-6 antibodies and anti-CD40 antibodies, heat
shock protein 90 inhibitors).
•Clinical trials on treatment of primary amyloidosis
(transplant, treatment with lenalidomide).
Doctoral Students:
Maria Joao Batista (Fundació Clínic)
Eva Calpe (Fundació Clínic)
Gerardo Ferrer (Fundació Clínic)
Susana García (Fundació Clínic)
Marta Pratcorona (Fundació Clínic)
Carles Codony (Fundació Clínic)
177
21/10/09 15:45:08
Hemato-Oncology
3. Myeloproliferative syndromes:
• Analysis and final evaluation of the Spanish protocol for the treatment of chronic myeloid leukemia
with imatinib at scaled doses versus imatinib in
combination with interferon (LMC/PETHEMA).
• Treatment of CML using new tyrosine kinase inhibitors.
• Role of polymorphisms of the genes of imatinib
transporter proteins in resistance to treatment of
CML with imatinib.
• Mechanisms of thrombosis in chronic myeloproliferative syndromes.
• Study of the prognostic value of evolutionary variables in primary myelofibrosis.
1
2
ate cytogenic risk: genetic mutations, gene expression profile, microRNA expression pattern.
•Biologic characterization of acute leukemia with
multiline dysplasia.
•Analysis of the prognostic value of molecular markers of AML in the results of hemopoietic precursor
transplant.
•Clinical trials of drugs for treating AML in phase II
and III (decitabine, tamibarotene).
•Implementation of a sequential treatment strategy
(intense cytoreduction-allotransplant).
I.F.: 377,48
PublicaTions
Original Articles
3
4
5
178
4.Acute leukemia:
•Biologic prognostic factors of AML with intermedi-
6
154-193 AREA5.indd 178
Mestre G, Garcia F, Martinez E, Milinkovic A, Leon A,
Mora B, Argelich R, Lozano JM, Pena J, Gatell JM,
Plana M. Short Communication Natural Killer Cells
and Expression of KIR Receptors in Chronic HIV Type
1-Infected Patients after Different Strategies of Structured Therapy Interruption. AIDS RES HUM RETROV .
24:1485-1495. I.F.:2,02.
Granell M, Urbano-Ispizua A, Pons A, Arostegui JI,
BLOOD. 112:4337-4342. I.F.:10,90.
Kiladjian JJ, Cervantes F, Leebeek FWG, Marzac C, Cassinat B, Chevret S, Cazals-Hatem D, Plessier A, GarciaPagan JC, Murad SD, Raffa S, Janssen HLA, Gardin C,
Cereja S, Tonetti C, Giraudier S, Condat B, Casadevall
N, Fenaux P, Valla DC. The impact of JAK2 and MPL
mutations on diagnosis and prognosis of splanchnic vein thrombosis: a report on 241 cases. BLOOD.
111:4922-4929. I.F.:10,90.
Ferrer A, Bosch F, Villamor N, Rozman M, Graus F,
19:135-141. I.F.:4,88.
Paiva B, Vidriales MB, Cervero J, Mateo G, Perez JJ,
Montalban MA, Sureda A, Montejano L, Gutierrez NC,
DeCoca AG, Heras ND, Mateos MV, Lopez-Berges MC,
Garcia-Boyero R, Galende J, Hernandez J, Palomera L,
Carrera D, Martinez R, DeLaRubia J, Martin A, Blade J,
Lahuerta JJ, Orfao A, Miguel JFS. Multiparameter flow
cytometric remission is the most relevant prognostic
factor for multiple myeloma patients who undergo autologous stem cell transplantation. BLOOD. 112:40174023. I.F.:10,90.
7
8
9
10
11
12
13
Perez-Galan P, Roue G, Lopez-Guerra M, Nguyen M,
Villamor N, Montserrat E, Shore GC, Campo E, Colomer D. BCL-2 phosphorylation modulates sensitivity
to the BH3 mimetic GX15-070 (Obatoclax) and reduces
its synergistic interaction with bortezomib in chronic
lymphocytic leukemia cells. LEUKEMIA. 22:1712-1720.
I.F.:6,92.
Roue G, Lopez-Guerra M, Milpied P, Perez-Galan P,
and Requires Oxidative Stress and Caspase-Independent Signaling. CLIN CANCER RES . 14:6907-6915.
I.F.:6,25.
Salaverria I, Zettl A, Bea S, Hartmann EM, Dave SS,
Wright GW, Boerma EJ, Kluin PM, Ott G, Chan WC,
Weisenburger DD, Lopez-Guillermo A, Gascoyne RD,
Delabie J, Rimsza LM, Braziel RM, Jaffe ES, Staudt LM,
Mueller-Hermelink HK, Campo E, Rosenwald A. Chromosomal alterations detected by comparative genomic
hybridization in subgroups of gene expression-defined
Burkitt’s lymphoma. HAEMATOL-HEMATOL J. 93:13271334. I.F.:5,52.
Hartmann E, Fernandez V, Moreno V, Valls J, Hernandez
L, Bosch F, Abrisqueta P, Klapper W, Dreyling M, Hoster
E, Muller-Hermelink HK, Ott G, Rosenwald A, Campo
E. Five-Gene Model to Predict Survival in Mantle-Cell
Lymphoma Using Frozen or Formalin-Fixed, ParaffinEmbedded Tissue. J CLIN ONCOL. 26:4966-4972.
I.F.:15,48.
Fernandez V, Jares P, Salaverria I, Gine E, Bea S, Aymerich M, Colomer D, Villamor N, Bosch F, Montserrat
93:132-136. I.F.:5,52.
Enjuanes A, Benavente Y, Bosch F, Martin-Guerrero
68:10178-10186. I.F.:7,67.
Salaverria I, Bea S, Lopez-Guillermo A, Lespinet V, Pinyol M, Burkhardt B, Lamant L, Zettl A, Horsman D, Gas-
21/10/09 15:45:11
14 16 18 19 20 21 154-193 AREA5.indd 179
23 24 25 26 27 28 29 Oncology and Hematology Area 5
17 22 mediate complication in autologous transplantation
for primary systemic amyloidosis. EUR J HAEMATOL.
80:182-184. I.F.:2,16.
Mateos MV, Hernandez JM, Hernandez MT, Gutierrez
NC, Palomera L, Fuertes M, Garcia-Sanchez P, Lahuerta
JJ, DeLaRubia J, Terol MJ, Sureda A, Bargay J, Ribas P,
Alegre A, DeArriba F, Oriol A, Carrera D, Garcia-Larana
J, Garcia-Sanz R, Blade J, Prosper F, Mateo G, Esseltine
DL, DeVelde HV, Miguel JFS. Bortezomib plus melphalan and prednisone in elderly untreated patients with
multiple myeloma: updated time-to-events results and
prognostic factors for time to progression. HAEMATOLHEMATOL J. 93:560-565. I.F.:5,52.
DeLaSerna J, Montesinos P, Vellenga E, Rayon C, Parody R, Leon A, Esteve J, Bergua JM, Milone G, Deben G,
Rivas C, Gonzalez M, Tormo M, Diaz-Mediavilla J, Gonzalez JD, Negri S, Amutio E, Brunet S, Lowenberg B,
Sanz MA. Causes and prognostic factors of remission
induction failure in patients with acute promyelocytic
leukemia treated with all-trans retinoic acid and idarubicin. BLOOD. 111:3395-3402. I.F.:10,90.
Lonial S, Richardson PG, Miguel JS, Sonneveld P,
Schuster MW, Blade J, Cavenagh J, Rajkumar SV, Jakubowiak AJ, Esseltine DL, Anderson KC, Harousseau JL.
Characterisation of haematological profiles and low risk
of thromboembolic events with bortezomib in patients
with relapsed multiple myeloma. BRIT J HAEMATOL.
143:222-229. I.F.:4,49.
Sonneveld P, Hajek R, Nagler A, Spencer A, Blade J, Robak T, Zhuang SH, Harousseau JL, Orlowski RZ. Combined pegylated liposomal doxorubicin and bortezomib
is highly effective in patients with recurrent or refractory multiple myeloma who received prior thalidomide/
lenalidomide therapy. CANCER. 112:1529-1537. I.F.:4,63.
Hochhaus A, Baccarani M, Deininger M, Apperley JF,
Lipton JH, Goldberg SL, Corm S, Shah NP, Cervantes
F, Silver RT, Niederwieser D, Stone RM, Dombret H,
Larson RA, Roy L, Hughes T, Muller MC, Ezzeddine R,
Countouriotis AM, Kantarjian HM. Dasatinib induces
durable cytogenetic responses in patients with chronic
myelogenous leukemia in chronic phase with resistance or intolerance to imatinib. LEUKEMIA. 22:1200-1206.
I.F.:6,92.
San-Miguel JF, Richardson PG, Sonneveld P, Schuster
MW, Irwin D, Stadtmauer EA, Facon T, Harousseau
JL, Ben-Yehuda D, Lonial S, Goldschmidt H, Reece D,
Blade J, Boccadoro M, Cavenagh JD, Neuwirth R, Boral
AL, Esseltine DL, Anderson KC. Efficacy and safety of
bortezomib in patients with renal impairment: results
from the APEX phase 3 study. LEUKEMIA. 22:842-849.
I.F.:6,92.
Bosch F, Ferrer A, Villamor N, Gonzalez M, Briones J,
Gonzalez-Barca E, Abella E, Gardella S, Escoda L, PerezCeballos E, Asensi A, Sayas MJ, Font L, Altes A, Muntanola A, Bertazzoni P, Rozman M, Aymerich M, Gine
E, Montserrat E. Fludarabine, cyclophosphamide, and
mitoxantrone as initial therapy of chronic lymphocytic
leukemia: High response rate and disease eradication.
CLIN CANCER RES. 14:155-161. I.F.:6,25.
Oriol A, Ribera JM, Bergua J, Mesa EG, Grande C,
Esteve J, Brunet S, Moreno MJ, Escoda L, HernandezRivas JM, Hoelzer D. High-dose chemotherapy and im-
Hemato-Oncology
15 coyne R, Ott G, Siebert R, Delsol G, Campo E. Genomic
profiling reveals different genetic aberrations in systemic ALK-positive and ALK-negative anaplastic large cell
lymphomas. BRIT J HAEMATOL. 140:516-526. I.F.:4,49.
Montoto S, Moreno C, Domingo-Domenech E, Estany
Garcia-Herrera A, Colomo L, Camos M, Carreras J,
J CLIN ONCOL. 26:3364-3371. I.F.:15,48.
Lenz G, Wright G, Dave SS, Xiao W, Powell J, Zhao H,
Xu W, Tan B, Goldschmidt N, Iqbal J, Vose J, Bast M,
Fu K, Weisenburger DD, Greiner TC, Armitage JO, Kyle
A, May L, Gascoyne RD, Connors JM, Troen G, Holte
H, Kvaloy S, Dierickx D, Verhoef G, Delabie J, Smeland
EB, Jares P, Martinez A, Lopez-Guillermo A, Montserrat
E, Campo E, Braziel RM, Miller TP, Rimsza LM, Cook
JR, Pohlman B, Sweetenham J, Tubbs RR, Fisher RI,
Hartmann E, Rosenwald A, Ott G, Muller-Hermelink
HK, Wrench D, Lister TA, Jaffe ES, Wilson WH, Chan
WC, Staudt LM. Stromal Gene Signatures in Large-BCell Lymphomas. NEW ENGL J MED . 359:2313-2323.
I.F.:52,59.
Navarro A, Gaya A, Martinez A, Urbano-Ispizua A, Pons
111:2825-2832. I.F.:10,90.
Rosinol L, Perez-Simon JA, Sureda A, DeLaRubia J,
DeArriba F, Lahuerta JJ, Gonzalez JD, Diaz-Mediavilla
J, Hernandez B, Garcia-Frade J, Carrera D, Leon A, Hernandez M, Abellan PF, Bergua JM, Miguel JS, Blade J.
A prospective PETHEMA study of tandem autologous
transplantation versus autograft followed by reducedintensity conditioning allogeneic transplantation in
newly diagnosed multiple myeloma. BLOOD. 112:35913593. I.F.:10,90.
Gaya A, Urbano-Ispizua A, Fernandez-Aviles F, Salamero O, Roncero JM, Rovira M, Martinez C, Talarn C,
Granell M, Carreras E, Montserrat E. Anemia associated
with impaired erythropoietin secretion after allogeneic
stem cell transplantation: Incidence, risk factors, and
response to treatment. BIOL BLOOD MARROW TR.
14:880-887. I.F.:3,80.
Fouillard L, Labopin M, Gratwohl A, Gluckman E, Frassoni F, Beelen DW, Willemze R, Montserrat E, Blaise
D, Atienza AI, Sierra J, Santos M, Gorin NC, Rocha V.
Results of syngeneic hematopoietic stem cell transplantation for acute leukemia: risk factors of outcomes
for adults transplanted in first complete remission.
DeLarrea CF, Cibeira MT, Rovira M, Rosinol L, Esteve
J, Blade J. Spontaneous rupture of the spleen as im-
179
21/10/09 15:45:13
30 Hemato-Oncology
31 32 Area 5 Oncology and Hematology
33 34 35 36 180
37 154-193 AREA5.indd 180
munotherapy in adult Burkitt lymphoma - Comparison
of results in human immunodeficiency virus-infected
and noninfected patients. CANCER. 113:117-125.
I.F.:4,63.
Lopez-Guerra M, Trigueros-Motos L, Molina-Arcas M,
Villamor N, Casado FJ, Montserrat E, Campo E, Colomer D, Pastor-Anglada M. Identification of TIGAR in the
equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia cells.
Lee SJ, Kukreja M, Wang T, Giralt SA, Szer J, Arora M,
Woolfrey AE, Cervantes F, Champlin RE, Gale RP, Halter
J, Keating A, Marks DI, Mccarthy PL, Olavarria E, Stadtmauer EA, Abecasis M, Gupta V, Khoury HJ, George B,
Hale GA, Liesveld JL, Rizzieri DA, Antin JH, Bolwell BJ,
Carabasi MH, Copelan E, Ilhan O, Litzow MR, Schouten
HC, Zander AR, Horowitz MM, Maziarz RT. Impact of
prior imatinib mesylate on the outcome of hematopoietic cell transplantation for chronic myeloid leukemia.
BLOOD. 112:3500-3507. I.F.:10,90.
Alvarez-Larran A, Arellano-Rodrigo E, Reverter JC,
Domingo A, Villamor N, Colomer D, Cervantes F. Increased platelet, leukocyte, and coagulation activation
in primary myelofibrosis. ANN HEMATOL. 87:269-276.
I.F.:2,34.
Gine E, Crespo M, Muntanola A, Calpe E, Baptista MJ,
Villamor N, Montserrat E, Bosch F. Induction of histone
H1.2 cytosolic release in chronic lymphocytic leukemia
cells after genotoxic and non-genotoxic treatment.
Lahuerta JJ, Mateos MV, Martinez-Lopez J, Rosinol
L, Sureda A, DeLaRubia J, Garcia-Larana J, MartinezMartinez R, Hernandez-Garcia MT, Carrera D, Besalduch
J, DeArriba F, Ribera JM, Escoda L, Hernandez-Ruiz B,
Garcia-Frade J, Rivas-Gonzalez C, Alegre A, Blade J,
SanMiguel JF. Influence of Pre- and Post-Transplantation Responses on Outcome of Patients With Multiple
Myeloma: Sequential Improvement of Response and
Achievement of Complete Response Are Associated
With Longer Survival. J CLIN ONCOL . 26:5775-5782.
I.F.:15,48.
Mercadal S, Briones J, Xicoy B, Pedro C, Escoda L,
Estany C, Camos M, Colomo L, Espinosa I, Martinez S,
Ribera JM, Martino R, Gutierrez-Garcia G, Montserrat E,
Lopez-Guillermo A. Intensive chemotherapy (high-dose
CHOP/ESHAP regimen) followed by autologous stemcell transplantation in previously untreated patients
with peripheral T-cell lymphoma. ANN ONCOL. 19:958963. I.F.:4,88.
Hasan SK, Mays AN, Ottone T, Ledda A, LaNasa G,
Cattaneo C, Borlenghi E, Melillo L, Montefusco E,
Cervera J, Stephen C, Satchi G, Lennard A, Libura M,
Byl JAW, Osheroff N, Amadori S, Felix CA, Voso MT,
Sperr WR, Esteve J, Sanz MA, Grimwade D, Lo-Coco F.
Molecular analysis of t(15;17) genomic breakpoints in
secondary acute promyelocytic leukemia arising after
treatment of multiple sclerosis. BLOOD. 112:3383-3390.
I.F.:10,90.
Rajkumar SV, Rosinol L, Hussein M, Catalano J, Jedrzejczak W, Lucy L, Olesnyckyj M, Yu Z, Knight R, Zeldis
JB, Blade J. Multicenter, randomized, double-blind,
placebo-controlled study of thalidomide plus dexa-
38 39 40 41 42 43 44 methasone compared with dexamethasone as initial
therapy for newly diagnosed multiple myeloma. J CLIN
ONCOL. 26:2171-2177. I.F.:15,48.
Ludwig H, Durie BGM, Bolejack V, Turesson I, Kyle RA,
Blade J, Fonseca R, Dimopouios M, Shimizu K, Miguel
JS, Westin J, Harousseau JL, Beksac M, Boccadoro M,
Palumbo A, Barlogie B, Shustik C, Cavo M, Greipp PR,
Joshua D, Attal M, Sonneveld P, Crowley J. Myeloma in
patients younger than age 50 years presents with more
favorable features and shows better survival: an analysis of 10 549 patients from the International Myeloma
Working Group. BLOOD. 111:4039-4047. I.F.:10,90.
Palumbo A, Rajkumar SV, Dimopoulos MA, Richardson
PG, Miguel JS, Barlogie B, Harousseau J, Zonder JA,
Cavo M, Zangari M, Attal M, Belch A, Knop S, Joshua D, Sezer O, Ludwig H, Vesole D, Blade J, Kyle R,
Westin J, Weber D, Bringhen S, Niesvizky R, Waage A,
VonLilienfeld-Toal M, Lonial S, Morgan GJ, Orlowski
RZ, Shimizu K, Anderson KC, Boccadoro M, Durie BG,
Sonneveld P, Hussein MA. Prevention of thalidomideand lenalidomide-associated thrombosis in myeloma.
LEUKEMIA. 22:414-423. I.F.:6,92.
Mateo G, Montalban MA, Vidriales MB, Lahuerta JJ,
Mateos MV, Gutierrez N, Rosinol L, Montejano L, Blade
J, Martinez R, DeLaRubia J, Diaz-Mediavilla J, Sureda
A, Ribera JM, Ojanguren JM, DeArriba F, Palomera L,
Terol MJ, Orfao A, Miguel JSFS. Prognostic value of
immunophenotyping in multiple myeloma: A study by
the PETHEMA/GEM cooperative study groups on patients uniformly treated with high-dose therapy. J CLIN
ONCOL . 26:2737-2744. I.F.:15,48.
Roman-Gomez J, Jimenez-Velasco A, Agirre X, Castillejo JA, Navarro G, Jose-Eneriz ES, Garate L, Cordeu
L, Cervantes F, Prosper F, Heiniger A, Torres A. Repetitive DNA hypomethylation in the advanced phase of
chronic myeloid leukemia. LEUKEMIA RES. 32:487-490.
I.F.:2,56.
Sanz MA, Montesinos P, Vellenga E, Rayon C, DeLaSerna J, Parody R, Bergua JM, Leon A, Negri S, Gonzalez
M, Rivas C, Esteve J, Milone G, Gonzalez JD, Amutio
E, Brunet S, Garcia-Larana J, Colomer D, Calasanz
MJ, Chillon C, Barragan E, Bolufer P, Lowenberg B.
Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline
monochemotherapy: long-term outcome of the LPA
99 multicenter study by the PETHEMA Group. BLOOD.
112:3130-3134. I.F.:10,90.
Ribera JM, Oriol A, Morgades M, Gonzalez-Barca E, Miralles P, Lopez-Guillermo A, Gardella S, Abella E, Garci
M. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients
with human immunodeficiency virus-associated diffuse
large B-cell lymphoma: results of a phase II trial. BRIT J
HAEMATOL. 140:411-419. I.F.:4,49.
Niesvizky R, Richardson PG, Rajkumar SV, Coleman M,
Rosinol L, Sonneveld P, Schuster MW, Irwin D, Stadtmauer EA, Facon T, Harousseau JL, Boral AL, Esseltine
DL, Anderson KC, Blade J. The relationship between
quality of response and clinical benefit for patients
treated on the bortezomib arm of the international,
randomized, phase 3 APEX trial in relapsed multiple
myeloma. BRIT J HAEMATOL. 143:46-53. I.F.:4,49.
21/10/09 15:45:15
Reviews
1
2
4
5
6
7
1
2
3
Cervantes F. Chronic myeloid leukemia 2008. MED
Montserrat E. Further progress in CLL therapy. BLOOD .
112:924-925. I.F.:10,90.
Blade J, Rosinol L. SMM: toward better predictors of
progression. BLOOD. 111:479-480. I.F.:10,90.
Bosch F. ZAP-70, proliferación celular y apoptosis en la leucemia linfática crónica. Grant: Ministerio Sanidad y Consumo, PI050213. Duration: 01/01/2006-30/12/2008.
Cervantes F. Estudio de la relación entre la presencia de
los polimorfismos genéticos en los genes MDR1, HOCT1
y AGP1 y la respuesta al tratamiento con imatinib en los
pacientes con leucemia mieloide crónica en fase crónica
de diagnóstico reciente. Grant: Ministerio Sanidad y Consumo, PI060038. Duration: 18/10/2006-30/12/2009.
Cervantes F. Red temática de investigación cooperativa de cáncer. Grant: Ministerio Sanidad y Consumo,
RD06/0020/0004. Duration: 01/01/2007-31/12/2010.
Blade J. Red temática de investigación cooperativa de cáncer. Grant: Ministerio Sanidad y Consumo, RD06/0020/0005.
Duration: 01/01/2007-31/12/2010.
Montserrat E. Red temática de investigación cooperativa de cáncer. Grant: Ministerio Sanidad y Consumo,
RD06/0020/0051. Duration: 01/01/2007-31/12/2010.
Montserrat E. Nuevos estudios inmunogenotípicos en la
clasificación y tratamiento de la leucemia mieloide aguda
(LMA) y síndromes mielodisplásicos. Grant: FIS, PI050195.
Duration: 23/12/2005-31/12/2008.
Thesis
Montserrat E. NoE - Strengthen and develop scientific and
technological excellence in research and therapy of leukemia (CML, AML, ALL, CLL, MDS, CMPD) by integration
of the leading national leukemia networks and their interdisciplinary partner groups in Europe. Grant: European
Commision, LSHC-CT-2004-503216. Duration: 01/01/200431/12/2008.
Bosch F. Factores pronósticos, biológicos y clínicos en el
linfoma de células del manto. Doctorand: Anna Ferrer del
Álamo. Facultat de Medicina, Universitat de Barcelona.
Editorials
Esteve J. Valor pronóstico del perfil de expresión génica
en el resultado del tratamiento post-remisión en los enfermos con leucemia mieloide aguda. Grant: Ministerio
Sanidad y Consumo, PI041085. Duration: 01/01/2005-30/06/2008.
Hemato-Oncology
3
Blade J, Rosinol L. Advances in therapy of multiple
myeloma. CURR OPIN ONCOL . 20:697-704. I.F.:3,69.
Hallek M, Cheson BD, Catovsky D, Caligaris-Cappio F,
Dighiero G, Dohner H, Hillmen P, Keating MJ, Montserrat E, Rai KR, Kipps TJ. Guidelines for the diagnosis
and treatment of chronic lymphocytic leukemia: a
report from the International Workshop on Chronic
Lymphocytic Leukemia updating the National Cancer
Institute-Working Group 1996 guidelines. BLOOD.
111:5446-5456. I.F.:10,90.
Cervantes F, Passamonti F, Barosi G. Life expectancy and
prognostic factors in the classic BCR/ABL-negative myeloproliferative disorders. LEUKEMIA. 22:905-914. I.F.:6,92.
Moreno C, Montserrat E. New prognostic markers in
chronic lymphocytic leukemia. BLOOD REV. 22:211-219.
I.F.:5,92.
Blade J, Rosinol L, Cibeira MT, DeLarrea CF. Pathogenesis
and progression of monoclonal gammopathy of undetermined significance. LEUKEMIA. 22:1651-1657. I.F.:6,92.
Dimopoulos MA, Kastritis E, Rosinol L, Blade J, Ludwig
H. Pathogenesis and treatment of renal failure in multiple myeloma. LEUKEMIA. 22:1485-1493. I.F.:6,92.
Palumbo A, Facon T, Sonneveld P, Blade J, Offidani M,
Gay F, Moreau P, Waage A, Spencer A, Ludwig H, Boccadoro M, Harousseau JL. Thalidomide for treatment
of multiple myeloma: 10 years later. BLOOD. 111:39683977. I.F.:10,90.
Montserrat E. Unitat clínico-biològica per l’estudi de linfomes i síndromes limfoproliferatius. Grant: Comissionat
19/10/2005-31/12/2008.
Cervantes F. Papel de la activación leucocitariia y plaquetaria en la trombosis de los síndromes mieloprolife-rativos
crónicos. Doctorand: Alberto Álvarez Larrán. Facultat de
Medicina, Universitat de Barcelona.
Cervantes F. European Treatment and Outcome Study for
CML. Grant: Desconocida, 07/350. Duration: 01/07/200730/06/2010.
181
Bosch F. Effect of the abnormal ZAP-70 expression in chronic lymphoproliferative disorders. Grant: Fundació Marató
TV3, 51810. Duration: 05/12/2005-04/12/2008.
154-193 AREA5.indd 181
21/10/09 15:45:18
Pathophysiology and Molecular Bases in Hematology
Team Members
Pathophysiology and
molecular bases in hematology
Team Leader:
■ Dolors Colomer (Hospital Clínic)
Tel.: 93 227 54 00 ext 3368
Fax: 93 227 55 72
182
IDIBAPS Members:
■ Josep Lluís Aguilar (Hospital Clínic)
■ Marta Aymerich (Hospital Clínic)
■ Teresa Estrach (Hospital Clínic)
■ Gael Roue (Fundació Clínic)
■ Maria Rozman (Hospital Clínic)
■ Neus Villamor (Hospital Clínic)
■ Joan Lluís Vives Corrons (Hospital Clínic)
Collaborators:
Mónica Lopez (Generalitat Catalunya)
Roberto Alonso (ISCIII)
Sandra Cabezas (IDIBAPS, RTICC)
Mireia Camós (IDIBAPS, RTICC)
Laia Rosich (IDIBAPS)
Silvia Xargay (Ministry of Science and Innovation)
Epidemiologic, genetic, molecular and pathophysiologic study of malignant hemopathies and of erythrocyte pathology.
1. Molecular bases of regulation of apoptosis induced
by drugs in lymphoid cancers. Search for new strategies to treat these diseases.
2. Cytologic, immunophenotypic and molecular studies of malignant hemopathies. Development of
new technologies for both diagnosing and monitoring minimal residual disease.
3. Promotion of cooperative strategies in the area of
molecular diagnosis of leukemia and lymphomas.
4. Design and implementation of internal and external
quality-control programs.
5. Cutaneous T and B-cell lymphomas. Clinical, histopathologic and immunophenotypic study. Prognostic factors and epidemiology.
6.Molecular study of congenital abnormalities of
erythrocytes and the pathophysiologic mechanisms
that play a role in the production and destruction of
erythrocytes as a cause of anemia or erythrocytosis.
7. Genetic and epidemiologic study of hemoglobinopathies and thalassemias.
154-193 AREA5.indd 182
Synergism between GX15-070, a BCL-2 protein inhibitor, and bortezomib,
a proteasome inhibitor, in mantle cell lymphoma (MCL). A) Primary cells
of patients with MCL were incubated with 5 or 10 nM of bortezomib and
different doses of GX15-070 (0.1-1 µM) for 18 hours. Cytotoxicity was
evaluated using flow cytometry by means of marking with annexin V-APC.
The linked arrows indicated similar cytotoxicity levels (cases 4 and 7). The
arrows in cases 2 and 9 indicate that incubation with GX15-070 sensitizes
the cells to bortezomib. B) Analysis of expression of Mcl-1, Bak and Noxa
using western blot after incubation for 18 hours with GX15-070 1 µM and/
or bortezomib 5 nM. C) Immunoprecipitation with Mcl-1 and subsequent
development with Bak and Noxa in cells treated with GX15-070 1 µM and/
or bortezomib 5 nM for 5 hours.
21/10/09 15:45:22
I.F.: 103,59
PublicaTions
Original Articles
1
12 13 14 15 16 17 18 Oncology and Hematology Area 5
154-193 AREA5.indd 183
11 Pathophysiology and
2 Marin-Aguilera M, Mengual L, Burset M, Oliver A, Ars
E, Ribal MJ, Colomer D, Mellado B, Villavicencio H,
Algaba F, Alcaraz A. Molecular Lymph Node Staging in
Bladder Urothelial Carcinoma: Impact on Survival. EUR
UROL. 54:1363-1372. I.F.:5,63.
3 Ferrer A, Bosch F, Villamor N, Rozman M, Graus F,
19:135-141. I.F.:4,88.
4 Perez-Galan P, Roue G, Lopez-Guerra M, Nguyen M, Villamor N, Montserrat E, Shore GC, Campo E, Colomer D.
BCL-2 phosphorylation modulates sensitivity to the BH3
mimetic GX15-070 (Obatoclax) and reduces its synergistic interaction with bortezomib in chronic lymphocytic
leukemia cells. LEUKEMIA. 22:1712-1720. I.F.:6,92.
5 Roue G, Lopez-Guerra M, Milpied P, Perez-Galan P,
and Requires Oxidative Stress and Caspase-Independent Signaling. CLIN CANCER RES. 14:6907-6915.
I.F.:6,25.
6 Fernandez V, Jares P, Salaverria I, Gine E, Bea S, Aymerich M, Colomer D, Villamor N, Bosch F, Montserrat
93:132-136. I.F.:5,52.
7 Enjuanes A, Benavente Y, Bosch F, Martin-Guerrero
68:10178-10186. I.F.:7,67.
8 Montoto S, Moreno C, Domingo-Domenech E, Estany
9 Salaverria I, Espinet B, Carrio A, Costa D, Astier L,
CANC. 47:1086-1097. I.F.:4,53.
10 Garcia-Herrera A, Colomo L, Camos M, Carreras J,
J CLIN ONCOL. 26:3364-3371. I.F.:15,48.
Bosch F, Ferrer A, Villamor N, Gonzalez M, Briones
J, Gonzalez-Barca E, Abella E, Gardella S, Escoda L,
Perez-Ceballos E, Asensi A, Sayas MJ, Font L, Altes A,
Muntanola A, Bertazzoni P, Rozman M, Aymerich M,
Gine E, Montserrat E. Fludarabine, cyclophosphamide,
and mitoxantrone as initial therapy of chronic lymphocytic leukemia: High response rate and disease eradication. CLIN CANCER RES. 14:155-161. I.F.:6,25.
Lopez-Guerra M, Trigueros-Motos L, Molina-Arcas M,
Villamor N, Casado FJ, Montserrat E, Campo E, Colomer D, Pastor-Anglada M. Identification of TIGAR in the
equilibrative nucleoside transporter 2-mediated response to fludarabine in chronic lymphocytic leukemia
cells. HAEMATOL-HEMATOL J. 93:1843-1851. I.F.:5,52.
Alvarez-Larran A, Arellano-Rodrigo E, Reverter JC, Domingo A, Villamor N, Colomer D, Cervantes F. Increased
platelet, leukocyte, and coagulation activation in primary
myelofibrosis. ANN HEMATOL. 87:269-276. I.F.:2,34.
Gine E, Crespo M, Muntanola A, Calpe E, Baptista MJ,
Villamor N, Montserrat E, Bosch F. Induction of histone
H1.2 cytosolic release in chronic lymphocytic leukemia
cells after genotoxic and non-genotoxic treatment.
Sanz MA, Montesinos P, Vellenga E, Rayon C, DeLaSerna J, Parody R, Bergua JM, Leon A, Negri S, Gonzalez
M, Rivas C, Esteve J, Milone G, Gonzalez JD, Amutio
E, Brunet S, Garcia-Larana J, Colomer D, Calasanz
MJ, Chillon C, Barragan E, Bolufer P, Lowenberg B.
Risk-adapted treatment of acute promyelocytic leukemia with all-trans retinoic acid and anthracycline
monochemotherapy: long-term outcome of the LPA
99 multicenter study by the PETHEMA Group. BLOOD.
112:3130-3134. I.F.:10,90.
VanBlerk M, Albarede S, Deom A, Gutierrez G, Heller
S, Nazor A, Pakkanen A, Rej R, Curran KM, Sarkany E,
Skitek M, Vives-Corrons JL, Zaikin E, Libeer JC. Comparison of evaluation procedures used by European
external quality assessment scheme organizers for haemoglobin concentration and leukocyte concentration.
ACCREDIT QUAL ASSUR. 13:145-148. I.F.:0,72.
Roue G, Pichereau V, Lincet H, Colomer D, Sola B.
Cyclin D1 mediates resistance to apoptosis through
upregulation of molecular chaperones and consequent
redistribution of cell death regulators. ONCOGENE.
27:4909-4920. I.F.:6,44.
Pereira MDM, Sibina MTC, Mateos EG, Corrons JLV.
Hemoglobinopathy Newcastle: use of chromatography
and first case reported in Spain. MED CLIN-BARCELONA. 130:455-458. I.F.:1,34.
183
Editorials
1
Grau JJ, Estrach T. Old masters as clinical photographers: multifocal breast cancer diagnosed 400 years
ago. BREAST CANCER RES TR . 111:11-13. I.F.:4,45.
21/10/09 15:45:25
Aymerich M. Proyecto de puesta a disposición de
muestras de ADN de pacientes diagnosticados de
varios tipos de tumores sólidos y hematológicos en la
población residente en España - Nodo de Enfermedades
Oncológicas del Banco Nacional de ADN. Grant: GenomaEspaña, GenEsp2006_07/010. Duration: 16/10/200615/10/2009.
Villamor N. Bases celulares de la respuesta al tratamiento
en pacientes con síndromes linfoproliferativos crónicos de
línea B. Grant: Ministerio Sanidad y Consumo, PI041051.
Duration: 01/01/2005-30/06/2008.
Estrach. Epidemiología y factores pronósticos de los pacientes afectos de linfoma cutáneo de células T (LCCT).
01/01/2006-30/12/2008.
Aymerich M. Desarrollo de un biobanco para muestras biológicas prospectivas de pacientes oncológicos como soporte a la investigación biomédica. Grant: Ministerio Sanidad y
Colomer D. Red temática de investigación cooperativa de cáncer. Grant: Ministerio Sanidad y Consumo,
RD06/0020/0014. Duration: 01/01/2007-31/12/2010.
Colomer D. Identificación de nuevas dianas con potencial
terapéutico en neoplasias linformes. Grant: Ministerio Educación y Ciencia, SAF2006-08850. Duration: 01/10/2006-30/09/2009.
Vives JL. CURSO ENERCA. Grant: Fundació Clínic per a la
Recerca Biomèdica. Duration: 01/01/2008-31/12/2999.
Pathophysiology and
Vives JL. European Network for Rare and Congenital Anaemias. Grant: European Commision, 2004110. Duration:
01/09/2005-31/08/2008.
Vives JL. Estudio de la variabilidad clínica y molecular
asociada a drepanocitosis, talasemia y déficit de G6PD. Correlación genotipo/fenotipo y aplicación de la reversión del
déficit de G6PD en la prevención de la anemia hemolítica.
01/01/2006-30/12/2008.
184
154-193 AREA5.indd 184
21/10/09 15:45:28
Hemotherapy-Hemostasis
Team members
Team Leader:
■ Antonio Ordinas (Hospital Clínic)
Tel.: 93 227 54 48
Fax: 93 227 93 69
1. To study the basic mechanisms that regulate the
function of blood cells and the interactions between
them, with the vascular wall and with other cells.
2. To evaluate the congenital and acquired defects of
hemostasis and their correction by means of drugs
and/or transfusions.
Technicians:
Marc Pino (Hospital Clínic)
Ful Navalón (Fundació Clínic)
Anghara Menéndez Montes (IDIBAPS)
Nurses:
Antonio Alonso (Hospital Clínic)
3. To characterize in the laboratory hemorrhagic and
thrombotic phenotypes and genotypes.
4. To analyze the efficacy and safety of new saving
strategies in transfusions of blood components.
5. To develop and evaluate the efficacy of synthetic
platelet substitutes.
6. Characterization of animal models of hemostasis,
preferably in mice.
Collaborators:
Rosa Brugués (Hospital Clínic)
Gabriela Gutiérrez (Hospital Clínic)
M. Rosa Hernández (Fundació Clínic)
Josep M. Jou (Hospital Clínic)
Santiago Maragall (Hospital Clínic)
Doctoral Students:
Jeroni Luna Cornadó (IDIBAPS)
Lola Bellido Martín
(CSIC Formació personal Investigador,MEC)
Laura Fernández Fernández
(CSIC Form Personal Investig, MEC)
Irene López-Vilchez (Fundació Clínic)
Marta Palomo de Udaeta (Fundació Clínic)
IDIBAPS Members:
■ Maribel Díaz-Ricart (Hospital Clínic)
■ Ginés Escolar (Hospital Clínic)
■ Ana M. Galán (Fundació Clínic)
■ Pablo García de Frutos (CSIC)
■ Miquel Lozano (Hospital Clínic)
■ Roberto Mazzara (Hospital Clínic)
■ Anna M. Merino (Hospital Clínic)
■ Joan Monteagudo (Hospital Clínic)
■ Arturo Pereira (Hospital Clínic)
■ Juan Carles Reverter (Hospital Clínic)
■ Cristina Ch. Sanz (Hospital Clínic)
■ M. Dolors Tàssies (Hospital Clínic)
185
Ultrastructural analyses of washed platelets exposed to microvesicles rich in FT (MV-FT). A) Platelets at rest. B) After the first minute of activation with MVFT, we found MV-FT of different sizes in the platelet open canalicular system (arrow) and we observed platelet activation with loss of shape and signs of
partial degranulation. C) After 5 minutes, the platelets return to a rest state by conserve the MV-FT in their interior.
154-193 AREA5.indd 185
21/10/09 15:45:32
1. Study of the mechanisms involved in the development of hemorrhagic and thrombotic diseases. Proteomic study of the determination of changes in the
vascular tree and the different blood cells in thrombotic and hemorrhagic diseases.
2. Evaluation of the physiologic and pathologic implication of circulating and/or intraplatelet tissue factor in
atherothrombosis.
3. Search for alternatives to platelet transfusion and development of potential synthetic platelet substitutes
with the ability to potentiate the physiologic mechanisms of hemostasis.
I.F.: 58,86
PublicaTions
Original Articles
1
2
4. New therapeutic measures in autoimmune diseases
of an essentially humoral nature. ABO-incompatible
kidney transplant as a model.
5.Evaluation of the participation of serotoninergic purinergic mechanisms in platelet functionalism. Study
of the antithrombotic potential of pharmacologic inhibitors.
6. Role of the phenotype/genotype of fibrinolysis
inhibitors and repercussion on global or specific
functional tests in hemorrhagic and thrombotic disease.
7. Study of the vitamin-K dependent protein GAS6 in
hemostasis and the vascular wall, using KO mice
for this gene.
3
4
5
6
186
7
8
154-193 AREA5.indd 186
Jimenez S, Tassies D, Espinosa G, Garcia-Criado A,
Plaza J, Monteagudo J, Cervera R, Reverter JC. Double
heterozygosity polymorphisms for platelet glycoproteins Ia/IIa and IIb/IIIa increases arterial thrombosis and
arteriosclerosis in patients with the antiphospholipid
syndrome or with systemic lupus erythematosus. ANN
RHEUM DIS. 67:835-840. I.F.:6,41.
J, Lozano L, Mazzara R, Macule F, Basora M, Salazar F.
Effectiveness and safety of tranexamic acid administration during total knee arthroplasty. VOX SANG. 95:3944. I.F.:2,59.
Carbo C, Arderiu G, Escolar G, Fuste B, Cases A, Carrascal M, Abian J, Diaz-Ricart M. Differential expression of
proteins from cultured endothelial cells exposed to uremic versus normal serum. AM J KIDNEY DIS. 51:603612. I.F.:3,98.
Alvarez-Larran A, Arellano-Rodrigo E, Reverter JC, Domingo A, Villamor N, Colomer D, Cervantes F. Increased
platelet, leukocyte, and coagulation activation in primary
myelofibrosis. ANN HEMATOL. 87:269-276. I.F.:2,34.
DelRio-Garma J, Pereira A, Arroyo JL, Mateo J,
Alvarez-Larran A, Martinez C, Muncunill J, Barbolla L.
ADAMTS-13 activity and von Willebrand factor levels
in methylene blue photo-inactivated plasma processed
by either the Springe method or an ‘in house’ system.
VOX SANG. 95:101-105. I.F.:2,59.
Navarro-Nunez L, Lozano ML, Palomo M, Martinez C,
Vicente V, Castillo T, Benavente-Garcia O, Diaz-Ricart M,
Escolar G, Riverat J. Apigenin inhibits platelet adhesion
and thrombus formation and synergizes with aspirin
in the suppression of the arachidonic acid pathway. J
AGR FOOD CHEM. 56:2970-2976. I.F.:2,53.
Hurtado B, Abasolo N, Domenech-Santasusana P,
Fuentes-Prior P, DeFrutos PG, Sala N. Confirmation of
inherited protein S deficiency by PROS I mutational
screening: Identification of three novel PROS/mutations and haplotype analysis of p.Q279X recurrence.
THROMB HAEMOSTASIS. 100:721-724. I.F.:3,50.
Diaz M, Sevilla P, Galan AM, Escolar G, Engel E, Gil FJ.
Evaluation of Ion Release, Cytotoxicity, and Platelet
9
10 11 12 13 14 15 Adhesion of Electrochemical Anodized 316 L Stainless
Steel Cardiovascular Stents. J BIOMED MATER RES B.
87B:555-561. I.F.:1,93.
Arderiu G, Perez-Pujol S, Escolar G, White JG, Diaz-Ricart M. External calcium facilitates signalling, contractile and secretory mechanisms induced after activation
of platelets by collagen. PLATELETS. 19:172-181.
I.F.:1,92.
Hurtado B, Munoz X, Mulero MC, Navarro G, Domenech P, DeFrutos PG, Perez-Riba M, Sala N. Functional
characterization of twelve natural PROS1 mutations
associated with anticoagulant protein S deficiency.
Tjwa M, Ido-Martin LB, Lin Y, Lutgens E, Plaisance S,
Bono F, Delesque-Touchard N, Herve C, Moura R, Billiau AD, Aparicio C, Levi M, Daemen M, Dewerchin M,
Lupu F, Arnout J, Herbert JM, Waer M, DeFrutos PG,
Dahlback B, Carmeliet P, Hoylaerts MF, Moons L. Gas6
promotes inflammation by enhancing interactions
between endothelial cells, platelets, and leukocytes.
BLOOD. 111:4096-4105. I.F.:10,90.
Lutgens E, Tjwa M, DeFrutos PG, Wijnands E, Beckers
L, Dahlback B, Daemen MJAP, Carmeliet P, Moons L.
Genetic loss of Gas6 induces plaque stability in expeximental atherosclerosis. J PATHOL. 216:55-63. I.F.:5,42.
Diaz-Ricart M, Palomo M, Fuste B, Lopez-Vilchez I,
Carbo C, Perez-Pujol S, White JG, Escolar G. Inhibition
of tyrosine kinase activity prevents the adhesive and
cohesive properties of platelets and the expression of
procoagulant activity in response to collagen. THROMB
RES. 121:873-883. I.F.:2,04.
DelRio-Garma J, Alvarez-Larran A, Martinez C, Muncunill J, Castella D, DeLaRubia J, Zamora C, Corral
M, Viejo A, Pena F, Rodriguez-Vicente P, Contreras E,
Arbona C, Ramirez C, Garcia-Erce JA, Alegre A, Mateo
J, Pereira A. Methylene blue-photoinactivated plasma
versus quarantine fresh frozen plasma in thrombotic
thrombocytopenic purpura: a multicentric, prospective
cohort study. BRIT J HAEMATOL. 143:39-45. I.F.:4,49.
Tonda R, Lopez-Vilchez I, Navalon F, Pino M, Hernandez
MR, Escolar G, Galan AM. Platelets interact with tissue
factor immobilized on surfaces: effects of shear rate.
EUR J CLIN INVEST. 38:34-42. I.F.:2,70.
21/10/09 15:45:35
Reviews
1
2
Fernandez-Fernandez L, Bellido-Martin L, DeFrutos PG.
Growth arrest-specific gene 6 (GAS6). THROMB HAEMOSTASIS. 100:604-610. I.F.:3,50.
Bellido-Martin L, DeFrutos PG. Vitamin K-dependent
actions of Gas6. VITAM HORM. 78:185-209. I.F.:3,89.
Editorials
1
Multicentrics
1
Gomez-Lopez A, Alastruey-Izquierdo A, Rodriguez D,
Almirante B, Pahissa A, Rodriguez-Tudela JL, CuencaEstrella A, Mensa J, Almela M, Reverter J, Soler C.
Prevalence and susceptibility profile of Candida metapsilosis and Candida orthopsilosis: Results from
population-based surveillance of candidemia in Spain.
ANTIMICROB AGENTS CH . 52:1506-1509. I.F.:4,39.
Escolar G. Factor Tisular circulante y asociado a las plaquetas: Papel en la formación de trombos oclusivos sobre
lesiones arteriales, implicaciones fisopatológicas, clínicas
y terapéuticas. Grant: Ministerio Educación y Ciencia,
SAF2006-08003. Duration: 01/10/2006-30/09/2009.
Pablo Garcia. Papel de GAS6 en patología humana: estudios usando modelos animales y celulares. Grant: Ministerio Educación y Ciencia, SAF2004-07539-CO2-01. Duration:
13/12/2004-12/03/2008.
García P. Mecanismos de activación plaquetar en la interacción leucocito-endotelio. Grant: Ministerio Educación y
Ciencia, BFU-2007- 61699. Duration: 01/12/2007-30/11/2010.
2
Carballeiraa MR, DeJuanb C, Reverter JC. Bilateral suprarenal hematoma in a 46-year-old male. MED CLINBARCELONA. 130:71-77. I.F.:1,34.
Lozano M. Platelets come back in from the cold.
BLOOD. 111:2951-2951. I.F.:10,90.
Reverter JC. Cancer y Tromboembolismo: Importancia de
la generación de trombina relacionada con las micropartículas procoagulantes circulantes y los polimorfirmos de
las mismas en el desarrollo de trombosis en los pacientes
de cancer. Grant: Ministerio Sanidad y Consumo, PI070387.
Duration: 26/11/2007-30/12/2010.
Reverter C. Eficacia de un tratamiento de rehabilitación cognitiva en adolescentes con trastornos del espectro de la esquizofrenia. Grant: Instituto de Salud Carlos III, PI07/90054.
Duration: 31/01/2008-30/12/2009.
Escolar G. Red HERACLES: Determinantes genéticos y ambientales de la disfunción vascular. Grant: Instituto de Salud
Carlos III, RD06/0009/1003. Duration: 29/02/2008-31/12/2010.
Thesis
Tassies D. Importancia de los polimorfismos genéticos
relacionados con la adhesión y función procoagulante de
las micropartículas durante la formación del trombo en
el síndrome antifosfolipídico: relación con las trombosis.
01/01/2006-30/12/2008.
Diaz M. Protección del endotelio vascular en la enfermedad
renal crónica: inhibidores del factor de transcripción NF
Kappa B y terapia antioxidante. Grant: Ministerio Sanidad y
Escolar G, Galan A. Factor tisular, inflamación y sistema serotoninérgico: contribución a las complicaciones isquémicas
mediadas por plaquetas. Doctorand: Irene López Vilchez.
Ordinas A. Grup de fisiopatologia, d’hemostasi i trombosi. Grant: Comissionat per a Universitats i Recerca,
2005SGR00952. Duration: 19/10/2005-31/12/2008.
187
154-193 AREA5.indd 187
21/10/09 15:45:37
Molecular and Translational Oncology
Team Members
Molecular and translational oncology
Team Leader:
■ Dr. Pere Gascón Vilaplana
(Hospital Clínic)
Tel.: 93 227 54 02
Fax: 93 454 65 20
188
IDIBAPS Members:
■ Juan José Grau (Hospital Clínic)
■ Joan Maurel (Hospital Clínic)
■ Begoña Mellado (Hospital Clínic)
■ Cristina Nadal (Hospital Clínic)
■ Núria Viñolas (Hospital Clínic)
Collaborators:
Vanessa Almendro (Fundació Clínic)
Elisabet Ametller (Fundació Clínic)
Jordi Codony (Fundació Clínic)
Susana Garcia Recio (Fundació Clínic)
Cristina Mayordomo (Fundació Bosch i Gimpera)
The principal strategic objectives of the laboratory
consist of 3 aspects:
1.A purely scientific aspect: to consolidate the lines of
research and the groups that work on each one.
2. The second objective is to obtain grants and funding for research in order to ensure proper functioning of the laboratory.
3. The third objective involves the expansion of the
laboratory to a larger laboratory that can meed the
scientific needs of the coming years.
The first (scientific) objective should be achieved by
increasing qualitative and quantitative scientific production. In particular, the gastrointestinal stem cell
lines and breast cancer lines that are in an initial stage.
We can attract researchers due to both the topic and
the quality of the research, either for a limited stay, to
prepare a doctoral thesis or to join the laboratory. In
this way, this year we have incorporated three new
people in the group, a new doctoral intern, a postdoctoral researcher and a research support technician.
With regard to the second objective (funding research),
we need to continue in the same vein established some
years ago in order to ensure continued funding of the
lines of research and favor the attracting/contracting of
new personnel. The laboratory currently has two FISS
(2007 and 2008), a grant from the Carlos III networks,
154-193 AREA5.indd 188
Patricia Fernández (Fundació Clínic)
Rafael Villanueva (Hospital Clínic)
Montserrat Muñoz (Hospital Clínic)
Technicians:
Raquel Longarón (Fundació Clínic)
Eva Maria Pastor (Fundació Clínic)
a grant from the Spanish Cancer Association and several research grants from the CELLEX Foundation.
The third point (expansion of the current space) is
essential to prevent asphyxiation due to growth. To
achieve this objective, the laboratory must show a
level of excellence in its research, improve the global
annual impact factor and, obviously, ensure the necessary funding required by a laboratory from the point of
view of personnel, equipment and fungible material.
ITumor chemoresistance mechanisms:
1.Mechanisms of resistance in colorectal cancer linked
to the extrinsic apoptosis pathway in vitro and in
vivo (Dr. Joan Maurel / Dr. Vanessa Almendro).
2.Change in signalling of the Fas receptor during
the acquisition of chemoresistance in colon cancer
(Dr. Vanessa Almendro).
3.Epithelial-mesenchymal transition and resistance to
chemotherapy (Dr. Elisabet Ametller / Dr. Vanessa
Almendro).
IIStem Cell, microenvironment and
metastasis mechanisms:
1. Implication of P substance in the regulation of avb3
and a5b1 in breast cancer cell lines (Dr. Pere Gascón
/ Dr. Vanessa Almendro).
2. Interaction between GPCRs and RTKs (Dr. Vanessa
Almendro).
21/10/09 15:45:44
3. Role of the PPT-I gene in the metastatic process
(Dr. Pere Gascón).
4. Stem cell mesenchymal transition mechanisms
(Dr. Cristina Nadal).
5. Pre-angiogenic micrometastasis of circulating cells
(Dr. Cristina Nadal).
IVStudy of the determination and
characterization of circulating tumor
cells:
1. In prostate cancer (Dr. Begoña Mellado)
2.In breast cancer. (Dr. Montse Muñoz, Dr. Rafael
Villanueva)
PublicaTions
Original Articles
1
3
4
5
6
154-193 AREA5.indd 189
cokinetics of the combination of pertuzumab (rhuMab
2C4) and capecitabine in patients with advanced solid
tumors. CLIN CANCER RES. 14:2726-2731. I.F.:6,25.
7 Gonzalez BO, Martin AG, Barcelo IB, FabregatIMayol X,
Mellado B, Perez MJR, Carrion LA, Herraez AC, Garcia
EC, Galaz CC, Lanza AA, Ibanez AH, Cebrian EA, Velasco AP. A Phase II Trial of Fixed-Dosed Rate Gemcitabine in Platinum-Resistant Ovarian Cancer. AM J CLIN
ONCOL-CANC. 31:481-487. I.F.:1,55.
8 VanCutsem E, Siena S, Humblet Y, Canon JL, Maurel J,
Bajetta E, Neyns B, Kotasek D, Santoro A, Scheithauer
W, Spadafora S, Amado RG, Hogan N, Peeters M. An
open-label, single-arm study assessing safety and
efficacy of panitumumab in patients with metastatic
colorectal cancer refractory to standard chemotherapy.
ANN ONCOL. 19:92-98. I.F.:4,88.
9 Awada A, Albanell J, Canney PA, Dirix LY, Gil T, Cardoso F, Gascon P, Piccart MJ, Baselga J. Bortezomib/
docetaxel combination therapy in patients with anthracycline-pretreated advanced/metastatic breast cancer:
a phase I/II dose-escalation study. BRIT J CANCER.
98:1500-1507. I.F.:4,64.
10 Font A, Salazar R, Maurel J, Taron M, Ramirez JL, Tabernero J, Gallego R, Casado E, Manzano JL, Carcereny E,
Guix M, Fernandez-Llamazares J, Rosell R. Cisplatin plus
weekly CPT-11/docetaxel in advanced esophagogastric cancer: a phase I study with pharmacogenetic assessment of XPD, XRCC3 and UGT1A1 polymorphisms.
CANCER CHEMOTH PHARM. 62:1075-1083. I.F.:2,57.
11 Spano JP, Chodkiewicz C, Maurel J, Wong R, Wasan H,
Barone C, Letourneau R, Bajetta E, Pithavala Y, Bycott
P, Trask P, Liau K, Ricart AD, Kim S, Rixe O. Efficacy of
gemcitabine plus axitinib compared with gemcitabine
alone in patients with advanced pancreatic cancer:
an open-label randomised phase II study. LANCET.
371:2101-2108. I.F.:28,64.
2
Grau JJ, Caballero M, Monzo M, Munoz-Garcia C,
ONCOL. 98:130-134. I.F.:2,38.
RESON IMAGING. 27:625-628. I.F.:2,21.
Marin-Aguilera M, Mengual L, Burset M, Oliver A, Ars
E, Ribal MJ, Colomer D, Mellado B, Villavicencio H,
Algaba F, Alcaraz A. Molecular Lymph Node Staging in
Bladder Urothelial Carcinoma: Impact on Survival. EUR
UROL. 54:1363-1372. I.F.:5,63.
ONCOL. 19:269-275. I.F.:4,88.
N, Carcereny E, Ramirez J, Filella X. Mucins CA 125,
CA 19.9, CA 15.3 and TAG-72.3 as Tumor Markers in
Patients with Lung Cancer: Comparison with CYFRA
21-1, CEA, SCC and NSE. TUMOR BIOL . 29:371-380.
I.F.:2,48.
Albanell J, Montagut C, Jones ET, Pronk L, Mellado B,
Beech J, Gascon P, Zugmaier G, Brewster M, Saunders
MP, Valle JW. A phase I study of the safety and pharma-
I.F.: 58,86
IIIPharmacodynamic studies and predictive
studies in the therapeutic response:
1. Predictive and pharmacodynamic study of the response to neoadjuvant chemotherapy in prostate
cancer. (Dr. B. Mellado).
2. NFKB and chemo resistance in prostate cancer (Dr.
B. Mellado).
189
21/10/09 15:45:49
12 Sobrero AF, Maurel J, Fehrenbacher L, Scheithauer W,
Abubakr YA, Lutz MP, Vega-Villegas ME, Eng C, Steinhauer EU, Prausova J, Lenz HJ, Borg C, Middleton G,
Kroning H, Luppi G, Kisker O, Zubel A, Langer C, Kopit
J, Burris HA. EPIC: Phase III trial of cetuximab plus irinotecan after fluoropyrimidine and oxaliplatin failure in
patients with metastatic colorectal cancer. J CLIN ONCOL. 26:2311-2319. I.F.:15,48.
13 Lipton A, Steger GG, Figueroa J, Alvarado C, Solal-Celigny P, Body JJ, DeBoer R, Berardi R, Gascon P, Tonkin
KS, Coleman RE, Paterson AHG, Gao GZM, Kinsey AC,
Peterson MC, Jun S. Extended Efficacy and Safety of
Denosumab in Breast Cancer Patients with Bone Metastases Not Receiving Prior Bisphosphonate Therapy.
CLIN CANCER RES. 14:6690-6696. I.F.:6,25.
14 Domingo-Domenech J, Pippa R, Tapia M, Gascon P,
Bachs O, Bosch M. Inactivation of NF-kappa B by proteasome inhibition contributes to increased apoptosis
induced by histone deacetylase inhibitors in human
breast cancer cells. BREAST CANCER RES TR. 112:53-62.
I.F.:4,45.
15 Padua D, Zhang XHF, Wang QQ, Nadal C, Gerald WL,
Gomis RR, Massague J. TGF beta primes breast tumors
for lung metastasis seeding through angiopoietin-like
4. CELL. 133:66-77. I.F.:29,89.
Multicentrics
1
2
Casali PG, Jost L, Reichardt P, Schlemmer M, Blay JY.
Gastrointestinal stromal tumors: ESMO Clinical Recommendations for diagnosis, treatment and follow-up.
ANN ONCOL. 19:35-38. I.F.:4,88.
Casali PG, Jost L, Sleijfer S, Verweij J, Blay JY. Soft
tissue sarcomas: ESMO Clinical Recommendations
for diagnosis, treatment and follow-up. ANN ONCOL.
19:89-93. I.F.:4,88.
Mellado B. Estudio de biomarcadores séricos y tumorales de activación de la via NF-KB en cáncer de próstata.
26/11/2007-30/12/2010.
Thesis
Gascon P. Estudi dels mecanismes de tall proteolític i rutes
de transducció de senyals de receptors de membrana de la
família “Epidermal Growth Factor” i factors de transcripció
(NOR-90) relacionats amb l’acció de drogues antitumorals.
Doctorand: Jordi Codony Servat.
Editorials
Patents
1
Pere Gascón, Vanessa Almendro. Anticuerpos para el tratamiento del cáncer.
2
Grau JJ, Estrach T. Old masters as clinical photographers: multifocal breast cancer diagnosed 400 years
ago. BREAST CANCER RES TR . 111:11-13. I.F.:4,45.
Aapro MS, Birgegard G, Bokemeyer C, Cornes P,
Foubert J, Gascon P, Glaspy J, Hellstrom-Lindberg E,
Link H, Ludwig H, Osterborg A, Repetto L, Soubeyran
P. Erythropoietins should be used according to guidelines. LANCET ONCOL. 9:412-413. I.F.:12,25.
190
154-193 AREA5.indd 190
21/10/09 15:45:51
Cell Proliferation and Signalling
Team members
Team Leader:
■ Oriol Bachs (UB-Faculty of Medicine)
Tel.: 93 403 52 86
Fax: 93 402 19 07
Collaborators:
Marta Bosch (IDIBAPS)
Sandra Guaita (Facultat Medicina)
Montserrat Jaumot (UB-Faculty of Medicine)
Maria Jesús Pujol (UB-Faculty of Medicine)
Eulalia Rius (UB-Faculty of Medicine)
Teresa Royo (IDIBAPS)
The general objective of the group is to analyze the
mechanisms that regulate cell proliferation and signalling in different experimental conditions and cell
models. To achieve this goal, the group is developing
4 major lines of research:
1. Cell proliferation and cancer.
2. Cell signalling.
3. Signalling and regulation of the cell cycle.
4. Cell cycle: transduction of signals and checkpoints.
1. Cell proliferation and cancer
The objective of this line of research is to analyze
the mechanisms that control progression of the cell
cycle and its alterations in oncogenesis. Specifically,
we are studying the following:
• The role of protein p27 in oncogenesis. There is evidence that reduced levels of p27 in tumors is linked
154-193 AREA5.indd 191
Technicians:
Sonia Brun (UB-Faculty of Medicine)
Ana Dominguez (UB-Faculty of Medicine)
Alba Fajardo (UB-Faculty of Medicine)
María Molinos (UB-Faculty of Medicine)
Jaume Planas (UB-Faculty of Medicine)
to a poor outcome. The aim is to identify the role of
p27 in tumor development.
•The role of acetylation of proteins that regulate the
cell cycle in the control of proliferation. The specific
aim is to study the functional relevance of acetylation of p27, cyclin A and cdk2.
•The role of the SET protein in oncogenesis. We are
studying whether the role of this protein in the development of tumors is mediated by the phosphatase PP2A or by its phosphorylation by CK2.
2.Cell signalling
In this line of research, we study the molecular mechanisms of endocytosis, intracellular protein and
cholesterol transport and the signalling processes in
the endocytic compartment and the plasma membrane that may be involved in different diseases, such as
those that cause accumulation of lipids and cholesterol or in cancer. Specifically, we are working on the
aspects described below:
•Role of annexin A6 in cell signalling. Analysis of
the role of annexin A6 (a) in the formation of H-Ras-
Doctoral Students:
Alba Gómez (UB-Faculty of Medicine)
Blanca Alvarez (UB-Faculty of Medicine)
Elena Gonzalez (UB-Faculty of Medicine)
Eva Lambea (UB-Faculty of Medicine)
Albert Lu (UB-Faculty of Medicine)
Francesca Mateo (UB-Faculty of Medicine)
María Pérez (UB-Faculty of Medicine)
Raffaella Pippa (Facultat Medicina)
Ignasi Salaet (UB-Faculty of Medicine)
Patricia Sanz (UB-Faculty of Medicine)
Maria Teresa Vidal (UB-Faculty of Medicine)
Miriam Vidal (UB-Faculty of Medicine)
Sandra Vila (UB-Faculty of Medicine)
Marta Sanchez (UB-Faculty of Medicine)
Serena Orlando (IDIBAPS)
Albert Herms (IDIBAPS)
Meritxell Reverter (Facultat Medicina)
Adam Kassan (IDIBAPS)
Alba Llopis (Facultat Medicina)
Carles Barceló (Facultat Medicina)
Noelia Marcos (UB-Faculty of Medicine)
Natalia de Olano (UB-Faculty of Medicine)
Cell proliferation and signalling
IDIBAPS Members:
■ Neus Agell (UB-Faculty of Medicine)
■ Rosa Aligué (UB-Faculty of Medicine)
■ Carles Enrich (UB-Faculty of Medicine)
■ Albert Pol (IDIBAPS)
■ Francesc Tebar (UB-Faculty of Medicine)
191
21/10/09 15:45:54
p120GAP complexes and in the inactivation of Ras
and (b) in the transport of caveolin and in the formation of caveolae.
• Biogenesis of lipid bodies. Study of the biogenesis
of lipid bodies and their role in the transport of caveolin, intracellular accumulation of lipids and proliferative activation.
• Role of calmodulin in the regulation of intracellular
traffic of EGFR. Analysis of the role of calmodulin
and of PKCd in the regulation of traffic and signalling and degradation of EGFR and transport of LDL
through the early and late compartments of the endocytic compartment.
3. Signalling and regulation of the cell cycle
This line of research focuses on identification of the molecular mechanisms that regulate control of the cell cycle via the pathway of MAP kinases activated by stress
in yeast cells and cultures of human normal and tumor
cells. This research is divided into two lines of work:
• Regulation of mitosis via the pathway of MAP kinases activated by stress in yeast cells. We aim to
identify a) the mechanisms by which Srk1 regulates
the restart of mitosis after blocking in phase G2 in
response to stress, b) the specific components regulated by Srk1 in blocking the exit from mitosis
produced by Srk1 and c) the molecular mechanisms
by which Srk1 negatively regulates the activity of
the p38/Sty1 kinase.
• Regulation of mitosis via the pathway of MAP kinases activated by stress in cultures of normal and tumor cells. We aim to identify a) the mechanisms by
which MK2 regulates the induction of apoptosis via
the E2F1 transcription factor and b) new substrates
of the MAPKAP-K2 kinase via the TAP purification
system and proteomic analysis.
•Regulation
of the functionality of K-Ras by phosphorylation and binding to calmodulin. We aim to
analyze the functional relevance of KRas and pre
PKC and of the interaction with calmodulin.
•Regulation of the functionality and intracellular
location of p21Cip1 by phosphorylation and binding to calmodulin. We are currently analyzing the
intracellular location of p21 in response to DNA damage and how its functionality may be regulated
by phosphorylation or binding to calmodulin.
•DNA replication checkpoint. We have shown that
while colon cancer cells are fully dependent on
ATR/ATM for inhibiting entry into mitosis in response to DNA synthesis inhibitors, the untransformed cells have parallel mechanisms, which allows
them to better maintain the integrity of the genome when DNA replication problems occur.
Localization of Cdc25 when mitosis-inhibiting
kinases Srk1 and Wee1 are overexpressed.
4. Cell cycle: transduction of signals
and checkpoints
The objective of this line of work is to analyze the intracellular mechanisms of transduction of the signals
that regulate the progression of the cell cycle and their
control mechanisms or checkpoints. In relation to this
general objective, in recent years, we have developed
the following lines of research:
Colocalization of the cdk4/6 inhibitor p16 and of PCNA
in the nucleus of NP18 cells (pancreatic cancer).
I.F.: 64,27
PublicaTions
Original Articles
192
1
2
154-193 AREA5.indd 192
Civico S, Agell N, Hernandez L, Campo E, Bachs O,
Balasch J. Increased messenger ribonucleic acid
expression of the cyclin-dependent kinase inhibitor
p27(Kip1) in cleavage-stage human embryos exhibiting developmental arrest. FERTIL STERIL. 89:15571562. I.F.:3,17.
Domingo-Domenech J, Pippa R, Tapia M, Gascon P,
Bachs O, Bosch M. Inactivation of NF-kappa B by proteasome inhibition contributes to increased apoptosis
induced by histone deacetylase inhibitors in human
3
4
breast cancer cells. BREAST CANCER RES TR. 112:5362. I.F.:4,45.
Lopez-Aviles S, Lambea E, Moldon A, Grande M, Fajardo
A, Rodriguez-Gabriel MA, Hidalgo E, Aligue R. Activation
of Srk1 by the mitogen-activated protein kinase Sty1/Spc1
precedes its dissociation from the kinase and signals its
degradation. MOL BIOL CELL. 19:1670-1679. I.F.:6,03.
Cubells L, DeMuga SV, Tebar F, Bonventre JV, Balsinde J, Pol A, Grewal T, Enrich C. Annexin A6-induced
inhibition of cytoplasmic phospholipase A(2) is linked
to caveolin-1 export from the Golgi. J BIOL CHEM.
283:10174-10183. I.F.:5,58.
21/10/09 15:45:59
5
Pol A. Papel de la caveolina y de los cuerpos lipídicos en
el control de la regeneración hepática. Grant: Ministerio
Enrich C. Red temática investigación cooperativa de cáncer.
Grant: Ministerio Sanidad y Consumo, RD06/0020/0008. Duration: 01/01/2007-31/12/2010.
Tebar F. Regulación por calmodulina de la activación, localización, tráfico y señalización celular del EGFR. Grant: Ministerio de Educación y Ciencia, BFU2007-67652. Duration:
01/12/2007-30/11/2009.
Enrich C. Ras/Mapk signalling regulates colesterol efflux.
Grant: Marato TV3, 0. Duration: 01/01/2008-31/12/2010.
Bachs O. Proteored. Grant: Genoma España. Duration:
01/06/2005-01/06/2010.
Enrich C. Estudio espacio-temporal de los complejos proteínicos de la annexina A6: Implicaciones en la regulación
del tráfico y la señalización. Grant: Ministerio de Educación y Ciencia, BFU2006-01151. Duration: 01/10/2006-30/09/2009.
Agell N. Regulación de la función de K-Ras y su localización
en microdominios de membrana plasmática por unión a
calmodulina y fosforilación en Ser181. Grant: Ministerio de
Aligué R. Mecanismos de regulación en la señalización de
las MAPK activadas por estrés y la división celular: Estudio
de la MAPKAP SRK1, nuevo componente del checkpoint
de entrada en mitosis en levadura. Grant: Ministerio de
Bachs O. Identificación de nuevas funciones celulares del
regulador de ciclo celular p27(Kip1). Grant: Ministerio de
Enrich C. Diana Caveola. Grant: Ministerio de Educación y
Ciencia. Proyetco Cenit (Consorcio Nanofarma), IP004543.
Duration: 01/01/2006-31/12/2009.
Agell N. IP: Presence: Research Encompassing Sensory
Enhancement, Neuroscience, Cerebral-Computer Interfaces
and ApplicationsCentre coordinador: Universitat Politecnica
de Catalunya. Grant: Universitat Politècnica de CatalunyaDocència, 27731. Duration: 01/01/2008-31/12/2009.
Moreto J, Llado A, Vidal-Quadras M, Calvo M, Pol A,
Enrich C, Tebar F. Calmodulin modulates H-Ras mediated Raf-1 activation. CELL SIGNAL. 20:1092-1103.
I.F.:4,15.
6 Grande M, Lambea E, Fajardo A, Lopez-Aviles S, Kellogg D, Aligue R. Crosstalk between Nap1 protein and
Cds1 checkpoint kinase to maintain chromatin integrity.
BBA-MOL CELL RES. 1783:1595-1604. I.F.:4,37.
7 Menendez M, Gonzalez S, Obrador-Hevia A, Dominguez
A, Pujol MJ, Valls J, Canela N, Blanco I, Torres A, Pineda-Lucena A, Moreno V, Bachs O, Capella G. Functional
characterization of the novel APC N1026S variant associated with attenuated familial adenomatous polyposis.
8 Lopez-Alcala C, Alvarez-Moya B, Villalonga P, Calvo M,
Bachs O, Agell N. Identification of essential interacting
elements in K-Ras/calmodulin binding and its role in
K-Ras localization. J BIOL CHEM. 283:10621-10631.
I.F.:5,58.
9 DeMattos SF, Alemany V, Aligue R, Tauler A. Increase
in Fru-2,6-P-2 levels results in altered cell division in
Schizosaccharomyces pombe. BBA-MOL CELL RES.
1783:144-152. I.F.:4,37.
10 Llado A, Timpson P, DeMuga SV, Moreto J, Pol A, Grewal
T, Daly RJ, Enrich C, Tebar F. Protein kinase C delta and
calmodulin regulate epidermal growth factor receptor
recycling from early endosomes through Arp2/3 complex
and cortactin. MOL BIOL CELL. 19:17-29. I.F.:6,03.
11 Hernandez D, Altuna M, Cuevas C, Aligue R, Albericio F,
Alvarez M. Synthesis and antitumor activity of mechercharmycin a analogues. J MED CHEM. 51:5722-5730.
I.F.:4,90.
12 Niemeier A, Niedzielska D, Secer R, Schilling A, Merkel
M, Enrich C, Rensen PCN, Heeren J. Uptake of postprandial lipoproteins into bone in vivo: Impact on osteoblast function. BONE. 43:230-237. I.F.:3,97.
Tebar F. Regulación por calmodulina de la activación, localización, tráfico y señalización celular del EGRF. Grant: Ministerio de Educación y Ciencia, BFU2007-67652. Duration:
01/12/2007-30/11/2009.
Bachs O. Red temática de investigación cooperativa de cáncer. Grant: Ministerio Sanidad y Consumo, RD06/0020/0010.
Duration: 01/01/2007-31/12/2010.
193
154-193 AREA5.indd 193
21/10/09 15:46:02
194-203 AREA6.indd 194
21/10/09 15:36:45
Area 6
International Health
Research Group on Epidemiology and International Health (GRESI) . . . . . . . 196
Hospital Epidemiology, Public Health and Pharmacology . . . . . . . . . . . . . . . . . . . . . . 201
Image: Bacteria Cell Cluster Abstract in Green Tones
194-203 AREA6.indd 195
21/10/09 15:36:48
Research Group on Epidemiology and International Health (GRESI)
Team Members
Area 6 International Health
Research group on epidemiology and
international health (GRESI)
Team Leader:
■ Pedro Alonso (Hospital Clínic)
Tel.: 93 227 54 00 (Ext.: 5706/
Fax: 93 227 98 53
IDIBAPS Members:
■ Carlos Ascaso (Facultat de Medicina)
■ Joaquim Gascón (Hospital Clínic)
■ Alfredo Mayor (Fundació Clínic)
■ Clara Menéndez (Hospital Clínic)
■ Denise Naniche (IDIBAPS)
■ Anna Roca (IDIBAPS)
■ Joaquín Ruiz (IDIBAPS)
Collaborators:
John J. Aponte (Fundació Clínic)
Azucena Bardají (Fundació Clínic)
Quique Bassat (Fundació Clinic)
Carlota Dobaño (Fundació Clínic)
Caterina Guinovart (Fundació Clínic)
Emili Letang (Fundació Clínic)
José Muñoz (Hospital Clínic)
Robert Pool (Fundació Clínic)
Jahit Sacarlal (Fundació Clínic)
Ruth Aguilar
Tamara Katherine Berthoud
Joseph John Campo
Hernando del Portillo
Raquel González
María Jesús Pinazo
Elizabeth Posada
Elisa Sicuri
Ned Hayes
196
One of the greatest imbalances between developed
and developing countries is the few resources that
are dedicated, overall, to research on the health problems that affect the poorest countries. These diseases,
known as poverty-related diseases, are not just the result of the poverty of these populations but also hinder
their development, generating a vicious circle of disease and poverty.
The objective of the Research Group on Epidemiology
and International Health is to research the diseases
that are the principal cause of morbidity and mortality
in developing countries. The group has a multidisciplinary focus that covers aspects from basic research
to epidemiology and the development of monitoring
194-203 AREA6.indd 196
Montse Renom
Nayra Gutiérrez
Ana Belen Ibarz
Bethuel Sigauque
Doctoral Students:
Cristina O’Callaghan (Beca FIS)
Eduard Rovira (Beca MEC)
Elisa Serra (Beca FIS)
Celia Serna
Maria Jesus Pons
Núria Diez
Rachid Ben Messaoud
Imane Jroundi
Nélia Manaca
Inácio Mandomando
Augusto Nhabomba
Diana Quelhas
Technicians:
Pau Cisteró (Fundació Clínic)
Alfons Jiménez (Fundació Clínic)
Diana Barrios
tools. The aim is to translate the results obtained to
the clinical practice and health care policies of the developing countries.
A large part of the research is carried out in collaboration with the Centro de Investigação em Saúde da Manhiça (CISM) in Mozambique, and with other institutions
in Africa, India, Papua New Guinea and Latin America.
1.Malaria
1.1. P
athophysiology of severe malaria and malaria in
pregnancy.
1.2.Epidemiologic studies to determine the disease
load due to P. vivax
21/10/09 15:36:51
1.3. Immunology: study of acquired immunity due
to natural exposure and immunity induced by
vaccines
1.4. Development of treatment and monitoring tools
• Vaccines: program to develop a clinical candidate for vaccine RTS,S/AS01E
• Clinical development of antimalarial drugs
• New drugs for preventive treatment of malaria
in children and pregnant women (IPTi and IPTp)
1.5. Evaluation of the effectiveness of malaria control
programs
5.Enteropathogens
5.1. E
pidemiological surveillance (disease load, etiology, molecular epidemiology, susceptibility to antibiotics, etc.) of diarrhea
5.2. S
tudy of the mechanism of antibiotic resistance
and virulence profile of enteroaggregative E. coli.
I.F.: 98,20
PublicaTions
Original Articles
1
2
3
4
Ruiz J, Mensa L, Pons MJ, Vila J, Gascon J. Development of Escherichia coli rifaximin-resistant mutants:
frequency of selection and stability. J ANTIMICROB
CHEMOTH. 61:1016-1019. I.F.:4,04.
Camps M, Vilella A, Marcos MA, Letang E, Muñoz J,
Pumarola T. Incidence of respiratory viruses among
travelers with a febrile syndrome returning from tropical and subtropical areas. J MED VIROL. 80:711-715.
I.F.:2,83.
Mendez-Arancibia E, Vargas M, Soto S, Ruiz J, Kahigwa
E, Schellenberg D, Urassa H, Gascon J, Vila J. Prevalence of different virulence factors and biofihn production
in enteroaggregative Escherichia coli isolates causing
diarrhea in children in Ifakara (Tanzania). AM J TROP
MED HYG. 78:985-989. I.F.:2,18.
Mensa L, Marco F, Vila J, Gascon J, Ruiz J. Quinolone
resistance among Shigella spp. isolated from travellers
194-203 AREA6.indd 197
5
6
7
8
returning from India. CLIN MICROBIOL INFEC. 14:279281. I.F.:2,98.
Arrizabalaga P, Sole M, Abellana R, Ascaso C. Renal
expression of adhesion molecules in Anca-associated
disease. J CLIN IMMUNOL. 28:411-419. I.F.:2,89.
11:193-200. I.F.:1,91.
Menendez C, Romagosa C, Ismail MR, Carrilho C, Saute
F, Osman N, Machungo F, Bardaji A, Quinto L, Mayor A,
Naniche D, Dobaño C, Alonso PL, Ordi J, Alonso P. An
autopsy study of maternal mortality in mozambique:
The contribution of infectious diseases. PLOS MED.
5:220- 226. I.F.:12,60.
Naniche D, Lahuerta M, Bardaji A, Sigauque B, Romagosa C, Berenguera A, Mandomando I, David C, Sanz
S, Aponte J, Ordi J, Alonso P, Menendez C. Mother-tochild transmission of HIV-1: association with malaria
International Health Area 6
3.HIV/AIDS
3.1. Prevention of vertical transmission of HIV/AIDS
3.2. Prevention of sexual transmission: acceptability
and viability of the use of microbicides and preparation of clinical trials of HIV vaccines
3.3. Infection and Epidemiology: incidence, prevalence and study of recent infections and acute
infections
3.4. Clinical Practice and Treatment: immune reconstitution after initiating antiretroviral treatment, acceptability and adherence to treatment
2. Chagas Disease
2.1. Epidemiology of Chagas disease in the immigrant
population and impact on the health care system
in Catalonia
2.2. Clinical studies of cardiac and digestive system
involvement
2.3. Research into biological markers of progression
and curing of the disease
2.4. Study of demographic, social and cultural differences and level of knowledge about the disease
among immigrants
2.5. Study of access to specialist care by the immigrant
population in Catalonia
4.Acute Respiratory Infections
4.1. E
pidemiological surveillance (disease load, etiology, molecular epidemiology, susceptibility to antibiotics, etc.) of pneumonia and of meningitis and
bacteremia
4.2. E
valuation of the impact of introducing the Hib vaccine in Mozambique
4.3. S
tudy of biomarkers for developing diagnostic
tools adapted to environments with limited resources and infrastructure
197
23/10/09 10:39:46
9
10 Research group on epidemiology and
11 12 13 14 Area 6 International Health
15 16 17 18 19 198
20 21 194-203 AREA6.indd 198
prevention, anaemia and placental malaria. HIV MED.
9:757-764. I.F.:3,35.
Muñoz J, Alonso D, Vilella A, Naniche D, Costa J, Gascon J. Measles in travelers: Are we aware enough?. J
TRAVEL MED. 15:124-125. I.F.:1,05.
Muñoz J, Vilella A, Domingo C, Nicolas JM, DeOry F,
Corachan M, Tenorio A, Gascon J. Yellow fever-associated viscerotropic disease in Barcelona, Spain. J TRAVEL
MED. 15:202-205. I.F.:1,05.
Mabunda S, Casimiro S, Quinto L, Alonso P. A countrywide malaria survey in Mozambique. I. Plasmodium
falciparum infection in children in different epidemiological settings. MALARIA J. 7:-. I.F.:2,47.
Sigauque B, Roca A, Oliveiras I, Martinez M, Mandomando I, Valles X, Espasa M, Abacassamo F, Sacarlal
J, Macete E, Nhacolo A, Aponte J, Levine MM, Sanz S,
Alonso P. Acute bacterial meningitis among children, in
Manhica, a rural area in Southern Mozambique. ACTA
TROP. 105:21-27. I.F.:2,00.
Muñoz J, Puente S, Lopez-Velez R, Domingo C, Ruiz
J, Ramirez G, Navarro M, DeOry F, Sanz S, Rivas P,
Turrientes MC, Tenorio A, Gascon J. Clinical and epidemiological features of imported dengue in Spain. MED
Bardaji A, Sigauque B, Bruni L, Romagosa C, Sanz S,
Mabunda S, Mandomando I, Aponte J, Sevene E, Alonso PL, Menendez C. Clinical malaria in African pregnant
women. MALARIA J. 7:-. I.F.:2,47.
Salvado E, Pinazo MJ, Muñoz J, Alonso D, Naniche D,
Mayor A, Quinto L, Gascon J. Clinical presentation and
complications of Plasmodium falciparum malaria in
two populations: travelers and immigrants. ENFERM
INFEC MICR CL. 26:282-284. I.F.:1,10.
Ruiz J, Herrera-Leon S, Mandomando I, Macete E, Puyol L, Echeita A, Alonso PL. Detection of Salmonella
enterica serotype typhimurium DT104 in Mozambique.
AM J TROP MED HYG . 79(6):918-920. I.F.:2,18.
Mushi AK, Schellenberg J, Mrisho M, Manzi F, Mbuya
C, Mponda H, Mshinda H, Tanner M, Alonso P, Pool
R, Schellenberg D. Development of behaviour change
communication strategy for a vaccination-linked malaria control tool in Southern Tanzania. MALARIA J. 7:-.
I.F.:2,47.
Gascon J, Albajar P, Canas E, Flores M, GomezIPrat
J, Herrera RN, Lafuente CA, Luciardi HL, Moncayo
A, Molina L, Muñoz J, Puente S, Sanz G, Trevino B,
Sergio-Salles X. Diagnosis, management and treatment
of chronic Chagas’ heart disease in areas where Trypanosoma cruzi infection is not endemic. ENFERM INFEC
MICR CL. 26:99-106. I.F.:1,10.
Sikora M, Ferrer-Admetlla A, Mayor A, Bertranpetit
J, Casals F. Evolutionary analysis of genes of two pathways involved in placental malaria infection. HUM
GENET. 123:343-357. I.F.:3,97.
Manzi F, Hutton G, Schellenberg J, Tanner M, Alonso
P, Mshinda H, Schellenberg D. From strategy development to routine implementation: the cost of Intermittent Preventive Treatment in Infants for malaria control.
BMC HEALTH SERV RES. 8:-. I.F.:1,36.
Schellenberg JRA, Mrisho M, Manzi F, Shirima K,
Mbuya C, Mushi AK, Ketende SC, Alonso PL, Mshinda
H, Tanner M, Schellenberg D. Health and survival of
22 23 24 25 26 27 28 29 30 31 32 young children in southern Tanzania. BMC PUBLIC
HEALTH. 8:-. I.F.:1,63.
Quelhas D, Puyol L, Quinto L, Serra-Casas E, Nhampossa T, Macete E, Aide P, Mayor A, Mandomando I, Sanz
S, Aponte JJ, Chauhan VS, Chitnis CE, Alonso PL, Menendez C, Dobaño C. Impact of intermittent preventive
treatment with sulfadoxine-pyrimethamine on antibody
responses to erythrocytic-stage Plasmodium falciparum antigens in infants in Mozambique. CLIN VACCINE
IMMUNOL. 15:1282-1291. I.F.:2,00.
Millet JP, DeOlalla PG, Carrillo-Santisteve P, Gascon J,
Trevino B, Muñoz J, Prat JGI, Cabezos J, Cordon AG,
Cayla JA. Imported malaria in a cosmopolitan European city: A mirror image of the world epidemiological
situation. MALARIA J. 7:-. I.F.:2,47.
Roca A, Quinto L, Abacassamo F, Morais L, Valles X, Espasa M, Sigauque B, Sacarlal J, Macete E, Nhacolo A,
Mandomando I, Levine MM, Alonso P. Invasive Haemophilus influenzae disease in children less than 5 years
of age in Manhica, a rural area of southern Mozambique. TROP MED INT HEALTH. 13:818-826. I.F.:2,47.
Guinovart C, Bassat Q, Sigauque B, Aide P, Sacarlal J,
Nhampossa T, Bardaji A, Nhacolo A, Macete E, Mandomando I, Aponte JJ, Menendez C, Alonso PL. Malaria in
rural Mozambique. Part I: Children attending the outpatient clinic. MALARIA J. 7:-. I.F.:2,47.
Bassat Q, Guinovart C, Sigauque B, Aide P, Sacarlal J,
Nhampossa T, Bardaji A, Nhacolo A, Macete E, Mandomando I, Aponte JJ, Menendez C, Alonso PL. Malaria in
rural Mozambique. Part II: Children admitted to hospital. MALARIA J. 7:-. I.F.:2,47.
Mandomando IM, Naniche D, Pasetti MF, Valles X,
Cuberos L, Nbacolo A, Kotloff KL, Martins H, Levine
MM, Alonso P. Measles-specific Neutralizing Antibodies
in Rural Mozambique: Seroprevalence and Presence
in Breast Milk. AM J TROP MED HYG . 79:787-792.
I.F.:2,18.
Mayor A, Serra-Casas E, Sanz S, Aponte JJ, Macete E,
Mandomando I, Puyol L, Berzosa P, Dobaño C, Aide P,
Sacarlal J, Benito A, Alonso P, Menendez C. Molecular
markers of resistance to sulfadoxine-pyrimethamine
during intermittent preventive treatment for malaria
in Mozambican infants. J INFECT DIS. 197:1737-1742.
I.F.:6,04.
Navarro P, Garcia-Esteve L, Ascaso C, Aguado J, Gelabert E, Martin-Santos R. Non-psychotic psychiatric disorders after childbirth: Prevalence and comorbidity in
a community sample. J AFFECT DISORDERS. 109:171176. I.F.:3,14.
Gene-Badia J, Ascaso C, Escaramis-Babiano G, Catalan-Ramos A, Pujol-Ribera E, Sampietro-Colom L.
Population and primary health-care team characteristics explain the quality of the service. HEALTH POLICY.
86:335-344. I.F.:1,14.
Lahuerta M, Aparicio E, Bardaji A, Marco S, Sacarlal
J, Mandomando I, Alonso P, Martinez MA, Menendez
C, Naniche D. Rapid spread and genetic diversification
of HIV type 1 subtype C in a rural area of Southern
Mozambique. AIDS RES HUM RETROV. 24:327-335.
I.F.:2,02.
Sacarlal J, Aponte JJ, Aide P, Mandomando I, Bassat
Q, Guinovart C, Leach A, Milman J, Macete E, Espasa
21/10/09 15:36:57
33 34 36 Reviews
1
Mayor A. Caracterización del ligando de P. falciparum implicado en adhesión a la placenta y de su papel en el desarrollo de la inmunidad frente a la malaria durante el embarazo.
18/10/2006-30/12/2009.
Ruiz J. Relevancia y caracterización epidemiológico molecular de Escherichia coli enteroagregativo como causa de diarrea en niños menores de 5 años. Grant: Ministerio Sanidad
Naniche D. Evaluación de parámetros inmunológicos durante el primer año de vida de los niños negativos para el
Virus de la Inmunodeficiencia Humana (VIH), nacidos de
madres VIH positivas en Mozambique. Grant: Ministerio
Menendez C. Evaluación de 4 combinaciones de artemisina
para el tratamiento de la malaria no complicada en niños
en Africa. Grant: Ministerio Sanidad y Consumo, PI070450
(EDCTP). Duration: 26/11/2007-30/12/2010.
Alonso P. Ayuda complementaria al proyecto europeo: Malaria Age Exposure. Grant: Ministerio Educación y Ciencia,
SAF2005-25642-E. Duration: 07/05/2006-07/05/2010.
Naniche D. Creación de una red europea-africana para la
preparación de centros africanos en ensayos de vacunas
con el VIH. Grant: Ministerio Sanidad y Consumo, PI071312.
Duration: 01/01/2008-30/12/2010.
Editorials
1
Gascon J, Pinazo MJ. Controlling vertical transmission
of Trypanosoma cruzi: the biggest challenge for imported disease in Spain. ENFERM INFEC MICR CL. 26:607608. I.F.:1,10.
Gascon J. Estudio de la infecció per Trypanosoma cruzi en
la població immigrant d’Amèrica Central i del Sud. Grant:
Agència d’Avaluació de Tecnologia Mèdica, 024/13/2004.
Duration: 01/04/2005-31/03/2008.
Alonso P. Grup de Recerca en Epidemiologia i Salut Internacional, GRESI. Grant: Generalitat de Catalunya,
2005SGR00253. Duration: 19/10/2005-31/12/2008.
Alonso P. Age of exposure and immunity to malaria in infants. Grant: Ministerio Sanidad y Consumo, AI07/90024.
Duration: 26/10/2007-30/12/2009.
Alonso P. Epidemiología y Salud Pública. Grant: Ministerio
Sanidad y Consumo, CB06/02/0010. Duration: 28/07/200627/07/2010.
194-203 AREA6.indd 199
Naniche D. Beca Ramón y Cajal. Grant: Ministerio Educación y Ciencia. Duration: 01/01/2004-01/04/2009.
2
Coll O, Menendez C, Botet F, Daya R, Carbonell-Estrany
X, Weisman LE, Anceschi MM, Greenough A, Gibss RS,
Ville Y. Treatment and prevention of malaria in pregnancy and newborn. J PERINAT MED. 36:15-29. I.F.:1,10.
Greenwood BM, Fidock DA, Kyle DE, Kappe SHI,
Alonso PL, Collins FH, Duffy PE. Malaria: progress,
perils, and prospects for eradication. J CLIN INVEST .
118:1266-1276. I.F.:16,92.
Naniche D. Projecte d’activitats relacionades amb el tractament antiretroviral del VIH/SIDA al centre de salut de
Manhiça, per col·laborar amb el programa de lluita contra
la sida de Moçambic. Grant: Fundació La Caixa, CO05215.
Duration: 01/11/2005-31/10/2008.
35 M, Ofori-Anyinam O, Thonnard J, Corachan S, Dubois
MC, Lievens M, Dubovsky F, Ballou WR, Cohen J, Alonso PL. Safety of the RTS,S/AS02A malaria vaccine in
Mozambican children during a Phase IIb trial. VACCINE.
26:174-184. I.F.:3,38.
Piron M, Verges M, Muñoz J, Casamitjana N, Sanz S,
Maymo RM, Hernandez JM, Puig L, Portus M, Gascon
J, Sauleda S. Seroprevalence of Trypanosoma cruzi
infection in at-risk blood donors in Catalonia (Spain).
TRANSFUSION. 48:1862-1868. I.F.:3,37.
Abellana R, Ascaso C, Aponte J, Saute F, Nhalungo
D, Nhacolo A, Alonso P. Spatio-seasonal modeling
of the incidence rate of malaria in Mozambique.
MALARIA J. 7:-. I.F.:2,47.
Castellsague X, Klaustermeier J, Carrilho C, Albero G,
Sacarlal J, Quint W, Kleter B, Lloveras B, Ismail MR,
DeSanjose S, Bosch FX, Alonso P, Menedez C. Vaccinerelated HPV genotypes in women with and without cervical cancer in Mozambique: Burden and potential for
prevention. INT J CANCER. 122:1901-1904. I.F.:4,56.
Calleri G, Behrens RH, Bisoffi Z, Bjorkman A, Castelli F,
Gascon J, Gobbi F, Grobusch MP, Jelinek T, Schmid ML,
Niero M, Caramello P. Variability in malaria prophylaxis
prescribing across Europe: A Delphi method analysis. J
TRAVEL MED. 15:294-301. I.F.:1,05.
Roca A. Etiología, epidemiología y clínica de las infecciones respiratorias virales en niños mozambicanos <5 años.
Grant: Ministerio Sanidad y Consumo, PI 050172. Duration:
01/01/2006-31/12/2008.
Alonso P. New Legal structures and sustain research centers
in Africa: The Manhiça Foundation. Grant: Bill and Melinda
Gates Foundation. Duration: 02/10/2006-01/10/2011.
Menendez C. Cost-effectiveness of Intermittent Preventive
Treatment in Infants (IPTi) for the control of Malaria and
Anaemia. Grant: Bill and Melinda Gates Foundation. Duration: 01/05/2006-30/01/2009.
199
Ascaso C. Análisis de la Variabilidad espacial y temporal
del producto de la atención primaria en Cataluña. Grant:
Ministerio de Educación y Ciencia, IP061581. Duration:
01/07/2007-01/07/2009.
Gascon J. Plataforma de atención integral a los pacientes
con enfermedad de Chagas en CCHB, Bolivia y BCN. Grant:
21/10/09 15:36:59
Agència Catalana de Cooperación al Desenvolupament. Duration: 01/10/2008-30/09/2009.
Gascon J. Projecte d’activitats relacionades amb el VIH/Sida
en el centre de salut de Manhiça i suport tècnic al programa
decontrol del VIH/Sida de Moçambic en el districte de Manhiça. Grant: Agència Catalana de Cooperación al Desenvolupament. Duration: 01/01/2008-31/12/2008.
Naniche D. African-European HIV vaccine development network. Grant: Imperial Science Technology - MRC. Duration:
24/02/2008-25/02/2011.
Menendez C. Acción complementaria para el proyecto de
investigación de infección por Plasmodium Vivax en embarazo. Grant: Ministerio de Educación y Ciencia, SAF200801389-E. Duration: 01/10/2008-01/10/2009.
Alonso P. Centro de investigación en salud para la mejora
del acceso de la población vulnerable a los servicios de salud y el conocimiento, manejo y gestión de las enfermedades prevalentes. Mozambique any 2. Grant: AECI - Agencia
Española de Cooperación Internacional, 07-CO1-005. Duration: 20/12/2008-19/12/2009.
Menendez C. Plataforma de diagnóstico, manejo y prevención de la malnutrición en Manhiça, Mozambique.
Grant: Àfrica Viva Fundació-Oficial. Duration: 01/01/200801/01/2009.
Alonso P. The development of a global malaria eradication
R&D Agenda. Grant: The Bill + MEelinda Gates Foundation,
50961. Duration: 25/07/2008-25/01/2010.
200
194-203 AREA6.indd 200
21/10/09 15:37:01
Hospital Epidemiology, Public Health and Pharmacology
Team members
Team Leader:
■ Antoni Trilla (Hospital Clínic)
Tel.: 93 227 57 54
Fax: 93 227 98 77
Collaborators:
Maria Jesús Bertran (Hospital Clínic)
Begoña Gómez (Hospital Clínic)
Jaume Grau (Hospital Clínic)
Amalia Lafuente (Hospital Clínic)
Yolanda López (Hospital Clínic)
Neus Riba (Hospital Clínic)
Josep Ribas (Hospital Clínic)
José Rios (IDIBAPS)
Montserrat Sallés (Hospital Clínic)
Ferran Torrés (IDIBAPS)
The team carries out clinical research and epidemiology studies, with a small component of basic research
in pharmacology, aimed at objectives relating to better prevention and control of transmissible diseases,
notably hospital infections and health-care emergencies, with safety and quality in clinical practice and in
the use of vaccines. Its objective also includes clinical
pharmacology, especially in the context of clinical trials (design, execution and analysis).
•Prevention and control of nosocomial infections
•Clinical Quality and Safety
•Management of health care emergencies
•Clinical trials
•Drug surveillance
•Health Care Management
At the same time, the team carries out research support
services via different units. The Clinical Trials Agency,
which provides support for all procedures relating to
clinical trials carried out in Hospital Clínic-IDIBAPS,
while the Clinical Trials Unit provides support to researchers in designing clinical trials (commercial and
noncommercial). It also includes the Statistical and
Methodologic Support Unit (USEM), which basically
provides assessment in planning and data analysis.
Part of the UASP also provides support in reviewing
and evaluating research projects (not clinical trials). All
these units also work for the Clinical Research Ethics
Committee.
194-203 AREA6.indd 201
Hospital epidemiology, public
health and pharmacology
IDIBAPS Members:
■ Joan Albert Arnaiz (Hospital Clínic)
■ José M. Bayas (Hospital Clínic)
■ Gonzalo Calvo (Hospital Clínic)
■ Xavier Carné (Hospital Clínic)
■ Carles Codina (Hospital Clínic)
■ Lluís Salleras (Hospital Clínic)
■ Anna Vilella (Hospital Clínic)
■ Miguel A. Asenjo (Hospital Clínic)
■ Andreu Prat (Hospital Clínic)
201
21/10/09 15:37:06
I.F.: 66,09
PublicaTions
Original Articles
1
202
DeLazzari E, Leon A, Arnaiz JA, Martinez E, Knobel H,
Negredo E, Clotet B, Montaner J, Storfer S, Asenjo MA,
Mallolas J, Miro JM, Gatell JM. Hepatotoxicity of nevirapine in virologically suppressed patients according
to gender and CD4 cell counts. HIV MED. 9:221-226.
I.F.:3,35.
2 Mallolas J, Pich J, Penaranda M, Domingo P, Knobel
H, Pedrol E, Gutierrez F, Barrufet P, Peraire J, Asenjo
MA, Vidal F, Gatell JA. Induction therapy with trizivir
plus efavirenz or lopinavir/ritonavir followed by trizivir
alone in naive HIV-1-infected adults. AIDS. 22:377-384.
I.F.:5,84.
3 Emery S, Neuhaus JA, Phillips AN, Babiker A, Cohen
CJ, Gatell JM, Girard PM, Grund B, Law M, Losso
MH, Palfreeman A, Wood R, Arnaiz JA. Major clinical
outcomes in antiretroviral therapy (ART)-naive participants and in those not receiving ART at baseline in the
SMART study. J INFECT DIS . 197:1133-1144. I.F.:6,04.
4 Martin M, DelCacho E, Codina C, Tuset M, DeLazzari E,
24:1263-1268. I.F.:2,02.
5 Soriano A, Bori G, Garcia-Ramiro S, Martinez-Pastor
JC, Miana T, Codina C, Macule F, Basora M, Martinez
JA, Riba J, Suso S, Mensa J. Timing of antibiotic prophylaxis for primary total knee arthroplasty performed
during ischemia. CLIN INFECT DIS. 46:1009-1014.
I.F.:6,75.
6 Camps M, Vilella A, Marcos MA, Letang E, Muñoz J,
Pumarola T. Incidence of respiratory viruses among
travelers with a febrile syndrome returning from tropical and subtropical areas. J MED VIROL. 80:711-715.
I.F.:2,83.
7 Lafuente S, Trilla A, Bruni L, Gonzalez R, Bertran MJ,
Pomar JL, Asenjo MA. Validation of the EuroSCORE
Probabilistic model in patients undergoing coronary
bypass grafting. REV ESP CARDIOL. 61:589-594.
I.F.:2,21.
8 Ramirez P, Garcia MA, Ferrer M, Aznar J, Valencia M,
Sahuquillo JM, Menendez R, Asenjo MA, Torres A. Sequential measurements of procalcitonin levels in diagnosing ventilator-associated pneumonia. EUR RESPIR
J. 31:356-362. I.F.:5,35.
9 Dominguez A, Oviedo M, Carmona G, Batalla J, Bruguera M, Salleras L, Plasencia A. Impact and effectiveness of a mass hepatitis A vaccination programme of
preadolescents seven years after introduction. VACCINE. 26:1737-1741. I.F.:3,38.
10 Muñoz J, Alonso D, Vilella A, Naniche D, Costa J, Gascon J. Measles in travelers: Are we aware enough?. J
TRAVEL MED. 15:124-125. I.F.:1,05.
11 Salleras L, Dominguez A, Plans P, Costa J, Cardenosa
N, Torner N, Plasencia A. Seroprevalence of varicella
zoster virus infection in child and adult population of
194-203 AREA6.indd 202
12 13 14 15 16 17 18 19 Catalonia (Spain). MED MICROBIOL IMMUN. 197:329333. I.F.:1,54.
symptoms in patients with schizophrenia and bipolar
disorders. PSYCHIAT RES. 161:131-141. I.F.:2,30.
Font D, Gomis R, Trilla A, Bigorra J, Pique JM, Rodes J.
Organization and functioning model of biomedical research structures. Situation and future challenges. MED
Bessa X, Balleste B, Andreu M, Castells A, Belosillo B,
Balaguer F, Castellvi-Bel S, Paya A, Jover R, Alenda
C, Tito L, Martinez-Villacampa M, Vilella A, Xicola RM,
Pons E, Llor X. A prospective, multicenter, populationbased study of BRAF mutational analysis for lynch
syndrome screeningand. CLIN GASTROENTEROL H.
6:206-214. I.F.:5,47.
Lafuente A, Bernardo M, Mas S, Crescenti A, Aparici M,
Gasso P, Goti J, Sanchez V, Catalan R, Carne X. -141C
Ins/Del polymorphism of the dopamine D2 receptor
gene is associated with schizophrenia in a Spanish population. PSYCHIAT GENET. 18:122-127. I.F.:2,26.
Kong NCT, Beran J, Kee SA, Miguel JL, Sanchez C,
Bayas JM, Vilella A, Calbo-Torrecillas F, DeNovales
EL, Srinivasa K, Stoffel M, Hoet B. A new adjuvant
improves the immune response to hepatitis B vaccine in hemodialysis patients. KIDNEY INT. 73:856-862.
I.F.:4,92.
Alecrim-Andrade J, Maciel-Junior JA, Carne X, Vasconcelos GMS, Correa HR. Acupuncture in migraine
prevention - A randomized sham controlled study with
6-months posttreatment follow-up. CLIN J PAIN. 24:98105. I.F.:2,55.
Rumke HC, Bayas JM, DeJuanes JR, Caso C, Richardus
JH, Campins M, Rombo L, Duval X, Romanenko V,
Schwarz TF, Fassakhov R, Abad-Santos F, VonSonnenburg F, Drame M, Sanger R, Balloun WR. Safety and
reactogenicity profile of an adjuvanted H5N1 pandemic
candidate vaccine in adults within a phase III safety
trial. VACCINE. 26:2378-2388. I.F.:3,38.
Sevene E, Mariano A, Mehta U, Machai M, Dodoo A,
Vilardell D, Patel S, Barnes K, Carne X. Spontaneous
Adverse Drug Reaction Reporting in Rural Districts of
Mozambique. DRUG SAFETY. 31:867-876. I.F.:3,54.
Reviews
1
Trilla A, Trilla G, Daer C. The 1918 “Spanish Flu” in
Spain. CLIN INFECT DIS. 47:668-673. I.F.:6,75.
Editorials
1
21/10/09 15:37:08
Multicentrics
1 Lundgren JD, Babiker A, El-Sadr W, Emery S, Grund
B, Neaton JD, Neuhaus J, Phillips AN, Gatell JM,
Arnaiz JA. Inferior clinical outcome of the CD4(+) cell
count guided antiretroviral treatment interruption
strategy in the SMART study: Role of CD4(+) cell
counts and HIV RNA levels during follow-up. J
INFECT DIS . 197:1145-1155. I.F.:6,04.
2 El-Sadr WM, Grund B, Neuhaus J, Babiker A,
Cohen CJ, Darbyshire J, Emery S, Lundgren JD,
Phillips A, Neaton JD, Gatell JM, Arnaiz JA. Risk for
opportunistic disease and death after reinitiating
continuous antiretroviral therapy in patients with HIV
previously receiving episodic therapy - a randomized
trial. ANN INTERN MED . 149:289-W62. I.F.:15,52.
3 Soriano V, Mocroft A, Rockstroh J, Ledergerber
B, Knysz B, Chaplinskas S, Peters L, Karlsson A,
Katlama C, Toro C, Kupfer B, Vogel M, Lundgren J,
Gatell JM, Arnaiz JA. Spontaneous viral clearance,
viral load, and genotype distribution of hepatitis C
virus (HCV) in HIV-infected patients with anti-HCV
antibodies in Europe. J INFECT DIS . 198:1337-1344.
I.F.:6,04.
4 Fox Z, Phillips A, Cohen C, Neuhaus J, Baxter
J, Emery S, Hirschel B, Hullsiek KH, Stephan C,
Lundgren J, Arnaiz JA, Gatell JM. Viral resuppression
and detection of drug resistance following
interruption of a suppressive non-nucleoside reverse
transcriptase inhibitor-based regimen. AIDS .
22:2279-2289. I.F.:5,84.
Trilla A. European Network for Highly Infectious Diseases. Grant: European Commision, 2006205. Duration:
01/07/2007-30/06/2010.
Carne X. Farmacologia Clínic i Farmacogenètica. Grant:
Duration: 19/10/2005-31/12/2008.
Vilella A. Planes de actuación frente a una pandemia de
gripe: Análisis sistemático de los actualmente vigentes en
España y desarrollo de un ejercicio de simulación para evaluar localmente su factibilidad. Grant: Ministerio Sanidad y
Carne X. European Clinical Research Infrastructures Network and biotherapy facilities: Preparation Phase for the
InfrastructureCentre coordinador: INSERM. Grant: INSERM DRCT Institut Thématique Santé Publique, 211738. Duration:
01/03/2008-28/02/2011.
Carne X. Impact on Clinical Research of European LegislationCentre coordinador: European Forum For Good Clinical
Practice. Grant: European Forum for Good Clinical Practice,
201002. Duration: 01/01/2008-31/12/2008.
Carne X. Consolidación del proyecto European Clinical Research Infrastructures Network and biotherapies facilities en
España. Grant: Ministerio Educación y Ciencia, CAC-200719. Duration: 19/11/2007-31/12/2008.
203
194-203 AREA6.indd 203
21/10/09 15:37:10
204-207 AREA7.indd 204
21/10/09 12:23:22
Groups Associated with the
Instituto de Investigaciones Sanitarias
Hospital Clínic-IDIBAPS
Transversal research group on Primary Care . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . . 206
Image: Stethoscope
204-207 AREA7.indd 205
21/10/09 12:23:24
Transversal research group on Primary Care
Team Members
Groups Associated with the Hospital
Clínic-IDIBAPS Health Care Research Institute
Team Leader:
■ Antoni Sisó Almirall (GESCLÍNIC)
Tel.: 93 227 99 24
Fax: 93 227 55 97
206
IDIBAPS Members:
■ Lluisa Benito Serrano (GESCLINIC)
■ Marta Catalán Adell (CAPSE)
■ Zoe Herreras Pérez (CAPSE)
■ Imma Garrell Lluís (CAPSE)
■ Joan Gené Badia (CAPSE)
■ Imma Grau Corral (Hospital Clínic)
■ Pilar Navarrete Duran (CAPSE)
■ Marta Navarro González (CAPSE)
■ Jacinto Ortiz Molina (GESCLINIC)
■ Anna Pereira Rosalen (CAPSE)
■ Alfonso Pérez Jiménez (CAPSE)
■ Montserrat Pinyol Martínez (GESCLINIC)
■ Marina Rovira (CAPSE)
■ Antoni Salvà Riquer (CAPSE)
■ Núria Sánchez Ruano (CAPSE)
Primary care is the point of entry of the public to
the health care system and the primary care centers
are where most of the population’s health problems
are resolved. In this environment, the relationship
between the patient and the family doctor and nurse
becomes key to preventing and curing disease and
promoting healthy habits. In the area of research, the
multidisciplinary and transversal nature of primarycare professionals leads to a biologic, psychologic
and social approach to patients and their illnesses,
both in the consulting room and in their homes. The
comprehensive approach to the person and the longitudinal care throughout life makes it possible to
carry out studies alone or in collaboration that are
aimed at gaining knowledge of the characteristics
of the population, individuals and diseases. Primary
care aims to develop its own research, join the existing research networks and groups, and work in coordination with other consolidated research teams
from different aspects:
• Population-based
descriptive studies and studies
evaluating interventions and monitoring, in an accessible, well-defined population, making use of the
experience of computerized clinical records.
• Research into results in health care.
• Description of the natural history of the patient and
the disease from a biologic, psychologic and social
perspective.
204-207 AREA7.indd 206
■ Laura Sebastián Montal (GESCLINIC)
■ Ethel Sequeira Aymar (CAPSE)
■ Salvador Sitjar Martínez de Sas (GESCLINIC)
■ Josep Miquel Sotoca (Hospital Clínic)
■ Josep M. Vilaseca (public health technician)
Collaborators:
Narly Benachi
Belén de Pedro
Noemí García
Lluís González de Paz
Concha Juan
Elena Mañes
•Studies of risk factors and preventive medicine.
•Analysis of morbidity and mortality of the most prevalent diseases.
in collaboration with the government, research organizations or groups that allow for implementation of translational research.
•Studies
• Continuity of patient care and management of chronic diseases
•Use of Health Care Services
• The Fragility – Geriatrics – Dependency
– Domiciliary Care Axis
•Use of drugs.
•Primary care and autoimmunity
•Atherogenesis, risk factors and cardiovascular
disease.
• Chronic pain
•Mental health, smoking and other addictions
•Respiratory diseases
•Digestive and liver diseases
•HIV-AIDS and other infectious diseases
21/10/09 12:23:27
I.F.: 9,78
PublicaTions
Original Articles
1
2
Editorials
1
Balaguer F, Ocana T, Garrell I, Ferrandez A. High risk
clinics: a new concept in colon and rectum cancer
prevention. MED CLIN-BARCELONA. 131:382-386.
I.F.:1,34.
Thesis
Gene-Badia J. Les dimensions del resultat assistencial de
l’Atenció Primària de la Salut. Doctorand: Mireia Sans Corrales. Universitat de Barcelona.
3
Siso A, Ramos-Casals M, Bove A, Brito-Zeron P, Soria
17:281-288. I.F.:2,25.
Iglesias M, Jungebluth P, Petit C, Matute MP, Rovira
I, Martinez E, Catalan M, Ramirez J, Macchiarini P.
Extracorporeal lung membrane provides better lung
protection than conventional treatment for severe
postpneumonectomy noncardiogenic acute respiratory distress syndrome. J THORAC CARDIOV SUR.
135:1362-U300. I.F.:3,35.
Cerda J, Mercade J, Lozano JJ, Manchado M, TingaudSequeira A, Astola A, Infante C, Halm S, Vinas J, Castellana B, Asensio E, Canavate P, Martinez-Rodriguez
G, Piferrer F, Planas JV, Prat F, Yufera M, Durany O,
Subirada F, Rosell E, Maes T. Genomic resources for a
commercial flatfish, the Senegalese sole (Solea senegalensis): EST sequencing, oligo microarray design,
and development of the Soleamold bioinformatic platform. BMC GENOMICS. 9:-. I.F.:4,18.
Groups Associated with the Hospital Clínic-IDIBAPS
Health Care Research Institute
207
204-207 AREA7.indd 207
21/10/09 12:23:29
Team Leader Index
Team Leader Index
A
L
Alberch, Jordi. .. .. .. .. .. .. .. .. .. .. .. 131
Lozano, Francisco . .. .. .. .. .. .. .. .. .. . 27
Alonso, Pedro . .. .. .. .. .. .. .. .. .. .. .. 196
Arroyo, Vicente . .. .. .. .. .. .. .. .. .. .. .. 88
B
M
Mengod, Guadalupe. .. .. .. .. .. .. .. .. 116
Mezquita, Cristóbal. .. .. .. .. .. .. .. .. 166
Bachs, Oriol . .. .. .. .. .. .. .. .. .. .. .. .. 191
Milà, Montserrat. .. .. .. .. .. .. .. .. .. .. 168
Balasch, Juan. .. .. .. .. .. .. .. .. .. .. .. .. 74
Montserrat, Emili . .. .. .. .. .. .. .. .. .. 177
Ballesta, Antonio M.
Barberà, Joan Albert. .. .. .. .. .. .. .. .. . 64
Bernardo, Miguel . .. .. .. .. .. .. .. .. .. 134
O
Ordinas, Antonio. .. .. .. .. .. .. .. .. .. .. 185
Bosch, Jaume. .. .. .. .. .. .. .. .. .. .. .. . 94
Brugada, Josep. .. .. .. .. .. .. .. .. .. .. .. 46
Bruix, Jordi. .. .. .. .. .. .. .. .. .. .. .. .. .. . 91
C
Campistol, Josep Mª . .. .. .. .. .. .. .. .. 50
Campo Güerri, Elías . .. .. .. .. .. .. .. .. 158
Carreras, Enric. .. .. .. .. .. .. .. .. .. .. .. 174
Carreras, Josep. .. .. .. .. .. .. .. .. .. .. .. 82
Castells, Antoni. .. .. .. .. .. .. .. .. .. .. 107
Cervera Segura, Ricard . .. .. .. .. .. .. .. 14
Closa, Daniel. .. .. .. .. .. .. .. .. .. .. .. .. . 38
Colomer, Dolors. .. .. .. .. .. .. .. .. .. .. 182
F
Farré, Ramon . .. .. .. .. .. .. .. .. .. .. .. .. 57
Fernández-Checa, José . .. .. .. .. .. .. 103
Forés I Viñeta, Joaquim . .. .. .. .. .. .. . 30
Franco Fernández, Rafael . .. .. .. .. .. 152
G
208
Panés, Julián. .. .. .. .. .. .. .. .. .. .. .. .. . 98
Parés, Albert. .. .. .. .. .. .. .. .. .. .. .. .. 101
Picado, César. .. .. .. .. .. .. .. .. .. .. .. .. 68
Planas, Anna M.. .. .. .. .. .. .. .. .. .. .. 150
Pons, Francesca. .. .. .. .. .. .. .. .. .. .. 163
Puig, Susana. .. .. .. .. .. .. .. .. .. .. .. .. 171
R
Rimola, Antoni. .. .. .. .. .. .. .. .. .. .. .. 105
Ros, Emili. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 54
S
Sánchez Vives, Maria Victoria . .. .. .. 146
Sánchez-Tapias, Jose. .. .. .. .. .. .. .. .. 85
Sanmartí, Raimon . .. .. .. .. .. .. .. .. .. . 12
Sisó Almirall, Antoni. .. .. .. .. .. .. .. .. 206
T
Gascón Vilaplana, Pere . .. .. .. .. .. .. 188
Torres, Antoni . .. .. .. .. .. .. .. .. .. .. .. . 60
Gatell Josep M. . .. .. .. .. .. .. .. .. .. .. . 19
Trilla, Antoni . .. .. .. .. .. .. .. .. .. .. .. .. 201
Gomis, Ramon. .. .. .. .. .. .. .. .. .. .. .. 110
Gratacós, Eduard . .. .. .. .. .. .. .. .. .. .. 77
U
Graus, Francesc. .. .. .. .. .. .. .. .. .. .. 120
Urbano Márquez, Álvaro. .. .. .. .. .. .. 127
Guañabens, Núria . .. .. .. .. .. .. .. .. .. . 83
208 Ind LIDERS.indd 208
P
V
H
Valls Solé, Josep. .. .. .. .. .. .. .. .. .. .. 124
Heras Fortuny, Magda. .. .. .. .. .. .. .. . 42
Vila Estapé, Jordi . .. .. .. .. .. .. .. .. .. .. 35
J
Y
Junqué, Carme . .. .. .. .. .. .. .. .. .. .. 142
Yagüe, Jordi . .. .. .. .. .. .. .. .. .. .. .. .. . 33
20/10/09 10:47:09
Journal index
JOURNAL PAGE
PAGE
CELL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 188
CELL RES. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..147, 162, 173
CELL SIGNAL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 110, 191
CEREB CORTEX. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 145
CHEMBIOCHEM. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 35
CIRCULATION . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 46
CLIN CANCER RES. .. .. .. .. .. .. .. .. .. .. 158, 162, 176, 177, 181, 187, 187, 188
CLIN CHEM LAB MED. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 155
CLIN EXP ALLERGY. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 68
CLIN EXP DERMATOL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 167
CLIN EXP PHARMACOL P. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 136
CLIN EXP RHEUMATOL . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 81
CLIN INFECT DIS. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 20, 21, 22, 29, 34, 60, 84, 200
CLIN J AM SOC NEPHRO . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 50
CLIN J PAIN. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 200
CLIN MICROBIOL INFEC. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 34, 35, 195
CLIN NEPHROL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..49, 53, 87
CLIN NEUROPHYSIOL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..120, 123, 124
CLIN RHEUMATOL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 15
CLIN THER . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 68
CLIN VACCINE IMMUNOL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 196
COMPR PSYCHIAT. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 138
CONT SHELF RES. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 37
CORNEA . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 26, 31
CRIT CARE MED . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 87, 104
CURR OPIN PULM MED. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 56, 59
CYTOKINE . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 14, 126, 155, 176, 181
DEMENT GERIATR COGN. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 120
DERMATOLOGY . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..167, 170, 171
DIABETES CARE . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 110
DIABETES OBES METAB . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 110
DIABETES RES CLIN PR. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 110
DIABETIC MED. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 110
DIABETOLOGIA . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 110
DIAGN MICR INFEC DIS . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..20, 34, 35
DIFFERENTIATION. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 110
DRUG SAFETY . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 200
ENFERM INFEC MICR CL . .. .. .. 14, 20, 21, 23, 26, 29, 34, 60, 155, 196, 197
ENVIRON HEALTH PERSP. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 167
EPILEPSY BEHAV. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 116, 123, 136, 142, 162
EUR HEART J . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 41, 42
EUR HEART J SUPPL . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 41
EUR J ANAESTH . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 42
EUR J CANCER. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 162, 170
EUR J CARDIOV PREV R. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 53, 127
EUR J CLIN INVEST . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 184
EUR J CLIN MICROBIOL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..19, 22, 29, 34, 78
EUR J CLIN NUTR. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .53, 127
EUR J HAEMATOL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 174, 177
EUR J NEUROL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 116,142, 149
EUR J NUCL MED MOL I. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .46, 56, 162
EUR J OBSTET GYN R B. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..73, 76, 77
EUR J OPHTHALMOL . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 15
EUR J PHARMACOL . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 116
EUR J RADIOL . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 142
EUR NEUROPSYCHOPHARM. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 136, 138
EUR PSYCHIAT. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 137, 138
EUR RADIOL . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 90, 97, 106
EUR RESPIR J . .. .. .. .. .. .. .. . 19, 21, 33, 34, 56, 59, 60, 63, 64, 67, 126, 158, 200
EUR UROL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 50, 181, 187
EUROPACE. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 45, 46
EXP BRAIN RES . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 123, 124
EXP HEMATOL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 26, 173
EYE. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 14
FASEB J. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 123
FEBS LETT. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .29, 151
FERTIL STERIL . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 73, 74, 158, 190
FETAL DIAGN THER . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 76, 167
GASTROENTEROLOGY. .. .. .. .. .. .. .. 87, 90, 94, 97, 98, 102, 106, 107, 158, 191
GASTROINTEST ENDOSC. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 97, 106, 158
GENE CHROMOSOME CANC. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..159, 167, 181
GENES BRAIN BEHAV. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 136
GENES IMMUN. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 32
GENET TEST. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 167
GUT . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 37, 94
GYNECOL ENDOCRINOL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .73, 135
HAEMATOL-HEMATOL J . .. .. .. . 158, 159, 160, 174, 176, 177, 178, 181, 184
HEAD NECK-J SCI SPEC. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 19
HEALTH POLICY . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 196
HEART. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 41
HEART RHYTHM. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 45
HEPATO-GASTROENTEROL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 97
HEPATOLOGY . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 87, 90, 91, 94, 100104, 106, 158
HIV CLIN TRIALS. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 19, 22
HIV MED. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 20, 22, 73, 196, 200
HORM METAB RES. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 110
HUM EXP TOXICOL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 127
HUM GENET . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 196
HUM MOL GENET. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 107
HUM REPROD . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 15, 73, 74, 77, 130, 165
Journal index
ACCREDIT QUAL ASSUR. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 181
ACTA BIOMATER. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 29
ACTA DIABETOL . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 110
ACTA NEUROPSYCHIATR . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..137,142
ACTA OPHTHALMOL SCAN. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 14
ACTA PSYCHIAT SCAND. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..137,138
ACTA TROP. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 196
ADDICT BEHAV. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 136
AESTHET PLAST SURG. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 30
AGING CELL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 116
AIDS. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 22, 23, 24, 59, 77, 200, 201
AIDS PATIENT CARE ST . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 20
AIDS RES HUM RETROV . .. .. .. .. .. .. .. .. .. .. .. .. 21, 26, 49, 84, 176, 196, 200
ALCOHOL ALCOHOLISM . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 138
ALIMENT PHARM THERAP . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 94, 97
ALLERGY . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 67, 68
AM HEART J. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 42, 46
AM J CARDIOL . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 41, 42, 45, 46, 53
AM J CLIN ONCOL-CANC. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 187
AM J CLIN PATHOL . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 155
AM J GASTROENTEROL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 87, 90, 93, 97, 102
AM J GERIAT PSYCHIAT. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 136
AM J KIDNEY DIS . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .37, 49, 50, 184
AM J MED . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 54
AM J MED GENET A. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 77, 165, 16
AM J MED GENET B. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 136
AM J OBSTET GYNECOL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 76, 78
AM J OPHTHALMOL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 14
AM J PHYSIOL-LUNG C . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 67
AM J PHYSIOL-RENAL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 50
AM J PSYCHIAT . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 137
AM J RESP CRIT CARE . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 20
AM J TRANSPLANT. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 19, 21, 34, 42, 49
AM J TROP MED HYG . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 35, 1975, 196,
ANAL CHEM. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 37
ANAT HISTOL EMBRYOL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 80
ANN ALLERG ASTHMA IM . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 68
ANN HEMATOL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..178, 181, 184
ANN ONCOL . .. .. .. .. .. .. .. .. .. .. .. 50, 119, 155, 158, 176, 178, 181, 187, 188
ANN RHEUM DIS. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 14, 15, 126, 184
ANN SURG . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 87, 97, 106, 107, 110
ANN THORAC SURG. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..41, 49, 60, 63
ANTIMICROB AGENTS CH . .. .. .. .. .. .. .. .19, 22, 29, 33, 34, 59, 93, 174, 185
ANTIVIR THER. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .19, 22, 77, 127
ARCH BRONCONEUMOL. .. .. .. .. .. .. .. .. .. .. .. .. .. 19, 60, 63, 64, 67, 68, 158
ARCH DERMATOL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 171, 173
ARCH DERMATOL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 171, 173
ARCH INTERN MED . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 19, 54, 127
ARCH NEUROLCHICAGO . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 119
ARCH ORTHOP TRAUM SU. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 29, 157
ARTERIOSCL THROM VAS . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 54, 93
ARTH RHEUM/AR C RES . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 14, 93, 126, 157, 162
ARTIF ORGANS. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 64
ATHEROSCLEROSIS. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 53, 93
AUTOIMMUN REV. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 14, 15
AUTOPHAGY. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 130
BBA-MOL CELL RES. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 191
BEST PRACT RES CL OB . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 77
BEST PRACT RES CL RH. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 14
BIOCHEM J. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 149
BIOESSAYS. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 151
BIOL BLOOD MARROW TR. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 173, 177
BIOL PSYCHIAT. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 116
BIOPHYS J. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 56
BIPOLAR DISORD. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 136, 137, 138, 142
BJOG-INT J OBSTET GY. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 77
BJU INT. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 49
BLOOD . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..31, 94, 119, 127, 159, 162, 173,
. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .176, 177, 178, 179, 181, 184, 185
BLOOD PRESSURE . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 54
BMC CANCER . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 159
BMC GENOMICS. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 205
BMC HEALTH SERV RES. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 196
BMC PUBLIC HEALTH. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 196
BONE . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 82, 191
BRAIN. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 110, 119
BRAIN INJURY . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 142
BREAST CANCER RES TR. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..181, 188, 190
BRIT J CANCER. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 187
BRIT J DERMATOL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 171
BRIT J HAEMATOL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 159, 177, 178, 184
BRIT J NUTR. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 127
BRIT J PSYCHIAT. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 137
BRIT J SPORT MED. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 80
CALCIFIED TISSUE INT . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 81
CANCER. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 106, 159, 177, 178
CANCER CHEMOTH PHARM . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 187
CANCER RES . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 90, 102, 158, 159, 176
CARDIOL CLIN. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 45
CARDIOLOGY . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 43, 45
JOURNAL 209
20/10/09 10:47:46
Journal index
JOURNAL 210
PAGE
IEEE T BIO-MED ENG. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .56, 135
IMMUNOL INVEST. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 14
INFLAMM BOWEL DIS . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .97, 141
INT CLIN PSYCHOPHARM. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 136
INT J BIOCHEM CELL B. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 87
INT J CANCER. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 197
INT J CLIN PRACT. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 110, 120
INT J COLORECTAL DIS. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 49
INT J DEV NEUROSCI. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .77, 141
INT J GERIATR PSYCH. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 137, 142
INT J NEUROPSYCHOPH. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 116, 136, 138
INT J RADIAT ONCOL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 136, 137, 138, 196
INVEST OPHTH VIS SCI. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 123
J AFFECT DISORDERS. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 136, 137, 138, 196
J AGR FOOD CHEM . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 184
J ALTERN COMPLEM MED. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 127
J AM ACAD DERMATOL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 167
J AM COLL CARDIOL . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 45, 54
J AM DIET ASSOC. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 53, 126
J AM SOC ECHOCARDIOG. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 42
J ANDROL . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 165
J ANTIMICROB CHEMOTH. .. .. .. .. .. .. .. .. .. .. .. . 19, 26, 29, 34, 35, 119, 195
J APPL PHYSIOL . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 64
J BIOL CHEM. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 64, 190, 191
J BIOMED MATER RES B . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 184
J CARDIOVASC ELECTR. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 45, 46
J CELL MOL MED. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 94
J CELL SCI. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 130
J CHILD ADOL PSYCHOP . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 136
J CLIN ENDOCR METAB. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 110, 158
J CLIN EXP NEUROPSYC. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 120
J CLIN IMMUNOL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 50, 157, 195
J CLIN INVEST . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..84, 104, 184, 197
J CLIN MICROBIOL . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 19, 20, 22, 29, 34, 78
J CLIN ONCOL . .. .. .. .. .. .. .. .. .. .. .. .. 159, 162, 176, 177, 178, 181, 187, 188
J CLIN PSYCHIAT. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 137, 142
J COMP NEUROL . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 116
J ENDOCRINOL INVEST. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 110
J GASTROINTEST SURG. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 37, 97, 106, 158
J GENE MED . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 77
J HAND SURG-AM. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 29
J HEART LUNG TRANSPL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 41, 42, 49, 157
J HEPATOL . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 84, 87, 90, 91, 93, 94,
J HYPERTENS . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..35, 41, 53
J IMMUNOL . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .11, 37, 110
J IMMUNOL METHODS . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 173
J INFECT DIS. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 20, 22, 23, 196, 200, 201
J INFECTION . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 20
J INVEST ALLERG CLIN . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 67, 68
J LIPID RES. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 87
J MAGN RESON IMAGING . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 29, 157, 162, 187
J MASS SPECTROM. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 37
J MED CHEM. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 191
J MED GENET. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 106
J MED VIROL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 20, 35, 195, 200
J MOL CELL CARDIOL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 54
J NEURAL TRANSM . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 119
J NEUROCHEM . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 116, 130, 149, 151
J NEUROIMMUNOL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..119, 120, 130
J NEUROL . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 29, 116, 119, 120, 123, 142, 149
J NEUROL NEUROSUR PS . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 120, 123
J NEUROL SCI. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 119, 120, 123
J NEUROPHYSIOL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 120, 123
J NEUROSCI. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 116, 130, 145, 149
J NEUROSCI RES. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 116, 149
J NEUROTRAUM. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 142
J NEUROVIROL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 19, 33
J PATHOL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 50, 184
J PERINAT MED. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .73, 76, 77, 78, 197
J PHARMACOL EXP THER. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 87, 149
J PHYSIOL-LONDON. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 124
J PROTEOME RES. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 37
J PSYCHIATR RES. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 94, 119, 135, 136, 137, 142
J PSYCHOPHARMACOL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 137, 138
J RHEUMATOL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 15, 29
J SURG ONCOL . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 19, 157, 162, 187
J SURG RES . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 63
J THEOR BIOL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 80
J THORAC CARDIOV SUR. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 64, 158, 205
J TRAVEL MED. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 84, 127, 196, 197, 200
J VIROL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 26
JAIDS-J ACQ IMM DEF . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..19, 23, 26
KIDNEY INT. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 200
LANCET. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 22, 23, 42, 49, 63, 78, 187
LANCET NEUROL . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 120
LEUKEMIA. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 158, 176, 177, 178, 179, 181
LEUKEMIA RES. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..159, 167, 178
LIVER INT. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 87, 93
LIVER TRANSPLANT. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 20, 34, 84, 104
LUPUS . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .15, 53, 205
MALARIA J. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 196, 197
MED CLIN-BARCELONA. .. .. .. .. .. .. .. .. . 15, 32, 42, 50, 54, 60, 67, 81, 90, 94,
. .. .. .. .. .. .. .. .. .. .. .. 97, 109, 110, 127, 136, 142, 159, 179, 181, 196, 200, 205
JOURNAL PAGE
MED DECIS MAKING . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 77
MED MICROBIOL IMMUN . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .26, 84, 200
MED TEACH. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 123
MEDICINE . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 13, 14, 15, 19
MENOPAUSE. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 73
MOL BIOL CELL . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..130, 190, 191
MOL CELL NEUROSCI. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 130
MOL CELL PROTEOMICS. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 110
MOL IMMUNOL . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 26, 170
MOL PHARMACOL . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 116
MOVEMENT DISORD. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 68, 119, 120, 141, 167
MULT SCLER. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 119, 120
NAT GENET. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 106, 170
NAT METHODS. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 151
NEFROLOGIA. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 49, 50
NEUROBIOL AGING . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..116, 119, 141
NEUROBIOL DIS. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..116, 119, 130
NEUROIMAGE . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 56, 142, 149
NEUROLOGIA . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 119, 120, 123, 173
NEUROLOGY. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 120, 121, 124, 158
NEUROPHARMACOLOGY. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 151
NEUROPSYCHOBIOLOGY. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 136
NEUROPSYCHOLOGIA . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .77, 141
NEUROREPORT. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 136, 142
NEUROSCI LETT . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 120, 123
NEUROTOX RES. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 116
NEUROTOXICOLOGY. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 116
NEW ENGL J MED . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 21, 41, 64, 87, 90, 159, 177
NUCL MED COMMUN. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 56, 135
OBES SURG . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 29, 97, 106, 107, 109, 110
OBSTET GYNECOL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 77
ONCOGENE . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 181
ORTHOPEDICS. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 29
P NATL ACAD SCI USA. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 145, 159
PAIN. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 123
PEDIATR INFECT DIS J. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 77
PEDIATR PULM . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 76
PEDIATR RES. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 77, 141
PEDIATRICS. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 14
PHARMACOGENOMICS. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 54
PLATELETS. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 184
PLOS GENET. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 110
PLOS MED . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 73, 195
POSTGRAD MED J . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 87
PRENATAL DIAG . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..73, 76, 78
PROG BRAIN RES. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 116
PROG NEURO-PSYCHOPH . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 137
PSYCHIAT GENET . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 136, 137, 138, 167, 200
PSYCHIAT RES . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 94, 135, 136, 137, 142, 200
PSYCHOPATHOLOGY. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 136, 138
PSYCHOPHARMACOLOGY. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 116
RADIOTHER ONCOL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 97, 162
REGUL PEPTIDES. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 110
REPROD BIOMED ONLINE. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 73, 109, 158
RESP PHYSIOL NEUROBI . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..37, 56, 59
RESP RES . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 67, 76
RETROVIROLOGY . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 31
REV ESP CARDIOL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 41, 42, 43, 45, 46, 64, 200
REV ESP ENFERM DIG. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 84
REV NEUROLOGIA. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 77, 141
RHEUM DIS CLIN N AM. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 14
RHEUMATOL INT. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 31
SCHIZOPHR RES. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 110, 136, 137, 138
SCIENCE. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .32, 159
SEMIN ARTHRITIS RHEU. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 11, 14, 15, 30
SEMIN DIAGN PATHOL. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 158
SEMIN NEUROL . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 123
SEMIN THROMB HEMOST . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 14
SLEEP. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 41, 56, 59, 120, 123, 142
SLEEP MED. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 41, 59
STROKE. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 54, 149
SUBST USE MISUSE. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 137
SURG ENDOSC. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 97, 106
SURGERY. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 84, 90, 104
SYNAPSE. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 56, 116
THORAX. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..20, 34, 59, 155
THROMB HAEMOSTASIS. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 184, 185
THROMB RES . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 184
TOXICOL IN VITRO. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 116
TOXICOL LETT . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 116
TRANSFUSION. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 197
TRANSPL IMMUNOL . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 104
TRANSPL P . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 42, 45, 157
TRANSPLANTATION . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 20, 34, 49, 50, 64, 162
TROP MED INT HEALTH. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 196
TUMOR BIOL . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 60, 155, 158, 187
ULTRASOUND OBST GYN. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..73, 76, 77, 78
VACCINE. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .22, 200
VASC PHARMACOL . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 63, 158
VIRCHOWS ARCH . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. . 158, 159
VOX SANG. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .26, 29, 184
WORLD J BIOL PSYCHIA. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 136, 137
WORLD J SURG . .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. 107
20/10/09 10:47:50
20/10/09 10:47:51

annu al scientific

Transcription

Similar documents

Power, Steering Proxes R888 sticks to the track whilst you stick to

Best Places to Work Genumark

an inspirational step-by-step

Useful advises to help you protect your Child From domestic

Life changes, the household changes Useful advises to help you

Get info about What Is The Song Roulette By System Of A Down About

SCIOTO SHOE MART